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Cancer is a disease of the genome, requiring mutation or epimutation of specific genes to develop.
The subsequent progression of cancer and response to therapies is also dictated to some degree by
new mutation and clonal selection on that novel variation. However, it is thought that the majority of
somatic mutations that occur in cancer are inconsequential passengers, and only a subset of functionally
important driver mutations are of importance for cancer biology. This project set out to adapt and
apply well-established methods from the field of molecular evolution to measure the selective forces
driving the development of cancers. The ultimate objective being an improved understanding of which
mutations help or hinder the progression of a cancer. Somatic cancer mutations were identified through
the analysis of paired tumour and non-tumour whole-exome sequence data from the same individual.
Primary data from 1005 patients was processed and complemented with additional publicly available
pre-processed somatic variant calls from 4728 patients. Tumours were classified by tissue of origin
and also their spectrum of substitution mutations. An advanced evolutionary analysis framework was
established, allowing somatic single nucleotide variant data to be analysed as traditional organismal
DNA sequence. Estimates of amino acid changing (non-synonymous) and synonymous mutation rates
were derived and maximum likelihood tests of selection applied to identify genes and regions of genes
subject to selective pressure during oncogenesis. While the meta-analysis of all patients provided
unprecedented power for such a study, more refined analyses based on the stratification of patients
gave insights into the pathways of importance for specific tissues of origin. Additionally, stratification
of patients by the relative frequencies of different mutation types in a tumour also provided insights into
how mutation profile influences the sites, genes and pathways that are perturbed in the development of
cancer. Of particular interest here, was to test the hypothesis that both (1.) mutation spectrum and (2.)
tissue of origin, set the evolutionary trajectory of a cancer. Building on this I sought to estimate their
relative contributions. During this work an unexpected, localised mutation pattern was discovered and
subsequent analysis demonstrated some loci to be highly susceptible to small segmental deletions in a
subset of cancers. In the absence of a justifiable model of neutral segmental deletion it was not possible
to infer whether these major mutations could be considered passengers or drivers of cancer progression.
In contrast, an advantage of the evolutionary approach applied to nucleotide substitutions in protein
coding sequences is that there is a justified model of neutral evolution (synonymous changes). Using this
approach, I have not only been able to detect genes harbouring putative cancer driver mutations, but
have also found evidence for genes subject to purifying selection in cancers where potentially disruptive
mutations appear to be deleterious to cancer progression. Such genes, if they are non-essential in the
adult organism, could provide a novel type of target for anti-cancer therapeutics.
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Chapter 1
Introduction
Normally the development of a complex multicellular organism consists of a sequence
of tightly regulated and limited cellular divisions, differentiation and programmed cell
death (apoptosis). Conversely, in cancer the normal checks and controls on cell di-
vision and death are substantially modified [Talavera et al., 2010]. When relatively
unrestrained proliferation of cells proceeds, benign growths can result [as reviewed in
Stratton et al., 2009]. If those excessively dividing cells acquire the ability to invade
adjacent tissue or migrate to distant locations through the blood and lymph systems
(metastasise) then a cancer (malignant tumour) has developed [as reviewed in Stratton
et al., 2009].
Cancer is a highly diverse disease covering over 100 different diseases originating in
most organs of the body [as reviewed in Stratton et al., 2009]. It is widely recognised
as the most common genetic disease, with one in three people developing some form of
cancer in their lifetime, and for one in five of those affected, the disease is fatal1. Cancer
is responsible for one in seven deaths worldwide, as the second leading cause of death
(following cardiovascular diseases) in high-income countries and third leading cause of
death (following cardiovascular diseases and infectious and parasitic diseases) in low-
income countries [AmericanCancerSociety, 2015]. Consequently, cancer is an enormous
1http://www.cancerresearchuk.org
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global health burden, with 14.1 million cases reported worldwide in 2012, 8.2 million of
which resulted in death. By 2030 the burden is expected to grow to 21.7 million new
cancer cases and 13 million cancer deaths simply due to the growth and ageing of the
population [AmericanCancerSociety, 2015]. However cancer survival rates have doubled
in the last 40 years. The 10-year cancer survival rate for adults in the UK is currently
50%, with 46% of men and 54% of women adult cancer patients diagnosed in 2010-
2011 in England and Wales predicted to survive 10 or more years [Cancer Research
UK, 2014]. The cost of cancer in the UK to society as a whole (including costs to
NHS and loss of productivity) is estimated to be £18.3 billion a year2, with the total
economic impact worldwide unknown but estimated to be the highest economic loss of
all leading causes of death worldwide, totalling hundreds of billions of dollars per year
[AmericanCancerSociety, 2015]. This cost is expected to increase due to the increasing
cost of cancer therapies as well as the increasing number of new cancer cases. Therefore
there are strong medical, social and financial implications to this genetic disease and a
better understanding of the mechanisms that lead to cancer is imperative for improving
diagnosis, treatment and prevention.
1.1 Cancer is a disease of the genome
Cancer is a disease of the genome, arising as a result of mutation or epimutation oc-
curring in the DNA sequence of the genomes of cancer cells [Strausberg et al., 2001]
(Figure 1.1).
Throughout life, the genome within cells of the human body is exposed to exogenous
and endogenous mutagens and suffers mistakes in replication, causing DNA damage.
In normal cells, these mutations are usually mitigated by DNA repair mechanisms,
and DNA damage-induced programmed cell death (apoptosis). However, occasionally
one of these mutations alters the function of a critical gene (e.g. DNA repair gene or
gene involved in apoptosis), providing a growth advantage to the cell in which it has
2http://www.gov.uk
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occurred, resulting in the emergence of an expanded clone derived from this cell (Fig-
ure 1.1). Acquisition of additional mutations that confer further advantages to the cell,
(such as an ability to evade apoptosis, an insensitivity to anti-growth signals, an unlim-
ited replicative potential, sustained angiogenesis and self-sufficiency in growth signals),
and consequent waves of clonal expansion, result in the evolution of the mutinous cells
that have the capability to invade surrounding tissues and metastasise [as reviewed in
Hanahan and Weinberg, 2000, 2011]. As can be seen from Figure 1.1, only a restricted
fraction of the cells in a primary tumour are considered to be highly metastatic, with
cells in tumour populations usually consisting of different sub-populations of cells with
distinct mutations, highlighting how phenotypically and biologically heterogeneous pri-
mary tumours are [Yokota, 2000].
Of the mutations that are implicated in cancer development, they can either be inherited
germline mutations known as risk alleles that predispose to cancer, or acquired somatic
mutations.
1.1.1 Somatic mutations
Mutations that occur during the lifetime of our cells are termed as somatic to distinguish
them from the germline mutations that are inherited from parents and passed down
to offspring [as reviewed in Stratton et al., 2009]. Cancer requires somatic acquired
changes in order to arise. Somatic mutations are thought to occur in the genomes of all
normal cells as they proceed through the rounds of cell division that take place during
development in utero and in replenishment of body tissues during postnatal life, with
additional somatic mutations accumulating during division of cancer cells [as reviewed
in Stratton, 2011]. These cancer-causing mutations occur in cancer genes, which can
be classified as either recessively acting tumour suppressor genes or dominantly acting
oncogenes [as reviewed in Stratton, 2011]. In total there are ∼400 known somatically
mutated cancer genes known to contribute to neoplastic change in one or more types
of cancer [as reviewed in Stratton, 2011].
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Figure 1.1: Malignant initiation and progression of human cancer. Pre-
malignant (benign) lesions are caused either by genetic alterations or environmental
factors which induce clonal expansion of cells. Accumulation of subsequent genetic
alterations occur in a single pre-malignant cell, converting the cell into a malignant one
which clonally expands and produces a primary tumour. New clones with invasiveness
and metastatic ability appear as a result of further acquisition of genetic alterations
conferring invasiveness and metastatic potential in cells, to produce fully malignant
cells. Adapted from Yokota [2000].
1.1.1.1 Tumour suppressors
The normal activity of tumour suppressors is to suppress growth and other behaviour
characteristics of cancer, so a loss of that activity is associated with cancer development
and progression.
Tumour suppressor genes typically have a recessive nature at the level of the cancer cell,
requiring mutation of both parental alleles of the gene, usually resulting in inactivation
of the encoded protein in order to lead to loss of function of the gene [Yang et al., 2003].
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Recessive cancer genes are characterised by a diverse pattern of mutation types, ranging
from single base substitutions to whole gene deletions, with the common outcome of
abolishing the protein function [as reviewed in Stratton et al., 2009]. In particular stop
codon mutations (stop-gained or stop-lost base substitutions) and frameshift INDELs
often result in a loss of gene function, knocking out the function of the encoded protein.
Such inactivations can also arise from epigenetic silencing [Vogelstein and Kinzler, 2004].
TP53 is an example of such a tumour suppressor gene, whose normal function as a tran-
scription factor is to upregulate expression of genes involved in cell cycle arrest [Levine,
1997], or to induce apoptosis in cells with damaged DNA independent of transcription
[Bálint E and Vousden, 2001]. TP53 is also involved in the regulation of DNA repair,
specifically through the nucleotide excision repair of UV damage, and through base
excision repair of hydrogen-peroxide induced damage [Smith and Seo, 2002]. Somatic
TP53 mutations occur in almost every type of cancer at rates from 38-50% in ovarian,
esophageal, colorectal, head and neck, larynx, and lung cancers to about 5% in primary
leukemia, sarcoma, testicular cancer, malignant melanoma, and cervical cancer [Olivier
et al., 2010]. When the function of TP53 is lost, cells can escape its apoptotic and
senescence effects causing a precancerous lesion to become cancerous [as reviewed in
Negrini et al., 2010]. Other examples of tumour suppressor genes include RB, whose
normal function is to block the cell cycle at the G1 phase [Yang et al., 2003] and BRCA1
which is normally involved in DNA damage response and repair pathways [Yang et al.,
2003]. When the normal processes of these genes are knocked out by mutation, the
genes take on the characteristics needed to facilitate cancer progression.
Tumour suppressor genes commonly become inactivated in cancer through the deletion
of one allele via a gross chromosomal event, such as the loss of an entire chromosome or
a chromosome arm, coupled with an intragenic mutation of the other allele [Vogelstein
and Kinzler, 2004]. This can result in a loss of heterozygosity (LOH). This refers to
pre-tumour cells that are heterozygous for alleles of a tumour suppressor gene (e.g. one
normal and one mutant allele), but the tumour cells have lost the normal functional
tumour suppressor allele meaning that they are no longer heterozygous. This can occur
Chapter 1. Introduction 6
either by a mutation that is inherited or a sporadic mutation that inactivates one copy
of the gene in a somatic cell. A second mutation, for example the deletion of a large
region or loss of entire chromosome in the other copy of the gene would lead to LOH in
the tumour suppressor gene and potentially have a proliferative advantage contributing
to tumourigenesis. Tumour suppressor genes can therefore be found by looking for
LOH in a tumour. If LOH is frequently seen in a specific region of the genome in
a particular tumour type, this suggests that a tumour suppressor gene that plays an
important role in the development of that tumour may be present in this region. An
example of LOH in tumour suppressor genes acting in cancer is in the DNA repair gene
BRCA2, which is known to often carry an inactivating recessive germline mutation
on one allele of the gene, conferring susceptibility to breast and ovarian cancer. This
gene is heterozygous at the germline mutant site, however a subsequent inactivating
mutation on the unaffected functioning allele of the gene can result in a LOH removing
BRCA2 activity leading to genome instability, a known mutator phenotype that can
lead to subsequent mutations driving the development and progression of cancer.
1.1.1.2 Oncogenes
Oncogenes are mutated versions of proto-oncogenes, whose normal role is typically in
promoting cell growth in the presence of a relevant growth signal [Yang et al., 2003].
The conversion of a proto-oncogene into an oncogene is often caused by a gain of
function mutation, resulting in activation of the encoded protein, conferring enhanced or
new activity [as reviewed in Stratton et al., 2009]. Oncogenes have a dominant nature,
requiring only one allele of the gene to be mutated in order to contribute to cancer
development [as reviewed in Stratton et al., 2009]. Mutations occurring in oncogenes
are therefore not likely to be knockout mutations. These changes are likely to be quite
specific in order to mediate increased expression of the gene, so high degrees of mutation
clustering are often seen in oncogenes. The repertoire of cancer-causing mutations in
oncogenes is more constrained compared to that of tumour suppressor genes, in regards
to the type of mutation class and the location of the mutation in the gene. For example,
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missense amino acid changes, in-frame indels and gene amplifications are all common
mechanisms by which oncogenes are activated, with most oncogenes activated through
genomic rearrangements such as translocations creating fusion genes [as reviewed in
Stratton et al., 2009].
Examples of known oncogenes are the RAS genes (KRAS, HRAS, and NRAS), which
encode proteins with guanosine-nucleotide binding activity and intrinsic guanosine
triphosphatase activity. When these genes are mutated in codon 12, 13, or 61, they
encode a protein that remains in the active state and continuously transduces signals by
linking tyrosine kinases to downstream serine and threonine kinases, inducing continu-
ous cell growth. Mutations of KRAS are common in carcinomas of the lung, colon, and
pancreas, whereas mutations of NRAS occur principally in acute myelogenous leukemia
and the myelodysplastic syndrome [Croce, 2008]. β-catenin is also an oncogene, involved
in cell growth and commonly mutated in colorectal cancer [Polakis et al., 1999]. Once
activated, β-catenin promotes tumour progression through persistent activation of one
of its downstream targets [Polakis, 1999].
Over 80% of known cancer genes are oncogenes. However this estimate is subject to
ascertainment bias, since most of these oncogenes are caused by chromosomal transloca-
tions and most of the ∼400 known cancer genes have been identified through cytogenetic
analyses biased towards detecting chromosomal rearrangements such as translocations
[as reviewed in Stratton, 2011].
1.1.2 Heritable cancer susceptibility
As well as somatically acquired mutations which are needed for the initiation of cancer,
germline mutations can also contribute by providing susceptibility alleles that increase
the lifetime risk of developing cancer. Germline mutations can influence cancer suscep-
tibility by directly altering the growth of the cancer clone, altering the mutation rate
in somatic cells or modulating the metabolism of carcinogens. These mutations are
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present in the fertilised egg from which the individual develops and are therefore found
in all somatic cells of the body [as reviewed in Stratton, 2011].
Well-known examples are BRCA1 and BRCA2, both of which have been identified
as genes known to contain germline mutations that confer a susceptibility towards
developing breast and ovarian cancer [Boulton, 2006, Cancer Genome Atlas Research
Network, 2011, Stephens et al., 2009]. BRCA2 was first discovered to be a germline gene
containing mutations predisposing to breast cancer in 1995 by Wooster et al. [1995].
Complete loss of either of these genes results in genome instability involving segmental
rearrangement, deletion and loss of heterozygosity in cancer [Waddell et al., 2015].
1.1.3 Viral oncogenes
Some viral genomes encode oncogenic proteins (viral oncogenes) and infection with such
viruses is associated with specific cancers. Oncogenic viruses can be broadly categorised
based on the nature of their genome as DNA or RNA viruses. Viral genomes are
commonly integrated into the cancer cell genome in order to become oncogenic [Zheng,
2010].
Examples of DNA viruses known to contribute to cancer are the human papillomavirus
which can lead to cervical cancer [Dürst et al., 1983] and head and neck cancer [Talbot
and Crawford, 2004], the Epstein Barr virus which is associated with various lymphoid
malignancies, human immunodeficiency virus (HIV) linked to non-Hodgkin lymphoma,
hepatitis B virus which can lead to liver cancer, human T-cell lymphocytic virus type 1
associated with adult T-cell leukemia/ lymphoma and human herpes virus 8 associated
with Kaposi’s sarcoma [Talbot and Crawford, 2004]. Hepatitis C is an example of an
RNA virus that is associated with liver cancer [Shiffman and Benhamou, 2015].
In addition to infection by exogenous viral genomes, the germline human genome con-
tains many integrated viral genomes (endogenous retroviruses) and other repetitive
elements that use the endogenous retroviral replication machinery (including reverse
transcriptase) to transpose (insert new copies) into the genome. The activation and
Chapter 1. Introduction 9
transposition of such endogenous elements has been implicated as a mutational process
in some cancers [Lee et al., 2012].
1.1.4 Contagious cancers
Two highly unusual cancers exist that have overcome the limitations of existing within a
single host by gaining the ability to spread between individuals [as reviewed in Murchi-
son, 2008]. Tasmanian devil facial tumour disease (DFTD) and canine transmissible
venereal tumour (CTVT) are the only known naturally occurring clonally transmissible
cancers, caused by direct communication from one host to another [Welsh, 2011].
DFTD is transmitted during fighting and courtship battles spread by the physical
transfer of facial tumour cells from one animal to another as an allograft. CTVT has
also been shown to be transmitted as an allograft, passed on during mating in which
malignant tumour cells from one dog are directly transferred to another dog via coitus,
licking, biting and sniffing of affected areas (genitals, nose and mouth) [Welsh, 2011].
DFTD is often fatal within 6 months, whereas most cases of CTVT are eventually
cleared by the host dog immune system. Tasmanian devil populations appear to be
lacking in genetic diversity which seems to result in the transplanted tumours cells not
being rejected, leading to progression of the cancer and ultimately a fatal outcome.
Although CTVT is ultimately rejected, it has been shown to develop into metastatic
CTVT in immunosuppressed dogs, supporting the idea that this contagious cancer is
cleared via immune-mediated rejection in healthy dogs [Welsh, 2011]. Accordingly, tu-
mours can be readily transmitted to immunocompromised organisms such as the nude
mouse [Xie et al., 2015]. This highlights the specific challenge that human cancer
presents - it is host-derived, so from its very starting point it is difficult for the im-
mune system to discriminate from healthy cells. There is also a similar challenge in
the treatment of human cancer; the need to identify a drug or other agent that will
specifically target a cancer cell without affecting a healthy cell, when both types are so
Chapter 1. Introduction 10
closely related. It is for these reasons we need to study the changes in cancer in detail,
as it is those specific changes that represent the targets for treatment.
1.2 The functional impact of mutations
Although somatic mutations are required for cancers to arise, not all somatic mutations
in a cancer genome contribute to the development of the tumour [as reviewed in Stratton
et al., 2009]. Based on this, each somatic mutation in a cancer cell genome can be
classified according to its functional impact, termed as either a “driver” or “passenger”
mutation.
The main focus of cancer genomics is in identifying the functionally important driver
mutations that are important in driving cancer development, and distinguishing them
from the passengers that are inconsequential to the cancer. This is vital in order to
understand the mechanisms that lead to cancer development and progression.
1.2.1 Driver mutations
Driver mutations are causally implicated in the development and progression of onco-
genesis [Pleasance et al., 2010a], occurring in cancer genes such as tumour suppressor
genes or oncogenes [Greenman et al., 2007]. It is these driver mutations that are re-
sponsible for removing function from a tumour suppressor gene or adding function to
a proto-oncogene (possibly by dis-inhibiting the encoded protein’s function through
activation).
Genes containing driver mutations are assumed to be more recurrently hit by mutation
in cancer than other genes. TP53 is an example of a validated cancer gene known to
be hit recurrently by driver mutations in many cancers [Forbes et al., 2011].
The number of driver mutations and hence the number of mutated cancer genes required
for an individual cancer to develop is speculated to be around five. However, this
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number is thought to be lower for hematopoietic cancers [as reviewed in Stratton,
2011].
1.2.2 Passenger mutations
Many other somatic mutations also accumulate in tumours, however they are not im-
plicated in oncogenesis as they do not confer a growth advantage to the cancer, and
are therefore termed passenger mutations. The passenger mutations present in cancer
cells are much more abundant than driver mutations [Bignell et al., 2010]. Although
passenger mutations do not help or hinder the cancer they can occur in genes that also
harbour driver mutations.
Although the primary target of cancer studies is to identify the driver mutations that
play a role in cancer initiation and progression with passenger mutations viewed as a
complication in the search for causal mutations, these passenger mutations can also pro-
vide a rich source of information reflecting the specific mutational processes (rather than
selection) underlying cancer in somatic cells, and hence are an important by-product
[Rubin and Green, 2009]. Such mutational trends could reflect passenger mutations
arising before carcinogenesis that are carried along by subsequent clonal expansion as
well as passenger mutations that occur within cancer cells [Rubin and Green, 2009].
1.3 Types of mutation event
Somatic driver mutations can exist in the form of point mutations (single nucleotide
variants (SNVs)), small insertions and deletions (indels), copy number variations or
large-scale genomic rearrangements caused by breakage and abnormal rejoining of DNA
[Cancer Genome Atlas Research Network, 2008, Strausberg et al., 2001]. These muta-
tions can occur in either the coding regions or non-coding regions of the human genome.
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1.3.1 Single nucleotide variants (SNVs)
Single nucleotide variants (SNVs) are the most common class of mutation in cancer [as
reviewed in Meyerson et al., 2010]. This type of mutation refers to a point substitution
in which a single nucleotide in the genome sequence is mutated. On average SNVs occur
at a rate of one per million nucleotides in human malignancies, however this number
varies between tumour types and even between individuals within tumour types [DeVita
et al., 2010].
Point substitutions can be further sub-categorised into coding and non-coding muta-
tions. Non-synonymous and synonymous mutations are both terms used to describe
mutations appearing in coding regions of the genome. Non-synonymous changes in the
DNA are those which cause a change to the encoded protein, and these are generally
known as missense mutations. Synonymous mutations, although present in coding re-
gions of the genome, do not affect the encoded protein, due to the redundancy seen
in the genome with more than one codon coding for the same amino acid. Synony-
mous mutations are generally assumed to not be as functionally important as non-
synonymous mutations are hence selectively silent, due to the fact that they do not
change the encoded protein [Massingham and Goldman, 2005]. All synonymous muta-
tions are therefore considered to be passengers with no role in oncogenesis [Youn and
Simon, 2011]. However it has been recently shown that synonymous mutations are not
necessarily selectively silent, and may be advantageous to cancer cells. Supek et al.
[2014] found that dosage-sensitive oncogenes have mutations in their 3’ UTRs that are
under selection.
Along with missense mutations, stop-gained (nonsense) and stop-lost mutations are
also considered non-synonymous single nucleotide mutations. A stop-gained mutation
refers to a point mutation which has resulted in a premature stop codon, and will likely
produce a truncated protein. A stop-lost mutation refers to the loss of a stop codon,
which can lead to reduced or a loss of protein function.
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Substitutions can be categorised into transitions and transversions depending on the
nucleotide change occurring, and more specifically on the structure of the base compo-
nent nucleotide (since nucleotides consist of a phosphate group, a pentose sugar and an
amino base) (Figure 1.2). Transitions involve a substitution between two purines or two
pyrimidine bases, whereas transversion involve the change of purine for a pyrimidine or
vice versa. Purine bases consist of two carbon rings and are larger than transversions
which have only one carbon ring.
These are twice as many possible transversions that could potentially occur in the
genome, however transition mutations occur at a significantly higher rate than transver-
sion mutations in normal human genomes. This difference is attributed to the molecular
mechanisms by which transitions are generated including the increased rate of C→T
transitions at CpG dinucleotides via a process called CpG deamination. This mecha-
nism involves a cytosine methylated at the 5-carbon undergoing hydrolytic deamination
to thymine at a relatively high rate. This mutation pattern is also observed in cancer,
with transitions found to be more frequent than transversions and CpG dinucleotides
shown to be a mutation hotspot, particularly in colorectal cancer [Rubin and Green,
2009].
1.3.2 Micro insertions and deletions (INDELs)
Small insertions and deletions (collectively termed indels) are not as abundant as single
nucleotide variants (SNVs), approximately ten-fold less common than single nucleotide
mutations [as reviewed in Meyerson et al., 2010], but can have much more damaging
effects. They frequently result in severe genetic diseases such as Tay-Sachs disease.
Indels are capable of causing frameshifts if the length of the indel is not divisible by
three, by altering the gene’s reading frame. Frameshift indels are presumed to be
deleterious to gene function [Hu and Ng, 2013], as they result in a completely different
translation of the protein, often affecting the normal stop codon which can make the
protein abnormally long or short.





















Figure 1.2: Transitions and transversions. Point mutations can be classified
according to their type of amino base substitution: transversions (TR) which involve
interchanges of purine for pyrimidine bases, and transitions (TS) which involve inter-
changes of two-ring purines (A↔G) or of one-ring pyrimidines (C↔T). A = adenine,
C = cytosine, G = guanine and T = thymine.
The other type of indel occurring in coding regions are those that have a length that is
divisible by three. These are termed “3n indels”, and result in insertions or deletions
of amino acids in the encoded protein.
1.3.3 Segmental copy number change
Copy number variants (CNVs) are a form of structural variation in the genome that
result in the cell possessing an abnormal number of copies of one or more sections of
DNA. Copy number variants can range from the gain or loss of chromosome arms (tens
of megabases) to focal amplifications and deletions (tens of kilobases) Beroukhim et al.
[2007, 2010], Bignell et al. [2010, 2004], Mullighan et al. [2007], Weir et al. [2007], Zhao
et al. [2004, 2005].
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In cancer, amplifications have been discovered in oncogenes such as MYC in aggressive
forms of breast cancer, correlating with poor prognosis and distant metastases [Singhi
et al., 2012]. Deletions in tumour suppressor genes such as PTEN in prostate cancer
have also been revealed [Dong, 2001]. A survey for somatic copy-number alterations in
cancer in Beroukhim et al. [2010] revealed repeatedly deleted and amplified sites in the
BCL2 family of apoptosis regulators and the NF- pathway.
1.3.4 Translocation
Chromosomal translocations are one of the most common types of genetic rearrange-
ment [Nambiar and Raghavan, 2011]. A translocation is an abnormal chromosome
region containing rearranged genetic material, usually from two non-homologous chro-
mosomes [as reviewed in Bunting and Nussenzweig, 2013]. Some translocations involve
the joining of a break to a sequence in the same chromosome (intra-chromosomal), how-
ever it is inter-chromosomal translocations that are usually recurrently seen in cancer
cells.
A minority of translocations form gene fusion events when two previously separated
genes become fused [as reviewed in Bunting and Nussenzweig, 2013], and most of-
ten this will cause a loss-of-function phenotype due to the genes being broken by the
translocation, sometimes inactivating tumour suppressors. For example the gene fusion
TEL1-AML can repress the expression of TEL1, a tumor suppressor gene [Nambiar
and Raghavan, 2011]. However, gene fusions can also result in oncogenes in which an
activated form of the protein is coded for by the fusion gene [Nambiar and Raghavan,
2011].
A chromosome that contains a translocation is termed a ‘derivative chromosome’, and
most are known to contain balanced reciprocal translocations. Reciprocal translocations
describe the exchange of genetic material between two chromosome arms. These can
be classified as either balanced or unbalanced, depending on whether the copy number
is affected. A balanced translocation has no affect on the overall copy number [as
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reviewed in Bunting and Nussenzweig, 2013]. Another type of translocation is the
Robertsonian translocation in which the long arms of two acrocentric chromosomes are
joined around a single centromeric region [as reviewed in Bunting and Nussenzweig,
2013]. Acrocentric chromsomes are those with centromeres situated near one end of
the chromosome, resulting in one chromosome arm being much shorter than the other.
There are five pairs of acrocentric chromosome pairs present in humans: 13, 14, 15, 21,
22.
The non-homologous end joining (NHEJ) DNA repair pathway has been shown to
contribute to the appearance of somatic chromosomal translocations by increasing the
amount of genomic instability, particularly when the much less error-prone homol-
ogous recombination DNA repair pathway is defective [as reviewed in Bunting and
Nussenzweig, 2013]. Classical non-homologous end-joining (C-NHEJ) causes a low
rate of translocations, however in its absence a NHEJ pathway called alternative end-
joining (A-EJ) or microhomology-mediated end-joining (MMEJ) becomes active and
produces an increased number of chromosome translocations. It has also been shown
that microhomology-based mechanisms are responsible for a minority of de novo human
translocations [as reviewed in Bunting and Nussenzweig, 2013]. De novo mutations are
those that are present in every cell of the body, much like a germline mutation, however
they are not present in the parents as a germline mutation would be expected to be.
This is due the mutation having occurred in a germ cell of one of the parents, or in
the fertilised egg. Supporting this mechanism of NHEJ as a source of translocation, it
has been shown that translocations between two sites are highly dependent on the fre-
quency of double-strand breaks, which are known to be repaired by NHEJ. For example,
when p53, which promotes apoptosis in cells with double-strand breaks, is deleted, the
overall frequency of translocation increases [as reviewed in Bunting and Nussenzweig,
2013], suggesting that an increase in double-strand breaks contributes to an increased
rate of translocation. Active transcription also correlates with translocation, with more
transcribed genes prone to translocation than transcriptionally silent genes [as reviewed
in Bunting and Nussenzweig, 2013].
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Chromosomal translocations, and their corresponding gene fusions, have an important
role in the initial steps of tumorigenesis [as reviewed in Mitelman et al., 2007]. His-
torically most gene fusions were found in haematological malignancies, however many
have since been found in solid tumours such as prostate cancer [as reviewed in Bunting
and Nussenzweig, 2013]. The first translocation identified in human neoplasia was
t(9;22)(q34;q11), signifying a translocation between chromosomes 9 and 22 with break-
points in bands 9q34 of BCR and 22q11 in ABL1 respectively, resulting in a fusion gene,
found in almost all cases of chronic myeloid leukemia (CML) [as reviewed in Mitelman
et al., 2007]. This translocation is known as the Philadelphia chromosome and is an
example of a balanced, reciprocal translocation between two non-homologous chromo-
somes, which causes overexpression of ABL1 [as reviewed in Mitelman et al., 2007].
This recurrent rearrangement was detected using cytogenetics, which before the advent
of second generation sequencing was used to identify chromosomal rearrangements in
relatively simple genomes such as those of leukaemias, lymphomas and sarcomas [as
reviewed in Meyerson et al., 2010]. In epithelial cancers the first two major recurrent
translocations identified were the TMPRSS2-ERG translocation in prostate cancer and
the EML4-ALK translocation in non-small cell lung cancer [as reviewed in Meyerson
et al., 2010].
The tyrosine kinase activity of BCR-ABL1 essential for cellular transformation has
been successfully targeted therapeutically in an example of personalised medicine. The
product of this translocation, a protein known as bcr-abl-tyrosine kinase, can be inhib-
ited by a specific drug called imatinib mesylate [Koss, 2007]. It is the tyrosine kinase
activity of BCR-ABL1 which is essential for cellular transformation [Deininger et al.,
2005], and that is also inhibited by the protein kinase inhibitor imatinib.
Translocations are often associated with the phenomenon known as chromothrypsis in
which one or a few chromosomes in a cancer cell harbour tens to hundreds of clustered
genome rearrangements [as reviewed in Forment et al., 2012]. This complex event is
likely to arise through chromosome breakage and inaccurate reassembly [as reviewed
in Forment et al., 2012]. The mechanism was first observed in chronic lymphocytic
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leukaemia (CLL), in which 42 genomic rearrangements were discovered in the long
arm of chromosome 4 through paired-end sequencing of a CLL genome [as reviewed
in Forment et al., 2012]. Chromothripsis occurs commonly in various human cancers,
including melanomas, sarcomas, gliomas, colorectal, oesophageal, renal and thyroid
cancers [as reviewed in Forment et al., 2012].
Chromothrypsis can also involve other chromosomal rearrangements as well as translo-
cation, such as tandem duplications, interstitial deletions and chromosomal inversions
[Zhang et al., 2013]. Similarly fusion genes are not just caused by translocations but
can also be the result of different types of chromosomal rearrangement.
1.3.5 Epimutation
While genomics involves the study of heritable or acquired alterations in the DNA
sequence, epigenetics is the study of heritable changes in gene activity caused by mech-
anisms other than DNA sequence changes. Mechanisms of epigenetic activity include
DNA methylation, small RNA-mediated regulation, DNA-protein interactions and hi-
stone modification.
Over the lineage of mitotic cell divisions from the progenitor fertilised egg, the cancer
genome can acquire epigenetic mutations. These mutations alter chromatin structure
and gene expression, manifesting at the DNA sequence level by changes in the methyla-
tion status of some cytosine residues [as reviewed in Stratton et al., 2009]. Epimutation
can also cause the abnormal transcriptional repression of active genes or the abnormal
activation of usually repressed genes in cancer.
Epigenetic mutations often affect tumour suppressor genes by functionally mirroring
loss of function mutations. For example, BRCA1 function is inactivated through
BRCA1 promoter methylation, causing transcriptional silencing, in a substantial num-
ber of triple-negative breast cancers [Xu et al., 2013]. Many cancer genes uncovered
by recent systematic sequencing encode proteins involved in chromatin modification
and remodelling. For example, the tumour suppressor genes SETD2 and MLL2 and
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the oncogene EZH2 are histone H3 methylases. The tumour suppressor genes KDM6A
and KDM5C are histone H3 demethylases. The tumour suppressors ARID1A, PBRM1,
BAP1, ATRX and DAXX are components of protein complexes responsible for restruc-
turing chromatin, and DNMT3A is involved in the maintenance of cytosine methylation
[as reviewed in Stratton, 2011]. These findings support a potentially important link be-
tween somatic mutation and epigenetic changes in some cancers.
1.4 Sources of mutation
Somatic mutations occur in the genomes of all dividing cells, both neoplastic and nor-
mal, arising as a result of misincorporation during DNA replication or through exposure
to endogenous or exogenous mutagens [Greenman et al., 2007].
In normal cells, these mutations either confer no growth or survival advantages to the
cell or they are repaired by endogenous DNA repair mechanisms. If the damaged DNA
is not able to be repaired, then the cell is programmed for apoptosis. However, in
cancer cells, mutations in genes that control DNA repair or apoptosis commonly occur,
meaning that other cancer-causing mutations in oncogenes and tumour suppressor genes
can accumulate in the cell, giving rise to a cancer.
1.4.1 Mutator phenotype
Many mutations are required for the neoplastic transformation of cells, therefore cancers
are often associated with an elevated mutation rate compared to normal cells; this is
known as a “mutator phenotype” [Loeb, 2001]. A mutator phenotype refers to a higher
mutation rate than normal during the part of the cell lineage in which predecessors of
the cancer cell already show phenotypic evidence of neoplastic change [as reviewed in
Stratton et al., 2009]. The rate of mutation acquisition can be increased by exogenous
and endogenous exposures that cause DNA damage, and can be mitigated by DNA
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repair processes, so in the event that repair processes fail, the somatic mutation rate
may also increase [as reviewed in Stratton, 2011].
There is also great variation in mutation rates between different tumour types, with
some tumour types exhibiting much higher mutation rates than others. There are
between 1000 and 10,000 somatic mutations in the genomes of most adult cancers, such
as breast, ovarian, colorectal, pancreas and glioma. However, cancers such as melanoma
and lung cancer have been shown to carry more than 100,000 mutations, with some
other cancers such as acute leukemias, medulloblastomas, carcinoids and testicular
germ cell tumours having relatively fewer mutations [as reviewed in Stratton, 2011].
Cancers with lower mutation rates tend to be childhood and young adult cancers, so
the low mutation frequency could be explained by the fact that the neoplastic cell has
been through relatively few DNA replications. For example, haematopoietic cancers
carry less than one mutation per million bases [as reviewed in Meyerson et al., 2010].
However it is also possible that a mutator phenotype is not necessary in these cancer
types for neoplastic transformation to occur. The very high prevalence of mutation
rates in some cancers is likely to be attributable to heavy mutagenic exposures such as
UV light and tobacco, the presence of known defective DNA repair mechanisms and
therapy with DNA-damaging agents [as reviewed in Stratton, 2011, Stratton et al.,
2009]. For example, melanomas known to be induced by ultraviolet radiation possess
on average ten mutations per million bases [as reviewed in Meyerson et al., 2010].
Additionally, cancers originating from epithelial cells such as colorectal, lung and gastric
cancers are also seen to exhibit a high mutation prevalence, thought to be due to the
high turnover of these cells and the fact that they are subject to recurrent exogenous
mutation exposure [Greenman et al., 2007]. These examples display the ability of
environmental exposures to increase the mutator phenotype further so that cells acquire
mutations much more quickly, increasing the lifetime risk of that cancer.
However, the variation in mutation rate between different cancers is not only at-
tributable to the mutation rate at the cell divisions that have taken place between
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the fertilised egg and the cancer cell; the number of mitoses in the lineage also account
for the differences in mutation prevalence [as reviewed in Stratton, 2011].
Cancer studies have also shown that there is wide variability in the number of somatic
changes within classes of cancer as well as between different cancer types [Greenman
et al., 2007], reflecting the different mutational processes operative in individual cancers
within a specific tumour type. For example tumours with mutations in mismatch repair
genes have higher mutation rates [as reviewed in Watson et al., 2013].
1.4.1.1 Mutational spectra
The mutational spectra are the mutational patterns incorporating information such
as the numbers of each class of mutation, the DNA sequences around each mutated
base (the sequence context) and in transcribed regions whether the transcribed or
untranscribed strand is preferentially mutated [as reviewed in Stratton, 2011]. The
mutational spectra therefore refers to the specific type of mutator phenotype.
For example, a specific mutator phenotype is observed in colorectal and endometrial
cancers, which typically exhibit elevated rates of acquisition of single nucleotide muta-
tion rates and indels at polynucleotide tracts; this is due to mutations in MLH1 and
MSH2 which cause defective DNA mismatch repair and subsequently microsatellite in-
stability [Lengauer et al., 1998]. A specific mutational signature is also known to be
associated with chemotherapy treatment. For example, in recurrent gliomas previously
treated with the DNA alkylating agent temozolomide, a very high number of mutations
with a signature typical of the therapeutic agent is observed [as reviewed in Stratton,
2011, Stratton et al., 2009].
Specific mutational spectra are also observed in cancers known to be affected by en-
vironmental mutagenic exposures. For example, lung cancers exhibit many C:G>A:T
transversions, which is a pattern similar to that induced by tobacco carcinogens in
experimental systems, suggesting that this particular mutator phenotype is caused by
the environmental carcinogen. Similarly, hepatocellular cancers also show C:G>A:T
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mutations that are likely to be caused by aflotoxins, which are known causative agents
in liver cancer development. Skin cancers show mostly C:G>T:A mutations which is a
known mutation pattern resulting from UV light, which again is a known aetiological
agent in skin cancer [as reviewed in Stratton, 2011].
As well as environmental exposures increasing mutation rate in cancer genomes, the
sequence context can also play a role, with regions of the genome known as “hotspots”
shown to be more susceptible to spontaneous mutations, showing that sporadic mu-
tations do not occur randomly across the genome. A common source of this elevated
mutation rate in hotspots is CpG deamination, the most frequent mutation observed
in the human genome. This is the process of a methylated cytosine being mutated
to thymine at CpG sites (Figure 1.3). For example, gastrointestinal tumours such as
oesophageal, colorectal and gastric have a high frequency of transitions at CpG dinu-
cleotides, which may be caused by CpG deamination reflecting increased methylation
levels in these tumours [as reviewed in Watson et al., 2013]. An additional example of
cancer types with a known mutational signature of a carcinogenesis mechanism depen-
dent on sequence context is observed in cervical, bladder, some head and neck cancers.
These cancer types frequently exhibit mutations at cytosines in the context of TpC
dinucleotides, changing the C to either a T or a G or (less often) an A. This signature
is characteristic of mutations caused by the APOBEC family of cytodine deaminases
[Lawrence et al., 2013].
Some cancers exhibit a mutator phenotype showing very large numbers of mutations
with specific mutational signatures seen in only a subclass of tumour types for which
the underlying pathogenesis is not understood. For example, in a subset of breast
cancers, sequencing of the coding sequence of 518 kinase genes revealed C>G mutations
occurring almost exclusively at cytosines following a thymine (TpC dinucleotides, with
T immediately 5’ to C) [Stephens et al., 2005]. This signature has also been seen in
other cancer types such as lung and ovarian cancer suggesting that the mutational
process underlying this profile is not specific to a single tumour type, and could be due
to a DNA repair defect or a shared mutagenic exposure [Greenman et al., 2007]. Other












Figure 1.3: CpG deamination. A methylated cytosine in a CpG island is mutated
to a thymine during the process of CpG deamination.
less well characterised mutational spectra can also result in chromosomal abnormalities
affecting chromosome number or increased rates of genomic rearrangement [Lengauer
et al., 1998]. For example, some breast cancers exhibit frequent tandem duplications,
for which the underlying mutagenic or DNA repair processes are unknown [as reviewed
in Stratton, 2011].
1.4.2 DNA replication errors
In normal cells, DNA is replicated with extraordinary fidelity (∼10-10 mutations per
base pair per cell division), achieved through a combination of polymerase base se-
lectivity, intrinsic proofreading 3’→5’ exonucleolytic activity and base-base mismatch
correction. There are three primary eukaryotic DNA polymerase replicative enzymes
functioning at DNA replication forks: Pol α (primase), Pol δ and Pol ε. Pol δ and Pol ε
are responsible for DNA synthesis on the lagging and leading strand respectively, with
polymerase domains (POL) within these polymerases discriminating between correct
and incorrect dNTPs prior to phosphodiester bond formation. DNA polymerase errors
occurring during DNA synthesis are corrected by the proofreading exonuclease (EXO)
present in each polymerase. Any base-base mispairs or primer-template slippage errors





















Figure 1.4: DNA replication. DNA is synthesised by polymerases α, δ and ε. The
polymerase domains (POL) of these three polymerases recruit dNTPs to the growing
DNA strand. The 3’→5’ proofreading exonucleases (EXO) present in Pol δ and Pol ε
correct any errors made by the polymerase domains. MMR corrects base-base mispairs
not fixed by the EXO domains, acting on both the leading and lagging strands (shown
only on the lagging strand here). Adapted from [Preston et al., 2010].
not successfully corrected by the proofreading machinery are repaired by MMR genes
by excising the errant bases (Figure 1.4). The role of Pol α is in priming both leading
and lagging strand syntheses, copying relatively short stretches of DNA, whereas Pol δ
and Pol ε synthesise the bulk of chromosomal DNA during cell division [Preston et al.,
2010].
In cancer it is the rare somatic copying errors made through DNA replication that can
go on to contribute to the initiation and development of cancer. If these mutations
are in the DNA replication machinery, such as polymerase genes, this can cause more
mutations to occur during DNA replication which in turn increases the risk of developing
cancer. The more mutations in different genes and the more that goes wrong in the
cell, the higher the chance of a cancer developing.
1.4.2.1 Base selectivity in Pol δ and Pol ε
It is estimated that each time a diploid mammalian cell replicates, replicative eukaryotic
DNA polymerases make approximately 100,000-1,000,000 errors per day [Preston et al.,
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2010], in which a non-complementary base is incorporated into the daughter strand.
The majority of these errors are base-base mispairs and ±1 slippage events. These
errors must be corrected by proofreading and MMR with almost 100% efficiency to
achieve a spontaneous mutation rate of ∼1010 per base pair per cell division, in order
to suppress a mutator phenotype that could lead to spontaneous tumorigenesis. Indeed,
mutations affecting base selectivity in Pol δ and Pol ε have been shown to confer mutator
phenotypes in yeast and mice [Preston et al., 2010].
1.4.2.2 Polymerase proofreading
Spontaneous errors made by the leading and lagging strand polymerases, Pol ε and
Pol δ respectively, trigger proofreading by their intrinsic 3’→5’ exonucleases. A third
eukaryotic polymerase, Pol γ, also has intrinsic 3’→5’ exonucleolytic proofreading ac-
tivity, however Pol γ is mitochondrial while Pol δ and Pol ε are nuclear [Preston et al.,
2010]. In yeast, point mutations that selectively inactivate exonucleolytic proofreading
activities of Pol δ and Pol ε confer moderate to strong mutator phenotypes [Preston
et al., 2010]. Mice studies show that a knock-in mutation in the exonuclease domain
of Pol δ leads to spontaneous formation of epithelial cancers in lung, thymus and skin;
and in engineered mice with defective Pol ε proofreading, mice exhibit a susceptibility
to developing spontaneous intestinal adenocarcinomas [Preston et al., 2010].
1.4.2.3 Mismatch repair (MMR)
Errors escaping proofreading activity during replication are corrected by MMR machin-
ery. There are two partially redundant pathways of the MMR system, depending on
the type of error: mispair mutations are repaired by the MutSα complex and primer-
template errors are repaired by either the MutSα or MutSβ complex (Figure 1.5).
The failure to repair the errors escaping proofreading through MMR has been shown to
contribute to cancer progression. For example, colorectal, gastric, ovarian, emdometrial
and lung cancers often display inactivation of the MMR pathway through mutation of











Figure 1.5: MMR pathways. Errors that escape 3’→5’ exonucleolytic proofreading
can be corrected by two MMR pathways: MutSα or MutSβ. If the error is a base-
base mispair, MutSα is employed to repair, however if a primer-template slippage has
occurred then MutSα or Mutβ can be recruited to fix the error. Adapted from [Preston
et al., 2010].
MMR genes which in turn results in a high incidence of indels at simple sequence repeats
known as microsatellite instability (MSI), as well as an increased SNV load [Preston
et al., 2010, Supek and Lehner, 2015]. Germline mutations have also been found in
MMR genes. For example, mutations in MSH2, the gene encoding one of the key
proteins required for MMR in both MutSα and MutSβ are frequently seen in hereditary
non-polyposis colorectal cancer (HNPCC) [Preston et al., 2010]. MLH1, another gene
required for MMR in both complexes, is also found to have mutations in HNPCC
families [Preston et al., 2010]. The majority of HNPCC patients inherit a mutation in
either MSH2 or MLH1, and a smaller percentage inherit mutations in PMS2 or MSH6.
HNPCC is known to increase the risk of developing colorectal cancer, which develops
when the wild-type allele is lost usually through LOH or gene silencing. However,
inherited MMR deficiency is only responsible for a small percentage of colorectal cancer
cases (1-5%) with most colorectal cancer cases with MSI resulting from acquired defects
in MMR, usually due to MLH1 promoter hypermethylation.
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MMR deficiency in some cancers has been shown to cause an unusual regional mutation
rate variation pattern [Supek and Lehner, 2015], which sheds light on the mechanism of
MMR and how it is related to chromatin structure. Schuster-Böckler and Lehner [2012]
show that the variation in regional mutation rate observed across the cancer genome is
determined by chromatin organisation, with cancer SNV density highly correlating with
genetic and epigenetic features of somatic cell chromatin structure. SNV density was
found to anti-correlate with early replication timing, associated with open chromatin
(euchromatin), and positively correlate with repressive histone modifications, such as
H3K9me3 marks associated with closed chromatin (heterochromatin), with mutation
rates elevated in more late-replicating heterochromatin-like domains and repressed in
early-replicating euchromatin regions [Schuster-Böckler and Lehner, 2012]. The asso-
ciation between chromatin structure and mutation rate variation is also shown to be
upheld over diverse tissue types (eg. melanoma, lung cancer, prostate cancer, leukemia),
mutation types (eg. transitions vs transversions, CpG vs non-CpG mutations) and ge-
nomic regions (eg. genic vs non-genic regions) [Schuster-Böckler and Lehner, 2012].
Supek and Lehner [2015] have used TCGA cancer data to investigate the mechanism
responsible for this chromatin-dependent variation in mutation rate across the genome.
They concluded that differential DNA repair rather than differential mutation supply
is the primary cause of fluctuating mutation rate across the genome. More specifically
they have shown that MMR is the underlying factor affecting the varying mutation rate,
with MMR-deficient cancers showing no reduction in mutation rates in early-replicating
euchromatin compared to late-replicating heterochromatin as is seen in MMR-proficient
cancers, with a very high mutation prevalence observed genome-wide in MMR-deficient
cancers (Figure 1.6). In MMR-proficient cancers, MMR is therefore more effective at
repairing replication errors in euchromatin early replicating regions than in late replicat-
ing heterochromatin. This increased efficiency in early replicating euchromatin could
be due to increased DNA accessibility to repair machinery in open chromatin, more
time available for repair, or the fact that most genes performing essential functions are
in euchromatin and replicated early so enhanced MMR has been evolutionarily selected
for in these regions of the genome as it is beneficial to the survival of the organism







































Figure 1.6: Variation in regional mutation rate explained by mismatch
repair (MMR). In MMR-proficient cancer genomes a variable mutation rate pattern
is observed in which the mutation rate is increased in late-replicating heterochromatin
compared to early-replicating euchromatin. In MMR-deficient cancer genomes, the
mutation rate pattern flattens, with an elevated mutation rate observed genome-wide,
suggesting that MMR is more effective in early-replicating euchromatin, suppressing
the accumulation of mutations in these regions.
[Supek and Lehner, 2015].
1.4.2.4 Proofreading and MMR acting in synergy
Proofreading and MMR have been shown to exhibit a synergistic relationship in the
repair of replication errors, with deficiencies in one being compensated by the function
of the other, and the loss of both pathways resulting in the accumulation of replication
errors [Preston et al., 2010].
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1.4.3 Environmental mutagenesis
Somatic spontaneous mutations occur in the genomes of normal cells as they go through
the cell cycle at a low frequency (i.e. replication errors). However, the rate at which
these cells acquire mutations can be increased by various environmental factors, all of
which are known to elevate the lifetime risk of cancer [as reviewed in Stratton, 2011].
The environmental exposure can sometimes induce a specific mutational spectrum in
the cancer sample. For example, lung tumours have a high proportion of G→T transver-
sions, attributable to exposure to polycyclic aromatic hydrocarbons from tobacco smoke
[as reviewed in Watson et al., 2013]. Melanomas are also known to exhibit a specific
mutational spectrum of an elevated proportion of C→T transitions in dipyrimidines,
caused by ultraviolet (UV) radiation-induced DNA damage and misrepair [Pleasance
et al., 2010a].
1.4.4 Oxidative DNA damage
Reactive oxygen species (ROS) include free radicals and non-radical species, which are
produced as by-products of normal cell metabolism, and have the potential to damage
proteins, lipids, carbohydrates, and nucleic acids. In normal cells, ROS-induced dam-
age is counteracted by defences including enzymes (catalase, superoxide dismutase,
glutathione peroxidase), as well as small molecular weight antioxidants both of endoge-
nous synthesis (glutathione, ubiquinol) and of dietary origin (vitamin C, vitamin E,
carotenes) [de Cavanagh et al., 2002]. As a result, a balance is established between the
generation and destruction of ROS, minimizing the damage to physiologically relevant
biomolecules.
Oxidative stress is an endogenous source of somatic mutation in cancer, and is defined
as a disturbance in the balance between the production of ROS and antioxidant defences
[Betteridge, 2000], in favour of a higher level of ROS [de Cavanagh et al., 2002]. For
example, a mitochondrial antioxidant enzyme MnSOD is found to be present at altered
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levels in most types of primary cancers and cell line cancers compared to the control
[Oberley, 2002].
1.4.5 Defects in repair processes
Cancer is a disease caused by damage to DNA, therefore how the damaged DNA is
repaired plays an important role in the development of cancer. DNA damaged by
intrinsic mechanisms such as replication defects and oxidative DNA damage as well as
exogenous environmental mutagenesis, are all repaired by various different endogenous
DNA damage repair mechanisms depending on the type of mutation incurred [Boulton,
2010]. In cancer, mutations often occur in DNA repair genes, preventing the repair of
mutation and increasing the risk of developing cancer.
There are several hereditary human diseases known to predispose to cancer that are
caused by defects in DNA repair mechanisms. For example, Xeroderma pigmentosum
and hereditary non-polyposis colorectal cancer that confers susceptibility to skin and
colorectal cancer respectively [Cleaver, 2005, Müller and Fishel, 2002].
1.4.5.1 Homologous recombination (HR)
Homologous recombination (HR) is responsible for repairing double-strand breaks (DSBs),
which occur if DNA is damaged in the S or G2 phase of the cell cycle, since there are
two copies of each chromosome in this stage of the cycle. Of all repair pathways avail-
able for the repair of DSBs, HR is the least error-prone as it is template-based. DSBs
are commonly caused by chemotherapy in cancer treatment.
Both BRCA1 and BRCA2, tumour suppressor genes linked to the development of in-
herited breast and ovarian cancer, have been found to be vital components of the ho-
mologous recombination machinery [Boulton, 2006, 2010]. 80% of people with germline
mutations in BRCA1 or BRCA2 will develop breast cancer by the age of 70 years [Boul-
ton, 2006]. BRCA2 is responsible for recruiting and loading the RAD51 repair protein
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onto DSBs, whilst BRCA1 signals the presence of DSBs to the cell cycle, although its
exact function in suppressing cancer development is unclear [Boulton, 2010]. It has
been shown in mice knock-out models, that the deletion of BRCA1 does not allow
the DSB to be processed and fixed by HR, allowing 53BP1 to inhibit DSB processing,
contributing to tumourigenesis [Bouwman et al., 2010, Bunting et al., 2010]. However,
this phenotype is rescued by also knocking out the 53BP1 protein in BRCA1-deficient
cells, which relieves the inhibition of DSB processing, so homologous recombination is
restored and the risk of developing cancer is suppressed once more. This finding is very
promising in terms of personalised medicine, as it has been proposed by Bunting et al.
[2010] that 53BP1 inhibitors could be used to treat carriers of BRCA1 mutations, to
suppress their susceptibility to tumour formation.
1.4.5.2 Classical non-homologous end joining (C-NHEJ)
Classical non-homologous end joining (C-NHEJ) is the only double strand break repair
pathway that can join DNA ends with no homology at the repair site [as reviewed in
Bunting and Nussenzweig, 2013].
C-NHEJ involves the binding of the heterodimer Ku70Ku80 to the DNA break, followed
by the recruitment of DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
and several other factors that mediate blunt-end ligation of the break by DNA ligase 4
(LIG4) [as reviewed in Bunting and Nussenzweig, 2013].
NHEJ has been implicated as a key source of genomic rearrangements in cancer, espe-
cially complex chromosome translocations that are associated with chromothrypsis [as
reviewed in Bunting and Nussenzweig, 2013].
Chapter 1. Introduction 32
1.4.5.3 Alternative end-joining (A-EJ)/ Microhomology-mediated end-joining
(MMEJ)
Alternative end-joining (A-EJ) uses microhomology to fix DSBs, and has been shown to
be the compensatory mechanism in HR-deficient cancers when homologous recombina-
tion is defective. However, like C-NHEJ, A-EJ is far more error-prone than HR, and so
causes a higher mutation rate [Ceccaldi et al., 2015]. POLQ has been implicated in this
pathway, shown to have increased expression levels in HR-deficient cancers [Ceccaldi
et al., 2015].
In cancer cells, A-EJ pathways join DSBs in aberrant ways which promote cancer
growth. This pathway, like C-NHEJ, also gives rise to an increased rate of translocations
[as reviewed in Bunting and Nussenzweig, 2013].
1.4.5.4 Nucleotide-excision repair (NER)
Nucleotide excision repair (NER) is another repair process that is disrupted in cancer
[Leibeling et al., 2006]. NER removes primarily bulky, helix-distorting adducts. These
substrates include cis-syn-cyclobutane dimers (CPDs) and pyrimidine (6-4) pyrimidone
photoproducts, both of which are formed between adjacent pyrimidines and are induced
by UV light [de Boer and Hoeijmakers, 2000]. Other NER substrates include bulky
chemical adducts such as large polycyclic aromatic hydrocarbons induced by compounds
in cigarette smoke; and distorting interstrand crosslinks induced by chemotherapeutic
agents such as cisplatin [de Boer and Hoeijmakers, 2000].
Defects in NER are associated with the hereditary human disease Xeroderma pigmen-
tosa [Cleaver, 2005], which is known to predispose to the development of skin cancer.
1.4.5.5 Base-excision repair (BER)
It is estimated that ∼20,000 potentially mutagenic lesions arise per diploid mammalian
cell per day as a result of intrinsic sources such as chemical instability of DNA under
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physiological conditions and exposure of DNA to active oxygen. The majority of these
mutations are repaired by base-excision repair (BER), which must occur efficiently
prior to DNA replication in order to minimise spontaneous mutation rate [Preston
et al., 2010]. BER is considered as the main pathway involved in removal of minor
base damage induced by alkylating and oxidising agents, which are generally not helix
distorting [de Boer and Hoeijmakers, 2000].
1.4.5.6 Mismatch repair (MMR)
Mismatch repair (MMR) is also a type of excision repair. MMR is a process by which
base-base mismatches and insertion-deletion loops which arise as a consequence of DNA
polymerase slippage during DNA replication are eliminated. However, in cancer this
process is sometimes defective. Mutation rates in tumour cells with MMR deficiency
are 100 to 1000-fold as compared with normal cells. For example, this is known to occur
in hereditary non-polyposis colon cancer in MSH2 and MLH1 [Müller and Fishel, 2002,
Peltomäki, 2001]. This mechanism is involved in the replication process, repairing base
pair mismatches that have escaped polymerase proofreading during DNA synthesis.
However, MMR machinery is also involved in apoptosis [Preston et al., 2010].
1.4.6 Structural genome instability
Genomic instability is characteristic of most human cancers [as reviewed in Negrini
et al., 2010]. There are various forms of genomic instability: chromosome instability
(CIN), microsatellite instability (MIN or MSI) and forms of genetic instability charac-
terised by increased frequencies of base-pair mutations [as reviewed in Negrini et al.,
2010]. It is well established that chromosome instability (CIN) and microsatellite in-
stability (MIN or MSI) predispose to cancer [Preston et al., 2010], and in hereditary
cancers is known to result from mutations in DNA repair genes [as reviewed in Negrini
et al., 2010]. However in sporadic cancers, the molecular basis of genomic stability is
less clear [as reviewed in Negrini et al., 2010].
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1.4.6.1 Chromosome instability (CIN)
CIN is the major form of genetic instability in human cancers. This refers to the high
rate by which chromosome structure and number changes over time in cancer cells
compared to normal cells [as reviewed in Negrini et al., 2010].
In hereditary cancers, the presence of CIN has been linked to mutations in DNA repair
genes. For example, germline mutations in genes associated with the repair of DSBs or
DNA interstrand cross links such as BRCA1, BRCA2, PALB2, BRIP1, RAD50, NBS1,
WRN, BLM and RECQL4 predispose to the development of various cancers including
breast, ovarian, leukemia and lymphoma [as reviewed in Negrini et al., 2010].
CIN characterises almost all sporadic human cancers, however rather than mutations
in DNA repair genes or other caretaker genes, it is possible that oncogene-induced
DNA replication stress is responsible for this genomic instability in human cancers [as
reviewed in Negrini et al., 2010]. According to this model, activated oncogenes induce
genomic instability through the mechanism of DNA replication stress. This is supported
by the findings that genomic instability preferentially affects common fragile sites which
are known to be particularly sensitive to DNA replication stress [as reviewed in Negrini
et al., 2010].
1.4.6.2 Microsatellite instability (MIN/ MSI)
Microsatellite instability (MIN) is a form of structural genome instability that is charac-
terised by the expansion or contraction of the number of oligonucleotide repeats present
in microsatellite sequences [as reviewed in Negrini et al., 2010]. These insertions and
deletions determined by MSI are often >8bp.
MIN is a hallmark of MMR loss, particularly relevant for colorectal cancer because
many of the genes involved in colorectal cancers have repetitive DNA in their coding
regions (e.g. APC, KRAS, BRAF) [Preston et al., 2010]. One of the best documented
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occurrences of MIN is in hereditary non-polyposis colon cancer, in which mutations in
DNA MMR genes such as MSH2 lead to MIN [Fishel et al., 1994].
1.4.7 Genome editing
Genome editing is an approach used to generate desired genetic modifications, and
is enabled by the induction of a DSB in a specific genomic target sequence. The
modifications are then created during endogenous subsequent DNA break repair [Urnov
et al., 2010]. This method exploits how DNA is damaged in cancer cells in order to
treat cancer.
This process is carried out using a zinc finger nuclease (ZFN), a sequence specific
endonuclease that can cleave the chosen target. ZFN-mediated gene disruption has
been applied to cancer therapy, specifically in the treatment of glioblastoma. In this
case the glucocorticoid receptor gene is disrupted.
The type II bacterial CRISPR(clustered, regularly interspaced, short pallindromic repeats)-
Cas9(CRISPR-associated protein) system can be engineered to introduce RNA-directed
DSBs using a mutated form of Cas9. CRISPR-Cas9-based genome editing enables the
rapid genetic manipulation of any genomic locus without the need for gene targeting by
homologous recombination, providing a simple strategy to develop conditional, ‘dele-
tion’ models in vivo in mice in less than six months. This is a flexible, fast and low-cost
platform to study gene function [Dow et al., 2015].
1.5 Detecting mutations
A central goal of cancer genetics is to identify cancer genes carrying driver mutations,
and distinguish those drivers from the more abundant but inconsequential passenger
mutations that are present in tumours. Many studies have attempted to do this; such
work has provided insights into the genetics of cancer initiation and progression.
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Traditionally, linkage and association studies were used to identify heritable cancer pre-
disposing mutations (e.g. the germline mutation BRCA2 which predisposes to breast
and ovarian cancer). For the identification of somatic changes a candidate screening
approach was typically adopted, in which candidate genes were PCR amplified and se-
quenced in tumours and their matched somatic tissue using capillary Sanger sequencing
[Bignell et al., 2006]. These candidates came from identified germline genes in linkage
and association studies as well as being based on functional candidacy (e.g. a gene that
is in the same pathway as a known germline mutated cancer gene, such as BRCA2, is
a candidate for these somatic mutation analysis studies). Using a candidate approach,
the first driver mutation in cancer was identified around 1980 in codon 12 of the onco-
gene HRAS; a G>T substitution causing a glycine to valine change [Reddy et al., 1982,
Tabin et al., 1982]. However, this approach is limited to screening what is known, and
does not have the ability to discover novel cancer genes.
The field of cancer genomics is, however, now in the process of being transformed by
advances in DNA sequencing technology, and with the recent advent of more econom-
ical methods such as next-generation sequencing it is possible to sequence a whole
cancer genome to detect somatic cancer-causing mutations. This is much faster and
cheaper than previously used traditional Sanger sequencing techniques. While these
next-generation sequencing prices are falling it is still expensive to sequence a whole
cancer genome, however we can now use established techniques such as targeted exome
capture to sequence just the exomes of cancer genomes.
1.5.1 DNA sequencing technologies
DNA sequencing is the process of determining the precise order of the four bases in the
genome: adenine (A), cytosine (C), guanine (G) and thymine (T).
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1.5.1.1 Sanger sequencing
Since the early 1990s, DNA has been sequenced using capillary-based, semi-automated
implementations of the Sanger biochemistry (Figure 1.7).
DNA to be sequenced is first prepared in one of two ways: for shotgun de novo se-
quencing, randomly fragmented DNA is cloned into a high-copy-number plasmid which
is then used to transform Escherichia coli (shown in Figure 1.7); or for targeted rese-
quencing (in cases where a reference sequence is available; the approach adopted after
the completion of the human genome sequencing project), PCR amplification is carried
out with primers that flank the target. This results in amplified templates of the DNA
sequence to be sequenced, either in the form of many clonal copies of a single plasmid
insert present within a spatially isolated bacterial colony that can be picked, or as many
PCR amplicons present within a single reaction volume [as reviewed in Shendure and
Ji, 2008].
Sequencing takes place as a ‘cycle sequencing’ reaction, in which cycles of template
denaturation, primer annealing and primer extension are performed. The primer is
complementary to the flanking sequence of the region of interest. For each round of the
primer extension, deoxynucelotides (dNTPs) are added to the reaction and polymerase
is used to synthesise a new strand complementary to the template. The primer exten-
sion is randomly terminated by the incorporation of fluorescently-labelled dideoxynu-
cleotides (ddNTPs), with each of the four different ddNTPs (ddATP, ddCTP, ddGTP
and ddTTP) carrying a different fluorescent label. ddNTPs differ from dNTPs by the
lack of a free 3’ OH group on the five-carbon sugar, so if a ddNTP is added to a growing
DNA strand then the chain is terminated as there is no free 3’ OH group available for
the addition of another dNTP. In the resulting mixture of end-labelled extension frag-
ments, the label on the terminating ddNTP of any given fragment therefore identifies
the nucleotide at the terminating position [as reviewed in Shendure and Ji, 2008].
The sequence is then determined using high-resolution electrophoretic separation of
the single-stranded fragments in the mixture of end-labelled extension products, in a
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Figure 1.7: Sanger capillary sequencing. In high-throughput shotgun Sanger
sequencing, DNA is fragmented, cloned to a plasmid vector and used to transform
E. coli. Then for each cycle sequencing reaction, a single bacterial colony is picked
and the plasmid DNA is isolated, before a ladder of ddNTP-terminated, dye-labelled
products is generated (within a microliter-scale volume). These are subjected to high-
resolution electrophoretic separation within one of 96 or 384 capillaries in one run of
a sequencing instrument. The fluorescently labelled fragments of discrete size pass
a detector, generating a sequence trace using the four-channel emission spectrum.
Adapted from Shendure and Ji [2008].
capillary-based polymer gel, to separate the fragments by size. This can be carried
out simultaneously in 96 or 384 independent capillaries, providing a limited level of
parallelisation. Laser excitation of fluorescent labels as fragments of discreet lengths
exit the capillary, together with four-colour detection of emission spectra, provides the
readout as a Sanger sequencing ‘trace’ [as reviewed in Shendure and Ji, 2008].
1.5.1.2 Next-generation sequencing
Next-generation sequencing (NGS) instruments provide higher throughput than tradi-
tional Sanger sequencing at an unprecedented speed by sequencing millions of short
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DNA fragments in parallel (Figure 1.8). The various platforms used to perform next-
generation sequencing include: 454, Illumina (Solexa), SOLiD and Polonator [as re-
viewed in Shendure and Ji, 2008]. The most widely used platform is Illumina, launched
in 2006 [Pabinger et al., 2014]. Illumina sequences DNA by measuring and analysing
signals which are emitted during the creation of the second DNA strand. In order to
produce detectable signals, template DNA is fragmented into small pieces, amplified
and immobilised on a glass slide before sequencing. Illumina applies a sequencing-by-
synthesis approach where only 1nt per sequencing cycle is incorporated using reversible
dye terminators [Pabinger et al., 2014]. This particular platform has the benefit of
being able to avoid problems when sequencing homopolymers (consecutive instances of
the same base, eg. AAA or GGG) longer than 8bp encountered by other platforms such
as Roche 454, which makes Illumina more suitable for identifying INDELs. However
this comes at the cost of only being able to sequence shorter fragments in Illumina
[Pabinger et al., 2014].
As in Sanger sequencing, the first step in next-generation (cyclic-array) sequencing is the
preparation of a library containing DNA templates for sequencing. This is accomplished
by the random fragmentation of DNA, followed by in vitro ligation of common adapter
sequences [as reviewed in Shendure and Ji, 2008].
The generation of clonally clustered amplicons to serve as sequencing features is then
achieved through various approaches depending on the platform. Illumina relies on
bridge-PCR (aka ‘cluster PCR’) to clonally amplify sequencing features, whereas 454,
SOLiD and Polonator all use emulsion PCR. In the bridge PCR approach adopted in
Illumina platform (Figure 1.9), both forward and reverse PCR primers are tethered
to a solid substrate by a flexible linker, so that all amplicons arising from any single
template molecule during the amplification remain immobilised and clustered to a single
physical location on the array. Extension is carried out using a Bst polymerase, and
the double stranded sequence is denatured using formamide. The resulting clusters of
amplified template consist of ∼1,000 clonal amplicons, and several million clusters can
be amplified to specific locations within each of the eight lanes on a single flow-cell.
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Figure 1.8: Next-generation sequencing. In cyclic-array shotgun sequencing,
common adaptors are ligated to fragmented DNA. An array of millions of spatially
immobilised PCR colonies (‘polonies’) are then generated using various different meth-
ods (e.g. bridge PCR used by the Illumina platform), with each polony consisting of
many copies of a single shotgun library fragment. All array features are then se-
quenced in parallel, using primer hybridisation, enzymatic extension reactions and
imaging-based detection of fluorescent labels incorporated with each extension. A
contiguous sequencing read for each array feature is built up using successive itera-
tions of enzymatic interrogation and imaging. Adapted from Shendure and Ji [2008].
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Figure 1.9: Illumina bridge PCR. Using the Illumina Genome Analyser (‘the
Solexa’) as a platform, amplified sequencing features are generated by bridge PCR.
The resulting clusters consist of ∼1000 clonal amplicons. An in vitro-constructed
adaptor-flanked shotgun library is PCR amplified, with both primers attached at their
5’ ends by a flexible linker densely coating the surface of a solid substrate (flow-cell). As
a consequence of this set-up, amplification products originating from a single member
of the template library will remain locally tethered near the point of origin. Adapted
from Shendure and Ji [2008].
Therefore, eight independent libraries can be sequenced in parallel in the subsequent
step, during the same instrument run [as reviewed in Shendure and Ji, 2008].
For the sequencing step, 454 and Illumina both use polymerase for their sequencing-
by-synthesis with 454 using pyrosequencing and Illumina using reversible terminators
(Figure 1.10). Both SOLiD and Polonator use ligase to synthesise with SOLid using oc-
tamers with two-base encoding and Polonator using nonamers to do this [as reviewed in
Shendure and Ji, 2008]. In Illumina sequencing, after cluster generation, the amplicons
are single stranded by linearisation and a sequencing primer is hybridised to a universal
sequence immediately flanking the region of interest. Each cycle of sequence interro-
gation then consists of single-base extension with a modified DNA polymerase and a
















Figure 1.10: Illumina sequencing. With the Solexa technology, each sequencing
cycle includes the simultaneous addition of a mixture of four modified deoxynucleotide
species each bearing one of four fluorescent labels and a reversibly terminating moiety
at the 3’ hydroxyl position. A modified DNA polymerase drives simultaneous extension
of primed sequencing features. This is followed by imaging in four channels and then
cleavage of both the fluorescent labels and the terminating moiety, before the next
cycle. Adapted from Shendure and Ji [2008].
mixture of four fluorescently labelled nucleotides, with each chemically cleavable label
corresponding to the identity of the nucleotide. These modified nucleotides are also
‘reversible terminators’ with a chemically cleavable moiety at the 3’ hydroxyl position,
which allows only one base to be incorporated in each cycle. After single-base extension
and acquisition of images in four channels, chemical cleavage of both groups sets up
for the next cycle, hence why the nucleotides are known as reversible terminators [as
reviewed in Shendure and Ji, 2008].
1.5.1.3 Targeted exome capture and sequencing
Exome sequencing (exome-seq) is performed using exome capture followed by next-
generation sequencing, to capture reads covering the exonic regions of the human
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Figure 1.11: Targeted exome capture. This approach can be applied to any
region of interest, but in the case of targeted exome capture the gene-specific oligonu-
cleotides capture just the exons in genes in the whole exome. Exons are captured from
both tumour DNA (left panel) and normal DNA (right panel). DNA from the starting
material (pond) is sheared and hybridised to the oligonucleotides that are specific to
exons only. The baits have tags that allow them to be isolated, by immobilisation on
beads for example as shown here. Captured DNA in then eluted and prepared into
sequencing libraries for sequencing. Adapted from Meyerson et al. [2010].
genome only. This is done using hybridisation to target the exome sequences (Fig-
ure 1.11). The exome encompasses the protein-coding regions of the genome, which
consists of the exons of genes only. The remainder of the genome, including the introns
of genes, is not translated into proteins and therefore is less likely to contain func-
tionally important driver mutations. Exome sequencing is also currently much more
economical than whole-genome sequencing, in terms of cost and time, since the ex-
ome only constitutes ∼ 1% of the genome [Chilamakuri et al., 2014, Meynert et al.,
2013, Rabbani et al., 2014]. For these reasons, cancer studies have focused mainly on
detecting mutations in whole-exomes rather then whole-genomes.
Target sizes of 35 to 50Mb are standard in exome capture, compared to the 3200Mb size
Chapter 1. Introduction 44
of the haploid genome. A typical targeted exome would encompass both protein-coding
regions, other functional regions of interest such as promoters, enhancers and regulatory
RNA genes, as well an some intronic regions. It is possible to see intronic and other
non-coding variants in exome capture data for three reasons: probe design, alternative
splicing and non-specific target capture [Meynert et al., 2013]. In targeted sequence
capture, the probe is designed to have a minimum length of 120-200bp. This means
that if an exon is shorter than the probe, some of the intronic sequences surrounding
the exon will also be captured. Alternatively, if the exon is larger than the probe, then
several probes will be needed to capture the exon, which also results in intronic variants
being inadvertently captured. Often, depending on the kit being used, a proportion of
the downstream splice junction is also captured (up to 10bp). Alternative splicing can
also play a role, since genes with multiple transcript types will have a particular exon
present in one transcript but not in another. Therefore variants in that exon can be
considered exonic in some cases and intronic in others. Finally, it is possible that up
to 50% of the sequence reads can be off-target, aligning to introns instead of exons.
A caveat of exome sequencing is that some exome-seq targets do not achieve sufficient
mapped read depth for variant detection, due to technical difficulties or probe fail-
ures. This is compared to whole-genome sequencing which has a greater uniformity
of sequence read coverage and reduced biases in the detection of non-reference alleles
[Meynert et al., 2014].
1.5.1.4 Whole-genome sequencing
Whole-genome sequencing provides a complete view of the human genome, including
the ability to detect mutations in distant enhancers and other regulatory elements
such as promoters, and other non-coding regions such as introns and non-coding RNAs
(including microRNAs), that are not captured in whole-exome sequencing [Pabinger
et al., 2014].
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The major potential of whole-genome sequencing for cancer is in the discovery of chro-
mosomal rearrangements which cannot easily be identified using exome sequencing,
including rearrangements of repetitive elements (e.g. active retrotransposons which
have been suggested to be involved in cancer) [as reviewed in Meyerson et al., 2010].
1.5.1.5 The challenge of tumour heterogeneity
The cellular heterogeneity of tumours poses a major challenge for the reliable detection
of genetic changes. The primary (solid) tumour is invariably infiltrated by a mixed pop-
ulation of non-cancerous cells, for example macrophages, endothelial cells and normal
cells from the tissue of origin [as reviewed in Meyerson et al., 2010]. Cancer sequencing
projects often attempt to minimise such issues by requiring tumour samples sent for
sequencing to contain >80% abnormal cells as scored by a pathologist [Cancer Genome
Atlas Research Network, 2008].
The second challenge of heterogeneity is that there are often sub-populations within
the wider population of cancer cells in a tumour [Cleary et al., 2014]. Measured sub-
populations can harbour distinct mutations, varying between regions of the tumour, be-
tween metastases and over time [Burrell et al., 2013]. Assuming (as is typically assumed)
that the cancerous cells of a tumour are monoclonal in origin, then the mutations lead-
ing to the development of the cancer and the earliest mutations post-transformation
are likely to be common to all cancerous cells in the tumour (excepting the possibility
of subsequent deletion). Most recent mutations however are likely to be present at a
lower frequency in the analysed tumour sample and are challenging to discriminate from
assaying or sequencing errors. Despite these challenges arising from heterogeneity, the
alternative is to use tumour derived cell lines which is potentially more problematic,
as the cells that grow from a tumour in culture may be rather unrepresentative of the
main cancer population within the tumour.
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The practical consequence of tumour heterogeneity is that standard variant detection
and genotype calling as applied in germline genetic analysis is not immediately appli-
cable to primary tumour analysis and modified assumptions and pipelines are required.
1.5.1.6 Depth of coverage and physical coverage
Depth of coverage is measured by the amount of over-sampling, representing the number
of sequenced reads that cover the site [as reviewed in Meyerson et al., 2010]. Sequence
coverage affects the ability to detect point mutations. Most whole-exome sequencing
studies aim for an average of 100 to 150-fold coverage, and whole-genome sequencing
studies aim for about 30 to 60-fold coverage, in order to reach deep coverage. This
is necessary owing to the heterogeneous nature of most tumours, which reduces the
sensitivity to detect mutations, and genomic regions of high GC content which typically
result in low or absent coverage [as reviewed in Watson et al., 2013].
There is considerable heterogeneity of target coverage encountered with exome sequenc-
ing technology, which can systematically affect the sensitivity to detect genuine mu-
tations. This can be accounted for by applying an empirical model relating the read
depth at a polymorphic site to the probability of calling the correct genotype at that
site which quantifies the amount of variation missed at a given coverage threshold, as
has been done in Meynert et al. [2013].
Physical coverage measures the number of fragments that span the site, and is based
on using paired-end or mate-pair reads, making it possible to sequence reads that are
of known chromosomal distance. This is an important consideration when detecting
rearrangements, since paired reads provide additional information to enhance mapping
accuracy of structural variants [Pabinger et al., 2014]. The expected distance between
the paired reads is used to uniquely place the reads on the reference genome, with
unexpected placement of read pairs can be used to detect a structural variation [as
reviewed in Meyerson et al., 2010].
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1.5.2 NGS variant analysis pipelines
The basic workflow of whole-exome and whole-genome sequencing projects is displayed
in Figure 1.12. After sequencing, a bioinformatic analysis pipeline must be employed to
successfully handle and analyse the huge amount of raw sequencing data output from
next-generation sequencing.
1.5.2.1 Quality assessment
The standard file format for NGS raw data is FASTQ, which is a text-based represen-
tation of biological sequences beginning with the sequence name followed by lines of
single-letter coded nucleotides or amino acids, and Phred-scaled base quality scores to
facilitate the assessment of sequence quality [as reviewed in Bao et al., 2014].
The first analysis step after sequencing is to assess the quality of the raw sequenc-
ing reads, preprocessing raw data before alignment. This involves removing, trimming
and correcting reads that do not meet defined standards, dependent on base quality
scores and sequence properties (e.g. primer contaminations, N content and GC bias)
[Pabinger et al., 2014]. Sequence artefacts that may compromise the quality of the raw
sequencing data include: base calling errors, INDELs, poor quality reads and adaptor
contamination [Pabinger et al., 2014]. Standard preprocessing procedure therefore in-
cludes: 3’ end adaptor removal, trimming of low quality bases at the ends of reads, and
read filtering by removing undesired sequences such as contamination from primers and
adaptors [as reviewed in Bao et al., 2014].
1.5.2.2 Alignment
Reads are aligned to a reference genome after they have been preprocessed to meet
a certain quality standard. Some examples of alignment programs are BWA, Stampy,
Bowtie/Bowtie2 and Novoalign. First-generation short-read aligners were optimised for
ungapped alignments, whereas more recent programs are better at dealing with longer























Figure 1.12: NGS variant analysis workflow. Whole-exome-seq or whole-
genome-seq samples are prepared in a library before being sequenced on a certain
platform. A pipeline follows consisting of the following steps: (i) quality assessment of
raw data, (ii) read alignment to a reference genome, (iii) germline and somatic variant
identification and (iv) annotation of detected variants to infer the biological relevance.
Pipeline results can be displayed using specific data visualisation tools such as circos
plots and genome browsers. Mutations can then be further filtered and prioritised
to find potential driver mutations, followed by validation in the lab. Adapted from
[Pabinger et al., 2014].
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read lengths and gaps allowing imperfect matches [as reviewed in Bao et al., 2014].
Current long-read alignment algorithms are classified as either using hash table indexing
or using compressed tree indexing based on Burrows-Wheeler transform [Pabinger et al.,
2014].
The use of paired-end reads in sequencing steps help in overcoming the problem of
ambiguity when mapping short reads to a reference genome [Pabinger et al., 2014],
since it is possible that a short-read sequence can be matched to multiple locations in
the reference genome if not using paired-end reads.
It is common practise to remove PCR duplicates after alignment in a further post-
alignment quality assessment step. PCR duplicates are a result of the PCR steps in
library preparations, which in turn can sometimes cause multiple reads that originate
from only one template being sequenced and interfere with variant calling statistics
[Pabinger et al., 2014].
1.5.2.3 Variant identification
Tools for genome-wide variant detection can be classified as either: (i) germline callers,
(ii) somatic callers, (iii) CNV identification and (iv) identification of other SVs including
translocations, inversions and large INDELs. However, cancer studies focus on detecting
somatic mutations by comparing sequences of tumour/normal pairs from one patient.
CNVs are the only large structural modification that can be detected in both whole-
exome and whole-genome sequencing studies [Pabinger et al., 2014].
Multiple sample variant calling is usually recommended, in which all reads across mul-
tiple samples from one genomic location are taken into account. This approach reduces
the possibility of calling randomly presented sequencing errors and increases the proba-
bility of calling alleles of low frequency or low coverage in a single sample. This increases
the accuracy and sensitivity of multi-sample variant calling, compared to that of single
sample variant calling. However, multi-sample variant calling is not always feasible
with very large sample sizes [as reviewed in Bao et al., 2014].
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1.5.2.4 Variant annotation
The functional impact of the identified mutations must be predicted in order to help
distinguish the potential driver mutations from the passenger mutations, by enabling
the downstream filtering and prioritisation of potential disease-causing variants for
further analysis in the lab. Most annotation tools focus on SNVs as they are more
easily identified and analysed than other forms of variation, although INDELs are also
covered by some tools. Annotation of structural variants is limited to CNVs. The most
commonly used public variant database used for this analysis step is dbSNP [Pabinger
et al., 2014].
Examples of software designed to annotate mutations with their predicted effects on
genes and protein function include Ensembl variant effects predictor [McLaren et al.,
2010] and snpEff [Cingolani et al., 2012]. Loss-of-function and gain-of-function conse-
quences of mutations can also be predicted using PolyPhen and SIFT [Flanagan et al.,
2010].
1.5.3 Cancer whole-exome and whole-genome next-generation sequenc-
ing projects
Ng et al. [2009] were the first to use targeted exome capture sequencing. By comparing
mutations in the exomes of control individuals and four patients with Freeman-Sheldon
syndrome (FSS), they demonstrated the re-discovery of mutations responsible for a
Mendelian trait. Adapting that approach to find the somatic mutations that underlie
the development and progression of cancer, Timmermann et al. [2010] captured and
sequenced tumour and matching normal colon tissue in the first study to work on
whole exome next-generation sequencing of primary colon cancers.
Pleasance et al. [2010a] were the first to apply whole-genome next-generation sequencing
to cancer, identifying somatic mutations in a whole malignant melanoma genome, in
the first comprehensive catalogue of somatic mutations from an individual cancer. This
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study also provides first insights into genomic alterations induced by ultraviolet light
exposure.
Major large-scale cancer sequencing projects are now underway, such as the Cancer
Genome Project (CGP) [Futreal et al., 2004] launched in the United Kingdom in 2000,
The Cancer Genome Atlas (TCGA) [Cancer Genome Atlas Research Network, 2008]
set up in the United States in 2006 and the International Cancer Genome Consortium
(ICGC) [Zhang et al., 2011] created in 2007 to coordinate the generation of compre-
hensive catalogues of genome alterations from 52 different cancer types [as reviewed in
Watson et al., 2013]. These initiatives aim to systematically decipher and catalogue the
spectrum of genetic variants in different cancer types using next-generation sequencing.
Glioblastoma (GBM) was the first cancer type to undergo comprehensive genomic char-
acterisation by the TCGA Research Network [Cancer Genome Atlas Research Network,
2008], in which a targeted approach was adopted using Sanger-based capillary sequenc-
ing of 601 selected genes in 91 tumour-normal exomes to identify somatic mutations.
This analysis revealed frequent mutations in the phosphatidylinositide 3-kinase (PI3K)
regulatory subunit PIK3R1.
The aim of the ICGC was to comprehensively characterise somatically acquired genetic
events in at least fifty classes of cancer, including those with the highest global incidence
and mortality, requiring the high-coverage sequencing of 20,000 cancer genomes or more.
The catalogues of somatic mutation from these cancers are combined with expression
and epigenetic profiles as well as clinical features from the same patients. This project
builds on the success of previous collaborative initiatives such as the Human Genome
Project and the HapMap consortium [as reviewed in Stratton et al., 2009].
This field has primarily focused on finding biomarkers (genes and pathways), for exam-
ple APC, which can be used to guide therapy. These are mostly from exome (disease
centric) studies, however many more whole genome sequencing studies are now starting
to come out. For example Waddell et al. [2015] have used whole-genome sequencing
and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinomas
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(PDACs) to uncover mutational mechanisms and copy number changes. A high preva-
lence of chromosomal rearrangements was discovered, with genomic instability found
to co-segregate with the inactivation of DNA maintenance genes (BRCA1, BRCA2 or
PALB2) and a mutational signature of DNA damage repair deficiency. These particu-
lar mutations would be difficult to capture with whole-exome sequencing, however they
can be with whole-genome sequencing.
1.5.3.1 TCGA Pan-Cancer analysis project
The Pan-Cancer analysis project was launched by The Cancer Genome Atlas (TCGA)
in 2012 to identify and analyse aberrations in the tumour genome and phenotype that
define cancer lineages [Weinstein et al., 2013]. The main aim was to define commonali-
ties, differences and emergent themes across different tumour types by assembling and
comparing coherent and consistent TCGA datasets across twelve different tumour types
(GBM, OV, BRCA, LUSC, LUAD, COAD, READ, KIRC, UCEC, BLCA, HNSC and
LAML) and six different genomic, epigenomic, tanscriptional and proteomic platforms
(mutation, copy number, gene expression, DNA methylation, microRNA and reverse
phase protein array) combined with clinical data, profiled over 5,074 samples. Tumour
types were selected based on data maturity, adequate sample size and publication of
primary analyses. Since the launch of the Pan-Cancer initiative, the integrated dataset
has undergone quality control, statistical analysis and interpretation by a consortium
of researchers.
The purpose of the project is to increase statistical power through increased sample size
to detect new patterns of functional genomic determinants of disease by using a col-
lated dataset, increasing the power to also detect rare genomic drivers in heterogeneous
tumours, as well as eliminating false-positives commonly seen in single tumour type
analyses. Since cancers from disparate tumour types have been shown to share certain
features, and cancers from the same organ have also been revealed to sometimes be quite
distinct, another imperative objective of this project is to uncover both tissue-specific
aspects of cancer as well as intrinsic molecular commonalities across many different
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tumour types. This addresses the role of mutational profile, as well as tissue of origin,
as an important determinant in the progression of cancer. The ultimate goal is that
the results from this project will help to inform clinical decision making for individual
cancers.
Recently published studies that have used the Pan-Cancer data in order to compre-
hensively identify candidate cancer genes over multiple cancer types include Lawrence
et al. [2014] and Kandoth et al. [2013], in which detected driver mutations have been
related to both cancer type and mutation spectra.
1.5.3.2 Distinguishing drivers from passengers
Many types of mutation have been uncovered using next-generation sequencing projects,
for example small-scale re-arrangements [Stephens et al., 2009], large-scale genomic
rearrangements [Stephens et al., 2011], loss of heterozygosity (LOH) [Zhao et al., 2010]
and homozygous deletions [Bignell et al., 2010]. Segmental duplications and aneuploidy
(abnormal number of chromosomes) have also been discovered in cancer using these
methods. For example a tandem duplication was identified in a small-cell lung cancer
genome in Pleasance et al. [2010b], shown to duplicate exons 3-8 of CDH7 in frame,
and in Bignell et al. [2006] testicular germ-cell tumours were found to be uniformly
aneuploid in protein kinase genes, with consistent chromosomal gains on 12p, 8q, 7,
and X and losses on 13q, 18q, 11q, and 4q. The oncogene TRRAP was also detected
through the next-generation sequencing of 14 melanoma exomes in Wei et al. [2011], by
uncovering a recurrent cytosine to thymine mutation. Puente et al. [2011] also set out to
identify new driver mutations in a genome-wide screen of chronic lymphocytic leukemia
(CLL), identifying the oncogenes NOTCH1, MYD88 and XPO1, which provided a
very interesting insight into the usefulness of combining whole-genome sequencing with
clinical data in identifying driver mutations in a study that was the first of its kind.
Although these next-generation sequencing studies have proven to be very informative
in identifying driver genes, they highlight limitations associated with these methods.
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Driver mutations have several characteristics that separate them from passenger muta-
tions; for example driver mutations tend to cluster in cancer genes whereas passengers
are more randomly distributed [as reviewed in Stratton et al., 2009]. However, the
overly simplistic approach that many studies have adopted of classing genes with an
excess of non-synonymous mutations or frequently occurring (recurrent) mutations as
driver genes, sometimes results in mistaking passengers for driver. These studies in-
terpret an excess of observed non-synonymous mutations compared with that expected
by chance as evidence for the presence of driver mutations, but do not include the
examination of synonymous mutations. It is therefore assumed in these studies that
the mutation rate across the genome is constant. However, mutation rate is known to
vary across the genome with hotspots experiencing higher rates of mutation. So for
example, in these studies a highly mutable locus could look like a cancer gene when in
fact there is no guarantee that these mutations are drivers, as it is possible that the
gene is being recurrently hit by passengers at a mutator hotspot. Therefore it is impor-
tant that fluctuations in the regional mutation rate across the genome are accounted
for [Yang et al., 2003].
Refined driver detection methods include using evolutionary conservation of a mutated
residue, which can indicate the importance of the mutational event, helping to discrim-
inate drivers from passengers. Algorithms such as Cancer-Specific High-Throughput
Annotation of Somatic Mutations (CHASM) [Carter et al., 2009] are used to score mu-
tational impact by amino acid conservation inferring probable functional mutations in
cancer [as reviewed in Watson et al., 2013]. Somatic missense mutations are ranked
using a many features classifier in order to identify driver mutations.
Vandin et al. [2012] also attempted to overcome the problems encountered by com-
mon approaches in cancer studies that predict driver mutations based solely on their
frequency of occurrence. Since this approach is known to be confounded by the obser-
vation that driver mutations target multiple cellular signalling and regulatory pathways
and thus each cancer patient may exhibit a different combination of mutations that are
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sufficient to perturb these pathways, Vandin et al. [2012] have dealt with the muta-
tional heterogeneity problem by applying an algorithm called Dendrix, to find driver
pathways de novo from somatic mutation data.
1.6 Cancer as an evolutionary process
The development and adaptation of cancer can be viewed as an evolutionary process,
and can therefore be defined in these terms, occurring through cell-level selection in
much the same way that a species evolves through Darwinian organism-level natural
selection [Talavera et al., 2010]. At least for the short term the formation of cancer is
a case of survival of the fittest [Darwin and Wallace, 1858].
Thus driver mutations can also be explained in this context. Driver mutations have
previously been described as mutations that are responsible for the development of
cancer. This is because they confer growth, developmental and survival advantages
on the cell in which they occur, and are therefore positively selected in the micro-
environment of the tumour tissue through adaptive molecular evolution. Thus cells
containing driver mutations will be best adapted for cancer development, with the
capability to proliferate and survive more effectively than their neighbours [as reviewed
in Stratton et al., 2009], and therefore increase in frequency and subsequently go on
to dominate the cell population, leading to the formation of a malignant tumour. For
example, a driver mutation that inactivates a tumour suppressor gene will confer a
selective advantage to the cancer, so that this cell is now better adapted to the needs
of the cancer by, for instance, being able to proliferate faster than other cells in the
population. Conversely, it is the passenger mutations present in cancer that do not
contribute to oncogenesis, as they do not confer a clonal growth advantage to the cancer
and therefore have not been selected [as reviewed in Stratton et al., 2009]. Passenger
mutations are present in the genomes of cancer cells because somatic mutations without
functional consequence often arise during cell division. Thus, cells that acquire driver
mutations will already contain passenger mutations and will carry them through further
Chapter 1. Introduction 56
rounds of mitosis, so that all cells of the final cancer contain passengers that were
originally present in an ancestor of the cancer cell when it acquired one of its drivers
[as reviewed in Stratton et al., 2009]. As well as driver and passenger mutations, some
somatic mutations may occur in the cancer genome that impair cell survival. These
mutations will be subject to negative selection, since they are detrimental to the cancer,
and therefore will be absent from the cancer genome [as reviewed in Stratton, 2011].
Unlike selection at the species level, selection in cancer cell populations is an example of
clonal selection, with cancer arising as an abnormal clone of cells that expand as a result
of somatically acquired mutations (Figure 1.13) [as reviewed in Stratton, 2011, Stratton
et al., 2009]. Clonal expansion is triggered by an initial driver mutation which confers a
selective advantage to the cell over other cells in the population, and so this cell increases
in frequency relative to cells without the driver mutation. The addition of a second
driver mutation to a single cell within this tumour population confers extra growth
advantages causing the cell to out-compete its neighbours once more. This process of
clonal expansion is driven by selective pressures from the tumour’s micro-environment
or the external environment. For example, therapeutic intervention with chemotherapy
can act as a strong selective pressure for the expansion of resistant sub-clones which
manifest as recurrences, while at the same time destroying some cancer sub-clones.
Other selective pressures of the tumour micro-environment include those that favour, for
example: the outgrowth of clones possessing immune-evasive phenotypes [de Miranda
et al., 2012]; cells that proliferate faster than their neighbours; and cells better adapted
to acquire blood carrying oxygen and nutrient supplies. Cancer is constantly evolving
in response to these changing selective pressures in the tumour micro-environment as
well as in response to competition with itself (other cancer cells) [Talavera et al., 2010].
This is an example of the “Red Queen Hypothesis” which describes co-evolutionary
relationships between different species as constant arms races, with each species rushing
to evolve an advantage over the other, suggesting that faster evolution is favoured
[Damore and Gore, 2011]. In terms of cancer, the different species are the different
cells in the tumour population. So cancer cells therefore have to continually evolve at
a fast rate to keep up with the ever-changing environment, and succeed in dominating
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the tumour population. The population of neoplastic cells present in the final cancer
derives from a single normal cell, as is shown in Figure 1.13, however the evolutionary
history of the cell lineages is very complex. This is due to the multiple waves of clonal
expansion that are thought to be required for the generation of the dominant sub-clone
that manifests as the symptomatic cancer [as reviewed in Stratton, 2011]. Each new
clonal expansion is initiated by an additional driver mutation, so there will be cases
where driver mutations have caused sub-clones to branch off from the current sub-clone
and then have failed to out-compete the subsequently dominant sub-clone. Therefore
in the final cancer, some of these minor sub-clones will still exist, while others will have
been extinguished. It is also possible that a minor sub-clone has branched off the current
dominant sub-clone, which in time will go on to out-compete the major sub-clone and
dominate the tumour. This will be due to a change in the micro-environment, for
example after the treatment of chemotherapy in which a minor sub-clone containing
a resistance mutation will preferentially expand to become the new major resistant
sub-clone.
Cancer development and progression is in principle an attractive model for the study of
evolution, due to the differences seen between cell-level selection in cancer and organism-
level selection in species evolution. These benefits include: a short generation time in
cancer lineages, meaning that analysis can be carried out on a much shorter time-scale;
a lack of meiotic recombination, which can be a confounding factor in evolutionary
analyses of eukaryotes and viruses; increased somatic mutation rate in cancer cells, the
merit of which is that DNA sequence diversity on which selection can act is increased,
providing strong signals of sustained positive selection [as reviewed in Stratton, 2011];
and the constantly challenging and changing environment including competition with
other cells in the cancer population, again maximising the ability to detect sustained
positive selection.
Cancers can therefore be defined as clonal proliferations, that arise owing to mutations
in a subset of genes that confer selective growth advantage on cells [Greenman et al.,
2007].
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Figure 1.13: The lineage of mitotic cell divisions in a cancer. From the
fertilised egg to a single cell within a cancer, somatic mutations may be acquired while
the cell lineage is still phenotypically normal, represented by passenger mutations
occurring before clonal expansion, caused by both intrinsic mutational processes during
normal cell division and exogenous environmental mutagens. The rest of the somatic
mutations in a cancer genome occur during the segment of the cell lineage in which the
cancer cell is already showing phenotypic evidence of neoplastic change, and it is driver
mutations that initiate this part of the lineage and continue to contribute to the clonal
expansion of the cancer. Passenger mutations also accumulate during clonal expansion
however they have no effect on the cancer cell. During clonal expansion processes such
as DNA repair defects that cause a mutator phenotype contribute to the mutational
burden. Chemotherapy can also contribute to the mutations seen in relapses after
treatment, in which driver mutations confer resistance to cancer therapy and are likely
to pre-date the initiation of treatment, existing previously as passenger mutations until
the selective environment changed. Adapted from Stratton et al. [2009].
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1.6.1 Detecting selection
The analogy between organism evolution and cancer progression has previously been
recognised. One method that has been widely used in studies of selection during evo-
lution is the “omega ratio”, and this approach has also been applied to cancer data in
order to distinguish driver mutations from passengers amongst all somatic mutations
present in a cancer genome, and ultimately identify the cancer genes.
The omega ratio compares non-synonymous substitution rates (Ka) to synonymous sub-
stitution rates (Ks) to give a ratio of Ka/Ks in order to detect selection [Massingham
and Goldman, 2005]. Ks acts as a proxy for neutral selection, since synonymous muta-
tions do not alter the encoded protein and so are assumed to be selectively neutral. The
synonymous rate is often used as a proxy for neutrality, which is the unbiased sampling
of mutations (the effect of mutation and drift but not selection). Biological selection is
hence expected to act only on non-synonymous mutations that alter the structure and
function of proteins. The value obtained from this observed ratio indicates what type
of selection is taking place: a value of <1 (a lower non-synonymous:synonymous ratio
compared with that expected by chance alone) suggests evidence for negative selection
overall; a value equal to 1 suggests no selection; and a selection pressure >1 (a higher
ratio of non-synonymous:synonymous mutations compared with what is expected by
chance) is indicative of positive selection, which is evidence for adaptive molecular evo-
lution favouring advantageous driver mutations [Greenman et al., 2007]. The omega
ratio is the comparison of two rates, so if the synonymous mutation rate is assumed to
represent neutrality and the non-synonymous mutation rate represents neutrality plus
some effect of selection, then the difference represents the net effect of selection, in this
case positive selection.
This is a well established technique in the field of molecular evolution, used to detect
selection acting on driver mutations in cancer. The benefit of using this approach over
previously used methods of cancer gene detection is that it accounts for the varying
regional mutation rate across the genome by using synonymous mutations as a control
to estimate a rate rather than a count. In the past cancer genes (those containing
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driver mutations) have been identified based on the presence of excess non-synonymous
mutations or recurrently occurring mutations in these genes, which does not account
for the fact that passenger mutations are not randomly distributed across the genome
and may be recurrently hitting “hot spots” of the genome.
However there are also certain limitations and confounding influences to the evolution-
ary approach adopted by using the omega ratio. For example, the underlying assump-
tion of this analysis is that since synonymous mutations do not alter the structure and
function of proteins they are biologically silent and therefore cannot be selected. How-
ever this is now known not to always be the case, as synonymous mutations have been
found to frequently act as driver mutations in human cancers [Supek et al., 2014]. It
is estimated in Supek et al. [2014] that between one in two and one in five synony-
mous mutations in oncogenes have been selected and therefore contribute to human
cancer. Hence the omega approach may be underestimating the effects of synonymous
mutations and confounding results.
Detecting selection in tumour cells cannot only highlight somatically mutated genes
and molecular functions that are beneficial to cancer progression by looking for signals
of positive selection, but also somatic mutations that are inhibitory to the development
of cancer by detecting negative selection in these genes.
1.6.2 Previously used approaches to detect selection in cancer
The omega ratio has previously been used in cancer studies to investigate the relative
contributions of driver and passenger mutations in human cancer genomes.
1.6.2.1 Site counts model
Some studies have used a “site counts model”, in which a rate of mutations is calculated,
e.g. C→T per C nucleotide. Although this model does not intrinsically account for
whether the changes are synonymous and non-synonymous, a separate omega ratio can
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be calculated at each site by calculating the non-synonymous substitution rate at non-
synonymous sites and dividing by the synonymous substitution rate at synonymous
sites. [Greenman et al., 2007] have used this approach in the meta-analysis of protein
kinase data. A deviation of the omega ratio from that expected by chance (>1) was
then interpreted as an indication of the presence of selection upon non-synonymous
mutations by the cancer. Over all coding regions of 518 kinase genes, a selection
pressure of 1.29 was calculated showing evidence of positive selection by demonstrating
an excess of non-synonymous mutations compared with that expected and therefore
suggesting the presence of driver mutations in the dataset. Even after the removal of
known cancer genes, the selection pressure indicated the presence of driver mutations
in genes not previously known to be implicated in cancer.
A limitation with this framework however is that a site counts model does not consider
that some nucleotide sites can act as both synonymous and non-synonymous depending
on the change that has occurred. This is a slightly crude approach which can be
improved by counting every nucleotide three times, once for each possible change, which
is how the software suite PAML [Yang, 2007] overcomes this difficulty in Markov models
of nucleotide substitution. Although this alters the rate estimates, the rate ratio is
preserved.
Greenman et al. [2007] also showed innovative thinking in introducing analysis of mu-
tational profile differences between cancers. For example, they showed that the se-
lection pressure was lower in cancers with defective DNA mismatch repair compared
with MMR-proficient cancers. However, since MMR-deficient cancers have a higher
prevalence of base substitutions than MMR-proficient cancers, it is possible that driver
mutations were overwhelmed by the higher number of passenger mutations in MMR-
deficient cancers, suggesting that this model encounters limitations when mutation
rates are very high. Greenman et al. [2007] also considered partitioning genes into
sub-regions with respect to detecting selection, and grouping by pathway and kinase
sub-class. Genes were divided into two groups: kinase domain and everything outside
the kinase domain. Over all genes they found a slightly higher selective pressure within
Chapter 1. Introduction 62
kinase domains, with a much higher selective pressure observed in the P-loops and ac-
tivation segments of the kinase domains, however these results also suggest that driver
mutations are present outside of the kinase domains too. Pathway analysis was carried
out by combining Reactome, Panther and INOH in a merged pathway database to test
for the presence of mutated pathways, of which the FGF signalling pathway showed
the highest enrichment of non-synonymous mutations. After grouping kinase genes by
subclass, the highest selection pressure was observed in calmodulin-dependent protein
kinases. Previous to this analysis, most reported protein kinase cancer genes were
members of the tyrosine kinase or serine/threonine kinase subclasses, so this analysis
suggested that other subclasses are also involved in oncogenesis.
1.6.2.2 Codon model
The omega ratio can also be calculated using a codon model, in which the single base
changes are not considered directly, instead just the change of one codon to another
(e.g. ATG→ ACG) and whether that change is synonymous or not. This overcomes the
problem of ambiguity of whether a nucleotide site is synonymous or non-synonymous,
as when the whole codon is considered the change can only be either non-synonymous
or synonymous and not both. This has been implemented in the more advanced evolu-
tionary style using likelihood models in Yang et al. [2003]. However, their weakness is
that they apply their method to just one gene in the genome, examining the spectrum of
p53 mutations in cancer. However they do not just use the gene as the unit of analysis,
splitting the gene by functional domains, the results of which suggest that amino acid
changes less often lead to cancer in structural domains compared with DNA-binding
and transactivation domains. Goldman and Yang [1994] also use a codon model which
is implemented in the codeml program from the PAML package to deal with single base
substitutions only. Whelan and Goldman [2004] have also used a codon model simi-
lar to the method used in Goldman and Yang [1994], however they have built on this
approach by including di-nucleotide and tri-nucleotide substitutions as well as point
mutations. Greenman et al. [2006] have adopted a codon-based evolutionary approach
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which has the advantage of being able to accommodate INDELs as well as substitu-
tions, however in doing so this has made it a less robust model in terms of its statistical
methodology than others such as [Yang et al., 2003] that just look at point mutations.
Evolutionary codon models already exist for protein-coding data, partly because func-
tionally important variants are more likely to be found in the coding regions of the
genome, hence why whole-exomes are preferentially used over whole-genomes in these
types of driver detection analyses. Other benefits of exome studies is that there are
more cancer exomes currently available than genomes, due to their relatively low se-
quencing cost. However this is starting to change and as sequencing costs continue to
fall, more whole-genome sequences will become available for variant analysis, as well as
more advanced evolutionary models to deal with them.
1.7 Personalised medicine
Recent technological advances in genomics are starting to allow for treatments tailored
to individuals to become a reality for cancer diagnosis and treatment. There have been
many studies dedicated to identifying the mutations involved in the development of
cancer, however it is only in the last decade that technological advances in genomic
analysis have started to deliver on the promise of personalised medicine [Fernald et al.,
2011], gearing towards more targeted treatment options for patients guided by the
predictive value of these studies.
Medical sequencing of tumours to guide treatment is one of the first practical realisa-
tions of true genome-based personalised medicine [Fernald et al., 2011]. An example of
this application currently in action is the use of the chemotherapy medication imatinib,
which works by inhibiting the proteins encoded by the ABL and KIT genes that are mu-
tated and activated in chronic myeloid leukemia and gastrointestinal stromal tumours
respectively [Gambacorti-Passerini, 2008]. Another example is the use of trastuzumab,
which is an antibody directed against the protein encoded by ERBB2 (HER2), which
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is commonly amplified and overexpressed in ∼20% of breast cancers [as reviewed in
Stratton, 2011, Stratton et al., 2009].
BRAF is also an attractive target for drug discovery strategies. Somatic mutations
were discovered in this gene in an early systematic sequencing screen in 2002. This gene
encodes a serine-threonine kinase and is mutated in 50-70% of malignant melanomas,
10-15% of colorectal cancers and 50% of papillary thyroid cancers. A substitution
mutation at valine 600 with glutamic acid (V600E) accounts for more than 90% of
all mutations resulting in constitutive activation of the BRAF encoded kinase. Due
to its deep ATP-binding pocket in which inhibitors can sit and because the BRAF
V600E mutation is activating, encouraging results have been seen in clinical trials
testing inhibitors of V600E mutant BRAF in 80% of patients with malignant melanomas
carrying the V600E mutation [as reviewed in Stratton, 2011].
Targeted drug development has also helped to elucidate the mechanisms of drug re-
sistance in recurrent tumours that arise from minor sub-clones containing resistance
mutations after drug treatment. Investigations into the genomes of recurrences has
identified some of the mutations that confer resistant, which in turn has offered oppor-
tunities for new cancer therapies [as reviewed in Stratton, 2011].
Direct targeting and inhibition has predominantly been used to target oncogenes. How-
ever this approach becomes a challenge when the mutated gene in question is a tumour
suppressor gene, since the proteins encoded by these genes are already inactivated by
their mutations. For this, the development of drugs that exhibit synthetic lethality
with the mutated cancer gene may be necessary, in which the cancer mutation and the
drug together cause the tumour cells death [Garber, 2002]. For example, two genes
are synthetic lethal if mutation of either gene alone is compatible with viability but
mutation of both leads to death. So inhibiting the product of a gene that is synthetic
lethal to the inactivating cancer-causing mutation in a tumour suppressor gene should
kill cells that harbour such mutations, while also having the benefit of sparing normal
cells [Kaelin, 2005].
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Many advances in molecular science have been made in the last decade to benefit
medicine, and next generation sequencing has revolutionised the discovery of genes
underlying cancer. These efforts include initiatives such as the Human Genome Project
[Lander et al., 2001], the International HapMap Project [Gibbs et al., 2003] and the
1000 Genomes Project [Consortium et al., 2012], and now the 100,000 Genomes Project
which is currently underway. By combining genetic associations with phenotypes and
drug response, personalized medicine has the potential to tailor treatments to a patient’s
specific genotype [Fernald et al., 2011].
1.8 Aims of investigation
I plan to use evolutionary signatures to uncover evidence of positive selection in can-
cer exomes, in order to functionally implicate driver mutations important for cancer
development, progression and survival.
1.8.1 Specific research objectives
Using well-established techniques from the field of molecular evolution, I wish to answer
the following questions:
• Which genes are enriched for driver mutations in cancer? Identify genes harbour-
ing driver mutations (rediscovery of known genes), and uncover candidate driver
mutations in genes.
• How does the tissue of origin influence the genes hit by driver mutations in cancer?
• To what extent are mutations in genes dictated by the mutation spectra?
• Is the path of selection and development of a cancer regulated by mutation spec-
trum or the tissue of origin? Which has more effect on the pathway of mutation?
For example, APC is frequently knocked out by premature stop codons in col-
orectal cancer, caused by C→T changes at CpG sites in mismatch repair, which
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suggests that the mutation spectra may be the driving force of these particular
mutations in this gene. However, is it this mutation spectra or the tissue of origin
(colorectal) that has more of an effect on the mutation pathway of this particular
cancer?
Ultimately the aim of identifying key changes in cancer genomes is to further understand
how genes are mutated in cancers relating to their mutation spectra and tissue subtypes,
to help aid the rational design of target cancer treatments and mediate prognosis.
1.8.2 Approach
In order to achieve these objectives, I propose an alignment strategy in which cancer-
specific mutations are edited onto the most up-to-date build of the human reference
genome (hg19). I then plan to use omega-based evolutionary analysis on a per-gene basis
to detect signals of positive selection in these alignments indicating driver mutation
enrichment, in combined as well as sub-type analyses of diverse tumour types. I will
also stratify the data based on mutation spectra classifications before evolutionary
analysis. Validation will be performed by rediscovery of known cancer genes.
To account for certain limitations of previous cancer studies, the varying coverage in
exome sequences will be quantified and accounted for by annotating nucleotide sites
as missing in cases where there is not sufficient coverage to confidently call a variant.
All exomes will be aligned consistently to hg19 reference genome in order to generate
a uniform set of sequences.
Chapter 2
Methodology and data sources
This chapter describes the exome sequences and mutation data used, the data process-
ing pipeline and how the data was prepared for evolutionary analysis. It also compre-
hensively documents the software versions, parameters and models used for evolutionary
analysis.
2.1 Datasets
2.1.1 The Cancer Genome Atlas (TCGA) data
The Cancer Genome Atlas (TCGA) is an ongoing large-scale genome sequencing project
[Cancer Genome Atlas Research Network, 2008].
A summary of the data we have used from TCGA for this project is shown in Table 2.1.
This dataset consists of paired tumour and normal exomes for 1005 patients over 17
cancer types, generated by next-generation sequencing. Exome sequencing refers to
the technique of sequencing all the protein-coding regions of the genome known as
the exome (exons of genes), which consists of first capturing all protein-coding ex-
ons, and then sequencing the targeted DNA using high-throughput massively-parallel,
next-generation sequencing (NGS) technology. The NGS platform used by TCGA to
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Table 2.1: TCGA dataset. This table summarises the paired tumour and normal
exome sequence data obtained from TCGA consisting of 17 different cancer types over
1005 patients, with a breakdown of the numbers of patients for each cancer type. Full
TCGA patient IDs and sample types can be found in Supplementary Appendix A
Cancer type Patient number
Acute myeloid leukemia (LAML) 53
Bladder urothelial carcinoma (BLCA) 15
Brain lower grade glioma (LGG) 50
Breast invasive carcinoma (BRCA) 110
Cervical squamous cell carcinoma and endocervical adenocarci-
noma (CESC)
14
Colorectal carcinoma (CRC)* 10
Glioblastoma multiforme (GBM) 208
Head and neck squamous cell carcinoma (HNSC) 85
Kidney renal clear cell carcinoma (KIRC) 175
Kidney renal papillary cell carcinoma (KIRP) 16
Lung adenocarcinoma (LUAD) 26
Lung squamous cell carcinoma (LUSC) 53
Ovarian serous cystadenocarcinoma (OV) 75
Prostate adenocarcinoma (PRAD) 39
Stomach adenocarcinoma (STAD) 19
Thyroid carcinoma (THCA) 19
Uterine corpus endometrial carcinoma (UCEC) 38
Total 1005
*Colorectal carcinoma (CRC) is a merged dataset including both colon adenocarcinoma
(COAD) and rectum adenocarcinoma (READ) patients, however in this case the 10
CRC patients were all COAD.
sequence exomes was the Illumina/Solexa Genome Analyser (Solexa), which is the most
widely used next-generation DNA sequencing technology. Other platforms used include
454/Roche Genome Sequencers, SOLiD and Polonator [Shendure and Ji, 2008].
Mitochondrial DNA (mtDNA) is not targeted in currently used exome-sequencing meth-
ods [Samuels et al., 2013], however it has been captured in the exome data from TCGA,
and so mutations in the mitochondrial genome have also been used in the TCGA anal-
ysis.
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Table 2.2: Published Lawrence dataset. This table summarises the cancer-
specific mutation data available in the published Lawrence et al. [2014] dataset, con-
sisting of 21 different cancer types (12 from TCGA and 14 from Broad Institute) over
4,728 patients, with a breakdown of the numbers of patients for each cancer type.
Cancer types highlighted in red have been used for evolutionary analysis in Chapter 5.
These patients contain both coding and non-coding SSNVs.
Cancer type Patient number




Chronic lymphocytic leukemia (CLL) 159
Colorectal (CRC) 233
Diffuse large B-cell lymphoma (DLBCL) 57
Esophageal adenocarcinoma (ESO) 141
Glioblastoma multiforme (GBM) 291
Head and neck (HNSC) 384
Kidney clear cell (KIRC) 417
Lung adenocarcinoma (LUAD) 404
Lung squamous cell carcinoma (LUSC) 177
Medulloblastoma (MED) 92
Melanoma (MEL) 118








Table 2.2 shows a summary of the data we have used from the published work of
Lawrence et al. [2014]. This dataset consists of cancer-specific mutations for 4,728
patients over 21 cancer types. They have also used next-generation paired tumour and
normal exome sequences. Mutations in mtDNA were not been included in the mutation
data provided by [Lawrence et al., 2014].
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Table 2.3: Patient overlap between TCGA and Lawrence datsets. This
table summarises the data present in both datasets, consisting of 11 cancer types
over 702 patients, with a breakdown of the numbers of patients for each cancer type.
Full patient IDs and sample types of the patients that appear in both datasets can be
found in Supplementary Appendix B. TCGA nomenclature has been used in this table,
however variations of cancer type names used by Lawrence et al. [2014] can be found
in Appendix A
Cancer type Patients
Acute myeloid leukemia (LAML) 51
Bladder urothelial carcinoma (BLCA) 15
Breast invasive carcinoma (BRCA) 107
Colorectal carcinoma (CRC) 8
Glioblastoma multiforme (GBM) 171
Head and neck squamous cell carcinoma (HNSC) 85
Kidney renal clear cell carcinoma (KIRC) 150
Lung adenocarcinoma (LUAD) 26
Lung squamous cell carcinoma (LUSC) 50
Ovarian serous cystadenocarcinoma (OV) 4
Uterine corpus endometrial carcinoma (UCEC) 35
Total 702
2.1.3 Overlap between TCGA and Lawrence datasets
Table 2.3 shows that 702 patients that overlap between the TCGA samples fully re-
processed in this work and those present in the Lawrence et al. [2014] data.
2.2 Obtaining exome sequences and mutation data
2.2.1 TCGA schema parsing
Next-generation whole exome sequences for both primary tumour and matched non-
tumour somatic normal samples (usually taken from blood) were obtained from the
TCGA Cancer Genome Hub1. Paired tumour:normal data was obtained for 1005 pa-
tients over 17 cancer types. Sequencing data was downloaded in BAM format, decrypted
1https://cghub.ucsc.edu
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and validated using Picard version 1.432. Each exome came to ∼20Gb in size, resulting
in a 40Tb dataset.
At the initiation of this project the Cancer Genome Hub was not developed and TCGA
exome sequences were only available from NCBI dbGaP [Tryka et al., 2014]. Obtaining
this data represented a significant barrier to analysis and its use required parsing in
order to obtain the samples for analysis. Alignment data could only be searched for,
accessed and downloaded based on a SRS ID from dbGaP, which gave no information
on the type of data. A schema was developed in order to identify the specific type of
data required using Perl scripts. The SRS IDs associated with the data from NCBI
were searched for, and then those particular sequences were requested and downloaded
using automated FASP downloading of data from NCBI3. Samples were subsequently
annotated with further information such as their sample type (i.e. tumour or normal)
using the sample Atlas ID, and their cancer type (e.g. GBM). Through quality control
and data cross-referencing, I identified several miss-annotations and other errors in the
dbGaP derived data that were reported back to TCGA for correction.
2.2.2 Retrieving Lawrence mutations
Additional cancer-specific mutations for 4,735 patients over 21 cancer types based on the
work of Lawrence et al. [2014] were downloaded as MAF format files from TumorPortal4
on a per gene basis. However seven of these patients contained no single nucleotide
mutations (only INDELs and other non-SNP mutations) so were discarded, resulting
in a set of 4,728 patients for analysis. A few mutations were removed from this set of
4,728 patients as they had been classed as SNPs but were in fact longer substitutions,
not single nucleotide variants. However this further removal did not alter the number
of patients in the set. There is a slight discrepancy between the numbers used in the
Lawrence et al. [2014] paper and those available for download. Lawrence et al. [2014]
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Figure S1 produced in the Supplementary material of the Lawrence et al. [2014] study
also record using a different number of patients for analysis. 4,729 patients were used
to create the figure despite the figure legend stating that 4,742 patients were used.
A Perl one liner was used in a Unix environment to download all available cancer-specific
mutations on a per gene basis in MAF format. A list of all gene names was produced
from a mySQL database to be passed to the Lawrence website for this retrieval. The
bash code for this process is shown in Listing 2.1.
1 # generate l i s t o f gene names from mySQL hg19 assembly database
2 Myblackadder −D codons hg19 −B −N −e ’ s e l e c t d i s t i n c t ( geneName ) from
genCodons ’ > geneNamesList
3 cat geneNamesList | grep −v ’ \ . ’ > geneNamesList . nodots
4 cat geneNamesList . nodotsSeps | s o r t −R > geneNamesList . nodotsSeps . Rand
5
6 # p e r l one l i n e r to download mutation data
7 f o r i in cat geneNamesList . nodotsSeps . Rand ; do wget −nd http ://
cancergenome . b r o a d i n s t i t u t e . org / data / per gene mafs / $ i . maf ; s l e e p 1 . $ ( (
RANDOM%10) ) ; done
Listing 2.1: Lawrence mutation data retrieval
2.3 Data processing pipeline
A summary of the data processing pipeline is shown in the flow diagram in Figure 2.1.
This mostly involved the exomes obtained from The Cancer Genome Atlas; however,
Lawrence et al. [2014] mutations were also incorporated where they could be for con-
sistency. This common pipeline was put in place in order to process this large amount
of data efficiently. Unless otherwise stated, the following steps refer to the processing
of the TCGA data.




specific	  variants	  to	  
reference	  
Masking	  regions	  of	  
low	  coverage	  
EVOLUTIONARY	  ANALYSIS	  












Figure 2.1: Data processing pipeline. Flow diagram illustrating the methods
involved in the data processing pipeline for both the TCGA and the Lawrence datasets
prior to evolutionary analysis.
2.3.1 Pre-processing data
TCGA pre-aligned BAM files as obtained were based on a mixture of hg18 and hg19
reference sequence alignments and a heterogeneous combination of alignment tool ver-
sions and parameters. These differences were not randomly distributed, but rather
they tended to cluster by disease type. Such biases could then lead to systematic biases
in a meta-analysis. To avoid such problems, reads were realigned and variants called,
selected and filtered in a common pipeline, described here, in the first part of the data
processing pipeline.
Initially however, data was handled via two alternative pre-processing approaches:
• Approach 1: Variants were called from pre-aligned exomes (BAMs pre-aligned
to hg18 reference genome). UCSC liftOver tool [Rosenbloom et al., 2015] was
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used to convert the genome coordinates from NCBI build 36 (UCSC hg 18) to
the more recent genome assembly NCBI build 37 (UCSC hg 19) positions. This
tool uses BED format, so VCF files were converted to BED format first using
BEDtools [Quinlan and Hall, 2010].
• Approach 2: Improved exome re-alignment to the more recent hg19 version
of the human reference genome was carried out prior to variant calling. This
approach used state-of-the-art algorithms and a more up-to-date human reference
genome to improve exome alignments especially around indels.
The purpose of running these two approaches together was to test the effectiveness
of re-aligning all exomes to the most recent reference genome in ‘Approach 2’, and
to ascertain whether this time-consuming process was worth the increased accuracy of
called variant results. Therefore, in ‘Approach 1’ exomes were not re-aligned to hg19
before variants were called, and in ‘Approach 2’ re-alignment was carried out before
variant calling.
Both methods were run simultaneously in order to get quick and easy preliminary results
from the faster ‘Approach 1’, and then eventually higher quality results from the more
time-consuming full processing ‘Approach 2’. Ultimately ‘Approach 2’ was adopted
for all data pre-processing, since it seemed feasible to be able to process this large
amount of data in a reasonable amount of time on the systems available. ‘Approach 2’
is described in the subsequent re-alignment and variant calling sections.
This pre-processing step was not performed on the Lawrence et al. [2014] dataset, since
the cancer-specific variants had previously been called, essentially in the same was as
was adopted in ‘Approach 1’ but with additional filtering applied.
2.3.1.1 Re-alignment to hg19 reference genome
To ensure a directly comparable uniform set of sequences with which to call variants
from more accurately, the exomes obtained from TCGA were all processed in the
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same way. FASTQ format reads were extracted from BAM files using Picard (ver-
sion 1.43), and reads were realigned to the most up-to-date GRCh37/ hg19 reference
human genome sequence using BWA pre-alignment (version 0.5.9, Li and Durbin [2009])
in conjunction with Stampy (version 1.0.12, Lunter and Goodson [2011]) read mapper,
outputting re-aligned reads as BAM files. Aligning to an exome rather than a genome
reference would have reduced the computational time, however an exome reference se-
quence was not available at the time. Additionally, exome reads are often mixed with
whole-genome sequencing data due to the nature of the exome capture process before
sequencing. Therefore, aligning reads to an exome reference could result in off-target
reads being mapped to exons in the reference, which could in turn cause false-positive
variant calls. Using a whole-genome reference is hence beneficial in terms of accu-
racy of downstream variant calling. Alignment processing to sort and merge re-aligned
runs was performed with Samtools (version 0.1.14, Li et al. [2009]), a utility suite for
handling BAM files. Duplicate reads were marked using Picard version 1.43 5.
2.3.1.2 Single nucleotide variant calling
Genome Analyis Toolkit (GATK, version 0.5506, McKenna et al. [2010]) was used to
generate a set of coordinate intervals identifying indels for local realignment around
these gap positions (indels) to improve gap edges. Subsequently, in preparation for
improved variant calling, GATK was also used to recalibrate base quality alignment
scores based on co-variates calculated across the aligned reads.
GATK (version 0.5974) was then used to uniformly call all single nucleotide variants in
tumour:normal pairs (BAM alignments) for each patient using joint calling on the whole
genome [DePristo et al., 2011]. At the time exon target regions were not available, so
variant calling was not able to be limited to just exons and was instead carried out on
the whole genome.
5http://picard.sourceforge.net
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The tumour exome was compared to both the normal exome and the hg19 reference in
order to distinguish the important cancer-specific variants: those present only in the
tumour sample; from the germline polymorphisms: present in both the tumour and
normal samples but not the reference sequence. Those present in tumour and normal
are inherited variants common to all cells of the body (Figure 2.2). There were also
cases of control-specific variants called, where the variant was present only in the normal
sample. It is possible that this was due to a somatic mutation that had arisen in the
control sequence only, however these are rare because the mutation rate in the control
sequence is much lower than in the cancer. Another possibility is that it was actually a
true germline variant that has been missed in the tumour sequencing. Instances of this
could result from a loss of heterozygosity (LOH) event occurring in the tumour so that
the copy of the tumour sequence harbouring the germline mutation had been lost and
therefore could not be seen. Whichever the case, these mutations are not cancer-specific
so are not expected to be important in oncogenesis.
The process of variant calling involved joint calling to get a joint estimate of cancer
and control variants, in which the paired tumour and normal samples from the same
individual were compared simultaneously to the reference genome for each patient,
rather than using single calling in which the control and cancer would be separately
compared to the reference and then those results compared. This approach reduced
the chance of false-positives (both cancer-specific and control-specific) when germline
events were occurring, as more reads were available in the tumour and normal to base a
variant call on, which in turn increased the power of the analysis in correctly calling true
germline variants. Another type of cancer-specific false-positive occurs when the tumour
and normal are both wild-type and an event is inaccurately detected in the tumour.
This is likely to be a result of a machine-sequencing error, incorrect local alignment
of individual reads and discordant alignment of pairs rather than insufficient coverage.
However, paired calling can also help reduce this type of false-positive [Meyerson et al.,
2010]. The increased coverage in joint calling also reduced the chance of having to
account for missing data, which is dealt with later on in this pipeline. Joint calling












Figure 2.2: Joint single nucleotide variant calling on TCGA data. Evo-
lutionary tree of the reference, tumour and normal sequences. During joint calling,
both the tumour and normal exome sequences were simultaneously compared to the
hg19 reference genome sequence in order to identify and distinguish the cancer-specific
SNVs from the germline and control-specific SNVs. The green square represents a
germline polymorphism, the orange square displays a control-specific variant and the
blue square highlights a cancer-specific variant. The red letters denote nucleotide bases
in the DNA sequences.
improved the sensitivity and specificity of the variant calling process, making this a
more informative way to call SNVs as opposed to single-sample calling.
Nucleotide substitution and small insertion/ deletion (indel) variants were annotated
with predicted coding effects using SnpEff [Cingolani et al., 2012], e.g. synonymous vs.
non-synonymous. This produced VCF files. The variants were also cross-referenced
with dbSNP to show if the variants were known to be segregating in the population or
whether they were novel SNVs.
All called variants and consequence annotations were loaded into a MySQL (version
5.5.12) database for processing and interrogation. The schema for the TCGA database
in MySQL (called tcga pair exome) is shown in Figure 2.3.
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The main tables in the mySQL database are:
• sample - patient/sample information.
• var site - variant site information, containing 107,637,070 different loci with vari-
ant sites in at least one sample (many sites are variant in more than one sample).
• var site sample - cancer/control genotypes and qualities for a given patient at
a given site, with 850,586,532 different genotypes (mappings between the variant
site and the sample).
• consequence - variant consequences, with consequences for each possible tran-
script that a specific mutation can occur on, with 9,090,332 different protein-
coding consequences for the variant sites. Some sites do not have protein-coding
consequences (e.g. introns), so will not be included in this table. Others have
multiple consequences because the gene in which they are located has multiple
transcripts, and the consequence system is based on transcripts rather than genes.
This table shows how a mutation affects every transcript in which it occurs. For
one transcript for a given gene, the mutation might cause a stop codon but for
another it might fall within an intron and have no effect (and therefore will not
be in this table).
sample, var site and var site sample are linked by sample id and var site id fields.
consequence is linked to the relevant variant sites through the var site id field.
The helper tables are:
• gene transcript - maps Ensembl gene and transcript IDs to each other for load-
ing variant annotations from snpEff
• tss disease - maps codes from the atlas IDs to the disease types for each sample
The database contains 1007 patients, however two of these do not contain any cancer-
specific SNVs so were not used for any analysis.




















































Figure 2.3: MySQL TCGA database schema. This diagram shows the struc-
ture of the MySQL database, tcga pair exome, containing the TCGA data. This
database consists of six tables: “sample”, “var site sample”, “tss disease”, “conse-
quence”, “var site” and “gene transcript”. For each table the fields have been listed in
this schema. Arrows show how the tables are linked by fields during database querying.
2.3.1.3 Selecting cancer-specific filtered variants
Using the MySQL database of all uploaded variants called on the 1005 TCGA patients,
non-synonymous and synonymous SNVs were selected based on the following criteria:
• Cancer-specific heterozygous SNVs: SNVs with a heterozygous genotype
(0/1) in the tumour sample and reference genotype (0/0) in the normal sample
for a given patient.
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• Control-specific heterozygous SNVs: SNVs with a heterozygous genotype
(0/1) in the normal sample and reference genotype (0/0) in the tumour sample
for a given patient.
• Germline SNVs: SNVs with either a heterozygous (0/1) or homozygous (1/1)
genotype in the tumour and normal sample for a given patient (not necessarily
the same genotype in both).
For each of these three categories, a minimum genotype quality of 40 and a minimum
SNV site quality score of 40 was used to filter out low quality SNVs. This selection
process was carried out purely using Perl scripts to mine the MySQL database of
variants.
Stop codon mutations were also re-annotated as non-synonymous or synonymous, so
that stop codon mutations were included in the evolutionary analysis. Non-synonymous-
start, start-lost, stop-gained and stop-lost mutations were all re-annotated as non-
synonymous-coding mutations. Synonymous-start and synonymous-stop mutations
were re-annotated as synonymous-coding mutations.
The set of cancer-specific heterozygous SNVs were filtered further by removing those
that occurred as control-specific heterozygous SNVs or germline SNVs in other samples,
on a per patient basis, to enrich for somatic only mutations. This filtered set of cancer-
specific SNVs was used for the next stage of data processing in the TCGA pipeline.
In this quality control (QC) step, the cancer-specific heterozygous SNV set prior to
filtering consisted of 525,675 variants. However, post-filtering, 244,634 cancer-specific
heterozygous SNVs remained, resulting in a loss of 53.46% (281,041) of the original
variants.
Homozygous cancer-specific SNVs were not selected in these subsets as they are harder
to interpret. They could be errors since they are much rarer than heterozygous SNVs,
as it is unlikely that a random somatic mutation will occur in exactly the same po-
sition on both alleles (copies) of a gene. Alternatively a germline mutation followed
by an additional somatic mutation in the tumour on the other allele could have taken
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place (0/1 in control, 1/1 in tumour). However, the model would become much more
complicated when having to deal with a genotype of 0/1 in the normal and 1/1 in the
tumour. This analysis has therefore been restricted to the classic model of 0/0 in the
normal and 0/1 in the tumour to identify cancer-specific heterozygous variants. It is
possible that within those homozygous cancer-specific mutations (genotype of 1/1 in
the tumour) that have been excluded in this analysis, some could be the result of a
loss of heterozygosity (LOH) in the tumour plus a somatic inactivating mutation on
the remaining allele, which would appear as homozygous (1/1) in the tumour but is
actually representing a heterozygous somatic mutation in the cancer. By filtering out
homozygous cancer-specific mutations these types of LOH events are not considered.
However, LOH events would be included in the identified germline variants, using the
criteria of either heterozygous (0/1) or homozygous (0/0) in the tumour and control
samples. With additional sequencing depth information these events could be confirmed
(by observing regions of low sequencing depth).
Lawrence et al. [2014] mutations had already been filtered prior to this analysis, so this
assignment of cancer-specific variants step was not necessary for the Lawrence data.
2.3.1.4 Ambiguity of SNV and INDEL counting
There was ambiguity in the counting of unique SNVs and INDELs when using the
‘consequence’ table from the tcga pair exome mySQL database (containing all filtered
heterozygous cancer-specific TCGA SNVs and INDELs). This specific table included,
for each unique mutation, the consequence the mutation could have in each possible
transcript for that gene. This meant that the same unique mutation in a gene in a
patient was sometimes represented multiple times, once for each possible transcript
that the mutation could occur on for that gene for any given patient. Therefore it was
important to consider this and ensure that each unique mutation was counted only once
regardless of how many transcripts existed for that gene.
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To create a unique set of SNVs for gene/patient/disease/genome-based analysis in
Chapter 3 and deal with the ambiguity of counting unique mutations multiple times,
for each mutation in a gene for any given patient the transcript with the single most
severe consequence was used for counting annotation types. Since some genes in the
genome are overlapping, for cases where a single mutation affected two genes, the mu-
tation was counted twice (in both genes) for gene-based analysis, but only once for
patient/disease/genome-based analysis.
This same system was used for INDEL counts in Chapter 7.
To resolve this issue in the evolutionary analysis in Chapters 4, 5 and 6, in overlapping
genes the SNV mutation was counted in both genes, so the mutation was counted twice,
and the consequence from the mutation occurring on the longest transcript was used
before being edited onto the longest reference transcript.
2.3.1.5 Data management
In total the data pre-processing, consisting of re-alignment and variant calling, took
approximately ten days to process a tumour and normal sequence for a single patient,
the re-alignment being the time-limiting step. Without the re-alignment (as described
previously in “Approach 1”), this pipeline only took ∼36 hours to run per patient.
However, the running time of “Approach 2”, that was adopted in this analysis, was
optimised by processing multiple samples in parallel. Figure 2.4 shows the rate at which
TCGA data was becoming available compared to how fast it was able to be processed.
The black curve shows the cumulative availability of TCGA data, and the red and
green curves represent the rate at which the data was processed using “Approach 1”
and “Approach 2” respectively, as described earlier. The two straight lines show the
predicted rate of analysis that could be achieved for “Approach 2”. The purple line was
the expected rate if 32 exomes were to be run simultaneously, and the blue straight line
demonstrated the predicted rate at which 48 exomes could be run simultaneously. As
























Variant calling from pre−aligned (hg18) BAM files
Re−aligned to hg19
Re−aligned to hg19 (projection: 32 simultaneous)
Re−aligned to hg19 (projection: 48 simultaneous)
Figure 2.4: Measuring and estimating computational run times for TCGA
data. This plot shows the time scale of running both “Approach 1” (in red) and
“Approach 2” (in green). A projection of expected rates using “Approach 2” is shown
by the straight lines for running 32 (purple) and 48 exomes (blue) in parallel.
can be seen from the graph, running 48 exomes in parallel was predicted to be sufficient
in order to keep up with the rate of incoming data.
2.3.2 Preparation of sequences for evolutionary analysis
Prior to evolutionary analysis, sequences were produced by editing the filtered set of
cancer-specific TCGA variants, as well as the cancer-specific Lawrence mutations, onto
reference transcripts. For TCGA data only, regions of the consensus sequence were
annotated as missing if coverage was too low to confidently call a variant. Finally,
edited transcript sequences were converted into the correct format for evolutionary
analysis, with one file per gene containing transcripts aligned over all patients for that
gene.
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2.3.2.1 Editing TCGA and Lawrence cancer-specific variants onto refer-
ence sequences
To ensure only cancer-specific SNVs were present in the sequences used for evolutionary
analysis, reference sequences were used and just the cancer-specific variants were edited
onto these sequences. The reason for preparing new sequences and not using the tumour
sequences already available, was to ensure that the germline polymorphisms which were
originally present in the tumour sequences were not present in these new sequences and
therefore could not confound the evolutionary analysis (which was used specifically to
test for positive selection acting on somatic driver mutations in cancer exomes).
The longest reference transcript sequences for each gene, together with the longest
transcript exon coordinates and corresponding Ensembl gene IDs, were obtained from
Ensembl API version 65 for the TCGA data and Ensembl version 75 for the Lawrence
sequences [Flicek et al., 2014], both Ensembl versions based on the hg19 reference
genome assembly. Transcript IDs change with new Ensembl versions (new annotations),
so the longest transcript for each gene may differ between the TCGA and Lawrence
methods.
The filtered set of non-synonymous and synonymous heterozygous cancer-specific TCGA
mutations were mapped and edited onto the longest hg19 reference transcripts (coding
sequence) for the relevant protein-coding gene from Ensembl 65 using the Ensembl API
and Perl (version 5.14.1)6. The set of pre-called filtered Lawrence et al. [2014] cancer-
specific mutations were also edited onto the reference transcripts in the same way, but
using longest transcripts from the more recent Ensembl version 75 instead. For each
patient, only one transcript sequence was used for editing. This process is shown in
Figure 2.5.
For the Lawrence variant data only, the following information was first required before
editing, since the TCGA variants were annotated with this information in the previous
variant calling stage:
6http://www.perl.org/
Chapter 2. Methodology and data sources 85
Patient 1:  ATGGTCTCCACCTACCGGGTGGCCGTGCTGGGGGTG... 
Patient 2:  ATGGTATCCACCTACCGGGTGGCCGTGCTGGGGGCG... 
Patient 3:  ATGGTCTCCACCTACCGGGTGGCCGTGCTGGGGGTG... 
Patient 4:  ATGGTCTCCACCTACCGGGTGGGCGTGCTGGGGGCG... 
Patient 5:  ATGGTCTCCACATACCGGGTGGCCGTGCTGGGGGCG... 
Patient 6:  ATGGTCTCCACCTACTGGGTGGCCGTGCTGGGGGTG... 
Patient 7:  ATGGTCTCCACCTACTGGGTGGCCGTGCTGGGGGCG... 
Patient 8:  ATGGTGTCAACCTACCGGGTGGCCGTGGTGGGGGCG... 
 
Figure 2.5: Edited TCGA and Lawrence reference transcripts. Each line
represents the DNA sequence for a single patient in the alignment, as only one tran-
script was used per patient. Cancer-specific SNVs edited onto both the TCGA and
Lawrence reference transcripts are highlighted in red.
• Ensembl gene ID
• Ensembl transcript ID
• Peptide position
The Ensembl gene ID was necessary to map the mutation to the longest reference
transcript sequence obtained from Ensembl, and the peptide position differs depending
on the transcript the mutation has occurred in, so only the peptide position with
the longest Ensembl transcript ID was used for editing the mutation onto the longest
reference sequence.
This information was obtained from Ensembl (v75) using Variant Effect Predictor
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The Lawrence cancer-specific mutations were annotated with this additional informa-
tion before they were able to be edited onto the longest reference transcripts.
The mutation information input into VEP does not change with Ensembl version,
not unless the assembly changes which it has not in this case. However, the output
annotations from VEP can change with new Ensembl versions, therefore the Lawrence
data will have more up-to-date Ensembl (v75) annotations than the TCGA data which
was processed using Ensembl 65.
At this point of data processing, some SNVs were not edited onto the reference se-
quences if the variant did not occur in the longest transcript for that gene. SNVs
were also excluded if more than one mutation occurred in the same codon, as this rare
occurrence complicates some of the assumptions underlying the analyses used later.
The sequences edited with the Lawrence cancer-specific SNVs were then ready for
evolutionary analysis.
2.3.2.2 Missing data annotation
During DNA sequencing, the depth of coverage (sequence depth) varies across the
genome. For example, CpG regions are particularly prone to low coverage depth, partly
due to these CG-rich regions remaining annealed during amplification in sequencing
[Veal et al., 2012]. The coverage depth refers to the number of times a nucleotide is
read during sequencing [Sims et al., 2014], so the coverage of reads over a site in a sample
is the alternate read depth plus the reference read depth. Sequence depth is measured
by the amount of over-sampling. In whole genome sequencing, to detect mutations
with high sensitivity the 3 billion nucleotides of the human genome are covered at least
30-fold, which requires the generation of 90 billion bases of sequence data per sample.
However, in cancer samples the number must be increased to account for the decreased
purity and increased ploidy[Meyerson et al., 2010]. The lower the coverage, the harder
it is to correctly genotype a site from next-generation sequencing data.
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Coverage data has been calculated for the TCGA data, so to account and correct for
the problem of varying coverage, regions of low coverage were annotated as missing on
the TCGA transcript sequences previously edited with cancer-specific variants. Where
there was insufficient coverage in either the tumour or control sample to be able to
confidently call a variant, the position was annotated as missing. This process was
put in place to help reduce the rate of calling cancer-specific false-negatives where
coverage was poor in the tumour, as well as cancer-specific false-positive mutations
where coverage was reduced in the normal. A false-positive could result from a true
heterozygote call for a non-reference allele (true germline mutation) present in the
normal sample that was missed due to a lack of read coverage at that site in the normal.
Conversely, a false-negative would result from low coverage in the tumour sample, at
sites where a true cancer-specific variant is present but is not detected due to low
coverage depth in the tumour. This was an important step in ensuring that cancer-
specific variants were not underestimated in cases where there was a lack of coverage
in the tumour sequence, resulting in cancer-specific false-negatives which would lead
to under-representation of selection in subsequent evolutionary analysis. This step was
also necessary in avoiding the over-estimation of variants in cases where there was a
lack of coverage in the normal sequence, resulting in control-specific false-positives and
potentially causing true germline mutations to appear as cancer-specific variants.
Germline variants could be mistaken for control-specific variants in the same way, by
missing variants present in the tumour sample, resulting in a higher than expected rate
of control-specific SNVs due to false-positives. Control-specific false-positives could also
be caused by MMR-deficient cancers or drug treated cancers in which the incidence of
LOH is increased (loss of allele in the tumour sample) so that again true germline
polymorphisms appear as control-specific. However, much less control-specific variants
are expected compared to cancer-specific variants, due to the mutator phenotype in
cancer.
A read depth threshold for missing data was chosen using the empirically calibrated
SNV detection sensitivity correction plot in Figure 2.6, which was developed to quantify
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how much variation is missed at a given coverage [Meynert et al., 2014, 2013] for
heterozygous SNV sites. This calibration recall curve sensitivity was created using
germline heterozygous coding SNVs from TCGA control (non-tumour) data, for whole
exome sequences (plotted in pink) and whole genome sequences (plotted in blue) for
comparison using the same samples, and from heterozygous HapMap 3.3 [Consortium
et al., 2010] variant positions located within coding sequence as determined by Ensembl
72 [Flicek et al., 2013] as a gold-standard set of SNP calls for each sample [Meynert
et al., 2014]. Since this project used whole exome sequences, the relevant curve is the
pink TCGA-WXS curve. Along the x-axis is the read depth, and along the y-axis
the sensitivity at varying coverages is shown. The sensitivity measures the confidence
that a heterozygous SNV site will be detected if it is truly present. For example, a
heterozygous site with a read depth of 10X corresponds to a sensitivity of 0.95 in whole
exome sequences (shown by black horizontal line on plot), estimating that there is a 95%
chance that a true-positive heterozygous SNV will be called at a site with a coverage of
at least 10X in normal samples. These heterozygous sites (with a coverage of >=10X)
in the normal sample therefore have a <5% chance of missing a heterozygous SNV
in the normal (and calling a false-positive cancer-specific variant which is actually a
germline polymorphism).
A read coverage filter of 10X was chosen as the threshold in this analysis, and was
applied to the TCGA normal samples. This coverage cut-off was chosen as it has
previously been shown in Meynert et al. [2014] that this threshold of 10X at per-site
mapped depths results in a 95% sensitivity in detecting heterozygous SNPs in TCGA
whole exome sequences. Therefore, since only the heterozygous cancer-specific SNVs
were edited onto the reference transcript sequences in the previous step of this analysis,
by masking all sites with a read depth of <10X all other polymorphic sites can be
reliably called at a sensitivity of 95%. For consistency the same read coverage filter was
also applied to the tumour samples (to avoid false-negative cancer-specific variants).
However, the problem of cellular heterogeneity encountered in cancer populations makes
this recall ability correction slightly less reliable in tumour samples, as it can not be
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known precisely the likelihood of missing a variant that is present in the tumour sample.
However, it is especially important to account for this missing variant calls bias in
cancer data compared to other types of data because of the often low frequency at
which cancer mutations can be found in a heterozygous cell population. So although
tumour heterogeneity makes this correction method difficult in terms of reliability, it
is also more useful in cancer genomes and has not been addressed previously in cancer
studies.
Sites with a coverage of <=10X in either the tumour or normal samples were annotated
with “N” in the edited sequence alignments using Perl (version 5.14.1).
The transcript sequences edited with cancer-specific mutations were then ready for
evolutionary analysis after the missing data had also been annotated onto the sequences,
as can be seen in Figure 2.7.
Coverage information was not available for the Lawrence et al. [2014] data and these
detection sensitivity issues were ignored in the published analysis of this data, so this
step was only carried out on the fully re-processed TCGA dataset.
2.3.2.3 Coverage depth across tumour and normal exomes
The process of targeted capture and sequencing of the exome (exome-seq), as was used
for this project, is known to produce a relatively heterogeneous profile of read coverage
over target regions when compared to the more homogeneous whole-genome sequencing
(WGS). As a result, WGS yields improved SNP detection sensitivity across regions of
interest [Meynert et al., 2014]. Site level SNP detection sensitivity is defined as the
mapped read depth directly over a polymorphic site that is required to reliably call that
polymorphism [Meynert et al., 2014]. Despite this, the exome contains fewer repetitive
elements than non-coding regions present in the whole genome, and also contains most
of the causal disease variants identified to date, which is why protein-coding exomes
continue to be the focus of investigations into disease-causing variants.
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Figure 2.6: TCGA heterozygous SNV detection sensitivity calibration
curve. Plot quantifying how much variation is missed at a given coverage, with
depth at heterozygous SNV position plotted along the x-axis, and sensitivity (confi-
dence of calling a true heterozygous SNV if truly present at that position) along y-axis.
This plot was generated based on germline heterozygous coding SNPs in whole exome
(TCGA-WXS) and whole genome (TCGA-WGS) TCGA control samples. The error
bars are one standard deviation from the mean. A horizontal line has been drawn
where a depth of 10X meets the TCGA-WXS curve (pink), at a sensitivity of 95% for
heterozygous SNVs. Plot taken from work by Meynert et al. [2014, 2013]
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Patient 1:  ATGGTCTCCACCTACCGGGTGGCCGTGCTGGGGGTG... 
Patient 2:  ATGGTATCCACCTACCGGGTGGCCGTGCTGGGGGCG... 
Patient 3:  ATGGTCTCCNNNNNNCGGGTGGCCGTGCTGGGGGTG... 
Patient 4:  ATGGTCTCCACCTACCGGGTGGGCGTGCTGGGGGCG... 
Patient 5:  ATGGTCTCCACATACCGGGTGGCCGTGCTGGGGGCG... 
Patient 6:  ATGGTCTCCACCTACTGGGTGGCCGTGCTGGGGGTG... 
Patient 7:  ATGGTCTCCACCTACTGGGTGGCCGTGCTGGGGGCG... 
Patient 8:  ATGGTGTCAACCTACCGGGTGGCCGTGGTGGGGGCG... 
 
Figure 2.7: Edited and annotated TCGA reference transcripts. Reference
transcripts edited with cancer-specific TCGA heterozygous SNVs, after having also
been annotated with missing data, shown as green “Ns”. The red letters denote the
cancer-specific SNVs that have previously been edited onto the sequences. Each line
represents a different patient, as only one transcript sequence was used per patient.
The issues that negatively impact on SNP detection sensitivity in exome-seq include:
PCR amplification, which tends towards lower coverage of GC-rich regions caused by
annealing during amplification and compromises the uniformity of coverage; and the
preferential capture of reference sequence alleles by exome-seq target probes, which bi-
ases the allele distribution away from alternate alleles at heterozygous sites [Meynert
et al., 2014]. To account for the reference allele bias in exome-seq, more reads are
required to successfully genotype heterozygous SNPs than would be needed in WGS,
and to account for the greater variability in coverage in exome-seq a greater mean
on-target depth is required to identify the same proportion of SNPs in exome-seq com-
pared to WGS. It is therefore important to access the coverage depth across the exome
(Figures 2.8 and 2.9), and quantify the depth required for reliable heterozygous SNP
detection in exome-seq, as has been done in this analysis (described above).
Figures 2.8 and 2.9 show the range of coverage across all 1,005 tumour exomes and all
1,005 normal exomes respectively, using a cumulative density function to assess what
fraction of the genome is covered by more than a certain number of reads. Figure 2.8
shows that the majority of sites (ranging from 55% to 90% of the target region covered)
have ≥10X fold coverage in the tumour exomes. Similarly, in Figure 2.9, the majority
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of sites (ranging from 60% to 90% of the target region covered) are shown to have ≥10X
fold coverage in the normal exomes.
BEDtools (coverage) [Quinlan and Hall, 2010] was used to read in both the 1,005 tumour
BAM files and a BED file containing the target capture regions from Illumina, who use
Nextera Rapid Capture Exome kit to prepare libraries for exome sequencing. Perl was
used to run this function over all 1,005 exomes in batches of 100 exomes, as is shown
in Listing 2.2 for 100 tumour exomes. The -hist option was used to output a summary
histogram for all features in the BED files, which was then used to plot a cumulative
frequency distribution in R. This process was repeated for the analysis of coverage in
the 1,005 normal exomes.
1 #! / usr / bin / p e r l −w
2
3 open (LIST , ”/ array11 /TCGA/ bam real igned /NEWTUMOUR/
BAMfileListTumour batch1” ) ;
4
5 my @ i n f i l e s ;
6
7 whi le ( de f ined (my $ l i s t=<LIST>) )
8 {
9 chomp $ l i s t ;
10
11 push ( @ i n f i l e s , $ l i s t ) ;
12 }
13
14 f o r each my $ i n f i l e ( @ i n f i l e s )
15 {
16 chomp $ i n f i l e ;
17
18 my $cmd = ” bedtoo l s coverage −h i s t −abam / array11 /TCGA/ bam real igned /
$ i n f i l e −b nexte ra rap idcaptur e exome ta rge t ed r eg i on s v1 . 2 . bed | grep ˆ
a l l > $ i n f i l e . h i s t . a l l . tx t ” ;
19
20 pr in t ”$cmd\n” ;
21 system ($cmd) ;
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22 }
Listing 2.2: perl script to retrieve coverage information over target exome regions
(run over BAM files in batches of 100)
It can be seen that the coverage varies over each exome in both distributions. It is
expected that the uniformity of read coverage would be improved in WGS, as well
as reducing bias of allele ratios, both of which would require a lower read coverage
than is required for the detection of SNPs in exome-seq. Other benefits of using WGS
over exome-seq include the improved detection of genomic rearrangements and disease-
causing polymorphisms in non-coding regions of the genome [Meynert et al., 2014].
2.4 Data analysis and software used
2.4.1 Evolutionary analysis in PAML
2.4.1.1 Selection and substitution models used
Evolutionary analysis was carried out in the software suite PAML (Phylogenetic Anal-
ysis by Maximum Likelihood) version 4 [Yang, 2007], a package of programs for phylo-
genetic analyses of DNA and protein sequences using maximum likelihood. The PAML
package includes the programs baseml and codeml amongst others. The program baseml
is used for the maximum likelihood analysis of nucleotide sequences. The program
codeml is formed by merging two old programs: codonml, which implements the codon
substitution model of Goldman and Yang [1994] for protein-coding DNA sequences,
and aaml, which implements models for amino acid sequences. These two are now
distinguished by the variable seqtype in the control file codeml.ctl, with a “1” for codon
sequences and “2” for amino acid sequences. The programs baseml, codonml and aaml
use similar algorithms to fit models by maximum likelihood, the main difference being
that the unit of evolution in the Markov model, referred to as a “site” in the sequence,
is a nucleotide, a codon or an amino acid for the three programs respectively. Markov
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Figure 2.8: Visualisation of coverage depth over 1005 TCGA tumour ex-
omes. The coverage per base for the normal samples has been plotted as a cumulative
distribution describing the fraction of targeted bases that were covered by more than
a certain number of reads. The black dashed line denotes a read depth of 10X, which
shows that the fraction of capture target bases covered by ≥ 10X ranges from 60%
to 90% in the normal exomes in the TCGA dataset, with the exception of one exome
that appears to have some problems with only 60% of capture target bases with read
depth recorded.
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Figure 2.9: Visualisation of coverage depth over 1005 TCGA normal ex-
omes. The coverage per base for the normal samples has been plotted as a cumulative
distribution describing the fraction of targeted bases that were covered by more than
a certain number of reads. The black dashed line denotes a read depth of 10X, which
shows that the fraction of capture target bases covered by ≥ 10X ranges from 60% to
90% in the normal exomes in the TCGA dataset.
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process models are used to describe substitutions between nucleotides, codons or amino
acids, with substitution rates assumed to be either constant or variable among sites. A
sites model was used in this analysis, as described below, which allows the substitution
rates to vary among sites.
Using the codeml program within this package, a codon-based model was implemented
to analyse single base substitutions and obtain an omega ratio. This model was chosen
over a single substitution site model such as JC69 [Jukes and Cantor, 1969], due to the
difficulty of dealing with the ambiguity of whether a single site is non-synonymous or
synonymous as without considering the sequence context in the codon a single site could
be both synonymous and non-synonymous depending on the change. This ambiguity
is removed at the codon level, since the codon site can only be non-synonymous or
synonymous. Therefore the added context of the codon sequence makes a codon model
more robust than a single nucleotide site model.
Parameters were estimated that provide the model that best describes the observed
data, using the codeml program within this package, to implement a codon-based
model which . Analysis in PAML was performed on a per gene basis. Three files for
each gene were required for the running of PAML: a control file (codeml.ctl), a tree
structure file (codeml.dnd) and a sequence data file (codeml.aln).
The tree file contained a list of the patient IDs in the sequence data file. This file shows
how the sequences are related, which in this case is equally as they are artificially
generated as opposed to species’ sequences.
The sequence data file for each gene contained the sequence alignments prepared for
PAML, over all patients in that gene with one reference transcript sequence per patient
containing edited cancer-specific mutations. The “native” format in PAML for this file
is the PHYLIP format [Felsenstein, 2005] shown in Figure 2.10. The first line con-
tains the number of sequences (patients) and the length of the sequence in nucleotides.
Subsequent lines of the file contain the name of the sequence (patient ID in this case)
followed by three spaces and the sequence.
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!4 60!
sequence 1   AAGCTTCACCGGCGCAGTCATTCTCATAAT!
CGCCCACGGACTTACATCCTCATTACTATT!
sequence 2   AAGNNNCACCGGCGCAATTATCCTCATAAT!
CGCCCACGGACTTACATCCTCATTATTATT    !
sequence 3   AAGCTTCACCGGCGCAGTTGTTCTTATAAT!
TGCCCACGGACTTACATCATCATTATTATT!
sequence 4   AAGCTTCACCGGCGCAACCACCCTCATGAT!
CGCCCACGGACTTACNNNNNNNNNACTATT!
Figure 2.10: PHYLIP data file format. An example sequence data file containing
four sequences (each representing a different patient) each of 60 nucleotides in length
over a whole single gene. Missing data is represented by Ns.
The control file (example in Appendix B) specified the names of the sequence data file,
the tree structure file, and models and options for the analysis. In the control file,
the variable seqtype was set to “1” (codonml), which carried out maximum likelihood
analysis on codons of protein-coding DNA sequences using codon substitution models
to detect positive selection. The non-default variables model and NSsites were set to
“0” and “0 1 2” respectively, which implements a site model in which the ω ratio is
allowed to vary among sites (among codons in this case) [Nielsen and Yang, 1998, Yang
et al., 2000]. By entering three values for NSsites (0,1,2), three models are fitted to
the same data: M0 (one ratio), M1a (nearly neutral) and M2a (positive selection) as
is explained in Table 2.4. M1a and M2a are useful as a pair of models in forming a
likelihood ratio test of positive selection. The more complex nested model M7 vs M8
is also used for the same comparison, which is a more powerful test than the M1a-
M2a comparison which may be more accurate. However, the simpler model M1a-M2a
was chosen in this analysis due to its faster run time and more robust framework.
The control variable codonFreq was set to “2”, which specifies the equilibrium codon
frequencies in the codon substitution model, calculated from the average nucleotide
frequencies at the three codon positions.
For each gene, PAML produced an omega (ω) ratio as a measure of the magnitude of
selection and log likelihood values as a measure of the fit of the model. The ω ratio
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Table 2.4: Parameters in the site models used by codeml. This table shows
the parameters used for each of the three codeml models that have been specified in this
PAML analysis. #p is the number of free parameters in the omega (ω) distribution.
Parameters in parentheses are not free, so are not counted. In the likelihood ratio test
comparing M1a (2 free parameters) against M2a (4 free parameters), the degrees of
freedom (df) = 4-2 = 2.
Model NSsites #p Parameters References




M1a (neutral + con-
straint)
1 2 p0 (p1 = 1 - p0), ω0
< 1, ω1 = 1
Nielsen and Yang
[1998], Yang et al.
[2005]
M2a (M1a + positive
selection)
2 4 p0, p1 (p2 = 1 - p0 -
p1), ω0 < 1, ω1 = 1,
ω2 > 1
Nielsen and Yang
[1998], Yang et al.
[2005]
is calculated using evolutionary non-synonymous and synonymous substitution rates
in codon model M0 (Equation 2.1), where Ka is the non-synonymous substitution rate
(number of non-synonymous changes at non-synonymous sites) and Ks is the synony-
mous substitution rate (number of synonymous changes at synonymous sites). Ks acts
as a proxy for neutral selection, as synonymous mutations are assumed to be selectively
neutral. The maximum likelihood framework estimated two log likelihood (lnL) val-
ues, lnL1 from model M1a and lnL2 from model M2a. Model M1a models purifying
selection as well as neutrality, constraining omega to less than or equal to 1 (Equa-
tion 2.2), whereas model M2a allows for positive selection as an additional parameter
(Equation 2.3). Model M2a is parametised with the same values as model M1a but





Model 1: ω <= 1 (2.2)
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Model 2: ω <= 1 | ω > 1 (2.3)
During this analysis a problem occurred in which it was discovered that Model M2a
was not always able to find the global maximum log-likelihood, sometimes reporting a
local log-likelihood optima instead. This resulted in a negative difference between the
log likelihoods of the two models, with the lnL value for M2a smaller than that of M1a.
A negative delta-lnL is not possible if true optima have been found, since of the two
nested models the one with two more parameters (M2a) should fit the data better than
M1a resulting in a positive delta-lnL. A negative delta therefore means that a local
optima has been found in the more complex model.
To overcome this problem and avoid obtaining a local log-likelihood optimum, the
“codeml” analysis was adapted to run ten times over each gene, instead of being re-
stricted to just one iteration. The least negative log-likelihood value for M2a from these
ten iterations was assumed to be the global optimum and so was then used to calculate
the p-value for that gene. However, the global log-likelihood was not always found
after ten iterations. dchisq in R cannot cope with a negative delta so in these cases the
negative differences were changed to 0 before a p-value was calculated, resulting in a
very insignificant p-value which would not affect the significant results.
Codeml was adapted for use on cancer data. These innovations included using pairwise
deletion at regions where data had been annotated as missing, by setting the cleandata
option to “0”, and including stop codon variants (stop-lost and stop-gained) in the
model by recoding them as non-synonymous variants in the evolutionary analysis. The
benefit of using pairwise deletion is that only sites which had missing characters in
the pair were removed, rather than removing all sites involving ambiguity characters
from all sequences using PAML’s default of complete deletion (cleandata = “1”). This
leaves more sequence information for PAML to work with which increases the power.
Using this option was made possible by the fact that all sequences in this analysis were
artificially generated and therefore treated as equally related, since cancer mutations
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for each patient had been edited onto the same reference transcript for each gene, as
opposed to using species data in which using pairwise deletion could lead to systematic
biases. The ambiguity character that has been used in this analysis is “N”, as is shown
in Figure 2.10.
2.4.1.2 Limitations of PAML
Saturation and recombination can both be limiting factors when using codeml in PAML
to estimate omega values. However neither are considered a problem in my dataset,
since all alignments input into PAML are artificially generated by editing the cancer-
specific SNVs onto a reference transcript for each patients, and hence all sequences are
sufficiently related to the reference transcript to be aligned. As a result, there is a lack
of divergence which can cause the saturation problem for which omega ratio estimations
are commonly criticised. Additionally, no recombination is present in this dataset since
cancer evolution is an example of clonal selection; this is why it was possible to edit
the cancer-specific variants for each gene onto the same reference transcript for each
patient.
2.4.2 Computational and statistical tests
2.4.2.1 P-value and FDR
As model M2a is nested within model M1a in codeml, we can calculate if the fit of the
observed data to the more complex than M1a model (M2a) is better than is expected by
chance. This is calculated as two times the difference in log-likelihood between models
compared to a χ2 distribution with two degrees of freedom (the difference in number of
free parameters between models)[Yang et al., 2005]. This was implemented using the
dchisq function in R version 3.0.0 [R Core Team, 2013], to generate a p-value for each
gene as a measure of the significance of positive selection.
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The set of p-values was then adjusted for multiple comparisons using p.adjust in R
version 3.0.0 [R Core Team, 2013]. The particular method we used was the “BH” (aka
“fdr”) method of Benjamini and Hochberg [Benjamini and Hochberg, 1995], which
controls the false discovery rate (FDR), the proportion of false discoveries expected
amongst the rejected hypotheses. This produced a set of FDR values, one per gene,
which was used as the final measure of significance for each gene accounting for mul-
tiple hypothesis testing. The false-discovery rate is a less stringent condition than the
family-wise error rate (controlled by other correction methods such as the Bonferroni
correction), so is more powerful as an adjustment method.
2.4.2.2 Log transformation of FDR
FDR values were plotted in R version 3.0.0 [R Core Team, 2013] against the omega
estimates calculated in PAML for each gene, with FDR along the y-axis and omega
along the x-axis. However, FDR values were log transformed for easier visualisation
of significant genes with small FDR values using log10(-log10(FDR)), so that the most
significant FDR values (smallest FDR values) were plotted at the top of the graph. The
“double logging” was employed to stretch the less-significant end of the distribution
which remains informative but is otherwise difficult to visualise. Logging presented
a problem for any FDR values of zero, since log10(-log10(0)) equals infinity and so
cannot be plotted. To overcome this, all FDR values of zero were changed to 1e-200 in
R (version 3.0.0) [R Core Team, 2013], which is then small enough to show on the plot
that these genes are highly significant.
2.4.2.3 Graphics
R (version 3.0.0) [R Core Team, 2013] package ‘RColorBrewer’ (version 1.0-5)7 was
used to highlight points in colour on the omega scatter plots in Chapter 4, Chapter 5
and Chapter 6 corresponding to significant genes after they had been plotted in R.
7http://colorbrewer.org
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2.4.3 Preparation for functional sub-region analysis
As an initial test for functional sub-region analysis of short linear motifs in PAML,
the TP53 gene was used as a prototype and was split into phosphorylation sites and
non-phosphorylation sites using Perl (version 5.14.1)8. The perl script split the set
of gene sequence alignments based on modification site annotations and produced two
output files, one containing the concatenated sites of interest (phosphorylation sites),
and the other containing the remainder of the gene. Gene codons were annotated us-
ing experimentally validated phosphorylation site coordinates taken from PhosPhoSite
version 1.0 [Hornbeck et al., 2012]. PhosPhoSite version 1.0 [Hornbeck et al., 2012] is
based on UniProt [UniProt Consortium, 2014] protein sequences, which was incompati-
ble with our transcripts that were sourced from Ensembl. A coordinate transformation
system was employed to overcome this annotation problem that used Exonerate (ver-
sion 2.2) [Slater and Birney, 2005] to map the protein sequence from PhosPhoSite to
the Ensembl sequence for the longest transcript we used. This was to ensure that the
sequences matched, and in cases where they did not match a coordinate transformation
system was implemented to transform the PhosPhoSite coordinates in order to realign
the proteins to the Ensembl transcripts so that the correct genomic position for each
site was reported.
Globular protein domain coordinates for all genes were obtained from Ensembl version
75 [Flicek et al., 2014] using Perl, in preparation for kinase domain analysis. These
coordinates were then applied as vector annotations to the gene-based data of the
protein kinase MAPK1 to split the data into kinase domain and remaining part of
gene, in the same way as was done for the phosphorylation site data.
For both linear motif and globular domain prototype analysis, each file containing either
the functional regions of the gene or the non-functional concatenated regions was then
ready to be run through PAML for evolutionary analysis, to obtain two separate omega
estimates for each gene.
8http://www.perl.org/
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Somatic single nucleotide variant
analysis
3.1 Introduction
The calling of cancer-specific variants is challenging due to heterogeneity between sam-
ples and variability between analysis pipelines [Alioto et al., 2014]. In this chapter I
characterise genome-wide SSNV patterns across different tissues of origin and compare
results between my own calling of TCGA samples (n=1,005) with the variant calls of
the Lawrence dataset (n=4,728). 701 patients with coding mutations overlap between
each dataset (an additional patient is present in both datasets but does not harbour
any coding mutations in the Lawrence dataset).
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Table 3.1: TCGA SSNV counts by cancer type. For the heterozygous filtered
TCGA cancer-specific SNVs, this table shows the total number of SSNVs over all
patients for each cancer type and in the whole dataset of 1005 patients, as well as
the mean number of SSNVs per patient for each cancer type and the whole dataset
calculated by dividing the total number by the number of patients in that cancer type
or dataset (rounded to the nearest whole number).


















Whole dataset 244,634 243
3.2 Results
3.2.1 Summary variant statistics on a per patient basis
3.2.1.1 TCGA SNVs
Following filtering against control-specific and germline variants the TCGA dataset
contains 244,634 heterozygous somatic (cancer-specific) single nulceotide variations (SS-
NVs); averaging at 243 SSNVs per patient (Table 3.1, Table 3.2). A breakdown of these
SSNVs by cancer type is shown in Table 3.1. These mutations include 185,378 non-
synonymous (missense) mutations and 59,256 synonymous mutations (Table 3.2).
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Table 3.2: TCGA SNV counts by mutation type. For the heterozygous fil-
tered TCGA cancer-specific SNVs, this table shows the total number of each mutation
type in the whole dataset of 1,005 patients, as well as the mean number of each mu-
tation type per patient calculated by dividing the total count for each class by 1,005
(rounded to nearest whole number). Stop-gained, stop-lost, start-lost and start-gained
(non-synonymous start) have been included in the non-synonymous coding category.
Synonymous-start and synonymous-stop have been included in the synonymous coding
category.
Mutation type Total no. of SSNVs Mean no. of SSNVs per patient
Non-synonymous coding 185,378 184
Synonymous coding 59,256 59
Total 244,634
Non-synonymous to synonymous mutations were present at a rate of 3.13 (2dp), where
stop and start codon mutations were included as non-synonymous (stop and start codon
mutations are included in later evolutionary analysis in calculation of omega ratios).
Rates were calculated using values from Table 3.2.
3.2.1.2 Lawrence SNVs
Lawrence data was processed through the Broad Institute’s filtering and annotation
pipeline using their analysis platform “Firehose” to obtain a set of cancer-specific mu-
tation calls. I filtered this dataset specifically for single nucleotide variants. The filtered
Lawrence et al. [2014] dataset consists of 1,663,133 SSNVs, averaging at 352 SSNVs
per patient (Table 3.3, Table 3.4). A breakdown of SSNVs by cancer type is shown
in Table 3.3. These mutations include 520,588 non-synonymous (missense), 200,694
synonymous, 44,501 nonsense (stop-gained), 174 nonstop (stop-lost) and 897,176 non-
coding mutations over all patients (Table 3.4). The 765,957 coding mutations in the
Lawrence dataset have been highlighted in green in Table 3.4, and used for all subse-
quent analysis in this chapter (for direct comparison with coding TCGA SSNVs) and
in the evolutionary analysis of subsequent chapters.
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Table 3.3: Lawrence SSNV counts by cancer type. For the Lawrence cancer-
specific SNVs, this table shows the total number of SSNVs over all patients for each
cancer type and in the whole dataset of 4,728 patients, as well as the mean number of
SSNVs per patient for each cancer type and the whole dataset calculated by dividing
the total count by the number of patients in that cancer type or dataset (rounded to
the nearest whole number). This dataset includes all coding and non-coding variants,
however a subset of coding mutations only have also been shown. Cancer types high-
lighted in red are those that have lost patients with no coding SSNVs in the coding
SSNVs dataset. 16 patients were lost altogether over six different cancer types.
Disease















BLCA 99 30736 310 99 26673 269
BRCA 892 82889 93 888 41953 47
CARC 54 1604 30 54 1564 29
CLL 159 7002 44 159 2718 17
CRC 233 121831 523 233 77141 331
DLBCL 57 12574 221 57 10660 187
ESO 141 101303 718 141 17280 123
GBM 291 48654 167 291 19047 65
HNSC 384 67329 175 384 58756 153
KIRC 417 26335 63 417 22240 53
LAML 196 7450 38 194 3701 19
LUAD 404 235951 584 400 137207 343
LUSC 177 262148 1481 177 60314 341
MED 92 1261 14 92 1085 12
MEL 118 284456 2411 118 72226 612
MM 206 78910 383 205 10038 49
NB 76 1766 23 76 1515 20
OV 316 41543 131 316 17545 56
PRAD 137 29132 213 133 2513 19
RHAB 32 283 9 31 235 8
UCEC 247 219976 891 247 181546 735
Whole
dataset
4,728 1,663,133 352 4,712 765,957 163
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Table 3.4: Lawrence SSNV counts by mutation type. For the Lawrence cancer-
specific SNVs, this table shows the total number of each mutation type in the whole
dataset of 4,728 patients, as well as the mean number of each mutation type per patient
calculated by dividing the total count for each class by 4,728 (rounded to nearest whole
number). Coding SSNVs have been highlighted in green, and used for all subsequent
analysis in this chapter. All other SSNVs in this table fall in non-coding regions that
have been captured by targeted exome capture techniques prior to sequencing.
Mutation type Total no. of SSNVs Mean no. of SSNVs per patient
3’ UTR 39,455 8
5’ UTR 13,216 3
Intron 784,909 166
Non-synonymous 520,588 110
Non-coding transcript 1,789 0
Nonsense mutation 44,501 9
Nonstop mutation 174 0
Promoter 7,743 2




Total coding SSNVs 765,957
Using just the coding mutation counts (non-synonymous, nonsense, nonstop and syn-
onymous), the ratio of non-synonymous (including nonsense and nonstop mutations)
to synonymous mutations was estimated at a rate of 2.82 (2dp) (Table 3.4). This is
lower than the non-synonymous:synonymous mutation ratio calculated for the TCGA
dataset, indicating an increased number of non-synonymous SSNVs relative to synony-
mous SSNVs in the TCGA dataset compared to the Lawrence dataset.
While the TCGA dataset consists of just heterozygous SSNVs (genotype of 0/1 in
the tumour sample), filtering of the Lawrence cancer-specific mutations is not well
documented. It is possible that they have not filtered out homozygous cancer-specific
SNVs (with a genotype of 1/1 in the tumour sample).
In Table 3.4 nonsense and nonstop mutations are also known as stop-gained and stop-
lost mutations, respectively. These stop codon mutations are often associated with a
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loss of function and hence are commonly seen in tumour suppressor genes. Amongst the
remaining coding base substitutions in Table 3.4, synonymous mutations do not alter
the encoded protein so are not considered to have a functional effect on the encoded
protein, and non-synonymous (missense) mutations change the encoded protein which
can result in either activation (in oncogenes) or inactivation (in tumour suppressor
genes) of the encoded protein.
In Table 3.4, ‘non-coding transcript’ refers to a mutation in a region of the genome
that is transcribed into RNA but is not translated into a protein. In this table syn-
onymous and silent mutations have been grouped together, since Lawrence et al. [2014]
have classed some synonymous mutations as silent. However these terms are not in-
terchangeable. Silent is the broad term for all DNA mutations without phenotype or
consequence that do not change the protein and they can occur in either non-coding
regions of the genome or in exons. Synonymous mutations on the other hand only oc-
cur in coding exons and do not change the encoded amino acid. However synonymous
mutations are not always silent. For example a synonymous non-silent mutation could
occur that does not alter the encoded amino acid but does knock out an exonic splicing
enhancer.
It should be noted that the total number of SSNVs recorded in the Lawrence paper
was 3,078,483, which is almost double the number of SSNVs (1,663,133) recorded in the
Lawrence dataset used in this analysis (Table 3.3, Table 3.4). A possible explanation
for this discrepancy could be that these missing variants were not in genes and were
therefore not downloaded for this analysis, since the MAF files were downloaded on a
per gene basis. However since Lawrence et al. [2014] used exome sequences, not many
mutations would have been captured outside of the genic regions so these mutations
would not account for much of the missing variation.
Chapter 3. Somatic single nucleotide variant analysis 109



























1 10 100 1000 10000
(a) TCGA



























1 10 100 1000 10000
(b) Lawrence
Figure 3.1: Histograms of mutation count distribution over all patients in
TCGA and Lawrence datasets. Histograms showing the distribution of coding
cancer-specific mutation counts for each patient over (A) whole TCGA dataset of
1,005 patients and (B) whole coding SSNVs Lawrence dataset of 4,712 patients. The
x-axis denotes the SNV count on a log scale (log transformed for easier visualisation),
but x-axis labels remain the original mutation count values. The y-axis represents
the frequency of patients for each mutation count class. The area under the graph
represents the total number of patients.
3.2.1.3 Comparison of TCGA and Lawrence datasets
In Figure 3.1, the coding mutation counts per patient over all tumour types have been
compared for each dataset. As can be seen from the histograms, the distributions are
very similar for both datasets, both displaying an approximately normal distribution
with most patients having an intermediate mutation frequency. However, both distri-
butions are slightly skewed to the left with a tail of very high mutation frequencies.
This is most likely to be caused by the presence of UCEC patients in both the TCGA
and Lawrence datasets that on average exhibit a higher SSNV rate than other tumour
types (Table 3.3).
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3.2.2 SSNVs on a per gene basis
Figure 3.2 shows the mutation frequency per patient for each gene in both the TCGA
and Lawrence datasets. In both plots the relative coding SNP abundance when number
of patients is taken into account has been shown, by dividing the total SNV count within
each gene by the number of patients in the dataset. So in the TCGA plot, each gene’s
SNV count has been divided by 1,005 and in the Lawrence plot each SNV count per
gene has been divided by 4,712. This allows a more direct comparison between datasets.
Both plots show that TTN exhibits the highest mutation frequency of all genes in both
the TCGA and Lawrence datasets. However TTN is known to be the largest gene in the
human genome with an open reading frame of 107,976 nucleotides. The length of this
gene could therefore introduce a bias, since length of gene has not been accounted for in
these plots. Within this analysis all cancer types have been combined so that the TCGA
and Lawrence plots consist of 17 and 21 different tumour types respectively. It should
also be noted that although there is considerable overlap between TCGA and Lawrence
patients with 701 coding patients over 11 tumour types overlapping both datasets, they
are not identical sample sets, with varying cancer types and patient numbers per specific
cancer type. These differences may influence the results seen in Figure 3.2, potentially
generating a bias towards genes that are more frequently mutated in certain tumour
types consisting of a larger proportion of patients. Consequently any differences cannot
solely be attributed to differences in pipelines.
In Figure 3.3, gene length has also been accounted for by dividing the average SSNV
count per patient for each gene by the length of the gene in nucleotides (using the
longest CDS length for each gene). By running this gene length correction, TTN is
removed from the top most frequently mutated genes. TP53 is now shown to contain
the most mutations (per nucleotide) of all genes in both the TCGA and Lawrence
datasets. TP53 is known to be the most mutated gene in cancer, supporting such
results. PTEN and VHL are also detected as being highly significantly mutated in both
the TCGA and Lawrence datasets, both of which are known cancer genes implicated in
tumour progression, with PTEN known to be causally implicated in glioma, prostate























































































































Figure 3.2: Mutation frequency on a per gene basis. For each gene, the coding
mutation frequency averaged over all patients has been plotted along the y-axis for
(A) the whole TCGA dataset and (B) the whole coding SSNVs Lawrence dataset of
4,712 patients. Genes with the highest mutation frequencies have been highlighted in
red.
and endometrial cancers and VHL known to be a driver gene in renal cancers [Futreal
et al., 2004].
A problem encountered in this gene-based analysis was that some genes did not have
a CDS length recorded in Biomart. It is possible to find non-coding transcripts for a
gene (nonsense-mediated mRNA decay (NMD) targets) annotated in Ensembl, which
could be the source of genic transcripts without CDS measures. However, since there are
usually multiple transcripts for a gene, it would be expected that at least one transcript
contained a CDS for each protein-coding gene. Therefore this was an unusual finding.
Furthermore, some gene IDs were not reported in Biomart at all (with or without a
CDS length).





























































































































































Figure 3.3: Mutation frequency on a per gene basis with gene length nor-
malisation. For each gene, the coding mutation frequency per nucleotide averaged
over all patients has been plotted along the y-axis for (A) the whole TCGA dataset
and (B) the whole coding SSNVs Lawrence dataset of 4,712 patients. The length of the
gene has been accounted for by dividing the mutation frequency per patient for each
gene by the length (in nucleotides) of the longest CDS (portion of the mRNA tran-
script that is translated into protein) of that gene. Genes with the highest mutation
frequencies per nucleotide have been highlighted in red.
3.2.3 Patients overlapping datasets
3.2.3.1 Mutation frequency comparison
701 patients with coding SSNVs are present in both the TCGA and Lawrence datasets.
For each of these patients I plotted the mutation frequency per Mb in the TCGA dataset
against the mutation frequency per Mb in the Lawrence dataset in Figure 3.4. I observed
a strong positive linear correlation between the TCGA and the Lawrence mutation
frequencies (Pearson’s cor=0.82, p-value <2.2e-16), illustrating a strong concordance
between the shared patients in the two datasets, with each analysis pipeline identifying
a similar total number of SSNVs per patient.
However, there seems to be a small subset of patients that are right-shifted in Fig-
ure 3.4, exhibiting a markedly higher mutation frequency in TCGA compared to that























































































































































































































































































































































Mutation frequency relationship between datasets
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Figure 3.4: Mutation frequency relationship between datasets for shared
patients. The TCGA and Lawrence mutation frequencies per Mb have been plotted
for the 701 patients that are present in both the TCGA and Lawrence datasets, to
investigate the concordance between the two different pipelines. Both the x-axis and
y-axis has been log transformed for clearer visualisation of the correlation, however
the axis labels are the true mutation frequency values. For each patient, the mutation
frequency in the TCGA dataset is plotted along the x-axis and the corresponding
mutation frequency in the Lawrence dataset is plotted along the y-axis.
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of Lawrence. These patients were identified as outliers in Figure 3.5. Colour-coding of
these 24 patients reveal that multiple cancer types are encompassed by these outlier pa-
tients (GBM, COAD, BRCA, OV and KIRC) however most (n=16; highlighted in red)
are of the tumour type GBM (total number of GBM patients shared by both datasets =
171). It was important to investigate this discrepancy as it could indicate that either a
systematic lack of sensitivity in the Lawrence calling pipeline or systematic over-calling
in my TCGA pipeline was responsible for skewing results, either of which would have
a detrimental effect on downstream analysis.
To investigate the group of 24 outliers further, the mutation spectrum of this subset
compared to the rest of the set was examined in Figure 3.6 and Figure 3.7, to decipher
if these 24 patients have a specific mutation spectrum in the TCGA dataset compared
to the Lawrence dataset, which could help elucidate the source of the observed high
mutation frequency in TCGA in terms of how SNVs have been called differently between
the two pipelines.
The group of 701 overlapping patients was split into two subsets: the 24 outliers and
the 677 non-outliers (remaining patients). The proportions of the six different possible
base-pair substitutions for each of the 24 outlier patients was plotted in Figure 3.6,
separately for the variants called in the TCGA dataset and the variants called in the
Lawrence dataset. The same was done for the non-outlier patients in Figure 3.7.
The mutation spectra for the TCGA outlier subset in Figure 3.6 is more uniform than
the mutation spectra observed in Lawrence for the outlier subset. The Lawrence out-
lier subset is also more similar to both the TCGA and Lawrence non-outlier subsets
in Figure 3.7, with much higher C→T substitutions than any other mutation class,
although the spectra in Figure 3.7 show much more variation in base-pair substitutions
across all patients, but this is expected since more patients were used for these plots
and because many patients from multiple cancer types have been grouped together that
are assumed not to have a specific mutation spectrum. This result leads to the spec-
ulation that the TCGA variant calling pipeline is miss-calling SNVs, and calling more
SNVs generally of all types of mutation making the spectrum more uniform across all























































































































































































































































































































































Mutation frequency relationship between datasets













































Figure 3.5: Mutation frequency relationship outliers. A subset of 24 outliers
each with a higher than expected TCGA mutation frequency compared to the mutation
frequency in the Lawrence dataset observed in Figure 3.4 have been highlighted here.
Dotted grey lines have been drawn on the plot to show the range of the mutation
frequencies of these patients. The patients have been colour-coded according to their
cancer type, shown in the legend.



































































































































































Overlap outliers in Lawrence data
(b) Lawrence
Figure 3.6: Mutation spectrum of patients in outlier subset from patients
overlapping both datasets. Outlier subset consists of 24 patients. For each patient
the proportion of each mutation class has been plotted along the y-axis in (A) the
TCGA dataset and (B) the Lawrence dataset.
six base-substitution classes. I speculated that this may be due to increased INDELs
in these patients, which can lead to spurious SNV calls around INDELs due to the
misalignment of flanking sequence. The TCGA pipeline did not specifically exclude
SSNV calls proximal to INDELs. It is undocumented whether the Lawrence pipeline
did.
To investigate this in just the 16 GBM patients, the mySQL TCGA database (tcga pair exome)
of variants was mined to look for a possible elevated rate of INDEL calls in these 16
GBM outlier patients. Within the subset of 16 GBM patients, the mean number of
INDELs per patient was found to be 16,289 (rounded to the nearest whole number),
compared to 202 INDELs per patient in the non-outlier subset containing 685 patients
(Figure 3.8). These two subsets were also compared to the average INDEL rate over
the whole TCGA dataset of 1,005 patients (1,037 INDELs per patient), and also over
the whole group of 701 overlap patients present in both TCGA and Lawrence datasets
(569 INDELs per patient). Figure 3.8 clearly displays an inflated INDEL rate in the
subset of 16 GBM outlier patients compared to the other 685 patients that overlap both















































































































































































Overlap non−outliers in Lawrence data
(b) Lawrence
Figure 3.7: Mutation spectrum of patients in non-outlier subset from pa-
tients overlapping both datasets. Non-outlier group consists of all 677 patients
not present in the outlier subset. For each patient the proportion of each mutation
class has been plotted along the y-axis in (A) the TCGA dataset and (B) the Lawrence
dataset.
datasets. Therefore, this higher rate of INDELs could explain the high rate of SNVs
that are being called in these 16 GBM patients, as a result of over-calling SNVs next
to INDELs. The INDEL rate in the 16 GBM patients was also compared to that of the
other 192 GBM patients present in the whole TCGA dataset, to ensure that the high
INDEL rate observed in the 16 GBM patients is specific to these 16 patients and is not
common to all GBM patients (which would not explain the high rate of SNVs in just
these 16 patients). Figure 3.8 shows that, as suspected, the INDEL rate is considerably
inflated in the 16 GBM outlier patients compared to both the whole GBM subset of
208 patients (3374 INDELs per patient) and the subset of 192 GBM patients exclusive
of the 16 outlier patients (2,298 INDELs per patient). Although it does seem that
GBM patients exhibit a slightly increased frequency of INDELs compared to the rest
of the TCGA patients when the 16 outlier patients are excluded, however a significant
increase in INDELs is observed in the 16 outliers. This result confirms that a higher
frequency of INDELs in the 16 GBM outlier patients is likely to be the cause of the
high rate of called SNVs in these same patients.
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Figure 3.8: INDEL counts in TCGA dataset. This bar plot shows the mean
number of cancer-specific heterozygous INDELs per patient in the 16 GBM outlier pa-
tients compared to the INDEL counts in: the whole TCGA dataset (1,005 patients),
the overlap group of 701 patients, the 685 non-outlier patients in the overlap group
(overlap patients excluding the 16 GBM outliers), all 208 GBM patients in the TCGA
dataset and the 192 GBM patients that are not present in the GBM outlier subset of
16 patients. INDELs were only included in each of these four datasets if the cancer
and control genotype quality >= 30. Includes only coding INDELs (since the “con-
sequence” table was used to mine the tcga pair exome database, which contains only
coding variants).
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3.2.3.2 Concordance of variants detected
As a powerful way to show the differences and similarities between the two analyses, a
QC check was performed to show how much variation was shared between the TCGA
and Lawrence analyses for the 701 overlapping patients.
117,289 variants were detected over the 701 overlapping patients in the TCGA pipeline
in this project, and 114,753 variants were detected in these same patients through the
Lawrence pipeline. 71,845 of these variants concur in both the TCGA and Lawrence
analyses, resulting in 61% (71,845 of 117,289) of the total TCGA variants being the same
as 63% (71,845 of 114,753) of the total Lawrence variants. The average concordance of
detecting the same variant in both analyses was therefore estimated as ∼62%.
Variants common to both analyses were found in 688 of the 701 patients, resulting in
13 patients (2%) that did not exhibit any shared variants between the two analyses.
3.2.4 Mutation spectra
The mutation profile can be defined as the mutational pattern incorporating information
such as the numbers of each class of mutation, the DNA sequence flanking each mutated
base and in transcribed regions whether the transcribed or untranscribed strand is pref-
erentially mutated [Stratton, 2011]. Different mutation spectra may indicate differing
underlying biology to tumours [Greenman et al., 2007, Pleasance et al., 2010a,b] and
could influence susceptibility of different genes to subsequent mutational perturbation.
There are potentially many alternate ways to define a mutation spectrum. For the
purposes of this work I define the mutation spectrum based on the relative proportions
of different nucleotide substitutions.
3.2.4.1 TCGA
Table 3.5 shows the relative proportions of the six different classes of nucleotide substi-
tutions in the TCGA dataset, for each of the 17 tumour types. The mean proportions of
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mutations have not been adjusted to account for the normal proportions of nucleotide
changes across the genome. However, for the purposes of tumour classification based
on mutation spectrum, as all tumours are assayed for mutational changes over a com-
mon interval (the targeted exome) this simple measure serves well for classification and
comparison between patients. A higher C→T rate relative to all other mutation types
is seen in the normal human genome and in cancer, and is also observed in Table 3.5
(highest proportions for each disease are highlighted in blue). However, for lung cancers
(LUAD and LUSC) C→A/G→T transversions are observed as the commonest change.
This is expected, as lung cancer is known to have a specific mutational signature de-
fined by elevated C→A/G→T substitutions caused by tobacco exposure [Pleasance
et al., 2010b].
In Table 3.6 the transition:transversion ratios have been calculated for each cancer type.
In germline cells and in cancer, transitions are usually more common than transversions
[Rubin and Green, 2009], which is the case for most cancers assayed here, particularly
STAD which displays the highest number of transition mutations (A→G/T→C and
C→T/G→A) relative to transversions. However, GBM, KIRC, LUAD, LUSC and OV
all exhibit an increased rate of transversions (A→C/T→G, A→T/T→A, C→A/G→T
and C→G/G→C) compared to transitions. For LUAD and LUSC this can be explained
by the increased frequency of C→A/G→T caused by tobacco in lung cancers.
Figure 3.9 displays the distribution of mutation frequencies and spectra over the 17
different tumour types present in the TCGA dataset of 1,005 patients. LUAD has the
highest median mutation frequency, which could be attributed to the mutator pheno-
type caused by exposure to tobacco in lung cancer.
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Table 3.5: Mutation profile proportions in TCGA dataset. For each of the 17
cancer types in the TCGA dataset, the mean proportion ± standard deviation (3dp)
per patient has been tabulated for each of the six mutation classes. The proportion
has been calculated as a proportion of the total number of variants in that cancer type
for that patient. For each patient the proportions were calculated and then the mean
and standard deviation was taken over all patient proportions for each cancer type.
The highest proportion for each cancer type is highlighted in blue.
Disease Mutational signature
A⇒C/ A⇒G/ A⇒T/ C⇒A/ C⇒G/ C⇒T/
T⇒G T⇒C T⇒A G⇒T G⇒C G⇒A
BLCA 0.044±0.021 0.115±0.078 0.050±0.035 0.118±0.051 0.218±0.129 0.455±0.124
BRCA 0.064±0.050 0.132±0.058 0.076±0.046 0.150±0.068 0.136±0.072 0.442±0.106
CESC 0.039±0.044 0.046±0.033 0.016±0.013 0.087±0.028 0.229±0.106 0.582±0.075
CRC 0.076±0.033 0.124±0.032 0.090±0.040 0.155±0.025 0.101±0.048 0.454±0.117
GBM 0.065±0.050 0.128±0.082 0.076±0.064 0.117±0.065 0.109±0.100 0.505±0.192
HNSC 0.033±0.023 0.106±0.050 0.059±0.040 0.180±0.131 0.144±0.077 0.478±0.148
KIRC 0.087±0.046 0.163±0.062 0.110±0.057 0.189±0.068 0.122±0.062 0.329±0.084
KIRP 0.102±0.052 0.191±0.069 0.110±0.068 0.144±0.074 0.115±0.052 0.338±0.159
LAML 0.058±0.093 0.165±0.161 0.062±0.147 0.108±0.116 0.120±0.164 0.487±0.227
LGG 0.056±0.069 0.177±0.108 0.038±0.039 0.090±0.070 0.081±0.064 0.557±0.149
LUAD 0.045±0.042 0.091±0.059 0.079±0.035 0.356±0.155 0.136±0.060 0.294±0.117
LUSC 0.032±0.012 0.109±0.044 0.082±0.029 0.348±0.115 0.140±0.057 0.289±0.102
OV 0.100±0.032 0.145±0.035 0.120±0.034 0.189±0.053 0.163±0.040 0.282±0.070
PRAD 0.070±0.051 0.131±0.161 0.056±0.083 0.151±0.122 0.090±0.063 0.503±0.126
STAD 0.073±0.048 0.106±0.050 0.060±0.040 0.127±0.043 0.075±0.033 0.559±0.089
THCA 0.087±0.098 0.153±0.111 0.162±0.150 0.090±0.104 0.079±0.082 0.430±0.183
UCEC 0.046±0.037 0.134±0.078 0.029±0.028 0.135±0.063 0.062±0.053 0.594±0.109
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Table 3.6: Transition:transversion ratios in TCGA data. For each of the 17
cancer types in the TCGA dataset, the transition:transversion ratio (3dp) has been
calculated by dividing the total number of transition mutations over all patients in
a cancer type by the number of transversions for that cancer type. The number of
patients in each subset has not been accounted for since that is not necessary when















































































































































































































































































































































































































Figure 3.9: Distribution of mutation rates and spectra across tumour types in the TCGA dataset. Using the filtered
set of cancer-specific heterozygous SNVs (non-synonymous and synonymous), the mutation frequency and spectra has been plotted
for each of the 17 tumour types over 1,005 patients. Each dot represents a single patient, with the y-axis value indicating the total
frequency of somatic SNVs in the exome per Mb. Tumour types have been ordered by their median somatic mutation frequency in
ascending order. Within each tumour type, individual patients have also been ordered in ascending somatic mutation frequency along
the x-axis. The mutation rates have been log transformed before plotting to spread out the data points for clearer visualisation, but
the annotated y-axis values are the actual frequencies. The lower panel shows the relative proportions of the six different possible
base-pair substitutions, as indicated in the legend. Sample sizes (patient numbers for each tumour type) are shown along the top of
the plot. R code used to generate plot can be found in Supplementary Appendix C where plot has been re-implemented from scratch.
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An interesting pattern is observed betweethe comparison of GBM patients in Figure 3.9
and in the corresponding distribution in the Lawrence dataset (Figure 3.14). The
mutation spectra of GBM differs between the two datasets, and is an obvious outlier.
In TCGA there is a sub-group of patients with very high mutation frequencies and a
very different mutation profile compared to the rest of the GBM patients. This pattern
is not observed in the Lawrence dataset. Since all GBM patients used in the TCGA
analysis were available to the Lawrence study, it was speculated that the GBM patients
with high mutation frequency and differing mutation profile in the TCGA dataset were
for some unknown reason excluded from the Lawrence dataset, and therefore not present
in the Lawrence dataset. To find out whether this was true, the patients common to
both datasets were identified. Of the 208 TCGA GBM patients, 171 are common to
both datasets, leaving 37 patients that are only present in the TCGA dataset. These
37 patients have been highlighted in black in Figure 3.10, showing that they are indeed
predominately the patients with the highest mutation frequencies and unique mutation
spectrum, explaining the difference between GBM in Figure 3.9 and Figure 3.14.
The question is then why were these 37 patients excluded from the Lawrence GBM
subset, when they were available for download at the time of the Lawrence et al. [2014]
study? Did they use different inclusion criteria? First, the tumour subtype was looked
into. Of the four distinct subtypes of glioblastoma (GBM): proneural, neural, classical
and mesenchymal, these 37 patients do not fall into a specific subtype and in fact cover
all four subtypes, so this cannot be the exclusion criteria. Second, the sample type
was investigated. 36 of the patients are primary tumours with blood derived normal
matched samples, and one is primary tumour with solid tissue sample. And the other
171 patients overlapping both datasets also use both primary tumour, blood derived
normal and solid tissue sample, so they cannot have filtered based on sample type.
Another possibility was that exclusion was based on the tissue source center. However,
again the 37 patients were from a variety of tissue source centers.
It is possible that these 37 GBM patients were excluded by Lawrence et al. [2014] due to
their distinctly different mutation spectra and high mutation rates compared to the rest
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of the GBM patients. Perhaps these patients have a high rate of INDELs and therefore
were discarded due to the difficulty in calling SNVs near INDELs. The 16 GBM patients
with high INDEL rates from the outlier set within the overlap patients also have a very
high mutation frequency (brown dots in Figure 3.10). This also matched up with the
mutation spectrum observed in the group of 16 GBM outliers (Figure 3.6) which is
more uniform than the other patients, due to general over-calling. However if these 37
patients (black dots) were excluded based on high INDEL rates then it should follow
that the 16 GBM patients would also be excluded from the Lawrence dataset, however
they are present in both datasets. TCGA have filtered their tumour samples based
on necrosis and heterogeneity data using stringent criteria (allowing samples with less
than 50% necrosis and at least 80% tumour nuclei), so these 37 patients clearly have
not been excluded due to high levels of necrosis.
The mutation spectra proportions have been displayed as a bubble plot in Figure 3.11,
using all 1,005 patients in the TCGA dataset. Of the 12 possible mutation changes,
the highest proportions are C→T and G→A transitions. This supports what is seen
generally in the human genome in evolution, since C→T is the most common point
mutation, corresponding to G→A occurring on the complementary strand of DNA,
which is why the proportions are identical for both C→T and G→A. In cancer however,
this pattern can be altered due to exposure to carcinogens such as tobacco smoke in
lung cancer and UV radiation in melanoma, which is what has been investigated in
this chapter by looking at the varying mutation spectra across both the TCGA and
Lawrence datasets in specific tumour types.
From the TCGA data I used 53 LUSC patients and 38 UCEC patients to generate
two further bubble plots (Figure 3.12), to inspect the mutation profile of tumour types
more closely and observe differences between tumour types. LUSC is known to have
a specific mutation spectrum caused by smoking, demonstrated by an elevated pro-
portion of C→A (G→T on the complementary strand) transitions [Pleasance et al.,
2010b], a pattern induced by tobacco’s carcinogens. This is reflected in my results and
provides evidence that the mutational spectrum of specific cancer types is influenced by




































































Figure 3.10: Mutation rates and spectra for TCGA GBM patients excluded
from Lawrence dataset. This plot has been taken from Figure 3.9 to investigate the
interesting mutation spectra observed in GBM in the TCGA dataset (compared to the
GBM mutation spectra in the Lawrence dataset). Dots highlighted in black represent
the 37 patients that are present in the TCGA dataset only. All other patients (grey
dots) are present in both TCGA and Lawrence datasets. Brown dots represent the 16
GBM patients present in the overlap outlier set in Figure 3.5, so these patients are
present in both the TCGA and Lawrence dataset.


















Figure 3.11: Mutation spectra bubble plot for whole TCGA dataset. For
whole TCGA dataset over all 17 tumour types and 1,005 patients, the proportions of
the 12 different possible base-pair substitutions have been shown, with the four possible
reference bases along the x-axis and the four possible alternate bases (that the reference
base has mutated to in the cancer) along the y-axis. The size of the red circles represent
the proportion of nucleotide substitutions from the total number of cancer-specific
mutations. Raw counts over whole dataset have been used to calculate proportions,
rather than mean values per patient. For each mutation class, the proportion was
calculated by dividing the mutation count for that mutation class by the total number
of mutations in the dataset.





































Figure 3.12: Mutation spectra bubble plots comparison by cancer type for
LUSC and UCEC in TCGA dataset. For (A) all 53 LUSC patients and (B) all 38
UCEC patients in the TCGA dataset, the proportions of the 12 different possible base-
pair substitutions have been shown, with the reference allele along the x-axis and the
alternate allele along the y-axis. The size of the red circles correspond to the size of the
proportion. Raw counts over whole dataset have been used to calculate proportions,
rather than mean values per patient. For each mutation class, the proportion was
calculated by dividing the mutation count for that mutation class by the total number
of mutations in the dataset.
environmental exposures. It can be seen that there is variation between the mutation
profiles of LUSC and UCEC, with C→T (G→A) being the most common change in
UCEC patients, however this is also the most common substitution observed in most
cancer types [Kandoth et al., 2013].
As illustrated here, mutational signatures have been shown to vary depending on differ-
ent environmental exposures. For example, Greenman et al. [2007] has shown substan-
tial variation in the mutational profiles of 210 diverse cancers reflecting the different
exposures acting on the different cancers. To investigate how mutation spectra vary
across tumour types in the TCGA dataset, a hierarchical cluster tree and heatmap
was generated in Figure 3.13 for the 1,005 patients in the TCGA dataset. Patients
were clustered according to their single nucleotide mutation spectrum. Interestingly,
the colour-coded panel corresponding to tumour type across the top of the heatmap
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shows that these patient clusters are not specific to certain tumour types, as might be
expected. So patients with the same tissue of origin do not necessarily have similar
mutation spectra, suggesting there is minimal correlation between mutation spectra
and tissue of origin.
3.2.4.2 Lawrence
Table 3.7 shows the relative proportions of the six different classes of nucleotide sub-
stitutions in the Lawrence dataset, for each of the 21 tumour types. As in the TCGA
dataset, LUAD and LUSC are shown to exhibit more C→A/G→T mutations. However,
interestingly NB also shares this mutation profile, suggesting that neuroblastoma and
lung cancers could be caused by a similar mutational mechanism perhaps as a result of
parental smoking.
MEL has been shown to harbour the highest number of transitions relative to transver-
sions in Table 3.8, with a much higher transition rate compared to other tumour types,
which is a known signature of UV exposure [Pleasance et al., 2010a].
Figure 3.14 displays the distribution of mutation frequencies and spectra over the 21
tumour types in the Lawrence dataset. In contrast to Figure 3.9, for the cases where
the same tumour type is present in both datasets, Figure 3.14 and Figure 3.9 do not
shown identical results. However, the numbers are variable for each of these cancer
types between datasets and the TCGA data contains fewer patients than the Lawrence
data, which could explain the differences. The biggest difference is observed in GBM,
which has previously been investigated in Figure 3.10. Figure 3.14 replicates what has
already been performed in the Lawrence et al. [2014] supplementary material. Although
these two plots do not look identical despite using the same data, a direct comparison
cannot be made as the patient numbers available for download were different from the
number of patients used in the Lawrence et al. [2014] main paper and from the number
of patients used for this plot in the supplementary material (which is also different from
the number stated in the main paper).
Chapter 3. Somatic single nucleotide variant analysis 130
Figure 3.13: Mutation spectra hierarchical cluster tree and heatmap over
whole TCGA dataset. This plot shows how all 1,005 patients in the TCGA dataset
cluster by their mutation spectra, over all 17 different tumour types. Each tumour
type is represented by a different colour in the horizontal panel across the top of the
heatmap. The 17 different colour codes are well mixed across the dataset suggesting
that, based on single nucleotide variants, these patients do not cluster by tumour type
as might be expected. A colour key shows the scale of values within the heatmap,
which are based on correlations between individuals, with a value of 1 indicating the
highest identity between two patients.
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Table 3.7: Mutation profile proportions in Lawrence dataset. For each of the
21 cancer types in the coding SSNVs Lawrence dataset of 4,712 patients, the mean
proportion ± standard deviation (3dp) per patient has been tabulated for each of
the six mutation classes for all coding SSNVs. The proportion has been calculated
as a proportion of the total number of variants in that cancer type for that patient.
For each patient the proportions were calculated and then the mean and standard
deviation was taken over all patient proportions for each cancer type. The highest
proportion for each cancer type is highlighted in blue.
Disease Mutational signature
A⇒C/ A⇒G/ A⇒T/ C⇒A/ C⇒G/ C⇒T/
T⇒G T⇒C T⇒A G⇒T G⇒C G⇒A
BLCA 0.023±0.022 0.079±0.051 0.029±0.023 0.111±0.066 0.249±0.100 0.509±0.083
BRCA 0.046±0.048 0.113±0.073 0.055±0.050 0.144±0.096 0.136±0.099 0.507±0.139
CARC 0.085±0.065 0.161±0.075 0.092±0.059 0.143±0.089 0.107±0.101 0.412±0.156
CLL 0.047±0.060 0.183±0.100 0.063±0.096 0.191±0.147 0.063±0.065 0.452±0.162
CRC 0.047±0.032 0.100±0.054 0.046±0.033 0.142±0.061 0.056±0.041 0.609±0.108
DLBCL 0.088±0.065 0.142±0.065 0.066±0.039 0.129±0.113 0.076±0.043 0.499±0.139
ESO 0.138±0.122 0.125±0.057 0.053±0.026 0.133±0.053 0.068±0.044 0.483±0.127
GBM 0.031±0.027 0.122±0.076 0.044±0.030 0.106±0.052 0.072±0.039 0.626±0.109
HNSC 0.031±0.030 0.110±0.071 0.059±0.063 0.153±0.089 0.156±0.091 0.492±0.145
KIRC 0.084±0.041 0.170±0.060 0.107±0.046 0.197±0.064 0.116±0.051 0.326±0.082
LAML 0.032±0.055 0.116±0.121 0.067±0.139 0.124±0.140 0.061±0.085 0.601±0.202
LUAD 0.036±0.043 0.087±0.047 0.083±0.057 0.365±0.148 0.123±0.059 0.306±0.138
LUSC 0.029±0.013 0.104±0.034 0.077±0.028 0.333±0.119 0.159±0.071 0.298±0.093
MED 0.038±0.086 0.106±0.122 0.041±0.068 0.205±0.173 0.063±0.123 0.547±0.205
MEL 0.023±0.021 0.054±0.043 0.030±0.020 0.051±0.053 0.031±0.042 0.810±0.148
MM 0.080±0.061 0.140±0.072 0.070±0.047 0.130±0.065 0.094±0.058 0.485±0.115
NB 0.051±0.164 0.059±0.068 0.052±0.065 0.427±0.241 0.100±0.134 0.311±0.208
OV 0.060±0.035 0.127±0.053 0.080±0.045 0.177±0.065 0.162±0.070 0.394±0.117
PRAD 0.053±0.059 0.124±0.118 0.055±0.056 0.154±0.118 0.087±0.083 0.526±0.178
RHAB 0.065±0.111 0.064±0.104 0.026±0.076 0.126±0.129 0.085±0.152 0.633±0.241
UCEC 0.037±0.031 0.114±0.069 0.032±0.026 0.146±0.068 0.078±0.075 0.592±0.115
It is clear from the pattern of mutation spectra across patients in Figure 3.14 that
melanoma (MEL) has the highest median mutation frequency of all the tumour types,
and rhabdoid tumour (RHAB) patients have the lowest mutation rates. These results
support findings of higher mutation rates in cancers affected by environmental exposures
such as UV radiation, and lower mutation rates in childhood cancers [Meyerson et al.,
2010, Stratton, 2011]. Most of the cancers shown in Figure 3.14 have a more common
intermediate frequency shown by the mutation frequency curves flattening out in the
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Table 3.8: Transition:transversion ratios in Lawrence data. For each of the
21 cancer types in the coding SSNVs Lawrence dataset of 4,712 patients, the tran-
sition:transversion ratio (3dp) has been calculated by dividing the total number of
transition mutations over all patients in a cancer type by the number of transversions
for that cancer type. The number of patients in each subset has not been accounted for
since that is not necessary when estimating ratios. The cancer type with the highest





























































































































































































































































































































































































































































































































































































































































Figure 3.14: Distribution of mutation rates and spectra across tumour types in the Lawrence dataset. Using the set
of cancer-specific coding SNVs, the mutation frequency and spectra has been plotted for each of the 21 tumour types over 4,712
patients. Each dot represents a single patient, with the y-axis value indicating the total frequency of somatic SNVs in the exome
per Mb. Tumour types have been ordered by their median somatic mutation frequency in ascending order. Within each tumour
type, individual patients have also been ordered in ascending somatic mutation frequency along the x-axis. The mutation rates have
been log transformed before plotting to spread out the data points for clearer visualisation, but the annotated y-axis values are the
actual frequencies. The lower panel shows the relative proportions of the six different possible base-pair substitutions, as indicated
in the legend. Sample sizes (patient numbers for each tumour type) are shown along the top of the plot. None of the 291 Lawrence
GBM patients were lost when filtering out the 16 patients with no coding SSNVs. R code used to generate plot can be found in
Supplementary Appendix C, re-implemented from scratch.
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The mutation spectra proportions have been plotted as a bubble plot in Figure 3.15,
using all 4,712 patients in the Lawrence dataset. Of the 12 possible mutation changes,
the highest proportions are C→T (G→A) transitions, as was seen in the TCGA dataset
in Figure 3.11.
In Figure 3.14 it can be seen that the majority of MEL patients appear to have a very
specific mutation profile with mostly C→T mutations (or G→A on the complemen-
tary strand), although the MEL patients with lower mutation frequencies have a much
smaller proportion of this particular mutation class. The larger group of melanoma
patients exhibit a spectrum indicative of UV-induced damage, since UV exposure is
known to cause a signature of high mutation rates in melanoma with mostly C→T
substitutions. To illustrate further how mutation spectra can vary within a particular
tumour type, the 118 MEL patients in the Lawrence dataset were split into two dis-
tinct groups based on their mutation spectra. This was done using cluster analysis and
plotted in a dendrogram in Figure 3.16. The red line shows where the data was split
into two groups. In Figure 3.17, the two MEL groups from Figure 3.16 were plotted
in two separate bubble plots. As can be seen the larger subset ‘Group 2’ has a far
higher proportion of C→T changes than the smaller ‘Group 1’, which is also observed
in Figure 3.14. ‘Group 1’ also has more C→T changes than any other change but it
is less pronounced than in ‘Group 2’. This much higher frequency of C→T transitions
compared to that normally expected in human evolution is a signature of UV radiation
[Pleasance et al., 2010a], which is known to contribute to the development of melanoma.
This result suggests that the smaller subset of patients with much lower mutation rates
may be affected by tumours that are not caused by UV-induced damage.
Approximately 50% of melanomas are known to harbour activating mutations in BRAF,
which are known to be most common in patients whose tumours arise on skin without
chronic sun-induced damage [Ascierto et al., 2012]. Among the BRAF mutations ob-
served in melanoma, over 90% are at codon 600, and among these over 90% are a single
nucleotide substitution resulting in a valine to glutamic acid change (BRAFV600E:
nucleotide 1799 T→A (A→T on complementary strand); codon GTG→GAG; genomic


















Figure 3.15: Mutation spectra bubble plot for whole Lawrence dataset. For
whole coding SSNVs Lawrence dataset over all 21 tumour types and 4,712 patients,
the proportions of the 12 different possible base-pair substitutions have been shown,
with the four possible reference bases along the x-axis and the four possible alternate
bases (that the reference base has mutated to in the cancer) along the y-axis. The
size of the red circles represent the proportion of nucleotide substitutions from the
total number of cancer-specific mutations. Raw counts over whole dataset have been
used to calculate proportions, rather than mean values per patient. For each mutation
class, the proportion was calculated by dividing the mutation count for that mutation
class by the total number of mutations in the dataset.














Figure 3.16: Dengrogram of MEL patients in coding SSNVs Lawrence
dataset clustered by single nucleotide variant spectra. Dendrogram generated
through cluster analysis shows how the 118 MEL patients in the Lawrence dataset
cluster by mutation spectra. A horizontal red line has been drawn at the point where
the data can be split into two groups (‘Group1’ on the left containing 104 patients
and ‘Group 2’ on the right containing 14 patients) with distinctly different mutation
spectra.
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(a) MEL group 1

















(b) MEL group 2
Figure 3.17: Mutation spectra bubble plots comparison by mutation signa-
ture for two MEL sub-groups in Lawrence dataset. For (A) all 104 patients in
MEL “group 1” and (B) 14 patients in MEL “group 2” in the coding SSNVs Lawrence
dataset of 4,712 patients, the proportions of the 12 different possible base-pair substi-
tutions have been shown, with the reference allele along the x-axis and the alternate
allele along the y-axis. The size of the red circles correspond to the size of the propor-
tion. Raw counts over whole dataset have been used to calculate proportions, rather
than mean values per patient. For each mutation class, the proportion was calcu-
lated by dividing the mutation count for that mutation class by the total number of
mutations in the dataset.
position 140453136). It therefore may be expected that the smaller subset of patients
with lower mutation rates are more commonly affected by BRAF mutations than the
larger group of melanoma patients with mostly C→T mutations, and could explain
the difference in mutation spectrum between the two groups. This was investigated
by searching for enrichment of BRAF mutations in both groups. In ‘Group 1’ there
are a total of 46,307 non-synonymous mutations (including 43,682 missense, 2,624 non-
sense and 1 nonstop) spread over 12,255 genes. In ‘Group 2’ there are a total of 702
non-synonymous mutations (including 652 missense and 50 nonsense) spread over 637
genes. Most of these genes in both groups are hit by a single non-synonymous mutation,
however the most commonly mutated gene in ‘Group 1’ is TTN hit 441 times, and in
‘Group 2’ is APC hit 8 times across the dataset. BRAF is the 11th most commonly hit
gene in ‘Group 1’ with 66 non-synonymous mutations in 64 different patients, and the
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12th most commonly hit gene in ‘Group 2’ with 3 non-synonymous mutations in 3 pa-
tients. Overall 69 of the 114 (61%) patients with melanoma have mutations in BRAF.
Within ‘Group 1’ 64 of the 104 (62%) patients harbour mutations in BRAF, however
within ‘Group 2’ only 3 of the 14 (21%) patients have non-synonymous mutations in
BRAF. Of the 66 BRAF mutations in ‘Group 1’, 59 (89%) are the V600E mutation.
Of the 3 BRAF mutations observed in ‘Group 2’, all (100%) are the V600E mutation.
Overall, this suggests that BRAF mutations are not the source of the specific mutation
profile in ‘Group 2’.
As has been shown previously [Pleasance et al., 2010a,b], lung cancer and melanoma are
known to have a specific mutational profile due to their exposure to tobacco smoke and
UV radiation respectively. Therefore it might be expected that other cancer types also
have a specific mutational profile, which has been investigated in Figure 3.18. However,
this figure shows that the clustering of 4,712 patients containing coding SSNVs in the
Lawrence dataset based on mutation spectra does not seem to correlate with the tissue
of origin, which was also seen in Figure 3.13. However, it is difficult to see how exactly
the tumour types are spread throughout the clusters, since there are so many patients
in this dataset. The fact that patients of the same cancer type do not cluster together
by mutational profile suggests that mutation spectra is not primarily dependent on the
tissue of origin.
3.2.4.3 TCGA and Lawrence dataset comparison
The mutation spectra of two different cancers from each dataset have been compared
in the heatmaps in Figure 3.19. GBM and OV have been compared from the TCGA
dataset, and CRC and NB from the Lawrence dataset. GBM and OV show very little
clustering by tumour type, suggesting that these two cancers do not have their own
distinctive mutation spectra which distinguishes them from each other. This result is
expected, as in Figure 3.9 GBM has some patients with a similar mutation profile to OV
patients. The similarities between the mutation spectra of some of the GBM patients
(with high mutation rates) and the OV patients in TCGA was the motivation for using
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Figure 3.18: Mutation spectra hierarchical cluster tree and heatmap over
whole Lawrence dataset. This plot shows how 4,712 patients in the coding SSNVs
Lawrence dataset cluster by their mutation spectra, over all 21 different tumour types.
Each tumour type is represented by a different colour in the horizontal panel across the
top of the heatmap. The 21 different colour codes are well mixed across the dataset,
suggesting that based on single nucleotide variants, these patients do not cluster by
tumour type as might be expected. A colour key shows the scale of values within
the heatmap, which are based on correlations between individuals, with a value of 1
indicating the highest identity between two patients.
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these two cancers in this heatmap comparison. However, slightly more clustering of
mutation profiles by tumour type is observed in the heatmap comparing CRC and NB
patients. A sub-group of CRC appears to have a specific mutational profile shown by
the cluster of blue in the colour-coded panel representing CRC patients. Colorectal
cancer is known to have a specific mutational spectrum with elevated rates of single
nucleotide substitutions at polynucleotide tracts caused by mutations in DNA mismatch
repair genes, supporting this finding.
Combined with results from Figure 3.13 and Figure 3.18 it can be concluded that
mutation spectra does not necessarily cluster by tissue of origin. However the varied
results suggest that mutational profile as well as tumour type should be corrected for



































(a) GBM and OV from TCGA dataset






(b) CRC and NB from Lawrence dataset
Figure 3.19: Mutation spectra hierarchical cluster tree and heatmap comparisons between two different tumour
types. Patients were clustered by their mutation spectra for (A) GBM and OV in the TCGA dataset and for (B) CRC and NB
in the coding SSNVs Lawrence dataset. In the comparison between 208 GBM patients and 75 OV patients, there appears to be
little clustering by tumour type, as can be seen by the colour-coded panel in (A). However, in the comparison between 233 CRC
patients and 76 NB patients in the Lawrence dataset, the colour panel representing the tumour types shows slightly more clustering
by tumour type, as some of the patients that have been clustered together by mutation spectra in (B) are also all CRC patients,
suggesting that this tumour type may have a specific mutation spectra in a subset of patients. Colour keys show the scale of values
within the heatmaps, which are based on correlations between individuals, with a value of 1 indicating the highest identity between
two patients. Each tumour type is represented by a different colour in the horizontal panel across the top of the heatmap, for which
there is also a key for each heatmap.
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3.3 Discussion
3.3.1 Transition mutations occur at higher rate than transversion mu-
tations in most cancers
The characterisation of somatic SNVs over the whole TCGA dataset of 1,005 patients
and the coding Lawrence dataset of 4,712 patients has revealed that most tumour types
exhibit an increased rate of transitions compared to transversions, with the exception
of glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), lung
adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and ovarian serous
cystadenocarcinoma (OV) in the TCGA dataset, and KIRC, LUAD, LUSC, neurob-
lastoma (NB) and OV in the Lawrence dataset. Analyses of neutrally evolving ge-
nomic sequences reveal that transition mutations occur at significantly higher rates
than transversions. This is also reflected in cancer sequencing studies [Rubin and Green,
2009], so the results in this analysis are expected. In the cases of LUAD and LUSC,
the increased transition mutational pattern is known to be perturbed by environmental
exposures that result in many more C→A/G→T transversions than is normally seen in
the human genome or in other cancer types, induced by tobacco carcinogens [Stratton,
2011], again an expected result. The increased transversion rates observed in other can-
cer types such as GBM, KIRC, NB and OV could therefore indicate interesting specific
mutational processes underlying the initiation and progression of these cancers.
3.3.2 Mutation spectra varies between and within tumour types
The results here show that there is a great deal of mutational heterogeneity both be-
tween tumour types and between samples within tumour types. For example, the six
substitution class classification system has revealed that mutation spectra does not
necessarily correlate with tissue of origin, suggesting that the mutational profile of a
cancer is also an important consideration when attempting to determine the underlying
mutational processes of cancers.
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Based on this finding, it was concluded that both tissue of origin and mutational spec-
trum should be controlled for before driver mutation detection analyses, by grouping
data by tumour type and also by partitioning data based on mutation spectra. Lawrence
et al. [2014] have only addressed how the tissue of origin affects the genes hit by driver
mutations, so by also incorporating mutational signatures this work can be built on
to provide a more comprehensive understanding of the mechanisms underlying cancer
progression and detect driver genes that would otherwise remain undetected due to a
lack of power. This work has been carried out in Chapter 6.
3.3.3 Increased rate of INDELs in subset of GBM patients
During the comparison of TCGA and Lawrence calling pipelines using the 701 patients
that have had their mutations called by both pipelines, a subset of 16 GBM patients
were found to have much higher mutation rates in the TCGA dataset compared to the
Lawrence dataset. These outliers were an artefact of the data that on further investi-
gation, as well as highlighting differences between the two calling pipelines, represented
a mutation spectrum of a very high rate of called INDELs in these patients. It is the
high rate of INDELs in these patients that are thought to have caused the high rate
of miss-called SNVs in the TCGA pipeline, as SNVs are more difficult to call next to
INDELs. It is possible that Lawrence have accounted for this in their pipeline by re-
moving SNVs around INDELs, thus avoiding false-positives. This signature is however
not representative of all GBM patients, suggesting the presence of a specific mutational
spectrum characterised by INDELs in a subset of GBM patients. It would be inter-
esting to further investigate the aetiology underlying this spectrum, which is carried
out to some extent in Chapter 7, where it is suggested that these called INDELs are
actually miss-called larger genomic rearrangements.
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3.3.4 Caveats
3.3.4.1 A→G/T→C mutational asymmetry
Single nucleotide mutations have been categorised into six classes in this analysis, as-
suming that complementary mutations (e.g. A→G and T→C on the complementary
strand) occur at the same rate. However it has been shown that A→G substitution rates
are elevated in all cancer types compared to the complementary rate of T→C mutations
on the coding strand, suggesting that mutation patterns within genes are influenced by
gene expression. The asymmetry has been found to be statistically significant in breast
cancer [Rubin and Green, 2009]. Therefore, the assumption of mutational symmetry
may not always be accurate and may justify using 12 single nucleotide mutation classes
for more refined mutational profiles, to improve the classification of cancers by their
specific mutational profile, especially in cancers where gene expression plays a signifi-
cant role. However, many cancer studies have used just six classes of base substitution
based on strand symmetry, rather than 12 [Alexandrov et al., 2013, Kandoth et al.,
2013, Lawrence et al., 2013], so this is considered common practice.
3.3.4.2 Incorporating sequence context into mutational spectra classifica-
tions
In this analysis, only the numbers of each class of mutation have been used to create
mutation profiles. However, it would be beneficial to further define mutational signa-
tures by incorporating the sequence context of each mutation into the set of features.
For example, in Alexandrov et al. [2013] information on the bases immediately 5’ and
3’ to each mutated base was incorporated on top of their six classes of base substitution
(C→A, C→G, C→T, T→A, T→C, T→G) to provide 96 possible substitution muta-
tions in their classification. This classification system would be particularly useful in
distinguishing mutational signatures that cause the same substitutions but in different
sequence contexts. For example, this 96 substitution classification would help aid the
distinction between C→T mutations at NpCpG trinucleotides thought to be related to
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the relatively elevated rate of spontaneous deamination of 5-methyl-cytosine [Alexan-
drov et al., 2013], and C→T mutations at TpCpN trinucleotides caused by over activity
of members of the APOBEC family of cytidine deaminases responsible for converting
cytidine to uracil and thought to be induced by certain classes of viruses [Alexandrov
et al., 2013, Lawrence et al., 2013].
3.3.4.3 Increased rate of called SNVs around INDELs in TCGA pipeline
As previously mentioned, the TCGA pipeline has been shown to over-call SNVs that
are proximal to INDELs, illustrated by the 16 GBM patients with much higher SNVs
called by the TCGA pipeline compared to the Lawrence pipeline. This shows that
GATK used by the TCGA pipeline to call SNVs and INDELs is not optimal at calling
SNVs around INDELs compared to the pipeline used in Lawrence et al. [2014]. The
TCGA data is also not effectively set up for detecting INDELs reliably; whole-genome
sequencing data would be better suited to the identification of INDELs [Meyerson et al.,
2010]. Furthermore TCGA is a smaller dataset than Lawrence so there is less power to
detect INDELs in the TCGA dataset. However, it is not known if Lawrence had the
same problems in variant calling and simply excluded SNPs proximal to INDELs after
variant identification, in which case an additional filtering step could be undertaken in
this analysis to remove suspected false-positive SNVs near INDELs.
It would be useful to also investigate INDELs in these 16 GBM patients in the Lawrence
dataset as well as in the TCGA dataset, since INDEL mutation data was also available
for download from the Lawrence dataset.
3.3.4.4 Lawrence filtering steps not well documented
Lawrence et al. [2014] have not been explicit about how their somatic SNVs were filtered
prior to analysis. For example, it was not mentioned if homozygous mutations were
removed from the Lawrence data as they were in the TCGA data, so it was assumed
that they were not excluded. It was also not clear what significance threshold was used
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for the highly significantly mutated genes in the MutSig analysis, so this had to be
calculated manually.
There was also confusion over the mutation type classifications, for example both silent
and synonymous terminology was adopted in the Lawrence mutation data. However,
it was assumed that these were all of synonymous consequence, since coding mutations
were referred to as only missense or synonymous in the Lawrence et al. [2014] paper,
and silent mutations were not mentioned.
Additionally, there is a discrepancy between the numbers of SNVs reported in the
Lawrence et al. [2014] paper and the number of SNVs analysed in the data available
for download, which is not explained anywhere in the documentation.
Finally, 37 GBM patients from the TCGA were not included in the Lawrence dataset
despite being available for download at the time of the [Lawrence et al., 2014] study.
The reason for this exclusion is not known, however it is suspected that it is due to the
very high mutation rates exhibited by these patients. It would be helpful to investigate
these patients further by measuring the INDEL rates, which could be elevated and
hence causing the high SNV mutation frequency. It is possible that these patients
were removed from the Lawrence dataset due to a high rate of INDELs and a resulting
high rate of false-positive SNVs near INDELs. However, if this was the case then the
16 outlier GBM patients present in both datasets with high INDELs found in TCGA
would also have been removed from the Lawrence dataset, which they have not been.
Further filtering information is needed to further understand these anomalies.
3.3.4.5 TCGA-Lawrence comparison
It was difficult to make direct comparisons between the TCGA and Lawrence datasets in
order to access the performances of the different pipelines, due to the fact that different
cancer types and patient numbers were covered by each of the datasets. However,
there was an overlap of 701 patients between the two datasets which made a direct
comparison possible. Further filtering of the Lawrence data in this analysis has been
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performed to attempt to make the comparison as fair as possible by only using the
coding mutations from the Lawrence dataset as has been used in the TCGA dataset,
and only using single nucleotide mutations in both datasets.
3.4 Methods
For this chapter the filtered set of cancer-specific heterozygous non-synonymous and
synonymous SNVs from TCGA were used. However, in this set the same mutation in
a patient is reported multiple times in cases where there are multiple possible tran-
scripts for the gene that it appears in. This is due to using the ‘consequence’ table in
the tcga pair exome database to create the filtered set of heterozygous cancer-specific
TCGA SNVs. The consequence of a mutation is vital for the evolutionary analysis
later on, and for that the consequence of the longest transcript was used. However this
set has been further filtered to contain each mutation in a patient once using the most
severe consequence. The Lawrence dataset as provided had already been filtered to
contain each mutation only once, however it was not documented which transcript was
used for each gene to give consequence information for each mutation.
3.4.1 Summary variant statistics on a per patient basis
The tabulated mean mutation frequencies were calculated in R by dividing the total
mutation count for each tumour type by the number of patients in that tumour type
subset to give a mean count per patient for each tumour type, rounded to the nearest
whole number. Histograms were generated in R using raw mutation counts for each
patient. Mutations were only counted once if they occurred in overlapping genes. This
was done for both TCGA and Lawrence datasets.
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3.4.2 SSNVs on a per gene basis
The total coding mutation count for each gene over the whole dataset was divided by
the number of patients in each dataset, so by 1005 in TCGA and 4712 in Lawrence, to
get the mean number of mutations per patient for each gene.
For the gene length normalised plots, the mean counts per patient were divided by the
CDS length of the transcript with the longest CDS length for each gene (not necessarily
the CDS length of the longest transcript) to give a mutation count per nucleotide. A
list of Ensembl CDS lengths was obtained from Biomart [Kasprzyk, 2011]. Perl was
used to find the length of the longest CDS for each gene.
A single mutation was counted twice in overlapping genes for this gene-based analysis.
3.4.3 Patients overlapping datasets
For the 701 coding patients that are present in both TCGA and Lawrence datasets,
a comparison was made between their mutation calls in TCGA and in Lawrence, by
plotting the mutation counts in the TCGA dataset against the corresponding counts in
the Lawrence dataset for each patient in R using the plot function.
To test the association/ correlation between the paired samples in Figure 3.4, a cor-
relation coefficient and p-value was calculated using cor.test in R. This test is given
two vectors of numbers: the mutation count for the 701 patients in TCGA and the
mutation counts for the 701 patients in the Lawrence dataset. The default method is
Pearson’s product-moment correlation, which was used here. The default alternative
hypothesis is two-sided, also used here, which means the alternative hypothesis is that
the true correlation is not equal to 0 and the null hypothesis (rival hypothesis) is that
the correlation is 0 (no correlation).
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3.4.3.1 INDELs in GBM outlier patients
The 16 GBM patients with elevated mutation rates observed in the TCGA dataset
compared to the Lawrence dataset were investigated further by mining the mySQL
database containing TCGA mutations to look for the presence of heterozygous cancer-
specific INDELs in these patients. To create Figure 3.8, the total number of INDELs
counted across each of the six groups of patients were divided by the number of patients
present in that subset in order to obtain a mean value per patient. In mining the
database, the same patient mutation appeared multiple times due to multiple possible
transcripts that the mutation could affect, therefore duplicate mutations for the same
patient were removed before calculating INDEL counts, and mutations in overlapping
genes were counted only once. Two patients in the database were not used in the filtered
set of cancer-specific SNVs as they contained no cancer-specific SNVs, so for consistency
these two patients were also removed from the INDEL datasets. The ‘consequence’ table
from tcga pair exome was used, meaning that only coding INDELs were included in this
analysis, ignoring all INDELs that occur in introns. The cancer-specific SNVs are also
only coding variants.
3.4.4 Mutation spectra
For Table 3.5 and Table 3.7, for each patient the mutation profile proportions were
calculated by dividing the number of mutations for each signature by the total number
of mutations in that patient. Then over all patients, the proportions for each signature
were summed and then divided by the number of patients to get the mean proportion
per patient. This was done for each cancer type subset to produce the tables. Standard
deviation was also calculated, all in R.
For Figure 3.9 and Figure 3.14, the mutation count for each patient was converted into
a mutation rate per Mb. This was done by dividing the mutation count by 40,000,000
to get the rate per base, and then multiplying by 1,000,000 to get the rate per Mb.
The mutation frequency over the whole exome was divided by 40,000,000 because 40
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Mb (∼1.3% of the whole genome) is the typical length of the exome target region
from an Illumina exome capture panel. The size of the target region using Illumina
would be 62 Mb if flanking regions relative to each bait were included, which they are
in Illumina, but is equivalent to 40Mb (for coding regions only) when compared to
other kits. Patients were then ranked in ascending order of their mutation frequency
and plotted as a distribution, and split by cancer type, to show the range of mutation
frequency within cancer types. In the same plot, the relative proportions of each of
the six SNV classes were calculated for each patient, and plotted as a cumulative bar
chart to show the variation of mutation spectra within cancer types relative to the
mutation frequency. This was done for both the TCGA dataset, and also separately
for the Lawrence dataset.
Bubble plots (Figure 3.11, Figure 3.12, Figure 3.15, Figure 3.17) were also generated
in R, using the symbols function to create circles corresponding to the size of the data
points representing proportions.
For the hierarchical cluster tree heatmaps in Figure 3.13, Figure 3.18 and Figure 3.19, a
directional substitution matrix (non-time-reversible, e.g. considering C→T as distinct
from T→C) was created before cluster analysis in R. Whereas in PAML, the evolution-





selection on whole TCGA dataset
4.1 Introduction
The purpose of this evolutionary analysis was to identify the driver mutations amongst
the set of candidate driver mutations found using the data processing pipeline (described
in Chapter 2) and distinguish them from the inconsequential passenger mutations.
This was done using measures of selection in the codeml program of PAML, to look
specifically for signals of positive selection in genes indicating the presence of driver
mutations. The aim was to find genes harbouring driver mutations and hence identify
the genic drivers of cancer.
Evolutionary analysis was carried out in PAML, using the filtered, heterozygous, cancer-
specific TCGA SNVs identified and processed in Chapter 2 and described in Chapter 3.
The numbers used in this preliminary evolutionary analysis are smaller than the pa-
tient numbers described previously however, since this analysis was carried out on a
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preliminary set containing just 998 patients before a further 7 patients were added to
the dataset.
Analysis was carried out on a per-gene basis, over all 17 cancer types in the dataset.
This chapter describes the prototype for more refined subsequent evolutionary analyses.
4.2 Results
4.2.1 Screen for positive selection in genes
Gene-based analysis was carried out in PAML using the codeml program, to show which
genes driver mutations are preferentially found in.
For each gene over the whole TCGA dataset of 998 patients, an omega ratio was
estimated as a measure of selection. An omega value >1 is evidence for positive se-
lection, suggesting that the gene harbours driver mutations in cancer, because the
non-synonymous substitution rate is greater than the synonymous substitution rate.
Conversely, an omega <1 is indicative of negative selection as the mode of selection,
as the non-synonymous mutations are being removed from the population. An omega
value of 1 suggests neutrality, so the non-synonymous substitution rate is equal to the
synonymous substitution rate. It is genes with omega values larger than 1 that are of
interest, since it is these genes that are under positive selection and are therefore likely
to contain cancer driver mutations.
A p-value was also calculated for each gene using the log likelihood values estimated
from the codeml models, which was used to calculate a FDR value, to increase the
confidence in the omega estimate for each gene.
The omega and FDR values have been plotted for each gene in Figure 4.1. FDR is
plotted along the y-axis representing the significance of the positive selection detected,
and the x-axis denotes the omega as a measure of the magnitude of selection.
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Figure 4.1: Preliminary TCGA gene-based omega analysis in PAML. This
plot shows the results obtained from gene-based analysis in PAML on the whole TCGA
dataset consisting of 998 patients over 17 different cancer types. The omega estimates
have been plotted along the x-axis (log transformed) and FDR values along the y-axis
(double log transformed). Each dot represents a gene. The blue vertical dashed line
indicates point of selective neutrality (omega = 1), so genes under positive selection
will fall on the right hand side of the vertical dashed line and some of these have been
highlighted in green. The blue horizontal line represents the 10% false discovery rate
threshold, which has been used as the significance threshold. Therefore all genes above
this line are significantly hit by driver mutations. Genes highlighted in pink are those
with significant FDR values supporting positive selection but omega values supporting
purifying selection.
Chapter 4. Preliminary evolutionary analysis 154
The blue vertical dotted line signifies an omega of 1 (log10(omega)=0), corresponding
to neutral selection, so all genes to the right of this line have an omega ratio greater
than 1 indicating that they are under positive selection. All genes to the left of this
line have more synonymous mutations than non-synonymous mutations and hence are
assumed to be under purifying selection. The blue horizontal line denotes the 0.1
false-discovery rate threshold (log10(-log10(FDR))=0), so no more than 10% of the
genes above this line are false-positives. FDR of 0.1 has been used as the significance
threshold in this analysis, so genes with a FDR<0.1 (above the horizontal blue line in
Figure 4.1) are considered to be significantly mutated. The top right quadrant of the
graph is therefore where we would expect to find candidate driver genes undergoing
strong signals of positive selection with significant p-values and omega ratios indicative
of positive selection, and some of these have been highlighted in green and annotated
with their gene name. Genes highlighted in pink are those with significant p-values,
but with omega values suggestive of purifying selection as the mode of selection acting
on these genes.
The vertical line of genes along the far right-hand side of the plot are those with no
synonymous mutations occurring (e.g. MMP3), so although they may have significant
p-values the omega ratios are effectively infinity because the non-synonymous rate is
divided by 0 in these cases and dividing by 0 gives a result of infinity. PAML automati-
cally sets these omega values to “1000” (log10(1000)=3). These genes contain only the
functionally important non-synonymous mutations.
In this preliminary TCGA dataset containing 998 patients, 25 genes have been found
to be under strong signals of positive selection and therefore significantly mutated in
cancer by driver mutations. These genes are listed in Table 4.1 with their omega and
p-values as well as their gene descriptions. This table only contains the genes in the top
right quadrant of Figure 4.1, so that is genes with both an omega suggestive of positive
selection (omega>1) and a FDR value significantly supporting evidence for positive
selection (FDR<0.1).
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Table 4.1: Ranked list of the 25 significantly mutated genes in TCGA
whole-dataset analysis. This tables shows the 25 genes found to be significantly hit
by driver mutations in the gene-based analysis in PAML on the whole TCGA dataset of
998 patients over 17 different cancer types. These genes have been classed as significant
based on the criteria that they have a FDR<0.1 and an omega>1, supporting evidence
for positive selection acting in these genes in cancer.
Gene Omega P-value Description
MUC6 1.10 1.73e-22 mucin 6, oligomeric mucus/gel-forming
RPL6 14.59 3.57e-22 ribosomal protein L6
EGFR 1.96 1.00e-21 epidermal growth factor receptor
MUC4 1.36 3.20e-14 mucin 4, cell surface associated
TP53 26.64 8.04e-14 tumor protein p53
INTS3 2.98 9.82e-12 integrator complex subunit 3
FRG2B 2.40 3.74e-09 FSHD region gene 2 family, member B
ANKRD36C 1.43 3.89e-09 ankyrin repeat domain 36C
DEPDC5 1.18 3.29e-07 DEP domain containing 5
CCDC144CP 3.42 4.30e-07 coiled-coil domain containing 144C, pseudogene
NOTCH4 1.29 2.46e-06 notch 4
ZSWIM8 2.40 3.88e-06 zinc finger, SWIM-type containing 8
ACKR4 1.96 7.15e-06 atypical chemokine receptor 4
DDX11 1.31 1.38e-05 DEAD/H (Asp-Glu-Ala-Asp/His) box helicase
11
GPATCH8 1.25 3.14e-05 G patch domain containing 8
MMP3 999.00 3.58e-05 matrix metallopeptidase 3 (stromelysin 1, pro-
gelatinase)
ANXA7 999.00 3.85e-05 annexin A7
PTEN 8.64 4.32e-05 phosphatase and tensin homolog
CYP27B1 999.00 7.09e-05 cytochrome P450, family 27, subfamily B,
polypeptide 1
HNRNPC 1.18 7.18e-05 heterogeneous nuclear ribonucleoprotein C
(C1/C2)
RPTN 999.00 7.28e-05 repetin
HNRNPCL1 1.47 9.49e-05 heterogeneous nuclear ribonucleoprotein C-like 1
POTEF 1.92 9.88e-05 POTE ankyrin domain family, member F
CEP164 3.89 1.05e-04 centrosomal protein 164kDa
DDX6 1.65 2.21e-04 DEAD (Asp-Glu-Ala-Asp) box helicase 6
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4.2.2 Power to detect known cancer genes
These results demonstrate that this omega analysis has sufficient power to detect signals
of positive selection in well-known cancer driver genes, for example the tumour sup-
pressor gene TP53. EGFR and PTEN have also previously been found to be implicated
in cancer and have been highlighted in green in Figure 4.1.
TP53 (tumour protein p53) encodes a regulator of the cell cycle machinery that can
suppress the growth of cancer cells as well as inhibit cell transformation [Hollstein et al.,
1994]. TP53 is the most commonly mutated gene in human cancer [Kandoth et al.,
2013], inactivated by mutations that alter or obliterate normal TP53 function. As seen
with other tumour suppressors, frameshift or nonsense mutations result in the loss of
TP53 protein expression in some cases. However most often it is missense mutations
that lead to a loss of TP53 wild-type activity [Muller and Vousden, 2014].
EGFR (epidermal growth factor receptor) is a growth factor receptor that induces cell
differentiation and proliferation upon activation through the binding of one of its lig-
ands. The receptor is located at the cell surface, where the binding of a ligand activates
tyrosine kinase activity in the intracellular region of the receptor. This tyrosine kinase
phosphorylates a number of intracellular substrates that activates pathways leading to
cell growth, DNA synthesis and the expression of other oncogenes [Voldborg et al.,
1997]. Activating mutations in EGFR have been found in 1520% of lung adenocarcino-
mas, and have been targeted by tyrosine kinase inhibitors such as gefitinib and erlotinib
in the treatment of high-stage lung adenocarcinomas [Siegelin and Borczuk, 2014].
PTEN (phosphatase and tensin homolog) is a tumour suppressor gene that is deleted or
mutated in a variety of human cancers including prostate, breast, brain, endometrial,
lung, and ovarian cancers [Dong, 2001, Li et al., 1997]. The lipid phosphatase activity
of PTEN is important for its tumour suppressor function, which operates by negatively
regulating the PI3KAKTmTOR pathway [Hollander et al., 2011].
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4.2.3 Candidate cancer genes
RPL6 has shown up as being very significant in this whole-dataset analysis, with a
significant p-value of 3.57e-22 and a high omega ratio of 14.59, both strongly supporting
positive selection acting on this gene in cancer. This gene is a ribosomal gene and has
not been causally implicated in cancer [Futreal et al., 2004], however it has been found
to be overexpressed in multidrug-resistant gastric cancer cells [Du et al., 2005].
4.2.4 Significant results for likely common false positives
TTN, MUC6 and MUC4 are all large genes that often show up as false-positives in
cancer studies [Lawrence et al., 2013]. This is due to their size and subsequently higher
number of mutations. However, in this evolutionary analysis, the size of the gene
has been accounted for with the use of a synonymous substitution rate as a neutral
proxy. All three of these genes are highlighted in Figure 4.1. TTN is highlighted in
pink as it has an omega value suggestive of negative selection, and MUC4 and MUC6
both have been highlighted in green, as they both have an omega ratio indicative
of positive selection. All three genes have significant p-values, which means there is
strong evidence supporting positive selection. However it is suspected that these genes
are false-positives.
4.2.5 Confounding signals of positive and negative selection within
genes
Interesting genes are highlighted in pink in Figure 4.1 as they have an omega suggestive
of negative selection (omega<1) but a significant p-value (strongly supporting good fit
for model of positive selection). This could suggest that both positive and purifying
selection is occurring in the same gene, but in different regions. Both TTN and HIF3A
are genes showing evidence for undergoing both positive and purifying selection, with
significant p-values and omega values close to 0 (indicating neutral selection). This
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suggests that these genes could be undergoing different modes of selection within the
same gene at different sites.
TTN often comes up as a false-positive in this type of analysis due to its size, how-
ever HIF3A could be a good candidate for sub-region analysis in which the gene is
partitioned into functional domains and those domains are analysed separately to pre-
vent competing signals confounding analysis. The purpose of this type of analysis is
to identify the functional region that positive selection is targeting within a gene to
further understand the mechanism involved in the progression of the cancer. HIF3A
(hypoxia-inducible factor 3) encodes a protein that regulates many adaptive responses
to low oxygen tension, and it is known that tumour hypoxia is a classical feature of
cancer [Masson and Ratcliffe, 2014]. Therefore HIF3A could be a target for cancer
driver mutations, but maybe has previously been missed in this type of analysis due to
the fact that only a specific domain is subject to positive selection and maybe other
parts of the gene are under purifying selection.
4.3 Discussion
Evolutionary analysis in PAML on a whole dataset has shown that PAML has sufficient
power to detect well-known cancer genes such as TP53 and EGFR, showing proof of
concept. Other genes such as MUC6 and MUC4 often show up as false-positives, so
more work is needed to further understand these genes, and why this analysis has
not successfully accounted for the size of the gene assuming that is the reason for the
aberrant results. Genes undergoing purifying selection but with significant p-values
such as TTN and HIF3A also require further analysis, to ascertain whether or not
different types of selection are acting on the same gene, especially in HIF3A which is
not normally found as a false positive. These genes are motivation for sub-gene analysis,
to understand if selection is acting on just a specific part of these genes and is being
confounded by other modes of selection simultaneously acting.
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This analysis has also uncovered a potential candidate gene suspected to be implicated
in cancer, RPL6, which is not already known to be a driver cancer gene. Many other
genes that have not yet been associated with cancer have also been revealed. However,
further work and validation is needed to conclude the role of these genes in cancer.
To further increase the confidence of results, the maximum likelihood estimated param-
eters could be used in the simulation of neutral evolution, to show what results would
be expected under a random distribution of the observed mutation profile.
4.4 Methods
Evolutionary analysis of the whole preliminary TCGA dataset of 998 patients was
carried out in PAML using the codeml program, as described in Chapter 2. This
meta-analysis was carried out on a per gene basis (using whole genes as the units of
analysis).
All patients were grouped together regardless of the type of mutations accumulated
(mutation spectrum) and the tissue of origin (of which there were 17), before evolu-




stratification by tissue of origin
5.1 Introduction
The evolutionary methods used previously in Chapter 4 on the TCGA dataset were
applied to the published Lawrence data, consisting of cancer-specific mutations in 4,712
patients over 21 cancer types.
The intention here was to refine the previous PAML analysis by stratifying the data by
cancer type, to parse out tissue specific signals of selection, using a much larger dataset
than was available for the TCGA data.
In the published work of Lawrence et al. [2014], cancer genes were also identified using
this same set of cancer-specific variants. However while only the coding SNVs were used
in the PAML analysis in this project, in the Lawrence et al. [2014] study both non-
coding and coding mutations were used including di-, tri- and oligonucleotide variants
(DNVs, TNVs and ONVs respectively) as well as INDELs.
However, Lawrence have used different methods to the ones used in this analysis, so in
this sub-type analysis the aim was also to compare the genes found to be significantly
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mutated in this PAML analysis to the results found by Lawrence and interpret the
differences to find similarities and potentially find novel candidate genes.
5.1.1 Lawrence study
A paper was published in 2014 by Lawrence et al. [2014] in which coding and non-
coding cancer-specific SNV, DNV, TNV, ONV and INDEL mutations were identified
over 4,742 patients over 21 different cancer types. Described here is their criteria for
defining significant genes.
5.1.1.1 MutSig software
Significantly mutated driver cancer genes were identified using the MutSig suite [Lawrence
et al., 2013]. Their methods for cancer gene detection involved using three statistical
tests, as is shown in Figure 5.1:
• MutSigCV - test for burden of protein-altering mutations, compared to a back-
ground model using “neighbouring” genes (i.e. genes that are clustered by char-
acteristics, not by genome location).
• MutSigCL - mutation clustering in hotspots.
• MutSigFN - enrichment in functional sites, which is essentially a measure of
cross-species evolutionary conservation for a site.
Each of these tests were separately applied by Lawrence et al. [2014] to each gene for
each of 21 distinct tissues of origin, but the main analyses concentrated on a metric
that combined these three tests into a single significance measure, the joint p-value,
per gene and tissue. Of the individual MutSig tests, MutSigCV is the most directly
comparable and analogous to my PAML analysis. In the MutSigCV test a background
mutation model utilises both silent and non-coding mutations and combined data from
multiple genes that were deemed to have similar mutation profiles. This combining of
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Figure 5.1: Statistical tests used to detect cancer genes in MutSig. The three
statistical tests in the MutSig suite used to detect cancer genes in the Lawrence et al.
[2014] study: MutSigCV, MutSigCL and MutSigFN. Schematic taken from Lawrence
et al. [2014] supplementary paper.
gene background models is a potential confounding factor for the Lawrence analysis
but it does serve to increase power as more ”background” sites can be considered to
parametrise the background model.
5.1.1.2 Data processing
Lawrence mutations were not all re-aligned to hg19 reference genome, so those originally
aligned to the hg18 build were lifted over (LiftOver, see Methods) to hg19 by converting
the coordinates of each mutation to build hg19.
5.1.1.3 Significance calculations: p-value and FDR
For my analysis of the Lawrence data I used log-likelihood derived p-values as a sig-
nificance measure and applied a false discovery rate (FDR) correction [Benjamini and
Hochberg, 1995] to account for multiple testing.
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Lawrence et al. [2014] used the same q-value correction procedure, based on the joint
p-values from all three MutSig tests.
In both analyses an arbitrary 10% FDR rate has been used as a threshold for signifi-
cance. Genes with q≤0.1 have therefore been classified as significantly mutated.
In the Lawrence analysis, 254 genes were classed as significant and were declared to be
members of the Cancer5000 list of candidate cancer genes. These genes were signifi-
cant in at least one of the 22 analyses (21 distinct tissues of origin plus the combined
“PanCan” set over all tumour types).
Cancer5000-S is a more stringently multiple hypothesis corrected list of genes, which
has had the Benjamini-Hochberg method applied again to yield new FDR values in
order to correct for the 22 analyses combined. There are 219 genes in the Cancer5000-S
list.
Overall, 260 genes are present in either Cancer5000, Cancer5000-S or both.
A significance threshold of q≤0.001 was used to class genes as highly significantly
mutated in Lawrence et al. [2014] (highlighted in red in subsequent plots and tables),
although they have not been explicit in stating this in their paper.
5.2 Results
The Lawrence data was partitioned by tissue of origin, and of the 21 cancer types
available only the 12 cancer types with at least 150 patients each were chosen for
analysis in PAML, as well as melanoma which was chosen for its interesting mutation
profile and high mutation rate. The PAML results for these 13 cancer types have been
presented in omega plots, akin to the plot in Chapter 4 to display results from PAML
analysis on the whole TCGA dataset. For each cancer type, an omega ratio and FDR
was plotted for each gene.
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In order to compare these results to the results in the Lawrence study, genes found
to be highly significantly mutated (q<=0.001) in MutSig for that particular cancer
type have been highlighted in red on the omega plots. Genes found to be significantly
mutated (q<=0.1) and therefore in the Cancer5000 list of genes in the Lawrence study
have been highlighted in orange in these plots.
Genes found to be significantly mutated and under strong positive selection in the
PAML analysis (omega>1 and FDR<=0.1) but not significant in the Lawrence study
have been highlighted in blue, and those with an omega suggestive of negative selection
but a significant p-value supporting positive selection (omega<1 and FDR<=0.1) and
not significant in the Lawrence et al. [2014] study have been highlighted in purple.
Ranked lists of all significantly mutated genes (omega>1 and FDR<0.1) in the PAML
analysis with their omega estimate and p-value have also been tabulated for each cancer
type, in descending order of significance (by ascending p-value). If these significant
genes are also significant in the Lawrence et al. [2014] study then they have been
highlighted according to their level of significance consistent with the omega plots:
red for highly significantly mutated genes (FDR<0.001) and orange for significantly
mutated genes (FDR<0.1), together with their three MutSig p-values (CL, CV, FN
and combined). In addition to these significant genes in the PAML analysis, the table
also includes genes that are significant in Lawrence et al. [2014] but are not classed as
significant in the PAML analysis. However I have still given the omega and p-value
obtained from PAML for these significant Lawrence et al. [2014] genes despite the fact
the p-value is not significant in the PAML analysis (and the omega may be <1).
For clarity a horizontal blue line has been drawn on these tables to separate significant
PAML genes from insignificant PAML genes. So all genes above the blue line in each
table are significant in the PAML analysis (omega>1 and FDR<0.1). All genes below
the line were not found to be significant in PAML analysis but are only shown in the
tables because they were significant in Lawrence et al. [2014]. “NAs” in the Lawrence
columns either mean that the gene has not been found to be significant in the Lawrence
analysis and so p-values have not been recorded in the Lawrence study, or that p-values
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were not calculated for all three MutSig tests in significant genes. “NA” in the PAML
column means that PAML has not produced results for that gene. Some significant
PAML genes have not been included in the tables if their Ensembl gene ID no longer
exists in the most recent version of Ensembl (release 78).
Genes in the omega plots and tables have been compared based on FDR rather than
p-value, which in the Lawrence dataset is based on the combined p-values from all three
MutSig tests. Individual MutSig test q-values were not available, so a direct comparison
was not able to be made between the MutSigCV (most directly comparable to PAML
method) q-values and the PAML q-values. Therefore, since p-values were available
for each of the three tests, the p-values for MutSigCV and PAML were plotted to
examine the relationship between the two for each cancer type, only for genes where
both a MutSigCV p-value and PAML p-value has been recorded, so this would be for
the genes present in the set of the 260 most significant Lawrence genes that have also
run successfully through PAML. PAML p-values are truncated at 0.5, because dchisq
uses a 1-tailed test (which is suitable in this case since only positive selection has been
measured), whereas MutSigCV p-values are not, however this is not observed in the
plots since only the more significant p-values have been plotted. GBM showed the
highest correlation so this is the only plot that has been shown here. All other cancer
types did not show a strong positive correlation between the two sets of p-values.
To investigate the effectiveness of the PAML analysis, recurrent mutations (non-synonymous
and synonymous) have also been counted for each cancer type and tabulated. Recur-
rent mutations are a partially independent method of looking for driver containing
genes. The top 35 recurrent mutations (ranked in descending order of recurrence) were
tabulated for each cancer type, for comparison with PAML results. Generally, genes
with recurrent mutations do tend to have significant results in PAML, however several
genes are found at a significant level that do not show as having a high rate of recur-
rent mutations, showing that a more complex model than simply counting mutations
in a gene is required to detect candidate cancer genes. Also both non-synonymous
and synonymous counts have been included in the recurrent counts, so this will also
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confound results since synonymous mutations are considered to be selectively neutral
and therefore assumed not to be driver mutations.
Synonymous mutations have been used in the background models in both this PAML
analysis and in the Lawrence analysis, assumed to be passenger mutations in cancer.
However it is estimated that between one in two and one in five synonymous mutations
in oncogenes are under selection equating to ∼6-8% of all selected single-nucleotide
changes in these genes [Supek et al., 2014], suggesting that synonymous mutations
could be acting as drivers, which will confound both the PAML and Lawrence analyses.
5.2.1 Acute myeloid leukemia (LAML)
In the PAML analysis of acute myeloid leukemia, for which 194 patients were analysed,
11 genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (top right quadrant of Figure 5.2). All 11 of these
genes were also found to be highly significant in the Lawrence et al. [2014] study, with
FDR<0.001 and have been highlighted and annotated in red in Figure 5.2. Lawrence
also find additional highly significant (red) and significant genes (orange) which are
not found to be significant in the PAML analysis. These are found in the bottom
right quadrant of Figure 5.2, so although these genes exhibit omega ratios suggestive
of positive selection they do not meet the 10% FDR threshold for positive selection.
The 11 significantly mutated genes in the PAML analysis have been tabulated in Ta-
ble 5.1, showing their corresponding omega estimate and p-value. Also shown for these
genes are the p-values from the MutSig analysis in the Lawrence study, for comparison.
MutSig results have also been tabulated for genes found to be significantly mutated in
the Lawrence study only (i.e. not significant in the PAML analysis). Overall, 26 genes
were found to be significantly mutated in at least one of the two analyses.
DNMT3A is the most highly significantly mutated gene in the PAML analysis of LAML,
with an omega of 475.62 and a p-value of 5.32e-72 (Table 5.1). DNMT3A is a DNA
methyltransferase involved in de novo methylation, a process known to be involved
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Figure 5.2: Gene-based omega analysis in LAML. Gene-based PAML results
have been displayed in this omega plot for 194 LAML patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. R code used to generate plot in Supplementary Appendix D.
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Table 5.1: Ranked list of significant PAML genes in LAML. The genes found
to be significantly mutated in LAML patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and sig-
nificantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
DNMT3A 475.62 5.32e-72 1.00E-16 9.99E-08 9.99E-08 1.11E-16
IDH1 816.36 2.27e-28 1.00E-16 4.00E-07 9.94E-01 1.11E-16
FLT3 128.20 7.24e-20 1.00E-16 9.99E-08 8.99E-07 1.11E-16
NRAS 999.00 3.73e-19 1.00E-16 9.99E-08 7.31E-02 1.11E-16
RUNX1 999.00 3.60e-16 4.02E-16 1.34E-01 1.47E-02 3.33E-16
IDH2 999.00 3.66e-11 1.00E-16 9.99E-08 3.44E-01 1.11E-16
KIT 154.77 4.84e-05 7.63E-06 4.56E-06 2.31E-01 1.05E-09
U2AF1 999.00 7.27e-05 1.70E-10 3.40E-06 9.99E-08 6.66E-16
PTPN11 999.00 8.70e-05 1.49E-11 8.70E-02 1.33E-01 1.17E-11
KRAS 999.00 1.20e-03 1.85E-13 1.14E-02 5.76E-01 6.52E-14
TET2 999.00 1.23e-03 1.00E-16 6.76E-01 1.24E-05 1.11E-16
TP53 5.48 5.98e-02 1.00E-16 1 9.20E-02 3.55E-15
SMC1A 999.00 8.65e-02 2.77E-06 1 3.30E-02 2.69E-05
SMC3 999.00 1.27e-01 6.21E-09 1 1.28E-01 9.82E-08
STAG2 999.00 1.76e-01 1.46E-08 1 8.64E-01 2.18E-07
ASXL1 140.33 2.14e-01 1.28E-06 1 8.13E-01 1.34E-05
RAD21 999.00 2.61e-01 1.56E-07 1 6.06E-01 1.96E-06
WT1 121.05 2.67e-01 5.23E-15 1.36E-03 9.95E-01 4.44E-16
PHF6 999.00 2.95e-01 1.10E-07 1 1.63E-01 1.42E-06
CEBPA 999.00 3.19e-01 7.39E-07 2.74E-01 7.28E-01 8.15E-06
PDSS2 NA NA 2.87E-04 3.30E-02 2.71E-01 5.15E-05
EZH2 NA NA 4.31E-04 8.27E-03 5.41E-01 3.37E-05
SFRS2 NA NA 1.44E-05 NA NA 1.44E-05
MXRA5 NA NA 1.75E-03 6.73E-03 3.79E-02 8.20E-05
PAPD5 NA NA 9.17E-05 3.40E-02 3.60E-02 2.99E-05
NPM1 NA NA 1.00E-16 9.99E-08 9.99E-08 1.11E-16
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in tumourigenesis, since aberrant promoter hypermethylation is known to be a ma-
jor mechanism for silencing tumour suppressor genes in many cancers [Baylin, 2005].
DNMT3A has only recently been uncovered as an important new tumour suppressor
in this cancer type [Gonzalez-Perez et al., 2013, Yang et al., 2015], although it has pre-
viously been shown to be recurrently hit with mutations in LAML patients [Ley et al.,
2010]. DNMT3A has also been detected in the Lawrence analysis as highly significantly
mutated in this cancer type, as well as in the combined “Pan-Cancer” dataset over all
21 cancer types [Lawrence et al., 2014].
The tumour suppressor TET2 is also found to be significant in both analyses, which
could be related to the role of DNMT3A in this cancer, since TET2 acts to remove CpG
methylation by converting 5-methyl-cytosine to 5-hydroxymethyl-cytosine [Yamazaki
et al., 2012]. TET2 is often inactivated by loss-of-function mutations in myeloid malig-
nancies [Solary et al., 2014]. It is possible that both DNMT3A and TET2 are targeted
by driver mutations in the pathway underlying cancer progression in AML.
Compared to the genes found through evolutionary analysis, recurrent mutation anal-
ysis for LAML shown in Table 5.2 shows that 100% (11/11) of the significant PAML
genes are recurrently mutated in LAML, so all significantly mutated genes in PAML can
also be found using just the recurrent mutation analysis. However there are also genes
containing recurrent mutations that are not significant in the PAML analysis, so using
recurrent analysis alone to find significant genes would likely find many false-positives.
Although not shown in Table 5.2 as it did not make the top 35 recurrent mutations,
KRAS also has a recurrent mutation mutated in two patients.
Table 5.3 shows the known cancer genes that have been successfully detected in acute
myeloid leukemia by both the PAML and recurrence analyses in this project, and also
by the Lawrence et al. [2014] MutSig analysis.
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Table 5.2: Ranked list of recurrent mutations in LAML. Ranked list of the
top 35 most recurrent SNVs in the LAML subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
DNMT3A 2 25457242 C T 21
IDH2 15 90631934 C T 16
IDH1 2 209113113 G A 12
FLT3 13 28592642 C A 11
DNMT3A 2 25457243 G A 7
U2AF1 21 44524456 G A 5
NRAS 1 115258744 C T 5
IDH1 2 209113112 C T 5
RUNX1 21 36231783 G A 4
KIT 4 55599321 A T 4
HERC6 4 89317923 A T 4
NRAS 1 115258747 C T 3
LPHN2 1 82434811 A T 3
KIAA1468 18 59947868 A T 3
IDH2 15 90631838 C T 3
DOCK11 23 117814959 A T 3
ABCA5 17 67280040 A T 3
ZNF540 19 38102400 A T 2
U2AF1 21 44524456 G T 2
TMEM62 15 43443922 A T 2
TET2 4 106164778 C T 2
SPICE1 3 113225485 T A 2
RUNX1 21 36252878 T C 2
RDBP 6 31921657 T A 2
RBBP4 1 33138072 G A 2
PTPN11 12 112926884 T C 2
POLRMT 19 630135 T C 2
PLEKHA2 8 38826929 A T 2
PEX5L 3 179519877 T A 2
PDSS2 6 107566825 T A 2
PAPD5 16 50257083 A T 2
OR4K1 14 20403747 A T 2
NRAS 1 115256530 G T 2
NRAS 1 115256528 T A 2
MXRA5 23 3229667 T A 2
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Table 5.3: Cancer gene detection success in acute myeloid leukemia. Known
cancer genes that have been detected as significantly mutated in all three of the afore-
mentioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014]
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5.2.2 Breast (BRCA)
In the PAML analysis of breast cancer, for which 888 patients were analysed, eight genes
were found to be significantly mutated with q≤0.1 and undergoing positive selection
with an omega ratio >1 (Figure 5.3). Of these significant genes, five were found to be
highly significant in the Lawrence et al. [2014] study with a q≤0.001, and one was found
to be significant (q≤0.1). The remaining two significant PAML genes, FGFR2 and
CDC42BPA, were both found to be near significance in the Lawrence study, although
not statistically significant. PAML analysis therefore has more power to detect these
genes than MutSig, especially in the case of FGFR2 which is known to be causally
implicated in cancer (Cancer Gene Census [Forbes et al., 2010]).
FGFR2 (fibroblast growth factor receptor 2) tyrosine kinase belongs to the fibrob-
last growth factor receptors (FGFRs) family, comprised of four kinases (FGFR1 to
FGFR4) that differentially respond to 18 fibroblast growth factor (FGF) ligands [Jain
and Turner, 2012]. FGFs and FGFRs play an important role in developmental signalling
pathways responsible for regulating various functions such as cell proliferation, survival
and migration [Rajith et al., 2013]. FGFR2 is comprised of an extracellular ligand
binding region, a single-pass transmembrane region and a split kinase domain [Rajith
et al., 2013]. Tyrosine kinases are enzymes which catalyse the phosphorylation of select
tyrosine residues in target proteins, using ATP [Paul and Mukhopadhyay, 2004], and
are commonly oncogenically activated in cancer. Constitutive oncogenic activation of
tyrosine kinases in cancer cells can be blocked by selective tyrosine kinase inhibitors
and thus the inhibition of these genes is considered as a promising approach for genome
based therapeutics [Paul and Mukhopadhyay, 2004]. In genome-wide association stud-
ies (GWAS) a locus within the second intron in FGFR2 is consistently associated with
breast cancer risk, supported by expression quantitative trait loci analysis which shows
that the signalling of this gene has an important role in mediating breast cancer risk
[Fletcher et al., 2013]. The predisposing allele is present in approximately 40% of west-
ern populations, although the associated increased risk is relatively small: 1.26-fold
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Figure 5.3: Gene-based omega analysis in BRCA. Gene-based PAML results
have been displayed in this omega plot for 888 BRCA patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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for heterozygotes and 1.63-fold for homozygotes, increasing the risk of developing oe-
strogen receptor (ER)-positive breast cancer, with only a minor effect on ER-negative
breast cancer [Jain and Turner, 2012]. As well as germline mutations conferring breast
cancer risk in FGFR2, somatic FGFR2 alterations are also known to cause constitutive
activation in breast cancer Reintjes et al. [2013]. In a small subset of breast cancers the
FGFR2 gene is amplified, however this is rare occurring at 1-2% of all breast cancers,
(4% of aggressive triple-negative breast cancers) Jain and Turner [2012]. Breast cancers
with FGFR2 gene amplification have shown high sensitivity to FGFR inhibitors and an
FGFR2 targeting antibody, potentially making amplified FGFR2 a good therapeutic
target. Somatic mutations have also been identified in other tumour types, with 12% of
endometrial carcinomas containing somatic mutations in FGFR2 that cause oncogenic
and constitutive activation. FGFR2 has also been implicated as a novel therapeutic
target in endometrial carcinoma, with drugs that inhibit the kinase activity of FGFR2
shown to inhibit transformation and survival of cells [Dutt et al., 2008].
CDC42BPA belongs to the serine/threonine protein kinase family, and is not a known
cancer gene. However, protein kinases are known to have an important role in cancer.
This gene could therefore potentially be a good candidate for kinase inhibitors in the
treatment of cancer.
TTN is the largest polypeptide encoded by the human genome (highlighted in purple
in Figure 5.3) and often comes up as a false-positive in cancer studies due to the
large number of mutations accumulated as a result of its large size. However, gene
length has been accounted for in this analysis, by dividing by the number of non-
synonymous mutations by the number of synonymous mutations to obtain a mutation
rate. Therefore it may be worthwhile cautiously entertaining the possibility that this
gene is a true-positive result. In the PAML results it had a FDR value of 0, which cannot
be log transformed since log10(-log10(0)) gives a value of infinity. Therefore this was
one of the FDR values that was changed to 1e-200 before being plotted in Figure 5.3.
Although this gene has a very significant q-value supporting positive selection, it has an
omega suggestive of negative selection, which has not been tested for in this analysis,
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since the significance measure (FDR) is only relevant for positive selection. This could
be an indication that both positive and negative selection is occurring in this gene in
different parts of the gene which is confounding the omega ratio results.
Overall, 35 genes were found to be significant in at least one of the two analyses (Ta-
ble 5.4). PIK3CA was found to be highly significant in the Lawrence study, however
PAML was not able to produce any results for this gene (Table 5.4).
Of the significant PAML genes, 88% (7/8) were hit by recurrent mutations in BRCA,
including TP53 and SF3B1 (Table 5.5). TP53 and SF3B1 were also identified in the
Lawrence study as being highly significant.
Table 5.6 shows the known cancer genes that have been successfully detected in breast
cancer by both the PAML and recurrence analyses in this project, and also by the
Lawrence et al. [2014] MutSig analysis.
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Table 5.4: Ranked list of significant PAML genes in BRCA. The genes found
to be significantly mutated in BRCA patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and sig-
nificantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
TP53 28.16 1.46e-93 6.01E-16 5.22E-08 5.22E-08 1.11E-16
SF3B1 4.79 8.07e-15 4.55E-05 9.89E-08 2.29E-02 1.04E-10
CDH1 3.23 1.63e-10 1.15E-15 4.00E-02 3.75E-01 3.61E-14
ERBB2 4.21 7.31e-10 5.64E-02 2.97E-07 4.75E-03 1.29E-06
MLL3 (KMT2C) 6.51 1.30e-07 1.27E-16 1.00E-01 2.92E-01 4.33E-15
FGFR2 2.21 4.50e-06 NA NA NA NA
CDC42BPA 999.00 3.06e-05 NA NA NA NA
MAP2K4 999.00 4.02e-05 3.52E-16 1.39E-01 2.34E-01 1.15E-14
KRAS 999.00 1.49e-04 9.98E-05 3.33E-05 1.37E-01 5.45E-08
CTCF 1.50 3.01e-03 9.13E-13 2.99E-03 2.40E-04 1.44E-15
CBFB 4.85 8.94e-03 1.00E-16 2.42E-01 3.94E-01 3.55E-15
FOXA1 1.60 1.09e-02 4.12E-06 1 2.17E-01 3.84E-05
TBX3 1.89 1.14e-02 6.82E-06 3.94E-01 9.39E-01 6.01E-05
AKT1 0.46 2.60e-02 1.00E-16 9.89E-08 1.98E-07 1.11E-16
MED23 999.00 2.62e-02 6.74E-06 1 3.15E-01 5.94E-05
RB1 3.20 3.13e-02 9.31E-09 2.99E-01 1.78E-01 1.43E-07
STAG2 999.00 3.78e-02 1.73E-05 1 7.44E-01 1.36E-04
GATA3 1.08 4.23e-02 1.00E-16 9.89E-08 3.25E-01 1.11E-16
PTEN 999.00 4.43e-02 1.00E-16 8.27E-03 1.01E-01 1.11E-16
CUL4B 999.00 9.17e-02 9.32E-06 1 6.78E-01 7.92E-05
CASP8 3.90 1.59e-01 5.79E-06 1 5.37E-01 5.19E-05
TBL1XR1 999.00 1.61e-01 6.70E-06 2.50E-02 7.94E-01 2.78E-06
HIST1H3B 3.47 1.93e-01 7.70E-05 4.85E-02 7.95E-02 1.22E-05
MAP3K1 3.65 1.96e-01 1.00E-16 1.91E-03 5.35E-01 1.11E-16
PIK3R1 3.45 2.04e-01 1.49E-10 3.16E-01 5.40E-02 2.91E-09
MYB 2.57 3.17e-01 2.02E-05 1 1.50E-02 1.56E-04
ARID1A 5.45 3.20e-01 2.66E-08 1.46E-01 1.17E-01 1.51E-08
RUNX1 1.24 4.81e-01 4.42E-16 1.08E-01 2.72E-01 1.44E-14
RAB40A 1.21 4.92e-01 2.07E-05 1 9.33E-01 1.59E-04
CDKN1B 0.21 5.00e-01 4.48E-07 1.49E-01 5.24E-01 5.17E-06
MLL (KMT2A) 1.02931 2.16e-01 2.12E-04 6.48E-04 2.70E-02 2.20E-07
SPEN 0.51 5.00e-01 2.52E-06 2.09E-03 1.46E-01 1.01E-07
NCOR1 3.75 5.00e-01 2.12E-09 1 4.74E-01 3.57E-08
PIK3CA NA NA 1.00E-16 9.96E-08 9.96E-08 1.11E-16
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Table 5.5: Ranked list of recurrent mutations in BRCA. Ranked list of the
top 35 most recurrent SNVs in the BRCA subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
PIK3CA 3 178952085 A G 119
PIK3CA 3 178936091 G A 53
PIK3CA 3 178936082 G A 35
AKT1 14 105246551 C T 18
TP53 17 7578406 C T 15
PIK3CA 3 178952085 A T 14
PIK3CA 3 178921553 T A 14
SF3B1 2 198266834 T C 11
TP53 17 7578263 G A 8
TP53 17 7578212 G A 8
PIK3CA 3 178938934 G A 8
TP53 17 7578271 T C 7
TP53 17 7578190 T C 7
TP53 17 7577539 G A 6
TP53 17 7577121 G A 6
PIK3CA 3 178936095 A G 6
TP53 17 7578394 T C 5
TP53 17 7578265 A G 5
TP53 17 7577120 C T 5
INF2 14 105246551 C T 5
ZRANB3 2 136173412 A G 4
USP6 17 5045959 T A 4
TP53 17 7578403 C A 4
TP53 17 7578203 C T 4
TP53 17 7574003 G A 4
STRN 2 37154061 A G 4
PIK3CA 3 178936094 C A 4
PIK3CA 3 178928079 G A 4
PIK3CA 3 178927980 T C 4
NUP93 16 56782199 G A 4
MBD5 2 148909577 T A 4
KCNJ3 2 155696027 C A 4
FAM172A 5 93101446 C A 4
ZNF567 19 37193020 G A 3
ZFYVE9 1 52640752 A C 3
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Table 5.6: Cancer gene detection success in breast cancer. Known cancer
genes that have been detected as significantly mutated in all three of the aforemen-
tioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014] study,
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Table 5.7: Ranked list of significant PAML genes in CLL. The genes found
to be significantly mutated in CLL patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and sig-
nificantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
SF3B1 999.00 1.76e-24 2.46E-16 1.00E-07 4.75E-01 1.11E-16
MYD88 999.00 3.93e-07 5.95E-16 1.00E-07 2.40E-06 1.11E-16
TP53 999.00 1.53e-06 1.00E-16 2.81E-03 1.00E-07 1.11E-16
XPO1 1.02 4.38e-03 5.37E-06 3.90E-04 1.90E-01 3.54E-08
HIST1H1E 999.00 5.03e-02 1.36E-06 1 7.73E-03 6.26E-07
RPS15 999.00 3.09e-01 1.67E-07 1 5.07E-01 2.09E-06
RPS2 21.24 4.08e-01 1.24E-04 1.50E-02 8.30E-01 1.89E-05
5.2.3 Chronic lymphocytic leukemia (CLL)
In the PAML analysis of chronic lymphocytic leukemia, for which 159 patients were
analysed, three genes were found to be significantly mutated with q≤0.1 and undergoing
positive selection with an omega ratio >1 (Figure 5.4). All three of these genes were
also found to be highly significantly mutated in the Lawrence et al. [2014] study.
Overall, just seven genes were found to be significantly mutated in at least one of the
analyses (Table 5.7).
In Table 5.8 100% (3/3) of the genes found to be significantly mutated in the PAML
analysis were also found to contain recurrent mutations in CLL.
Table 5.9 shows the known cancer genes that have been successfully detected in chronic
lymphocytic leukemia by both the PAML and recurrence analyses in this project, and
also by the Lawrence et al. [2014] MutSig analysis.
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Figure 5.4: Gene-based omega analysis in CLL. Gene-based PAML results
have been displayed in this omega plot for 159 CLL patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. R code used to generate plot in Supplementary Appendix D.
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Table 5.8: Ranked list of recurrent mutations in CLL. Ranked list of the
13 recurrent SNVs in the CLL subset of the Lawrence dataset, sorted by recurrence
in descending order. For each unique mutation, the gene, chromosome, position, ref
and alt alleles and how many patients the mutation occurs in (recurrence) have been
tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
SF3B1 2 198266834 T C 9
MYD88 3 38182641 T C 9
XPO1 2 61719472 C T 3
SF3B1 2 198266611 C T 3
VWF 12 6125705 C A 2
TP53 17 7577556 C A 2
TP53 17 7577141 C A 2
TP53 17 7577120 C T 2
RPS2 16 2012609 T C 2
NRAS 1 115256529 T C 2
MYD88 3 38182259 T C 2
GNB1 1 1737942 A G 2
EGR2 10 64573248 G T 2
Table 5.9: Cancer gene detection success in chronic lymphocytic leukemia.
Known cancer genes that have been detected as significantly mutated in all three of
the aforementioned analyses, overlapping the MutSig analysis in the Lawrence et al.
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5.2.4 Colorectal (CRC)
In the PAML analysis of colorectal cancer, for which 233 patients were analysed, 71
genes were found to be significantly mutated with q≤0.1 and undergoing positive se-
lection with an omega ratio >1 (Figure 5.5). The most significant of these genes is
APC, mutations in which are known to be the most common inactivation in this type
of cancer [Fodde, 2002]. This gene is also shown to be highly significantly mutated in
Lawrence. This result shows that both methods have the power to successfully detect
this cancer gene.
Overall 80 genes were found to be significantly mutated in at least one of the two
analyses (Table 5.10).
Of all the genes found to be highly significantly mutated in the Lawrence study, all but
BRAF were also found to be significant in the PAML analysis. A possible explanation
for this could be the presence of clustering of missense mutations in this gene observed
in Figure 5.6. MutSig uses a test called MutSigCL that specifically measures and
accounts for clustering in hotspots within genes. This has not been accounted for in
the PAML method, which could explain why BRAF has not come up as a significant
gene in PAML analysis.
A candidate cancer gene that has been shown to be significantly mutated in PAML
analysis but not in the Lawrence analysis is DNMT1. This gene is involved in DNA
methylation (the major form of epigenetic information in mammalian cells), which is
a methyl transfer reaction performed by trans-acting enzymes known as DNA methly-
trasferases such as DNMT1 involving the covalent addition of a methly group to the
5’-position of cytosince predominantly within the CpG dinucleotide [Robertson, 2001].
Two distinct methyl transfer activities can be distinguished, based on the methyla-
tion status of the substrate: maintenance DNA methyltrasferase activity refers to the
conversion of hemimethlyated substrates to a fully methylated state; whereas de novo
methyltransferase activity refers to the addition of new methyl groups at sites pre-
viously unmethlyated. All DNA methyltransferases are capable of performing both
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Figure 5.5: Gene-based omega analysis in CRC. Gene-based PAML results
have been displayed in this omega plot for 233 CRC patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.10: Ranked list of significant PAML genes in CRC. The genes found
to be significantly mutated in CRC patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and signifi-
cantly mutated respectively in the Lawrence study. Table has been truncated to n=35
rows from a total of 80 significant genes for CRC. R and Perl code used to produce
list in Supplementary Appendix E. Full version of table can be found in Supplementary
Appendix F.
PAML results Lawrence et al. [2014] p-values
Gene Omega P-value CV CL FN Combined
APC 13.75 3.65e-176 1.26E-15 9.28E-08 9.98E-01 1.11E-16
KRAS 999.00 1.00e-118 6.79E-04 9.00E-08 4.23E-06 1.25E-09
TP53 23.09 2.20e-61 4.53E-15 2.34E-06 9.00E-08 1.11E-16
PIK3CA 9.81 7.38e-51 5.94E-03 9.00E-08 1.15E-04 9.76E-09
FBXW7 8.59 4.26e-31 1.00E-16 7.74E-04 1.89E-01 1.11E-16
NRAS 999.00 4.75e-23 3.87E-16 9.00E-08 2.76E-03 1.11E-16
CDC27 0.98 8.16e-16 3.44E-01 2.46E-06 9.98E-01 5.00E-05
SMAD4 999.00 5.36e-13 1.27E-15 7.26E-03 1.10E-03 1.11E-16
CTC-554D6.1 999.00 5.24e-11 NA NA NA NA
NRAP 2.97 2.77e-08 NA NA NA NA
ERBB3 5.95 5.03e-08 5.96E-04 7.07E-04 4.47E-01 5.80E-06
PPP2R1A 1.03 5.90e-08 NA NA NA NA
ERBB2 1.34 7.17e-08 NA NA NA NA
ABCA8 3.40 1.25e-07 NA NA NA NA
DNMT1 2.08 1.68e-07 NA NA NA NA
RAF1 3.58 8.34e-07 NA NA NA NA
PCBP1 999.00 8.44e-07 4.71E-03 1.50E-05 1.35E-03 2.76E-07
HLCS 1.55 1.55e-06 NA NA NA NA
TRIM23 999.00 1.57e-06 7.85E-01 1.47E-05 1.03E-01 4.47E-05
PTEN 3.45 3.65e-06 NA NA NA NA
MYO3A 1.95 3.70e-06 NA NA NA NA
DNAH5 1.83 5.13e-06 NA NA NA NA
CUL2 999.00 5.15e-06 NA NA NA NA
MORC2 999.00 5.48e-06 NA NA NA NA
ACPP 652.61 6.03e-06 NA NA NA NA
SFI1 999.00 6.49e-06 NA NA NA NA
NEB 1.13 9.33e-06 NA NA NA NA
DKK2 2.57 1.20e-05 NA NA NA NA
SMAD2 5.33 1.30e-05 1.83E-11 1.39E-03 1.98E-02 7.55E-14
CLEC18C 1.13 1.53e-05 NA NA NA NA
NEDD9 999.00 2.51e-05 NA NA NA NA
RBBP7 999.00 3.55e-05 NA NA NA NA
GPHN 999.00 3.71e-05 NA NA NA NA
ZNHIT6 999.00 5.28e-05 NA NA NA NA
PTPDC1 2.91 6.31e-05 NA NA NA NA
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Figure 5.6: Missense mutation clustering in BRAF. Mutation pattern in BRAF
with mutation key. This plot shows the clustering of missense mutations that is occur-
ring in the BRAF gene at a specific position over all cancer types, taken from URL:
http://cancergenome.broadinstitute.org/. This could explain why MutSig is able to
detect this gene as significant in Lawrence et al. [2014], and why PAML is not.
reactions, however the predominant mammalian DNA methyltransferase DNMT1 is
unusual in that its relative de novo activity is 1-2 orders of magnitude lower than its
maintenance activity, and is known as the ‘maintenance’ methyltransferase since it is
believed to be the primary enzyme responsible for copying methylation patterns after
DNA replication [Robertson, 2001]. Other DNA methyltransferases such as DNMT3A
and DNMT3B have approximately equal ratios of de novo methyltransferase activ-
ity:maintenance DNA methyltransferase activity. DNMT1 was the first methyltrans-
ferase to be identified [Bestor et al., 1988], and is the most abundant methlytransferase
in somatic cells [Robertson, 2001].
Genomic methylation patterns are frequently altered in tumour cells, and when hyper-
methylation events occur within the promoter of a tumour suppressor gene expression
of the associated gene can be silenced and provide the cell with a selective growth
advantage [Robertson, 2001], hence why this gene is of great interest.
DNMT1 has long been suspected as a candidate cancer gene, particularly in this tumour
type, but has never been confirmed as one. For example, Eads et al. [1999] investigated
the molecular basis of aberrant de novo hypermethylation of CpG islands observed in a
a subset of human colorectal tumours, hypothesising that one potential mechanism was
through the up-regulation of DNA (cytosine-5’)-methyltransferases such as DNMT1.
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However, it was concluded that the deregulation of DNA methyltransferase gene ex-
pression did not play a role in establishing tumour-specific abnormal DNA methylation
patterns in human colorectal cancer.
Three sites are recurrently mutated in DNMT1 in the Lawrence colorectal subset:
E432K, A544P and E1531Q. Almost all of the changes are non-synonymous point mu-
tations, and so not necessarily knock-outs, since mutations that knock out function of
a gene are typically more likely to be in the form of frameshift indels, nonsense point
mutations that introduce a stop codon or large deletions. Therefore these mutations
could be either activating or inactivating the function of the protein encoded by the
gene. Since abnormal methlyation of CpG islands associated with tumour suppressor
genes can lead to transcriptional silencing [Eads et al., 1999], inactivating the gene
through epigenetic means, it can be hypothesised that these putative driver mutations
in DNMT1 are activating mutations that re up-regulating methyltransferase activity to
cause hypermethylation of a tumour suppressor gene substrate. The mutations localise
to two regions of the protein: N-terminal interaction domains and C-terminal catalytic
domains.
The proto-oncogene serine/threonine-protein kinase, RAF1, is also significant in the
PAML analysis but not in the Lawrence study. However it has previously been im-
plicated in colorectal cancer, known to be important in the RAS/MAPK1 signaling
pathway, and is involved in the control of cell proliferation [Slattery et al., 2012]. This
is a cancer gene that Lawrence has failed to detect, but that PAML has successfully
identified.
Of all the genes highly significantly mutated in Lawrence, PCBP1 is the only gene not
known to be implicated in cancer. This gene was also detected by the PAML analysis,
so in this case both methods have detected a novel candidate cancer gene.
91% (64/70) of the significant genes in the PAML analysis of CRC were hit by recurrent
mutations. Mutations in the top most significantly mutated genes in PAML, APC
and KRAS, are amongst the top 35 most recurrent mutations in Table 5.11, with one
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particular mutation in APC occurring in 19 patients and a KRAS mutation occurring
31 times across all patients.
Table 5.12 shows the known cancer genes that have been successfully detected in col-
orectal cancer by both the PAML and recurrence analyses in this project, and also by
the Lawrence et al. [2014] MutSig analysis.
Chapter 5. Tissue of origin sub-type analysis 189
Table 5.11: Ranked list of recurrent mutations in CRC. Ranked list of the
top 35 most recurrent SNVs in the CRC subset of the Lawrence dataset, sorted by
recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
KRAS 12 25398284 C T 31
KRAS 12 25398284 C A 23
BRAF 7 140453136 A T 20
APC 5 112175639 C T 19
TP53 17 7578406 C T 15
KRAS 12 25398281 C T 15
APC 5 112173917 C T 12
PIK3CA 3 178936091 G A 9
TP53 17 7577539 G A 8
PIK3CA 3 178952085 A G 8
KRAS 12 25378562 C T 8
FBXW7 4 153249384 C T 8
TP53 17 7578212 G A 7
TP53 17 7577120 C T 7
SMAD4 18 48591919 G A 7
CDC27 17 45216162 A C 7
APC 5 112173704 C T 7
APC 5 112128143 C T 7
NRAS 1 115256530 G T 6
KRAS 12 25398285 C A 6
APC 5 112175423 C T 6
APC 5 112174631 C T 6
APC 5 112164616 C T 6
APC 5 112116592 C T 5
TP53 17 7578263 G A 4
TP53 17 7577548 C T 4
TP53 17 7577121 G A 4
TP53 17 7577022 G A 4
PIK3CA 3 178936082 G A 4
PIK3CA 3 178916876 G A 4
FBXW7 4 153249385 G A 4
ERBB3 12 56478854 G A 4
ERBB2 17 37881332 G A 4
EMR3 19 14772866 G A 4
APC 5 112175390 C T 4
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Table 5.12: Cancer gene detection success in colorectal cancer. Known cancer
genes that have been detected as significantly mutated in all three of the aforemen-
tioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014] study,
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5.2.5 Endometrial (UCEC)
In the PAML analysis of endometrial cancer, for which 247 patients were analysed,
666 genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.7).
UCEC is known for its high mutation rate across all genes, which explains why there
is such a high rate of significant gene detection in the PAML analysis. The Lawrence
analysis has identified far fewer significant genes in comparison, which suggests that
PAML is less conservative. However, all 16 of the genes found to be highly significantly
mutated in the Lawrence study have also been found to be significant in the PAML
analysis, which shows good synergy between the two methods.
Of the 666 significant PAML genes, DNAH5 is one that has not been detected by the
MutSig analysis. This gene encodes outer dynein arm components, and mutations in
this gene are a common cause of primary ciliary dyskinesia with outer dynein arm de-
fects and is frequently mutated in patients with myeloma [Hornef et al., 2006]. However,
DNAH5 is not a known cancer gene in UCEC or in any other cancer type, and [Lawrence
et al., 2014] did not detect this gene in any of their 22 analyses. Recently, however, this
gene has been shown to potentially play an important role in colorectal cancer, shown to
be downregulated in both colon and rectal cancers compared to normal control tissues
[Xiao et al., 2015]. DNMT1 could therefore represent a novel candidate cancer gene
in endometrial cancer, and has been considered as a potential candidate biomarker for
diagnosis, prognosis and as a therapeutic target for this particular malignancy.
To illustrate the power of PAML to detect known cancer genes, MYC associated factor
X (MAX) was detected as significantly significant by the PAML analysis, but was
not significant in the MutSig analysis. This gene is known to be associated with the
following cancers: pheochromocytoma; endometrioid carcinoma; and colon carcinoma
[Futreal et al., 2004]. Tumour-specific inactivation of this gene was discovered in small
cell lung cancers, and in MAX-deficient lung cancers the inactivation of the chromatin
remodeler BRG1 revealed a preferential toxicity, suggesting a novel therapeutic target
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Figure 5.7: Gene-based omega analysis in UCEC. Gene-based PAML results
have been displayed in this omega plot for 247 UCEC patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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for the treatment of patients with MAX-deficient tumours [Romero et al., 2014]. If this
gene functions through a similar pathway in endometrial cancer then this could suggest
a putative role of MAX as a candidate cancer gene in UCEC.
Overall, 687 genes were found to be significant across both studies (Table 5.13).
87% (577/666) of the significant genes found in UCEC through PAML analysis are hit
by recurrent mutations. The top five most significantly mutated genes from PAML are
PIK3CA, PTEN, CTNNB1, KRAS and FGFR2. These genes are also found to be hit
by some of the most recurrent mutations in this cancer type (Table 5.14).
Table 5.15 shows the known cancer genes that have been successfully detected in en-
dometrial cancer by both the PAML and recurrence analyses in this project, and also
by the Lawrence et al. [2014] MutSig analysis.
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Table 5.13: Ranked list of significant PAML genes in UCEC. The genes
found to be significantly mutated in UCEC patients in the PAML analysis have been
sorted by p-value in ascending order (descending order of significance) in this table.
Genes highlighted in red and orange are found to be highly significantly mutated and
significantly mutated respectively in the Lawrence study. Table has been truncated
to n=35 rows from a total of 687 significant genes for UCEC. R and Perl code used
to produce list in Supplementary Appendix E. Full version of table can be found in
Supplementary Appendix F.
PAML results Lawrence et al. [2014] p-values
Gene Omega P-value CV CL FN Combined
PIK3CA 15.57 7.80e-133 1.00E-16 9.41E-08 5.64E-07 1.11E-16
PTEN 9.43 9.90e-113 1.85E-16 6.83E-08 8.28E-01 1.11E-16
CTNNB1 4.53 3.98e-98 6.34E-02 9.00E-08 9.00E-08 1.18E-06
KRAS 7.52 3.99e-66 1.00E-16 5.02E-08 1.12E-03 1.11E-16
FGFR2 3.34 2.39e-33 1.12E-03 5.01E-08 4.85E-02 1.15E-09
FBXW7 8.43 4.24e-31 7.14E-16 6.25E-03 1.27E-02 1.11E-16
TP53 14.06 3.14e-30 2.55E-15 1.94E-07 6.48E-08 1.11E-16
BCOR 1.19 2.87e-22 2.97E-01 5.99E-05 1.19E-04 1.29E-06
PPP2R1A 2.26 4.47e-18 8.01E-03 4.32E-07 1.01E-01 5.01E-08
MUC16 1.26 3.64e-17 NA NA NA NA
PIK3R1 8.46 3.79e-17 8.18E-16 9.57E-08 4.46E-01 1.11E-16
ARID1A 4.46 1.53e-15 1.00E-16 9.52E-01 6.99E-01 3.55E-15
CTCF 18.07 1.16e-13 1.00E-16 6.00E-03 3.94E-01 2.22E-16
ARHGAP35 2.10 1.89e-13 2.05E-13 6.36E-01 2.06E-01 5.35E-12
KIAA2026 1.41 1.06e-12 NA NA NA NA
NEB 2.02 2.01e-12 NA NA NA NA
ASCC3 2.07 1.35e-11 NA NA NA NA
CUX1 1.20 1.59e-11 3.26E-07 6.90E-02 9.95E-01 3.86E-06
KIF20B 3.16 1.92e-11 NA NA NA NA
CNOT1 8.96 2.37e-11 NA NA NA NA
DNAH5 1.61 5.94e-11 NA NA NA NA
ZNF709 7.80 1.98e-10 NA NA NA NA
CCDC132 1.27 4.96e-10 NA NA NA NA
ZNF781 4.41 1.39e-09 NA NA NA NA
TXNL1 4.90 2.38e-09 NA NA NA NA
SMC4 1.22 2.69e-09 NA NA NA NA
TAF1 4.52 3.77e-09 NA NA NA NA
MYCN 2.01 6.03e-09 1.50E-01 2.53E-05 6.41E-02 1.97E-04
MDN1 2.30 7.14e-09 NA NA NA NA
SFRP4 999.00 1.17e-08 NA NA NA NA
INTS7 2.54 1.28e-08 NA NA NA NA
ZNF43 1.35 1.58e-08 NA NA NA NA
MAX 999.00 1.65e-08 NA NA NA NA
RSBN1L 5.89 1.66e-08 1.21E-02 3.28E-04 8.83E-01 1.03E-04
ZNF180 1.89 2.01e-08 NA NA NA NA
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Table 5.14: Ranked list of recurrent mutations in UCEC. Ranked list of the
top 35 most recurrent SNVs in the UCEC subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
PTEN 10 89692904 C G 25
PTEN 10 89692905 G A 17
KRAS 12 25398284 C T 16
PTEN 10 89717672 C T 14
FGFR2 10 123279677 G C 14
BCOR 23 39921444 T C 13
PIK3CA 3 178952085 A G 12
PIK3CA 3 178916876 G A 12
KRAS 12 25398284 C A 12
PIK3CA 3 178936091 G A 10
PPP2R1A 19 52715971 C G 9
PIK3CA 3 178936082 G A 9
ARID1A 1 27106354 C T 9
POLE 12 133253184 G C 8
PIK3R1 5 67588951 C T 8
CTNNB1 3 41266113 C T 8
CTNNB1 3 41266113 C G 8
PTEN 10 89692904 C T 7
KRAS 12 25398281 C T 7
PIK3CA 3 178952085 A T 6
PIK3CA 3 178917478 G A 6
KIAA2026 9 5968511 G A 6
CTNNB1 3 41266101 C T 6
CTNNB1 3 41266097 G A 6
CTCF 16 67655479 C T 6
ARHGAP35 19 47424921 C T 6
TPP2 13 103292684 C T 5
TP53 17 7577539 G A 5
SMC4 3 160151484 C T 5
SLCO1B3 12 21011428 G A 5
POLE 12 133250289 C A 5
PIK3CA 3 178916891 G A 5
MYO10 5 16694613 C T 5
MYF6 12 81101837 C T 5
KRAS 12 25398284 C G 5
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Table 5.15: Cancer gene detection success in endometrial cancer. Known
cancer genes that have been detected as significantly mutated in all three of the afore-
mentioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014]
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5.2.6 Glioblastoma multiforme (GBM)
In the PAML analysis of glioblastoma multiforme, for which 291 patients were analysed,
20 genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.8).
A potential candidate cancer gene called HERC1 has been identified by the PAML anal-
ysis, undetected by MutSig. The HERC1 protein belongs to the HERC protein family
of ubiquitin ligases characterized by the presence of an HECT domain and one or more
RCC1-like domains [Nguyen et al., 2015]. This family consists of two subgroups accord-
ing to their sizes and domain architecture, with HERC1 as one of the two giant HERC
proteins containing other functional domains such as two RLDs, a C-terminal HECT,
a WD40, a SPRY (spl A and RyR) domain and several other minor motifs [Nguyen
et al., 2015]. A homozygous nonsense variant in HERC1 was identified through exome
sequencing as the causal variant of a novel autosomal-recessive neurological condition
characterized by megalencephaly, thick corpus callosum and severe intellectual disabil-
ity. HERC1 is also found to interact with an upstream negative regulator of the mTOR
pathway, which has been shown to have a role in the regulation of brain development
[Nguyen et al., 2015]. The role of this gene in a pathway of the brain and with a muta-
tion known to cause disease specifically in this tissue supports this gene as a candidate
for glioblastoma mutliforme.
Overall, 32 genes were found to be significant in at least one of the two analyses (Ta-
ble 5.16).
Figure 5.9 shows the relationship between the PAML and MutSig p-values for the most
significant genes. A strong positive correlation is observed between the two p-values
(Pearson’s cor = 0.61, p-value = 1.76e-11).
Again significant PAML genes are shown to be genes containing recurrent mutations for
this cancer type, with 95% (19/20) of the significant genes containing recurrent muta-
tions. For example EGFR, TP53, PTEN and PIK3CA are all significantly mutated in
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Figure 5.8: Gene-based omega analysis in GBM. Gene-based PAML results
have been displayed in this omega plot for 291 GBM patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.16: Ranked list of significant PAML genes in GBM. The genes found
to be significantly mutated in GBM patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and sig-
nificantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
EGFR 3.99 4.26e-73 2.43E-15 9.99E-08 9.99E-08 1.11E-16
TP53 35.63 3.41e-38 1.00E-16 9.99E-08 9.99E-08 1.11E-16
PTEN 999.00 7.57e-20 1.00E-16 9.10E-02 4.91E-01 3.55E-15
PIK3CA 999.00 1.13e-16 1.58E-16 9.99E-08 4.66E-02 1.11E-16
PIK3R1 999.00 5.82e-12 5.53E-16 5.53E-06 1.29E-01 1.11E-16
IDH1 348.57 4.22e-08 4.51E-13 4.99E-07 9.16E-01 1.11E-16
JPH1 1.01 1.53e-06 NA NA NA NA
NUP210L 999.00 8.28e-06 5.52E-04 1.05E-01 8.40E-02 9.59E-05
PODNL1 999.00 1.01e-05 NA NA NA NA
ZFP42 999.00 1.55e-05 NA NA NA NA
GLT8D2 999.00 1.83e-05 NA NA NA NA
MAP3K1 1.48 2.10e-05 3.67E-03 5.14E-05 6.35E-02 2.21E-06
SPTA1 11.51 2.12e-05 NA NA NA NA
TPTE2 999.00 4.34e-05 NA NA NA NA
NF1 8.02 1.08e-04 1.00E-16 6.80E-02 8.73E-01 3.55E-15
TMPRSS6 999.00 1.39e-04 NA NA NA NA
RB1 4.33 2.37e-04 1.26E-15 2.33E-01 5.20E-02 2.22E-15
CYP4F22 999.00 3.15e-04 NA NA NA NA
EPHA1 1.53 4.81e-04 NA NA NA NA
HERC1 999.00 5.43e-04 NA NA NA NA
SLC26A3 999.00 1.76e-03 2.62E-07 2.40E-01 4.60E-02 1.90E-07
KEL 2.48 2.88e-03 6.00E-07 2.60E-02 8.80E-01 6.74E-06
BRAF 0.79 6.56e-03 4.99E-02 1.00E-06 1.38E-03 6.85E-07
MUC17 1.84 1.73e-02 1.59E-06 2.71E-01 5.02E-01 1.63E-05
SETD2 999.00 1.15e-01 1.25E-03 1 2.00E-03 7.99E-05
CHD8 999.00 1.26e-01 6.85E-07 1 3.86E-01 7.61E-06
STAG2 999.00 1.54e-01 1.19E-10 1 7.87E-01 2.34E-09
AZGP1 999.00 1.81e-01 3.79E-06 1 7.65E-01 3.56E-05
RPL5 999.00 1.98e-01 1.18E-09 1 3.92E-01 2.07E-08
QKI 16.83 3.32e-01 7.86E-05 1 3.36E-03 2.77E-05
DDX5 NA NA 6.32E-05 1.65E-02 8.08E-01 1.12E-05
CD1D NA NA 5.73E-04 1.00E-03 9.89E-01 7.59E-06







































































Figure 5.9: Comparison of PAML and MutSig p-values in GBM. This scat-
terplot shows the relationship between the p-values obtained from the MutSigCV test
in the Lawrence study and the p-values obtained from the PAML analysis in this
project, for the GBM subset only. P-values have been double log transformed to show
increasing significance with PAML p-value plotted along the x-axis and MutSigCV
along the y-axis. Only genes with more significant p-values (<0.05) have been plotted.
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the PAML analysis as well as the Lawrence analysis, and they also all contain recurrent
mutations (Table 5.17).
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Table 5.17: Ranked list of recurrent mutations in GBM. Ranked list of the
top 35 most recurrent SNVs in the GBM subset of the Lawrence dataset, sorted by
recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
IDH1 2 209113112 C T 13
EGFR 7 55221822 C T 13
EGFR 7 55233043 G T 12
TP53 17 7577538 C T 6
TP53 17 7578406 C T 5
PTEN 10 89717672 C T 5
EGFR 7 55221821 G A 5
BRAF 7 140453136 A T 5
TP53 17 7577120 C T 4
TP53 17 7577094 G A 4
PIK3CA 3 178936091 G A 4
EGFR 7 55220274 C T 4
EGFR 7 55211080 G A 4
C17orf70 17 79516489 C T 4
ZDHHC4 7 6628405 G A 3
TSHZ2 20 51870661 G A 3
TPTE2 13 20039688 G A 3
TP53 17 7578457 C T 3
TP53 17 7578263 G A 3
TP53 17 7578190 T C 3
TP53 17 7577548 C T 3
TP53 17 7577539 G A 3
SPINT1 15 41146113 C T 3
RB1 13 48953730 C T 3
PTEN 10 89720852 C T 3
PTEN 10 89692904 C T 3
PIK3R1 5 67589138 G A 3
PCBD2 5 134263015 A G 3
NUMB 14 73766352 G T 3
MAP3K1 5 56160697 C T 3
KLK5 19 51451834 C T 3
HCN2 19 603979 C T 3
FTMT 5 121187598 C T 3
EHD4 15 42193062 G A 3
EGFR 7 55223543 C T 3
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5.2.6.1 Re-analysis after exclusion of 16 GBM outlier patients
The GBM analysis in PAML was repeated after removing the 16 GBM outlier patients
from the GBM dataset. The 16 outlier patients are those that exhibited much higher
SNV rates in the TCGA dataset than in the Lawrence dataset, possibly as a result of
an increased INDEL rate compared to other patients causing an increase in SNV calls
around misaligned reads.
After the exclusion of the 16 outlier patients, the remaining 275 GBM patients were
run through PAML which found 22 genes to be significantly mutated (Figure 5.10),
compared to 20 in the full GBM dataset of 291 patients (Figure 5.8). The three genes
not significantly mutated in the analysis of the whole GBM subset but that reached
significance in the re-analysis were DNAH2, MUC17 and TSHz2. CYP4F22 was no
longer significantly mutated in the re-analysis, despite being significant in the original
GBM PAML analysis.
Of the three genes found to reach significance in the re-analysis, MUC17 was already
found to be significantly mutated in the MutSig analysis carried out by [Lawrence
et al., 2014] (highlighted in orange in Table 5.18 and Table 5.16). DNAH2 and TSHZ2
however, had not been detected as significantly mutated genes in the Lawrence study.
This suggests that by removing the patients with potentially false-positive SNV calls,
the PAML analysis is better equipped to detect more of the genes detected by [Lawrence
et al., 2014], and has detected two potential candidate genes not previously known to
be cancer genes (DNAH2 and TSHZ2).
Figure 5.11 shows the relationship between the PAML and MutSig p-values for the most
significant genes, using the PAML p-values calculated in the re-analysis of the 275 GBM
patients (excluding the 16 outlier patients). A positive correlation is observed between
the two p-values (Pearson’s cor = 0.53, p-value = 2.50e-08), however this is a weaker
correlation than that previously observed in Figure 5.9 before the removal of the 16
outlier patients. This is an unexpected result, as removing those 16 outlier patients
was predicted to remove some of the difference in SNV rates observed between the
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Figure 5.10: Gene-based omega analysis in GBM (excluding 16 outlier pa-
tients). Gene-based PAML results have been displayed in this omega plot for the
GBM subset containing 275 patients (exclusive of the 16 outlier patients) to show the
omega ratios and FDR values for each gene, together with their level of significance
in the Lawrence study. Genes highlighted in red and orange are those shown to be
highly significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) re-
spectively in the Lawrence study (over 291 GBM patients). Genes highlighted in blue
are potential candidate cancer genes shown to reach significance (FDR≤0.1) in the
PAML analysis, however do not reach significance in the Lawrence study. Genes high-
lighted in purple are examples of genes that do not reach significance in the Lawrence
study, and have conflicting results in the PAML analysis (with a significant p-value
supporting positive selection, but an omega value indicative of negative selection). R
code used to generate plot in Supplementary Appendix D.
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Table 5.18: Ranked list of significant PAML genes in GBM (excluding 16
outlier patients). The genes found to be significantly mutated in the subset of 275
GBM patients (exclusive of the 16 outlier patients) in the PAML analysis have been
sorted by p-value in ascending order (descending order of significance) in this table.
Genes highlighted in red and orange are found to be highly significantly mutated and
significantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study of all 291 GBM patients. R
and Perl code used to produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
EGFR 3.50 4.69e-64 2.43E-15 9.99E-08 9.99E-08 1.11E-16
TP53 30.60 1.71e-31 1.00E-16 9.99E-08 9.99E-08 1.11E-16
PTEN 999.00 1.52e-19 1.00E-16 9.10E-02 4.91E-01 3.55E-15
PIK3CA 999.00 4.43e-15 1.58E-16 9.99E-08 4.66E-02 1.11E-16
PIK3R1 999.00 5.85e-12 5.53E-16 5.53E-06 1.29E-01 1.11E-16
IDH1 408.97 4.22e-08 4.51E-13 4.99E-07 9.16E-01 1.11E-16
JPH1 1.01 1.53e-06 NA NA NA NA
NUP210L 999.00 9.45e-06 5.52E-04 1.05E-01 8.40E-02 9.59E-05
PODNL1 730.78 1.01e-05 NA NA NA NA
GLT8D2 999.00 1.43e-05 NA NA NA NA
MAP3K1 1.48 1.52e-05 3.67E-03 5.14E-05 6.35E-02 2.21E-06
ZFP42 999.00 1.55e-05 NA NA NA NA
SPTA1 10.87 3.92e-05 NA NA NA NA
TPTE2 999.00 4.36e-05 NA NA NA NA
MUC17 2.14 1.32e-04 1.59E-06 2.71E-01 5.02E-01 1.63E-05
TMPRSS6 999.00 1.39e-04 NA NA NA NA
TSHZ2 1.15 2.10e-04 NA NA NA NA
NF1 8.00 2.67e-04 1.00E-16 6.80E-02 8.73E-01 3.55E-15
RB1 4.33 2.78e-04 1.26E-15 2.33E-01 5.20E-02 2.22E-15
EPHA1 1.53 4.81e-04 NA NA NA NA
HERC1 999.00 5.51e-04 NA NA NA NA
DNAH2 2.45 5.57e-04 NA NA NA NA
SLC26A3 999.00 1.88e-03 2.62E-07 2.40E-01 4.60E-02 1.90E-07
KEL 2.37 2.34e-03 6.00E-07 2.60E-02 8.80E-01 6.74E-06
BRAF 0.79 6.56e-03 4.99E-02 1.00E-06 1.38E-03 6.85E-07
SETD2 999.00 1.13e-01 1.25E-03 1 2.00E-03 7.99E-05
CHD8 999.00 1.26e-01 6.85E-07 1 3.86E-01 7.61E-06
STAG2 999.00 1.73e-01 1.19E-10 1 7.87E-01 2.34E-09
AZGP1 999.00 1.81e-01 3.79E-06 1 7.65E-01 3.56E-05
RPL5 999.00 1.98e-01 1.18E-09 1 3.92E-01 2.07E-08
QKI 24.93 3.32e-01 7.86E-05 1 3.36E-03 2.77E-05
DDX5 NA NA 6.32E-05 1.65E-02 8.08E-01 1.12E-05
CD1D NA NA 5.73E-04 1.00E-03 9.89E-01 7.59E-06
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two methods, and hence increase the correlation between the p-value results for both
approaches.
Removal of the 16 GBM outlier patients did not significantly affect the recurrence
analysis in Table 5.19, suggesting that the SNVs removed were not recurrent mutations,
supporting the hypothesis that the high rate of mutations in the 16 outlier patients were
mis-called SNVs near INDELs rather than recurrent driver mutations. As seen in the
previous GBM analysis including the 16 outlier patients (Table 5.17), 95% (21/22)
of the significant mutated genes in the PAML re-analysis were also found to harbour
recurrent mutations (same mutation present in more than patient).
Table 5.20 shows the known cancer genes that have been successfully detected in
glioblastoma multiforme by both the PAML and recurrence analyses in this project,
and also by the Lawrence et al. [2014] MutSig analysis. The same overlap genes were
detected in both the GBM analysis including the 16 outliers and in the GBM re-analysis
excluding the 16 outliers.







































































Figure 5.11: Comparison of PAML and MutSig p-values in GBM (ex-
cluding 16 outlier patients). This scatterplot shows the relationship between the
p-values obtained from the MutSigCV test in the Lawrence study over all 291 GBM
patients, and the p-values obtained from the PAML re-analysis in this project for the
275 GBM patient subset exclusive of the 16 outlier patients. P-values have been dou-
ble log transformed to show increasing significance with PAML p-value plotted along
the x-axis and MutSigCV along the y-axis. Only genes with more significant p-values
(<0.05) have been plotted.
Chapter 5. Tissue of origin sub-type analysis 208
Table 5.19: Ranked list of recurrent mutations in GBM (excluding 16 out-
lier patients). Ranked list of the top 35 most recurrent SNVs in the GBM subset
of the Lawrence dataset containing 275 patients (excluding the 16 outlier patients),
sorted by recurrence in descending order. For each unique mutation, the gene, chro-
mosome, position, ref and alt alleles and how many patients the mutation occurs in
(recurrence) have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
IDH1 2 209113112 C T 13
EGFR 7 55221822 C T 12
EGFR 7 55233043 G T 11
TP53 17 7577538 C T 6
TP53 17 7578406 C T 5
EGFR 7 55221821 G A 5
BRAF 7 140453136 A T 5
TP53 17 7577120 C T 4
PTEN 10 89717672 C T 4
EGFR 7 55220274 C T 4
ZDHHC4 7 6628405 G A 3
TSHZ2 20 51870661 G A 3
TPTE2 13 20039688 G A 3
TP53 17 7578457 C T 3
TP53 17 7578190 T C 3
TP53 17 7577539 G A 3
TP53 17 7577094 G A 3
SPINT1 15 41146113 C T 3
RB1 13 48953730 C T 3
PTEN 10 89720852 C T 3
PTEN 10 89692904 C T 3
PIK3R1 5 67589138 G A 3
PIK3CA 3 178936091 G A 3
PCBD2 5 134263015 A G 3
NUMB 14 73766352 G T 3
MAP3K1 5 56160697 C T 3
KLK5 19 51451834 C T 3
HCN2 19 603979 C T 3
FTMT 5 121187598 C T 3
EHD4 15 42193062 G A 3
EGFR 7 55223543 C T 3
EGFR 7 55211080 G A 3
DST 6 56566691 G A 3
CNTNAP4 16 76383006 G T 3
C17orf70 17 79516489 C T 3
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Table 5.20: Cancer gene detection success in glioblastoma multiforme.
Known cancer genes that have been detected as significantly mutated in all three of
the aforementioned analyses, overlapping the MutSig analysis in the Lawrence et al.
[2014] study, the PAML analysis and the recurrence analysis. The same nine cancer
genes were detected in both the set of 291 GBM patients including the 16 outlier
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5.2.7 Head and neck (HNSC)
In the PAML analysis of head and neck cancer, for which 384 patients were analysed,
12 genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.12).
Amongst the three genes identified as significant in this cancer type by my approach in
PAML but not in MutSig, is F-box and WD-40 domain protein 7 (FBXW7). This gene
is a known cancer gene previously shown to be associated with colorectal, endometrial
cancer and T-cell acute lymphocytic leukemia (T-ALL) [Futreal et al., 2004].
Overall, 30 genes were found to be significantly mutated in at least one of the analyses
(Table 5.21). AJUBA was found to be highly significant in the Lawrence study, however
PAML has failed to produce results for this gene. The majority of mutations are
INDELs in this gene so a significant result would not be expected in PAML, however
this does not explain why no results at all have been reported. This could be an issue
with the cluster from which PAML was run.
83% (10/12) of the significant PAML genes in HNSC are hit by recurrent mutations.
PIK3CA is the most significant gene in the PAML analysis (also highly significant in
Lawrence), and is also shown to contain the most recurrent mutation in this cancer
type which affects 22 patients in the HNSC dataset (Table 5.22).
Table 5.23 shows the known cancer genes that have been successfully detected in head
and neck cancer by both the PAML and recurrence analyses in this project, and also
by the Lawrence et al. [2014] MutSig analysis.
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Figure 5.12: Gene-based omega analysis in HNSC. Gene-based PAML results
have been displayed in this omega plot for 384 HNSC patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.21: Ranked list of significant PAML genes in HNSC. The genes
found to be significantly mutated in HNSC patients in the PAML analysis have been
sorted by p-value in ascending order (descending order of significance) in this table.
Genes highlighted in red and orange are found to be highly significantly mutated and
significantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
PIK3CA 999.00 1.09e-91 7.39E-07 9.89E-08 3.13E-05 1.98E-12
TP53 14.19 7.02e-84 1.40E-15 5.14E-08 5.14E-08 1.11E-16
CDKN2A 1.94 2.13e-33 8.94E-16 2.76E-03 9.89E-08 1.11E-16
HRAS 999.00 4.01e-16 1.91E-08 7.91E-07 4.42E-04 5.83E-14
NFE2L2 999.00 2.32e-14 2.11E-10 2.27E-06 7.91E-07 7.77E-16
CASP8 999.00 5.61e-10 1.62E-16 3.65E-02 1.57E-02 1.11E-16
MLL2 (KMT2D) 4.26 6.06e-08 1.00E-16 1 1.22E-01 3.55E-15
PRB3 2.19 3.12e-07 NA NA NA NA
FBXW7 5.44 5.18e-07 NA NA NA NA
FAT1 5.57 1.04e-06 4.22E-16 9.78E-01 3.64E-03 3.33E-16
RAC1 999.00 1.04e-06 3.81E-08 3.99E-05 4.61E-01 6.45E-11
MACF1 1.21 2.46e-05 NA NA NA NA
TGFBR2 3.09 2.47e-04 8.40E-08 1.70E-02 5.83E-01 4.08E-08
B2M 999.00 3.58e-04 1.56E-06 1.45E-01 2.52E-01 1.61E-05
EPHA2 999.00 3.09e-03 4.06E-15 5.82E-01 3.53E-01 1.22E-13
NSD1 9.55 4.45e-03 1.00E-16 5.64E-01 3.10E-02 3.55E-15
HLA-A 0.65 6.71e-03 1.45E-06 7.60E-01 6.45E-03 2.46E-07
EP300 3.53 1.50e-02 5.29E-05 1.03E-03 1.12E-01 1.06E-06
ZNF750 4.47 1.64e-02 1.12E-07 2.25E-02 1.91E-03 6.14E-09
PTEN 999.00 4.51e-02 5.06E-09 2.57E-01 4.30E-01 8.10E-08
CTCF 4.26 1.27e-01 3.57E-06 1 1.60E-01 3.38E-05
HLA-B 999.00 1.59e-01 2.71E-06 1 9.60E-02 2.64E-05
RASA1 3.64 2.93e-01 1.36E-05 5.30E-02 1.90E-01 1.10E-04
MAP4K3 1.35 4.81e-01 9.78E-03 2.63E-02 3.92E-02 1.33E-04
RHOA 0.38 5.00e-01 1.62E-04 1.18E-05 3.10E-02 2.18E-08
OTUD7A 0.08 5.00e-01 9.07E-04 2.73E-03 1 2.43E-05
NOTCH1 0.86 5.00e-01 1.00E-16 2.44E-01 4.73E-01 3.55E-15
IPO7 0.45 5.00e-01 1.77E-01 1 1.00E-05 8.42E-05
AJUBA NA NA 9.01E-14 1 8.09E-01 2.43E-12
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Table 5.22: Ranked list of recurrent mutations in HNSC. Ranked list of the
top 35 most recurrent SNVs in the HNSC subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
PIK3CA 3 178936091 G A 22
PIK3CA 3 178936082 G A 15
CDKN2A 9 21971120 G A 14
TP53 17 7578406 C T 9
CDKN2A 9 21971186 G A 9
TP53 17 7578212 G A 8
TP53 17 7577538 C T 8
TP53 17 7577094 G A 8
PIK3CA 3 178952085 A G 8
TP53 17 7577120 C T 7
TP53 17 7578263 G A 6
TP53 17 7577548 C T 6
TP53 17 7577539 G A 6
CDKN2A 9 21971028 C T 6
CDKN2A 9 21971000 C A 6
RHOA 3 49412905 C G 5
CDKN2A 9 21971029 C T 5
TP53 17 7578395 G A 4
TP53 17 7577022 G A 4
NFE2L2 2 178098810 C G 4
MB21D2 3 192516720 G C 4
HRAS 11 534285 C A 4
EP300 22 41565529 G A 4
TP53 17 7579358 C A 3
TP53 17 7578524 G A 3
TP53 17 7578461 C A 3
TP53 17 7578394 T C 3
TP53 17 7578271 T A 3
TP53 17 7578190 T C 3
TP53 17 7577556 C A 3
TP53 17 7577106 G A 3
TP53 17 7577046 C A 3
PRB3 12 11421068 G A 3
NFE2L2 2 178098960 C G 3
MAPK1 22 22127164 C T 3
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Table 5.23: Cancer gene detection success in head and neck cancer. Known
cancer genes that have been detected as significantly mutated in all three of the afore-
mentioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014]
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5.2.8 Kidney clear cell (KIRC)
KIRC is the most common form of kidney cancer [Kaelin, 2010].
In the PAML analysis of kidney clear cell cancer, for which 417 patients were analysed,
12 genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.13).
VHL is the most significant result in the PAML analysis as would be expected, since this
gene is mutated or silenced in over 50% of sporadic kidney renal clear cell carcinomas
and is known to be causally implicated in both sporadic and germline kidney renal clear
cell carcinomas [Kaelin, 2004].
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) is
a known cancer gene that has been detected by the PAML analysis as a significantly
mutated gene in this cancer type, however it has not been detected by the MutSig
analysis. PIK3CA is associated with colorectal, gastric, glioblastoma and breast cancers
[Futreal et al., 2004].
Overall 20 genes were found to be significant in at least one of the analyses (Table 5.24).
75% (9/12) of the significant PAML genes in KIRC are hit by recurrent mutations. As
expected VHL contains many recurrent mutations across all KIRC patients, and is the
most recurrently mutated gene in KIRC (Table 5.25).
Table 5.26 shows the known cancer genes that have been successfully detected in kidney
clear cell cancer by both the PAML and recurrence analyses in this project, and also
by the Lawrence et al. [2014] MutSig analysis.
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Figure 5.13: Gene-based omega analysis in KIRC. Gene-based PAML results
have been displayed in this omega plot for 417 KIRC patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.24: Ranked list of significant PAML genes in KIRC. The genes
found to be significantly mutated in KIRC patients in the PAML analysis have been
sorted by p-value in ascending order (descending order of significance) in this table.
Genes highlighted in red and orange are found to be highly significantly mutated and
significantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
VHL 6.33 2.25e-35 1.00E-16 9.84E-01 9.31E-01 3.55E-15
GUSB 1.97 9.91e-08 1.13E-01 1.00E-06 8.15E-01 1.07E-05
SETD2 11.05 2.23e-07 1.63E-15 6.81E-03 5.38E-03 2.22E-16
PIK3CA 999.00 2.89e-06 NA NA NA NA
TCEB1 999.00 3.46e-06 4.45E-04 4.82E-03 5.37E-01 2.39E-05
CCDC120 150.76 6.70e-06 4.76E-02 1.00E-04 4.58E-01 4.36E-05
EGFR 999.00 8.32e-06 NA NA NA NA
BAP1 7.70 1.61e-05 1.00E-16 6.64E-03 2.59E-01 2.22E-16
DNAH9 5.48 3.61e-05 NA NA NA NA
NFAT5 85.79 1.59e-04 NA NA NA NA
ARHGAP31 1.56 2.35e-04 NA NA NA NA
PBRM1 5.44 2.35e-04 1.00E-16 1 7.90E-02 3.55E-15
MTOR 2.47 7.06e-04 5.27E-05 1.52E-05 8.07E-01 2.05E-08
KDM5C 4.71 3.96e-03 1.97E-16 4.67E-01 4.98E-01 6.55E-15
RHEB 999.00 9.97e-03 5.74E-03 7.06E-04 2.29E-01 2.13E-05
PTEN 999.00 6.25e-02 1.00E-16 2.45E-01 6.88E-01 3.55E-15
TP53 4.87 8.35e-02 9.53E-12 1 2.50E-02 2.12E-10
MPO 999.00 2.13e-01 2.90E-02 1 1.00E-04 2.80E-05
ATM 3.48 5.00e-01 9.71E-04 1.05E-01 4.27E-03 2.19E-05
ARID1A 3.75 5.00e-01 6.38E-07 1 1.53E-01 7.13E-06
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Table 5.25: Ranked list of recurrent mutations in KIRC. Ranked list of the
top 35 most recurrent SNVs in the KIRC subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
VHL 3 10183797 T A 7
VHL 3 10183725 C A 7
VHL 3 10183863 G A 5
VHL 3 10183734 C A 5
VHL 3 10191572 G T 3
VHL 3 10191558 T C 3
VHL 3 10191513 T C 3
VHL 3 10191479 C G 3
VHL 3 10191469 A G 3
VHL 3 10188321 G T 3
VHL 3 10188240 T A 3
VHL 3 10183817 C T 3
VHL 3 10183794 G A 3
VHL 3 10183776 G C 3
VHL 3 10183752 T A 3
VHL 3 10183748 C T 3
VHL 3 10183665 C T 3
PIK3CA 3 178936091 G A 3
PBRM1 3 52621464 G A 3
LIN28A 1 26742193 A C 3
ZNF780B 19 40540306 G A 2
ZNF732 4 265967 C G 2
ZNF687 1 151261955 T G 2
ZNF462 9 109688141 T A 2
ZNF43 19 21992281 A C 2
ZNF292 6 87970404 G T 2
ZNF273 7 64388663 T A 2
ZMAT5 22 30134342 C A 2
ZFYVE9 1 52703736 T A 2
ZFR2 19 3833722 A T 2
ZFAND2B 2 220072989 T C 2
ZDHHC1 16 67428940 T A 2
WWP2 16 69964089 G C 2
VHL 3 10191570 T C 2
VHL 3 10191488 C T 2
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Table 5.26: Cancer gene detection success in kidney clear cell cancer.
Known cancer genes that have been detected as significantly mutated in all three of
the aforementioned analyses, overlapping the MutSig analysis in the Lawrence et al.
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5.2.9 Lung adenocarcinoma (LUAD)
In the PAML analysis of lung adenocarcinoma, for which 400 patients were analysed,
15 genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.14).
Catenin (cadherin-associated protein) beta 1 (CTNNB1) has been detected as signif-
icantly mutated in this cancer type by PAML but not by MutSig, and is a known
cancer gene associated with colorectal, ovarian, hepatoblastoma and pleomorphic sali-
vary gland adenoma amongst other tumour types [Futreal et al., 2004].
Overall, 30 genes were found to be significant in at least one of the analyses (Table 5.27).
The top three hits, XIRP2, FLG and MUC16 had FDR values of infinity as their p-
values were 0, therefore these genes have come up as highly significant in the PAML
analysis. However, Lawrence has not detected these as significant. It is possible that
these are false-positive results, especially MUC16 since this gene is known to appear
as a false-positive in similar such cancer studies [Lawrence et al., 2013]. FLG generally
has a very high mutation rate, caused by the presence of highly mutable long simple
tandem repeats (STRs) in this gene, and has been linked to autoinflammatory diseases
[Ross, 2014].
79% (11/14) of the significantly mutated PAML genes in LUAD are hit by recurrent
mutation (Table 5.28). XIRP2 is not hit by recurrent mutations in this cancer. This
supports the speculation that it may be a false-positive.
Table 5.29 shows the known cancer genes that have been successfully detected in lung
adenocarcinoma by both the PAML and recurrence analyses in this project, and also
by the Lawrence et al. [2014] MutSig analysis.
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Figure 5.14: Gene-based omega analysis in LUAD. Gene-based PAML results
have been displayed in this omega plot for 400 LUAD patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.27: Ranked list of significant PAML genes in LUAD. The genes
found to be significantly mutated in LUAD patients in the PAML analysis have been
sorted by p-value in ascending order (descending order of significance) in this table.
Genes highlighted in red and orange are found to be highly significantly mutated and
significantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
FLG 1.45 0.00e+00 NA NA NA NA
MUC16 1.08 0.00e+00 NA NA NA NA
XIRP2 1.27 0.00e+00 NA NA NA NA
KRAS 2.23 2.16e-137 3.91E-08 9.89E-08 9.89E-08 1.16E-13
TP53 14.13 1.77e-43 4.02E-15 1.62E-04 5.04E-08 1.11E-16
EGFR 0.96 1.04e-24 2.58E-06 9.89E-08 2.08E-03 6.61E-12
BRAF 2.82 7.11e-11 3.55E-03 5.93E-07 5.86E-01 6.29E-08
PIK3CA 2.92 4.95e-10 3.71E-02 3.96E-07 4.26E-02 2.70E-07
KEAP1 999.00 1.06e-08 4.12E-15 3.52E-01 1.36E-05 1.11E-16
CTNNB1 999.00 2.15e-08 NA NA NA NA
OOEP 999.00 2.03e-07 NA NA NA NA
ATM 2.12 3.07e-05 4.97E-03 1.44E-02 1.42E-02 2.60E-05
NBPF15 1.10 5.90e-05 NA NA NA NA
RAD50 1.58 9.90e-05 NA NA NA NA
GALC 999.00 1.60e-04 NA NA NA NA
ERBB2 1.52 3.68e-04 7.80E-03 6.50E-06 3.94E-01 1.32E-06
RIT1 3.49 7.03e-04 5.27E-07 1.22E-02 1.36E-01 4.17E-08
STX2 999.00 8.51e-04 3.42E-03 1.27E-02 2.23E-02 3.93E-05
MAP2K1 2.61 3.26e-03 4.72E-04 1.11E-02 8.89E-01 4.95E-05
STK11 4.08 3.61e-03 1.00E-16 9.87E-01 7.00E-02 3.55E-15
SLC4A5 4.91 1.85e-02 2.58E-04 1.55E-02 1.47E-01 3.19E-05
CDKN2A 1.34 3.79e-02 3.70E-09 1.49E-01 9.89E-08 1.19E-14
U2AF1 999.00 9.70e-02 2.87E-07 7.71E-06 2.83E-05 7.98E-13
MET 0.95 1.09e-01 2.44E-06 1.03E-03 2.15E-03 2.64E-09
RB1 2.34 3.37e-01 9.01E-06 1 3.61E-01 7.68E-05
SMARCA4 1.17 4.75e-01 5.88E-14 1 2.63E-01 1.61E-12
RBM10 2.39 5.00e-01 3.58E-08 1 1.91E-01 5.03E-07
ARID1A 2.41 5.00e-01 5.02E-07 3.73E-01 5.43E-01 5.73E-06
NF1 1.04 5.00e-01 2.20E-10 6.50E-01 4.30E-02 4.21E-09
NBPF1 NA NA 4.94E-01 2.94E-05 9.02E-03 3.25E-05
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Table 5.28: Ranked list of recurrent mutations in LUAD. Ranked list of the
top 35 most recurrent SNVs in the LUAD subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
KRAS 12 25398285 C A 55
KRAS 12 25398284 C A 20
EGFR 7 55259515 T G 13
U2AF1 21 44524456 G A 10
KRAS 12 25398284 C G 8
TP53 17 7578457 C A 7
TP53 17 7577120 C A 6
PIK3CA 3 178936091 G A 6
KRAS 12 25398284 C T 6
KRAS 12 25398281 C T 5
KRAS 12 25398282 C A 4
EGFR 7 55241708 G C 4
CTNNB1 3 41266113 C T 4
BRAF 7 140481402 C A 4
TTN 2 179553413 G T 3
TP53 17 7579377 G A 3
TP53 17 7579312 C A 3
TP53 17 7578500 G A 3
TP53 17 7578469 C A 3
TP53 17 7578461 C A 3
TP53 17 7578455 C G 3
TP53 17 7578442 T C 3
TP53 17 7578406 C T 3
TP53 17 7578263 G A 3
TP53 17 7578212 G A 3
TP53 17 7577538 C G 3
TP53 17 7577536 T C 3
TP53 17 7577535 C A 3
TP53 17 7577114 C A 3
TP53 17 7574000 C A 3
TBC1D12 10 96162370 G A 3
SLC6A17 1 110734898 G T 3
RAD50 5 131895051 G T 3
PI15 8 75737548 G T 3
NRAS 1 115256529 T A 3
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Table 5.29: Cancer gene detection success in lung adenocarcinoma. Known
cancer genes that have been detected as significantly mutated in all three of the afore-
mentioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014]
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5.2.10 Lung squamous cell carcinoma (LUSC)
In the PAML analysis of lung squamous cell carcinoma, for which 177 patients were
analysed, eight genes were found to be significantly mutated with q≤0.1 and undergoing
positive selection with an omega ratio >1 (Figure 5.15).
DMD is the only gene that PAML has found to be significant but that did not reach
significance in Lawrence. DMD encodes the protein dystrophin found in cardiac and
skeletal muscle. It is a highly complex gene and is the largest known human gene en-
compassing 2.6 million base pairs of DNA and containing 79 exons [Nowak and Davies,
2004]. Both DMD-associated dilated cardiomyopathy and Duchenne and Becker mus-
cular dystrophy are caused by mutations in this gene, however it has not been identified
as a cancer causing gene in the Cancer Gene Census [Futreal et al., 2004]. Recently
however, Wang et al. [2014] validated DMD as a tumour suppressor in common human
mesenchymal tumors featuring myogenic differentiation, including gastrointestinal stro-
mal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), and likely
anti-metastatic factor. An intragenic deletion was found to be a frequent mechanism
by which myogenic tumours progress to high-grade, lethal sarcomas. These results sug-
gest that therapies in development for muscular dystrophies may also have relevance
in the treatment of cancer. Although lung squamous cell carcinoma is a cancer of the
epithelial cells rather than a myogenic cancer affecting the muscular tissue, the fact
that this gene has now been validated as a tumour suppressor gene is promising for its
candidature as a cancer gene in other cancer types.
Overall, 14 genes were found to reach significance in at least one of the two analyses
(Table 5.30).
Of the significantly mutated PAML genes, 67% (6/9) contain recurrent mutations in-
cluding PIK3CA and TP53 (Table 5.31).
Table 5.32 shows the known cancer genes that have been successfully detected in lung
squamous cell carcinoma by both the PAML and recurrence analyses in this project,
and also by the Lawrence et al. [2014] MutSig analysis.
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Figure 5.15: Gene-based omega analysis in LUSC. Gene-based PAML results
have been displayed in this omega plot for 177 LUSC patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.30: Ranked list of significant PAML genes in LUSC. The genes
found to be significantly mutated in LUSC patients in the PAML analysis have been
sorted by p-value in ascending order (descending order of significance) in this table.
Genes highlighted in red and orange are found to be highly significantly mutated and
significantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
TP53 5.26 8.14e-34 1.00E-16 9.89E-08 9.89E-08 1.11E-16
NFE2L2 999.00 6.89e-23 1.93E-02 9.89E-08 9.89E-08 3.24E-08
PIK3CA 11.23 1.73e-22 6.91E-05 9.89E-08 1.86E-02 1.55E-10
MLL2 (KMT2D) 2.52 1.37e-06 1.67E-12 1 4.68E-01 4.02E-11
CDKN2A 1.82 8.59e-06 1.00E-16 2.63E-01 9.89E-08 1.11E-16
HRAS 999.00 3.83e-05 6.90E-04 3.82E-03 1.61E-02 1.38E-05
DMD 1.78 5.61e-05 NA NA NA NA
KEAP1 999.00 6.84e-05 9.69E-11 3.80E-02 1.62E-01 8.56E-11
FBXW7 0.79 2.13e-04 2.89E-03 8.27E-03 5.45E-02 5.61E-05
RB1 999.00 1.36e-01 6.16E-08 1 7.34E-01 8.32E-07
HLA-A 999.00 1.87e-01 7.06E-05 1 7.73E-03 1.83E-05
ARID1A 1.01 5.00e-01 2.68E-06 7.70E-02 8.88E-01 2.61E-05
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Table 5.31: Ranked list of recurrent mutations in LUSC. Ranked list of the
top 35 most recurrent SNVs in the LUSC subset of the Lawrence dataset, sorted
by recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
PIK3CA 3 178936091 G A 10
SUMF1 3 3940376 G T 6
TP53 17 7578457 C A 5
RAPGEF4 2 173740429 T C 5
PTPRD 9 9372392 T G 5
ZNF566 19 36982883 T C 4
TPO 2 1461103 A G 4
TP53 17 7579312 C A 4
SSFA2 2 182790804 C T 4
SLCO1B3 12 21239914 T C 4
SLC9A7 23 46520751 T C 4
PDSS2 6 107486359 G C 4
OTOA 16 21766513 A G 4
NFE2L2 2 178098810 C G 4
NEK7 1 198270426 G T 4
GSTA1 6 52669326 C A 4
FIG4 6 110075002 G A 4
DNAH14 1 225164811 C G 4
DNAH14 1 225164801 C T 4
DIP2C 10 393257 A C 4
CDH16 16 66954690 C T 4
CD2AP 6 47557303 T C 4
C7orf31 7 25177201 C T 4
ATP8A2 13 26470951 T C 4
AFF2 23 147847963 A T 4
ZNF804B 7 88645165 C G 3
ZNF717 3 75834823 T A 3
ZNF343 20 2483188 A G 3
ZNF33B 10 43123392 G A 3
ZGPAT 20 62354858 T C 3
ZFP41 8 144342202 G C 3
WDR20 14 102638729 C T 3
URB1 21 33762766 C T 3
UBR1 15 43302963 G C 3
UBE2H 7 129581039 C T 3
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Table 5.32: Cancer gene detection success in lung squamous cell carcinoma.
Known cancer genes that have been detected as significantly mutated in all three of
the aforementioned analyses, overlapping the MutSig analysis in the Lawrence et al.
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5.2.11 Melanoma (MEL)
In the PAML analysis of melanoma, for which 118 patients were analysed, 105 genes
were found to be significantly mutated with q≤0.1 and undergoing positive selection
with an omega ratio >1 (Figure 5.16).
NRAS and BRAF were found to be the most significantly mutated genes in the PAML
analysis, and were also found to be highly significant in the Lawrence study. This re-
sult is expected since these two genes have both been causally implicated in melanoma.
BRAF is a serine/threonine kinase that is commonly activated by somatic point muta-
tion in human cancer. About 50% of melanomas harbour activating BRAF mutations,
with over 90% of these at V600E [Ascierto et al., 2012]. NRAS is an N-ras oncogene
and is mutated in approximately 20% of melanomas [Atefi et al., 2015].
F-box and WD-40 domain protein 7 (FBXW7) was amongst the genes detected as
significantly mutated in melanoma only in the PAML analysis. This gene is a known
cancer gene previously shown to be associated with colorectal, endometrial cancer and
T-cell acute lymphocytic leukemia (T-ALL) [Futreal et al., 2004].
Many genes are mutated in melanoma due to the high mutation rate observed in this
cancer type. Overall, 113 genes were found to be significantly mutated in at least one
of the analyses (Table 5.33).
88% (91/103) of the significantly mutated PAML genes for MEL are hit by recurrent
mutations. NRAS and BRAF, as expected, are amongst those affected by recurrent
mutations (Table 5.34). Somatic activating mutations in BRAF have been found in
approximately 50% of melanomas [Ascierto et al., 2012]. In this Lawrence dataset of
118 melanoma patients, BRAF is shown to be hit recurrently by the same mutation
in 62 patients; this is the V600E mutation (T→A (A→T on complementary strand)
single nucleotide substitution at codon 600 (genomic position 140453136) resulting in
a valine to glutamic acid change) that has been shown to be the most common BRAF
mutation in melanoma, accounting for over 81% of all BRAF mutations in melanoma
[Ascierto et al., 2012].
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Figure 5.16: Gene-based omega analysis in MEL. Gene-based PAML results
have been displayed in this omega plot for 118 MEL patients to show the omega
ratios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.33: Ranked list of significant PAML genes in MEL. The genes found
to be significantly mutated in MEL patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and signifi-
cantly mutated respectively in the Lawrence study. Table has been truncated to n=35
rows from a total of 113 significant genes for MEL. R and Perl code used to produce
list in Supplementary Appendix E. Full version of table can be found in Supplementary
Appendix F.
PAML results Lawrence et al. [2014] p-values
Gene Omega P-value CV CL FN Combined
NRAS 121.02 2.36e-39 4.11E-13 9.89E-08 4.17E-04 1.11E-16
BRAF 1.62 7.32e-14 2.90E-16 9.89E-08 9.89E-08 1.11E-16
THSD7B 1.69 4.81e-11 NA NA NA NA
SUCO 2.17 2.76e-10 NA NA NA NA
MYOCD 0.96 3.11e-08 7.80E-01 1.03E-05 1.28E-01 9.06E-05
CNTN5 1.57 3.13e-08 NA NA NA NA
ISX 1.13 3.13e-08 NA NA NA NA
CCDC148 4.06 4.84e-08 NA NA NA NA
PPP6C 999.00 1.35e-07 2.25E-07 1.90E-02 9.03E-01 2.75E-06
UNC13C 2.09 1.40e-07 NA NA NA NA
BRPF1 999.00 3.83e-07 NA NA NA NA
GRID2 1.45 3.92e-07 NA NA NA NA
PRB3 999.00 5.02e-07 NA NA NA NA
MCTP1 3.29 9.38e-07 NA NA NA NA
TP53 999.00 1.27e-06 3.54E-15 7.95E-03 7.56E-04 2.22E-16
OR4A16 3.06 2.59e-06 3.58E-02 1.78E-04 2.46E-01 8.37E-05
CDH6 1.60 3.96e-06 NA NA NA NA
ZNF813 3.24 5.97e-06 NA NA NA NA
FAM83B 1.30 8.38e-06 NA NA NA NA
FRMD4B 2.73 1.11e-05 NA NA NA NA
KRTAP5-10 999.00 1.22e-05 NA NA NA NA
C7 1.25 1.42e-05 NA NA NA NA
WDR33 1.27 1.55e-05 NA NA NA NA
VWA3B 1.13 1.64e-05 NA NA NA NA
CDK4 999.00 1.83e-05 5.24E-04 1.26E-01 6.18E-03 2.31E-05
OR52N1 2.27 2.19e-05 1.73E-02 2.54E-04 2.64E-01 6.75E-05
SYT1 1.81 2.31e-05 NA NA NA NA
OR4K5 2.86 2.47e-05 NA NA NA NA
ADAMDEC1 2.22 2.63e-05 NA NA NA NA
PRB4 999.00 3.53e-05 NA NA NA NA
RP1 1.73 4.00e-05 NA NA NA NA
BAAT 999.00 4.41e-05 NA NA NA NA
KLHL13 1.55 5.06e-05 NA NA NA NA
RYR2 1.09 5.68e-05 NA NA NA NA
SLC39A12 3.29 5.86e-05 NA NA NA NA
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Table 5.34: Ranked list of recurrent mutations in MEL. Ranked list of the
top 35 most recurrent SNVs in the MEL subset of the Lawrence dataset, sorted by
recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
BRAF 7 140453136 A T 62
NRAS 1 115256529 T C 13
KIAA0907 1 155904250 C T 11
NRAS 1 115256530 G T 7
C7orf36 7 39605969 G A 7
UTP11L 1 38478324 G A 6
SLC30A6 2 32390905 C T 6
SLC30A6 2 32390904 C T 6
MRPS31 13 41345346 C T 6
DSG4 18 28980822 G A 6
UMPS 3 124449234 G A 5
RPL37 5 40835322 G A 5
RBM22 5 150080667 C T 5
RAC1 7 6426892 C T 5
PCDH15 10 55583112 G A 5
MCTP1 5 94289029 C T 5
LRRC29 16 67260962 C T 5
ISX 22 35478537 C T 5
GRID2 4 94344033 G A 5
C1orf9 1 172501872 G A 5
ZNF716 7 57528531 G A 4
TRHDE 12 73046174 C T 4
TRHDE 12 73015380 C T 4
THSD7B 2 138373853 G A 4
STK19 6 31940123 G A 4
RPS27 1 153963240 T C 4
PPP6C 9 127912080 G A 4
NDUFB9 8 125551345 C T 4
NDUFB9 8 125551344 C T 4
MYOCD 17 12661487 C T 4
MYH1 17 10400301 C T 4
MCTP2 15 94983621 C T 4
LUZP2 11 25098972 C T 4
KCNH7 2 163374667 C T 4
KCNB2 8 73850273 C T 4
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Table 5.35: Cancer gene detection success in melanoma. Known cancer genes
that have been detected as significantly mutated in all three of the aforementioned
analyses, overlapping the MutSig analysis in the Lawrence et al. [2014] study, the







Table 5.35 shows the known cancer genes that have been successfully detected in
melanoma by both the PAML and recurrence analyses in this project, and also by
the Lawrence et al. [2014] MutSig analysis.
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5.2.12 Multiple myeloma (MM)
In the PAML analysis of multiple myeloma, for which 205 patients were analysed,
six genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.17).
Zinc finger protein 717 (ZNF717) was found to be significantly mutated in the PAML
analysis, however it was not identified by the MutSig approach. This gene is a zinc
finger protein which has not been implicated as having a role in cancer. However,
another zinc finger protein, ZNF311, has been suggested as a novel putative tumour
suppressor gene, suppressing the growth and invasiveness of gastric cancer [Yu et al.,
2013]. Another zinc finger protein, ZNF143, was suggested to be involved in cellular
motility through a ZEB1-E-cadherin-linked pathway in colon cancer cells, increasing
cell migration and invasion [Paek et al., 2014]. Additionally, ZNF278 was presented as
a potential oncogene in colorectal cancer in Tian et al. [2008], shown to promote cell
growth, with knockdown of this gene suppressing proliferation. These findings suggest
a role for other zinc finger proteins such as ZNF717 as tumour suppressors in gastric
cancers, however it is possible that zinc finger proteins have tumourigenic roles in other
tumour types. For example, ZNF652 was shown to interact with the breast tumour
suppressor CBFA2T3 to repress transcription indicating a role for ZNF652 in breast
cancer [Kumar et al., 2006].
Overall just 13 genes were found to be significant in at least one of the analyses (Ta-
ble 5.36).
83% (5/6) of the significantly mutated PAML genes for MM are hit by recurrent muta-
tion. The top three most significantly mutated MM genes in PAML analysis are NRAS,
KRAS and BRAF. These genes also contain the most recurrent mutations (Table 5.37).
Table 5.38 shows the known cancer genes that have been successfully detected in mul-
tiple myeloma by both the PAML and recurrence analyses in this project, and also by
the Lawrence et al. [2014] MutSig analysis.
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Figure 5.17: Gene-based omega analysis in MM. Gene-based PAML results
have been displayed in this omega plot for 205 MM patients to show the omega ra-
tios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.36: Ranked list of significant PAML genes in MM. The genes found
to be significantly mutated in MM patients in the PAML analysis have been sorted
by p-value in ascending order (descending order of significance) in this table. Genes
highlighted in red and orange are found to be highly significantly mutated and sig-
nificantly mutated respectively in the Lawrence study. Genes shown below the blue
horizontal line are not found to be significant in the PAML analysis but have been
tabulated due to their significance in the Lawrence study. R and Perl code used to
produce list in Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
NRAS 999.00 2.23e-44 6.71E-16 9.99E-08 6.11E-03 1.11E-16
KRAS 999.00 4.07e-34 1.00E-16 9.99E-08 5.99E-01 1.11E-16
BRAF 999.00 6.10e-13 8.88E-05 9.99E-08 2.83E-04 1.98E-10
ZNF717 1.74 3.77e-08 NA NA NA NA
DIS3 5.12 1.14e-06 6.47E-09 2.63E-03 2.08E-02 6.93E-11
NEB 367.60 2.00e-05 NA NA NA NA
TP53 999.00 6.24e-03 1.00E-16 1 1.98E-04 1.11E-16
PRDM1 999.00 8.55e-03 1.82E-03 2.85E-02 1.73E-03 1.26E-05
TRAF3 999.00 6.08e-02 8.05E-07 1 1.57E-01 8.81E-06
FAM46C 0.80 2.11e-01 1.73E-07 2.99E-01 7.64E-03 4.85E-08
INTS12 999.00 2.48e-01 1.25E-04 1.95E-02 4.02E-02 3.79E-06
IRF4 999.00 3.13e-01 2.18E-02 2.91E-04 3.23E-03 2.28E-05
IDH1 999.00 4.36e-01 4.91E-03 1.00E-03 8.19E-01 4.48E-05
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Table 5.37: Ranked list of recurrent mutations in MM. Ranked list of the
top 35 most recurrent SNVs in the MM subset of the Lawrence dataset, sorted by
recurrence in descending order. For each unique mutation, the gene, chromosome,
position, ref and alt alleles and how many patients the mutation occurs in (recurrence)
have been tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
NRAS 1 115256529 T C 11
NRAS 1 115256530 G T 9
KRAS 12 25398281 C T 9
KRAS 12 25380275 T G 8
PARK2 6 162242837 G A 5
BRAF 7 140453136 A T 5
ZNF717 3 75787829 C G 4
TRAF3IP1 2 239270793 G T 4
NRAS 1 115258745 C G 4
NRAS 1 115256528 T G 4
KCNK1 1 233765476 C A 4
CACNA2D3 3 54997793 G T 4
ZNF717 3 75786993 T A 3
WASH3P 15 102515470 T C 3
TMEM131 2 98611675 G T 3
TMEM100 17 53798740 G T 3
STK3 8 99849608 G A 3
RHBDL2 1 39400050 C A 3
RASGEF1C 5 179614811 C A 3
PXDNL 8 52269072 G A 3
PTPRK 6 128334135 C A 3
PPP1R1C 2 182934001 C T 3
PIK3R4 3 130398753 C T 3
PDGFRA 4 54248127 G A 3
NOTCH2 1 120574304 G A 3
NGEF 2 233877708 G T 3
MPDZ 9 13224823 C A 3
LRRN2 1 204623728 G T 3
LMF1 16 907531 A T 3
KRAS 12 25398284 C T 3
KRAS 12 25398284 C G 3
KRAS 12 25380276 T C 3
KRAS 12 25378562 C T 3
IRF4 6 394972 A G 3
HDAC5 17 42163067 A G 3
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Table 5.38: Cancer gene detection success in multiple myeloma. Known
cancer genes that have been detected as significantly mutated in all three of the afore-
mentioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014]
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5.2.13 Ovarian (OV)
In the PAML analysis of ovarian cancer, for which 316 patients were analysed, just
two genes were found to be significantly mutated with q≤0.1 and undergoing positive
selection with an omega ratio >1 (Figure 5.18).
The only gene identified as significantly mutated in my approach that was not also
identified by the MutSig analysis was myosin 3A (MYO3A). This is not a known cancer
gene, and hence could potentially be a putative cancer gene. MYO3A is a class III
myosin, which contain a conserved N-terminal kinase domain and central motor domain,
and a C-terminal tail that varies in sequence between isoforms [Quintero et al., 2013].
There are two isoforms of class III myosins expressed in vertebrates: MYO3A and
MYO3B. Both isoforms are localized to actin bundle-based structures in sensory cells,
including the calycal process of photoreceptors and the stereocilia of inner ear hair cells,
and play a role in maintaining the length of the actin-bundled structures. Disruption
of the MYO3A gene is associated with nonsyndromic deafness. However, studies have
found that class III myosins are not only expressed in the inner ear and retina but
also in the brain, intestine, and testes. Furthermore, modifications in the MYO3A gene
were found to be associated with bladder cancer in which MYO3A was found along with
five other genes to be a gene methylation biomarker for this cancer type [Chung et al.,
2011], and colon cancer in which a genome-wide association study found that single
nucleotide polymorphisms in the intronic region of the MYO3A gene were associated
with an increased risk for this cancer type [Lascorz et al., 2010].
Overall only six genes were found to be significant across both analyses (Table 5.39).
Of the significant genes from PAML analysis, 100% (2/2) were found to be hit by
recurrent mutation, including TP53 which is the most significantly mutated gene in
both the PAML and Lawrence analyses. This gene is also hit by multiple recurrent
mutations (Table 5.40).
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Figure 5.18: Gene-based omega analysis in OV. Gene-based PAML results
have been displayed in this omega plot for 316 OV patients to show the omega ra-
tios and FDR values for each gene, together with their level of significance in the
Lawrence study. Genes highlighted in red and orange are those shown to be highly
significantly mutated (FDR≤0.001) and significantly mutated (FDR≤0.1) respectively
in the Lawrence study. Genes highlighted in blue are potential candidate cancer genes
shown to reach significance (FDR≤0.1) in the PAML analysis, however do not reach
significance in the Lawrence study. Genes highlighted in purple are examples of genes
that do not reach significance in the Lawrence study, and have conflicting results in the
PAML analysis (with a significant p-value supporting positive selection, but an omega
value indicative of negative selection). R code used to generate plot in Supplementary
Appendix D.
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Table 5.39: Ranked list of significant PAML genes in OV. The genes found
to be significantly mutated in OV patients in the PAML analysis have been sorted by
p-value in ascending order (descending order of significance) in this table. Genes high-
lighted in red and orange are found to be highly significantly mutated and significantly
mutated respectively in the Lawrence study. Genes shown below the blue horizontal
line are not found to be significant in the PAML analysis but have been tabulated due
to their significance in the Lawrence study. R and Perl code used to produce list in
Supplementary Appendix E.
Gene
PAML results Lawrence et al. [2014] p-values
Omega P-value CV CL FN Combined
TP53 44.55 1.20e-87 3.90E-15 5.36E-08 5.36E-08 1.11E-16
MYO3A 999.00 2.67e-05 NA NA NA NA
CDK12 999.00 2.45e-02 9.21E-09 1 2.92E-01 1.42E-07
NF1 404.17 2.98e-02 7.17E-08 1 1.19E-01 9.58E-07
RB1 999.00 1.09e-01 2.86E-09 1 5.95E-01 4.74E-08
BRCA1 999.00 1.66e-01 2.38E-12 1 1.62E-01 5.64E-11
Table 5.41 shows the known cancer genes that have been successfully detected in ovarian
cancer by both the PAML and recurrence analyses in this project, and also by the
Lawrence et al. [2014] MutSig analysis.
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Table 5.40: Ranked list of recurrent mutations in OV. Ranked list of the top 35
most recurrent SNVs in the OV subset of the Lawrence dataset, sorted by recurrence
in descending order. For each unique mutation, the gene, chromosome, position, ref
and alt alleles and how many patients the mutation occurs in (recurrence) have been
tabulated.
Gene Mutation Recurrence
Chromosome Position Ref Alt
TP53 17 7578190 T C 11
TP53 17 7577120 C T 11
TP53 17 7577538 C T 9
TP53 17 7578406 C T 8
TP53 17 7578265 A G 7
TP53 17 7577121 G A 7
TP53 17 7577539 G A 6
TP53 17 7578461 C A 5
TP53 17 7578403 C T 5
TP53 17 7577094 G A 5
TP53 17 7578394 T C 4
TP53 17 7577559 G A 4
TP53 17 7578275 G A 3
TP53 17 7578271 T C 3
TP53 17 7578263 G A 3
TP53 17 7577548 C T 3
TP53 17 7577022 G A 3
TP53 17 7574003 G A 3
ZNF536 19 31039137 G C 2
WNT11 11 75898143 C T 2
UXS1 2 106761805 C G 2
UBTF 17 42292477 A G 2
TUBA3C 13 19751364 C T 2
TRPV6 7 142583147 G T 2
TRPC7 5 135692447 T A 2
TP53 17 7579311 C A 2
TP53 17 7578556 T C 2
TP53 17 7578555 C T 2
TP53 17 7578555 C A 2
TP53 17 7578534 C A 2
TP53 17 7578454 G A 2
TP53 17 7578442 T C 2
TP53 17 7578370 C A 2
TP53 17 7578290 C T 2
TP53 17 7578268 A C 2
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Table 5.41: Cancer gene detection success in ovarian cancer. Known cancer
genes that have been detected as significantly mutated in all three of the aforemen-
tioned analyses, overlapping the MutSig analysis in the Lawrence et al. [2014] study,
the PAML analysis and the recurrence analysis.
Known cancer gene
TP53
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5.3 Discussion
Evolutionary analysis in PAML was performed on mutations from the published dataset
of Lawrence et al. [2014] to identify genes containing driver mutations in 13 different
types of cancer, and the results were compared to the published results of Lawrence
et al. [2014].
As well as showing that both methods can detect known cancer genes, a novel candidate
driver gene was identified in colorectal cancer from the PAML analysis.
MutSig is a less well-established framework in comparison to PAML, with several under-
lying assumptions. However, Lawrence et al. [2014] is still a complementary approach
that has been used in combination with the PAML method.
5.3.1 Comparison of cancer gene detection methods
Clearly both methods pick up many of the same genes, however PAML misses some of
the genes that MutSig picks up and vice versa. Some of the difference can be attributed
to the fact that in the PAML analysis only the coding mutations have been used whereas
Lawrence have used both coding and non-coding. Also before PAML analysis INDELs
and larger substitutions were filtered out to leave just SNVs since the codon model used
in PAML is not suitable for larger mutations.
However it is not just the filtering of the data that differs but the framework of the
tests. The statistical test performed in PAML is quite different to that of MutSig.
5.3.1.1 Mutation clustering in genes
MutSig may be superior at finding genes with clustered mutations in cancer. For
example in CRC, the gene BRAF is detected using MutSig when it is not in PAML.
This could be partly accounted for by one of the statistical tests that MutSig uses,
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MutSigCL, to account for clustering, which appears to be occurring in this gene. PAML
may not be as powerful in these cases.
5.3.1.2 Technical difficulties in PAML
Some of the genes that Lawrence have found to be significant, PAML has failed to
return results for. Probably issues are:
1. There are no mutations or only one point mutation per gene, which means there
will be no alignment to calculate model parameters from. In these cases, Lawrence
may have significant results from INDELs.
2. It is rare but occasionally, particularly for short compositionally biased genes,
PAML is unable to parametise its models and fails its convergence test.
5.3.1.3 Power to detect different modes of selection in PAML
Lawrence et al. [2014] did not have the power to detect both positive and negative
selection occurring at the same time since they have not used selection to measure,
whereas the advantage of using the PAML approach was that is was a well validated
approach and may be able to pick up signals of genes undergoing both positive and
purifying selection.
5.3.1.4 Higher false-positive rate in PAML
PAML seems to be finding very large genes (e.g. TTN) significant, although these
are suspected to be false-positives since they often come up in such studies as false-
positives. Lawrence do not get these same spurious results, which suggests that their
methodology is superior at removing false-positives [Lawrence et al., 2013].
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5.3.2 Novel candidate cancer gene in colon adenocarcinaom: DNMT1
The most interesting discovery by PAML is the detection of DNMT1 in colorectal cancer
as a significantly mutated gene. This gene was not detected in the Lawrence study, and
is therefore a good candidate cancer gene for experimental validation.
5.3.3 Relating tissue of origin and mutation to path of selection
The aim of this chapter was to investigate how the tissue of origin relates to the genes
hit by mutation. It can be seen from the above results in PAML and both the Lawrence
study that there is merit in partitioning data by tissue of origin, since different genes
are hit by driver mutations in different cancer types, showing that different mechanisms
are occurring in different organs, as is already known to be the case.
5.3.4 Complex codon model vs recurrent mutation count
Many of the genes found to be significantly mutated using the evolutionary method in
PAML are also often the genes with the highest recurrence of a particular mutation,
often containing more than one particular recurrent mutation. However many genes
identified through PAML were not recurrently mutated, therefore it is necessary to use
such a complex codon model to detect cancer genes rather than just counting recurrent
mutations in a gene. Also the recurrent counts stated in this chapter are inclusive of
both synonymous and non-synonymous mutations. The number of synonymous muta-
tions have not been stated, but these could be involved in processes such as alternate
splicing. Most are expected to be within CpG dinucleotides, which they are, however
this has not been shown in this chapter.
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5.4 Methods
Lawrence cancer-specific mutations for each gene were downloaded in MAF format,
for all 4728 patients over all 21 cancer types. INDELs and substitutions longer than
one nucleotide were removed, along with non-coding SNVs leaving 4712 patients for
evolutionary analysis.
5.4.1 Partitioning data by tissue of origin
Patients were partitioned by cancer type prior to editing the cancer-specific mutations
onto the reference transcripts for each gene. From the available 21 cancer types, only
13 were chosen for analysis in PAML. The criteria for this being that they had sufficient
patient numbers available for increased power in PAML, so only cancer types with at
least 150 patients were used, with the exception of melanoma (MEL) which only had
118 patients. Melanoma was included because it is known to have such a interesting and
specific mutational profile caused by exposure to UV radiation, as well as a generally
high mutation rate (mutator phenotype).
5.4.2 PAML analysis
For each cancer type, patient alignments edited with the Lawrence cancer-specific mu-
tations were run through PAML in the same way as was done for the whole TCGA
dataset, on a per gene basis as before.
An omega plot was generated in R for each of the 13 cancer types in the same way as
has been done for the whole-dataset TCGA analysis in Chapter 4. Tables were also
created listing the most significant genes for each cancer type.
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5.4.3 Recurrent mutations
A basic analysis to find the recurrence of particular mutations across all patients was
carried out on each of the 13 cancer types, by simply counting how many patients car-
ried the mutation. The top 35 most recurrent mutations (mutations occurring most fre-
quently in the dataset) were tabulated for each cancer type. This analysis included both




stratification by mutation spectra
6.1 Introduction
Mutation spectra does not necessarily cluster by cancer type as has been discovered
in Chapter 3 over both the TCGA dataset and the Lawrence dataset. This was the
motivation for the analysis in this chapter, in which different types of mutation spectra
have been accounted for in order to further inform our evolutionary analysis.
Addressing the question of how mutation spectra influences the genes hit by driver
mutation in cancer, the published Lawrence data used in Chapter 5 has been stratified
by mutation spectra before evolutionary analysis in PAML. Results from the different
types of mutation spectra were compared to find if patterns of positive selection occur
in the same places in these different groups of cancer, or if as hypothesised the patterns
differ by mutation spectra.
As in Chapter 5, only the coding cancer-specific SNVs have been used for this analysis.
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6.2 Results
The data was split into six discrete groups based on the mutational profiles of the
patients.
Again to interpret the results from PAML plots akin to the ones generated in Chapter 4
and Chapter 5 have been plotted for each of the six different mutation spectra groups.
Gene lists were also produced for each group containing only the genes with significant
q-values (FDR) in ranked order of significance. Genes with an omega <1 have not been
included.
6.2.1 Mutational signatures across Lawrence dataset
The 4,728 patients in the Lawrence dataset were split into six groups each with a
distinct mutational signature, based on the relative proportions of their single nucleotide
changes (of which there are six classes). This was done using cluster analysis in R to
group together patients with similar mutation spectra (Figure 6.1). The six groups were
chosen arbitrarily, using a height cut-off of 0.65 to ensure six substantially sized groups
of patients. However, 138 of the 4,728 patients had to be excluded from subsequent
analysis since they were not present in any of the large clustered groups. The excluded
patients fell into 12 small distinct groups at a height cut-off of 0.65. This indicated that
the mutation spectra of these excluded patients were varied and not common across
the dataset, and evolutionary analysis of these 12 small sample groups would not have
much power in detecting cancer genes. 4,590 patients were split across the six groups
chosen for analysis: 453 in group 1, 1,073 in group 2, 375 in group 3, 457 in group 4,
1,526 in group 5 and 706 in group 6.
The proportions of each of the six classes of single nucleotide change in each mutational
signature is shown in Figure 6.2.
The specific spectra of Signature 2 exhibits an elevated proportion of C→T transition
mutations compared to any other mutation. Signatures 5 and 6 show a similar pattern,



















Figure 6.1: Lawrence patients clustered by mutation spectra. Dendrogram
to show how the 4,728 patients in the Lawrence dataset have been clustered according
to their relative proportions of each of the six classes of single nucleotide changes. The
red horizontal line shows the arbitrary height (h=0.65) at which the dataset has been
split into 18 clustered groups (clusters with a distance of less than 0.65 between them).
Green rectangles highlight the six largest distinct mutation spectra signatures (includ-
ing 4,590 patients) within these 18 groups, which were used for subsequent analysis.
12 small groups containing 138 patients altogether were excluded from analysis, due to
their small group sizes (marked with red X). The y-axis represents the height, which is
a measure of the similarity of the clusters (greater the height, greater the difference).
The patients are plotted along the x-axis in an order according to their relationship of
similarity with other patients. Along the x-axis: 1 = ‘Signature 1’; 2 = ‘Signature 2’;
3 = ‘Signature 3’; 4 = ‘Signature 4’; 5 = ‘Signature 5’; 6 = ‘Signature 6’.









































































































































































































































































































































































































































































Figure 6.2: Mutational signatures across the Lawrence dataset. The rela-
tive proportions of each of the six classes of single nucleotide changes over the 4,728
Lawrence patients in (A) Signature 1, (B) Signature 2, (C) Signature 3, (D) Signa-
ture 4, (E) Signature 5 and (F) Signature 6. Patients have been plotted along the
x-axis, in the same order in each plot for comparison. R code used to generate plots in
Supplementary Appendix G.
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also exhibiting a higher frequency of C→T mutations, however it is not as pronounced
as in Signature 2. Signature 4 has a more uniform mutation profile, with a roughly even
distribution of each of the six mutation classes. However there is generally an elevated
proportion of this particular mutation class observed in the human population. This
is due to instability at CpG islands and deamination. It is this elevated rate of C→T
that is thought to lead to a higher rate of transitions over transversions in the genome.
Figure 6.3 shows how the six mutational signatures are enriched for certain tumour
types. A statistical test for enrichment of tumour types within the six different signa-
tures was performed in R using Pearson’s Chi-squared test for count data. Table 6.1
shows the observed number of patients within each of the six groups for each cancer
type, as well as the results from the chi-squared test: the expected number of patients
per group that would be expected under the null hypothesis for each tumour type (no
significant difference between groups); and the p-value to test the significance of the
statistical hypothesis. It can be seen that all p-values for all cancer types are highly
significant (at the 1% significance level, with p-value <0.01), rejecting the null hypoth-
esis for each test and indicating that for all of the 21 different cancer types the observed
patient counts are not evenly spread amongst the six signatures and that there is enrich-
ment of tumour type in certain signatures. The most significant p-value was calculated
for LUAD (p-value = 9.19e-115), showing that there is significant enrichment of this
cancer type in Signature 1 (235 LUAD patients observed compared to 66 expected).
Signature 1 shows the most significant enrichment of tumour type, with 52% of the
patients within this signature having lung adenocarcinoma (LUAD) and 20% with
lung squamous cell carcinoma (LUSC). This specific signature exhibits an elevated
prevalence of C→A substitutions which is consistent with exposure to the polycyclic
aromatic hydrocarbons in tobacco smoke [Alexandrov et al., 2013, Lawrence et al.,
2013], which is known to cause lung cancer. Therefore this result is expected.
Signature 2 has a very high prevalence of C→T mutations which is seen in melanoma
as a result of mutations caused by the misrepair of ultraviolet-induced covalent bonds
between adjacent pyrimidines [Lawrence et al., 2013]. However, in Figure 6.3, this
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Figure 6.3: Enrichment of tumour types within each mutational signature.
The number of patients with a particular tumour type, out of the total number of
patients in each mutational spectra group, has been plotted as a pie chart for (A)
Signature 1, (B) Signature 2, (C) Signature 3, (D) Signature 4, (E) Signature 5 and
(F) Signature 6. The percentages at which each tumour type is present within the
mutational signature are also shown.
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Table 6.1: Statistical test for tumour type enrichment within mutational
signature groups. Using Pearson’s Chi-squared test for count data, a goodness-of-fit
test was performed in R for each tumour type, to test whether the observed counts
of patients are statistically significantly different between each of the six mutational
spectra groups for a given tumour type. The null hypothesis is that the observed counts
are all equal amongst the six groups. For each tumour type, the p-value is statistically
significant, rejecting the null hypothesis and showing that the patient counts are are
not evenly split between groups. Expected counts are rounded to the nearest integer.
P-values are rounded to 2 decimal places.





1 2 3 4 5 6
BLCA 1 16 58 0 18 5 16 1.50e-29
BRCA 9 223 124 41 311 162 145 1.06e-92
CARC 2 9 0 14 19 7 9 1.29e-05
CLL 18 25 1 15 75 23 26 6.95e-25
CRC 1 123 1 6 74 28 39 9.21e-67
DLBCL 2 9 0 11 31 4 10 3.35e-13
ESO 0 20 6 21 71 12 22 1.48e-30
GBM 2 103 0 0 165 19 48 1.06e-106
HNSC 27 105 66 13 117 50 63 6.50e-28
KIRC 10 0 13 159 133 100 69 1.69e-74
LAML 7 53 8 21 54 16 27 2.14e-17
LUAD 235 6 21 33 44 58 66 9.19e-115
LUSC 89 3 14 30 1 34 29 2.42e-38
MED 9 41 2 2 14 17 14 1.38e-14
MEL 0 104 2 2 7 3 20 7.20e-92
MM 0 23 4 28 131 16 34 1.61e-74
NB 34 8 0 6 2 10 10 5.75e-15
OV 1 29 35 38 107 103 52 2.18e-36
PRAD 1 37 9 12 57 16 22 5.77e-20
RHAB 0 22 1 3 3 2 5 4.05e-13
UCEC 5 114 10 2 92 21 41 3.09e-62
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signature is shown to be enriched in breast cancer (BRCA) present at 21% whereas
melanoma (MEL) is present at only 10%. Gastrointestinal tumours such as colorectal
cancer also show extremely high frequencies of C→T (at CpG dinucleotides), and in
this signature colorectal cancer (CRC) is present at 11%.
Signature 3 has been shown to have elevated rates of both C→G and C→T substitu-
tions. This signature is also shown to be enriched with breast cancer (BRCA) present at
33%, head and neck cancer (HNSC) present at 18% and bladder cancer (BLCA) present
at 15%. Head and neck cancer and bladder cancer have previously been shown to ex-
hibit elevated rates of C→G and C→T mutations [Alexandrov et al., 2013, Lawrence
et al., 2013], supporting these results. This pattern is characteristic of mutations caused
by the APOBEC family of cytidine deaminases, which are innate immunity enzymes
that are induced by certain classes of viruses. The human papillomavirus (HPV) has
previously been implicated in head and neck cancers, indicating that a subset of both
bladder (also suggested by [Lawrence et al., 2013]) and breast cancers could have a viral
aetiology.
Signature 4, which exhibits a uniform distribution of the six classes of substitution,
is enriched with kidney clear cell cancer (KIRC) with 35% of patients exhibiting this
cancer type.
Signatures 5 and 6 show an enrichment of breast cancer (BRCA) occurring at 20% and
23% respectively. Both these signatures exhibit elevated C→T, however signature 6
has a slightly higher prevalence of C→A and C→G mutations than signature 5, and
signature 5 with a slightly higher prevalence of T→C than signature 6.
For all six signatures, the sequence context immediately 5’ and 3’ to the mutated
nucleotide was not considered, which would help to further elucidate the mutational
processes that may be underlying each specific signature.
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6.2.1.1 Signature 1
Signature 1 (Figure 6.2) contains 453 patients. These patients have mostly C→A
changes.
Analysis in PAML has revealed that the most significantly mutated genes in these
patients are KRAS, TP53 and PIK3CA (FIgure 6.4) and other well known cancer
genes have also been detected as containing driver mutations (e.g. PTEN, BRAF and
EGFR).
In total, 38 genes were found to be significantly mutated in Signature 1, and the top
most significant 35 of these have been tabulated in Table 6.2 with their omega estimate,
p-values and gene descriptions.
GO term analysis in GOrilla has produced the top ten processes enriched for the sig-
nificant genes in this analysis (Table 6.3).
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Figure 6.4: Gene-based omega analysis in PAML for Signature 1. For each
gene in the group of 453 patients in Signature 1, the omega estimate and FDR value
from PAML analysis has been plotted to show the patterns of selection across the
dataset. R code used to generate plot in Supplementary Appendix H.
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Table 6.2: Ranked list of significantly mutated genes in Signature 1. Signif-
icantly mutated genes (omega>1 and FDR<0.1) from PAML analysis of Signature 1
have been tabulated in ascending order by p-value (descending order of significance).
List has been truncated to n=35 rows out of a total of 38 significant genes. Full table
in Supplementary Appendix J. Code used to generate table in Supplementary Appendix
I.
Gene Omega P-value Description
DNAH9 1.39 0.00e+00 dynein, axonemal, heavy chain 9
USH2A 1.09 0.00e+00 Usher syndrome 2A (autosomal recessive, mild)
FLG 1.45 0.00e+00 filaggrin
XIRP2 1.02 0.00e+00 xin actin-binding repeat containing 2
CSMD3 1.20 0.00e+00 CUB and Sushi multiple domains 3
MUC17 1.36 0.00e+00 mucin 17, cell surface associated
PKHD1 1.09 0.00e+00 polycystic kidney and hepatic disease 1 (autoso-
mal recessive)
MUC16 1.21 0.00e+00 mucin 16, cell surface associated
PCLO 1.13 0.00e+00 piccolo presynaptic cytomatrix protein
KRAS 17.33 9.69e-112 Kirsten rat sarcoma viral oncogene homolog
TP53 7.67 1.18e-51 tumor protein p53
PIK3CA 4.50 1.16e-19 phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha
NFE2L2 999.00 3.06e-13 nuclear factor, erythroid 2-like 2
KEAP1 999.00 2.28e-08 kelch-like ECH-associated protein 1
EGFR 1.67 6.48e-08 epidermal growth factor receptor
PTEN 3.26 8.63e-08 phosphatase and tensin homolog
BRAF 2.74 1.02e-07 v-raf murine sarcoma viral oncogene homolog B
KMT2D 2.11 2.31e-07 lysine (K)-specific methyltransferase 2D
POLE 1.07 5.68e-07 polymerase (DNA directed), epsilon, catalytic
subunit
MIB1 999.00 1.47e-06 mindbomb E3 ubiquitin protein ligase 1
HRAS 999.00 1.53e-06 Harvey rat sarcoma viral oncogene homolog
XRRA1 999.00 4.84e-06 X-ray radiation resistance associated 1
NRAS 999.00 6.44e-06 neuroblastoma RAS viral (v-ras) oncogene ho-
molog
ATL3 999.00 8.00e-06 atlastin GTPase 3
ING1 999.00 9.63e-06 inhibitor of growth family, member 1
GNRHR 1.41 1.04e-05 gonadotropin-releasing hormone receptor
INTS7 1.26 1.11e-05 integrator complex subunit 7
CDH10 1.36 2.14e-05 cadherin 10, type 2 (T2-cadherin)
C10ORF68 3.08 3.66e-05 Homo sapiens coiled-coil domain containing 7
(CCDC7), transcript variant 5, mRNA.
RAD50 1.37 4.06e-05 RAD50 homolog (S. cerevisiae)
SMC4 3.09 4.99e-05 structural maintenance of chromosomes 4
CAPN5 2.19 5.69e-05 calpain 5
XPO4 1.08 7.95e-05 exportin 4
COL11A1 2.76 8.75e-05 collagen, type XI, alpha 1
DROSHA 999.00 9.35e-05 drosha, ribonuclease type III
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Table 6.3: Enriched GO terms in Signature 1. Top 10 enriched GO terms in
Signature 1, using process ontology from GOrilla.
Process description P-value FDR q-value Enrichment (N, B, n, b)
fibroblast growth factor recep-
tor signaling pathway
1.24E-9 1.64E-5 23.72 (18208,166,37,8)
neurotrophin TRK receptor sig-
naling pathway
6.64E-8 4.37E-4 14.26 (18208,276,37,8)
neurotrophin signaling pathway 7.42E-8 3.26E-4 14.06 (18208,280,37,8)
Fc-epsilon receptor signaling
pathway
7.65E-8 2.52E-4 18.72 (18208,184,37,7)
positive regulation of Rac pro-
tein signal transduction
7.7E-8 2.03E-4 295.26 (18208,5,37,3)
epidermal growth factor recep-
tor signaling pathway
1.26E-7 2.77E-4 17.40 (18208,198,37,7)
ERBB signaling pathway 1.4E-7 2.63E-4 17.14 (18208,201,37,7)
activation of MAPKK activity 1.69E-7 2.78E-4 39.06 (18208,63,37,5)
response to radiation 2.18E-7 3.19E-4 9.82 (18208,451,37,9)
Fc receptor signaling pathway 4.92E-7 6.48E-4 14.23 (18208,242,37,7)
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Figure 6.5: Gene-based omega analysis in PAML for Signature 2. For each
gene in the group of 1,073 patients in Signature 2, the omega estimate and FDR value
from PAML analysis has been plotted to show the patterns of selection across the
dataset. R code used to generate plot in Supplementary Appendix H.
6.2.1.2 Signature 2
Signature 2 (Figure 6.2) contains 1073 patients. These patients have mostly C→T
changes.
In total, 218 genes were found to be significantly mutated in Signature 2, and the top
most significant 35 of these have been tabulated in Table 6.4 with their omega estimate,
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p-values and gene descriptions.
GO term analysis in GOrilla has produced the top ten processes enriched for the sig-
nificant genes in this analysis (Table 6.5).
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Table 6.4: Ranked list of significantly mutated genes in Signature 2. Signif-
icantly mutated genes (omega>1 and FDR<0.1) from PAML analysis of Signature 2
have been tabulated in ascending order by p-value (descending order of significance).
List has been truncated to n=35 rows out of a total of 218 significant genes. Full table
in Supplementary Appendix J. Code used to generate table in Supplementary Appendix
I.
Gene Omega P-value Description
DNAH5 1.08 0.00e+00 dynein, axonemal, heavy chain 5
FLG 1.89 0.00e+00 filaggrin
LRP1B 1.06 0.00e+00 low density lipoprotein receptor-related protein
1B
MUC16 1.24 0.00e+00 mucin 16, cell surface associated
FAT4 1.12 0.00e+00 FAT atypical cadherin 4
PIK3CA 101.61 1.23e-263 phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha
TP53 29.08 2.16e-121 tumor protein p53
KRAS 30.44 4.65e-110 Kirsten rat sarcoma viral oncogene homolog
APC 4.08 2.00e-96 adenomatous polyposis coli
CTNNB1 4.61 1.68e-75 catenin (cadherin-associated protein), beta 1,
88kDa
PTEN 36.39 7.22e-58 phosphatase and tensin homolog
NRAS 14.96 5.13e-55 neuroblastoma RAS viral (v-ras) oncogene ho-
molog
FBXW7 12.07 1.34e-48 F-box and WD repeat domain containing 7, E3
ubiquitin protein ligase
BRAF 2.91 5.25e-27 v-raf murine sarcoma viral oncogene homolog B
IDH1 6.30 4.27e-26 isocitrate dehydrogenase 1 (NADP+), soluble
CDKN2A 1.81 1.47e-20 cyclin-dependent kinase inhibitor 2A
ERBB2 1.80 4.94e-16 v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2
ISX 2.26 2.13e-14 intestine-specific homeobox
EGFR 1.30 2.28e-13 epidermal growth factor receptor
BCOR 1.14 7.48e-12 BCL6 corepressor
MACF1 1.12 4.89e-11 microtubule-actin crosslinking factor 1
IDH2 1.49 7.95e-11 isocitrate dehydrogenase 2 (NADP+), mito-
chondrial
HRAS 999.00 9.01e-11 Harvey rat sarcoma viral oncogene homolog
XPO1 4.57 1.35e-10 exportin 1 (CRM1 homolog, yeast)
PPP6C 999.00 1.87e-10 protein phosphatase 6, catalytic subunit
SUCO 2.48 1.20e-09 SUN domain containing ossification factor
GRID2 1.30 3.47e-09 glutamate receptor, ionotropic, delta 2
ARID1A 2.30 6.51e-09 AT rich interactive domain 1A (SWI-like)
PIK3R1 6.28 7.09e-09 phosphoinositide-3-kinase, regulatory subunit 1
(alpha)
FGFR2 1.34 7.63e-09 fibroblast growth factor receptor 2
POSTN 1.06 1.44e-08 periostin, osteoblast specific factor
PRAMEF20 999.00 2.78e-08 PRAME family member 20
PRB3 18.92 2.93e-08 proline-rich protein BstNI subfamily 3
RP1 1.57 7.99e-08 retinitis pigmentosa 1 (autosomal dominant)
THSD7B 1.55 8.20e-08 thrombospondin, type I, domain containing 7B
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Table 6.5: Enriched GO terms in Signature 2. Top 10 enriched GO terms in
Signature 2, using process ontology from GOrilla.
Process description P-value FDR q-value Enrichment (N, B, n, b)
regulation of cell differentiation 1.45E-6 1.91E-2 2.34 (18208,1376,204,36)
positive regulation of macro-
molecule metabolic process
2.49E-6 1.64E-2 1.92 (18208,2372,204,51)
fibroblast growth factor recep-
tor signaling pathway
2.77E-6 1.21E-2 5.91 (18208,166,204,11)
neurotrophin TRK receptor sig-
naling pathway
2.93E-6 9.65E-3 4.53 (18208,276,204,14)
neurotrophin signaling pathway 3.46E-6 9.12E-3 4.46 (18208,280,204,14)
regulation of organ morphogen-
esis
8.43E-6 1.85E-2 5.87 (18208,152,204,10)
positive regulation of gene ex-
pression
8.83E-6 1.66E-2 2.19 (18208,1428,204,35)
regulation of cell cycle phase
transition
9.18E-6 1.51E-2 4.76 (18208,225,204,12)
regulation of cellular compo-
nent organisation
9.66E-6 1.41E-2 2.04 (18208,1750,204,40)
positive regulation of Rac pro-
tein signal transduction
1.36E-5 1.79E-2 53.55 (18208,5,204,3)
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Figure 6.6: Gene-based omega analysis in PAML for Signature 3. For each
gene in the group of 375 patients in Signature 3, the omega estimate and FDR value
from PAML analysis has been plotted to show the patterns of selection across the
dataset. R code used to generate plot in Supplementary Appendix H.
6.2.1.3 Signature 3
Signature 3 (Figure 6.2) contains 375 patients, over 17 of the 21 different cancer types
in the Lawrence data. These patients have mostly C→T and C→G changes.
In total, 19 genes were found to be significantly mutated in Signature 3, tabulated in
Table 6.6 with their omega estimate, p-values and gene descriptions.
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Table 6.6: Ranked list of significantly mutated genes in Signature 3. Signif-
icantly mutated genes (omega>1 and FDR<0.1) from PAML analysis of Signature 3
have been tabulated in ascending order by p-value (descending order of significance).
Code used to generate table in Supplementary Appendix I.
Gene Omega P-value Description
PIK3CA 16.66 5.45e-109 phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha
TP53 8.57 3.89e-69 tumor protein p53
NFE2L2 999.00 6.28e-11 nuclear factor, erythroid 2-like 2
ERBB3 7.67 1.40e-08 v-erb-b2 avian erythroblastic leukemia viral onco-
gene homolog 3
C3orf70 999.00 3.59e-08 chromosome 3 open reading frame 70
CDKN2A 1.81 1.50e-07 cyclin-dependent kinase inhibitor 2A
SRCAP 13.22 1.72e-07 Snf2-related CREBBP activator protein
SYNE1 1.32 5.73e-07 spectrin repeat containing, nuclear envelope 1
NUP93 1.43 3.09e-06 nucleoporin 93kDa
FGFR3 1.09 4.07e-06 fibroblast growth factor receptor 3
KMT2C 3.55 9.10e-06 lysine (K)-specific methyltransferase 2C
FBXL13 999.00 1.44e-05 F-box and leucine-rich repeat protein 13
POLQ 413.82 3.01e-05 polymerase (DNA directed), theta
KLF5 999.00 3.14e-05 Kruppel-like factor 5 (intestinal)
DNMT3A 999.00 5.30e-05 DNA (cytosine-5-)-methyltransferase 3 alpha
SLC22A10 999.00 6.04e-05 solute carrier family 22, member 10
MAP1A 999.00 7.04e-05 microtubule-associated protein 1A
CASP8 999.00 9.47e-05 caspase 8, apoptosis-related cysteine peptidase
SETDB1 2.24 1.99e-04 SET domain, bifurcated 1
GO term analysis in GOrilla has produced the top ten processes enriched for the sig-
nificant genes in this analysis (Table 6.7).
DNA polymerase theta (POLQ) has been detected as a significantly mutated gene in
this particular mutational signature, with a very high omega value (413.82) suggesting
that this gene is under positive selection in this subset of cancers, and a significant
p-value (3.01e-05) supporting the model of positive selection in PAML.
POLQ is a gene that encodes the protein POLθ, an A-family DNA polymerase, and was
first identified by Sharief et al. [1999]. DNA polymerases are enzymes that synthesise
DNA in genome replication, but also play an important role in protecting the cell
against DNA damage [Lange et al., 2011]. POLQ maps to chromosome 3 and contains
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Table 6.7: Enriched GO terms in Signature 3. Top 10 enriched GO terms in
Signature 3, using process ontology from GOrilla.
Process description P-value FDR q-value Enrichment (N, B, n, b)
positive regulation of cell aging 1.23E-5 1.62E-1 357.02 (18208,6,17,2)
chromatin organisation 1.61E-5 1.06E-1 10.07 (18208,638,17,6)
regulation of neuron apoptotic
process
2.36E-5 1.04E-1 22.79 (18208,188,17,4)
regulation of transcription from
RNA polymerase II promoter
4.16E-5 1.37E-1 5.35 (18208,1602,17,8)
regulation of leukocyte apop-
totic process
4.38E-5 1.15E-1 42.84 (18208,75,17,3)
replicative senescence 4.49E-5 9.85E-2 194.74 (18208,11,17,2)
regulation of neuron death 5.1E-5 9.59E-2 18.71 (18208,229,17,4)
positive regulation of muscle cell
apoptotic process
5.39E-5 8.86E-2 178.51 (18208,12,17,2)
positive regulation of cellular
amino acid metabolic process
6.22E-5 9.1E-2 17.78 (18208,241,17,4)
organelle organisation 6.28E-5 8.26E-2 4.29 (18208,2248,17,9)
an N-terminal ATP-binding domain and C-terminal DNA polymerase motifs A, B and
C [Sharief et al., 1999].
This novel candidate cancer gene is of great interest, as it has not previously been
associated with cancer. In the work of Heitzer and Tomlinson [2014], two other replica-
tive DNA polymerases (POLE and POLD1) were originally discovered to be enriched
with germline exonuclease domain mutations (EDMs) in human cancers predisposing to
polymerase proofreading associated polyposis (PPAP), which is a disease characterised
by multiple colorectal adenomas and carcinoma. POLE was also found to harbour so-
matic EDMs in sporadic colorectal and endometrial cancers. In tumours with EDMs,
the 3’ exonuclease proofreading activity is affected, causing an ‘ultramutator’ pheno-
type with an increase in base substitutions, but microsatellite stability is maintained.
However POLQ was not investigated in this work.
Two papers recently published in Nature [Ceccaldi et al., 2015, Mateos-Gomez et al.,
2015] investigated the role of POLQ in cancer and genome stability, presenting POLQ
Chapter 6. Mutation spectra sub-type analysis 270
as a druggable target in cancers with defective homologous recombination (HR) path-
ways. In Mateos-Gomez et al. [2015], next-generation sequencing showed that repair
by alternative non-homologous end-joining (alt-NHEJ), also known as microhomology-
mediated end-joining (MMEJ), yields non-TTAGGG nucleotide insertions at fusion
breakpoints of dysfunctional telomeres. The enzymatic activity of POLQ was identi-
fied as being responsible for these random insertions, establishing POLQ as a crucial
alt-NHEJ factor in mammalian cells. Additionally, in mice Mateos-Gomez et al. [2015]
found that the inhibition of POLQ resulted in the suppression of alt-NHEJ at dysfunc-
tional telomeres and hindered chromosomal translocations at non-telomeric loci, and
loss of POLQ caused increased rates of homology-directed repair evident by recombi-
nation of dysfunctional telomeres and the accumulation of RAD51 at double-strand
breaks. It was also shown that the depletion of POLQ had a synergistic effect on cell
survival in the absence of BRCA1 or BRCA2, suggesting that, in tumours carrying
mutations in homology-directed repair genes (such as BRCA1 or BRCA2), the inhibi-
tion of mutagenic POLQ could represent a valid therapeutic target. Supporting this
notion, Ceccaldi et al. [2015] reported an inverse correlation between HR activity and
POLQ expression in epithelial ovarian cancers (EOCs), with the knockdown of POLQ
in HR-proficient cells upregulating HR activity and RAD51 nucleofilament assembly,
while knockdown of POLQ in HR-deficient EOCs enhanced cell death. Furthermore,
POLQ contains RAD51 binding motifs which block RAD51-mediated recombination,
further supporting the role of POLQ as an inhibitor of HR. Consistent with the results
in Mateos-Gomez et al. [2015], genetic inactivation of POLQ and the HR gene FANCD2
in mice resulted in embyronic lethality. Ceccaldi et al. [2015] concluded that the results
revealed a synthetic lethal relationship between the HR pathway and POLQ-mediated
repair in EOCs, with HR-deficient cells not able to survive in the absence of POLQ,
again identifying POLQ as a novel druggable target in HR-defective tumours.
In both studies increased expression of POLQ was indicated to be driven by HR defi-
ciency, in which the compensatory alt-NHEJ mechanism is promoted, and hence POLQ
has been suggested as a synthetic lethal target in HR-deficient tumours. However driver
mutations have not been identified in this gene in cancer, presenting POLQ as a novel
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finding in this evolutionary analysis. Consistent with the findings from Mateos-Gomez
et al. [2015] and Ceccaldi et al. [2015] that POLQ is overespressed in EOCs and other
HR-deficient tumours [Ceccaldi et al., 2015] and upregulated in a wide range of human
cancers [Mateos-Gomez et al., 2015], it is speculated that the putative driver mutations
in POLQ in Signature 3 patients are activating mutations modifying the function of
POLQ by upregulating POLQ expression so that alt-NHEJ is promoted and HR is sup-
pressed, rather than inactivating mutations removing function. Since alt-NHEJ is more
error prone than HR, and has been shown to lead to chromosomal translocations, it is
predicted that activating mutations in POLQ contribute to genomic instability within
tumours by inhibiting HR. Interestingly this gene has not been found to be significantly
mutated in any cancer type in either the PAML analysis or the MutSig Lawrence anal-
ysis, suggesting that mutations in this gene are not tissue-specific but rather mutation
spectrum dependent. The mutational profile observed in Signature 3 exhibits mostly
C→A, C→G and C→T mutations, a signature typical of tumours with abnormalities
in DNA maintenance, specifically defective HR-based DNA double-strand break repair
[Alexandrov et al., 2013]. Signature 3 is also enriched for breast cancer, a tumour type
known to be associated with mutations in genes involved in the maintenance of genome
stability, such as BRCA1 and BRCA2 [Boulton, 2006]. Hence, Signature 3 could rep-
resent a mutational signature specific to HR-deficient tumours, supporting the role of
POLQ as an oncogene associated with a mutation spectrum characterised by genomic
instability, further validating POLQ as a potential therapeutic target in HR-deficient
cancers.
POLQ was also suggested to maintain genomic stability at stalled or collapsed replica-
tion forks by promoting fork restart, in response to replication stress induced by UV
light for example [Ceccaldi et al., 2015]. The mechanism for this is unknown, but was
suggested to be mediated through interaction with HR, since RAD51 binding by POLQ
was enhanced in cells under replicative stress. Therefore in tumours such as melanoma
that are known to be induced by environmental exposures causing replicative stress,
inactivating mutations in POLQ could potentially lead to the development of cancer
Chapter 6. Mutation spectra sub-type analysis 272
through increased abnormalities in replication fork progression. In this case POLQ
could be acting as a tumour suppressor gene.
To further investigate the POLQ mutations that were detected in the subset of 375
patients in Signature 3, UniProt [Consortium et al., 2014] and InterPro [Mitchell et al.,
2014] were used to identify domains and post-translational modification sites in POLQ,
and Plot Protein [Turner, 2013] was used to visualise the locations of the mutations
relative to functional regions. Of all 19 SNVs in POLQ over Signature 3 patients, only
exonic mutations were used for this analysis, of which there were 15 unique mutations
(all missense) over 13 different patients (Figure 6.7). The discarded four mutations
were intronic variants, with three present in a single breast cancer (BRCA) and one in
a lung squamous cell carcinoma (LUSC). The patients harbouring missense mutations
were as follows: two LUSC; three endometrial (UCEC), with one patient containing
two mutations; one BRCA; three bladder (BLCA), with one patient harbouring two
mutations; and four head and neck cancers (HNSC). Both BRCA and UCEC, known
HR-deficient associated tumour types, are amongst the cancer types affected by putative
driver mutations in this particular signature, again supporting the role of POLQ as a
cancer gene in HR-defective tumours.
Table 6.8 lists the amino acid changes highlighted in Figure 6.7, and shows which
mutations are present in domains and post-translational modification sites.
Both Figure 6.7 and Table 6.8 show that seven of the POLQ missense SNVs called in the
Signature 3 patients are located in POLQ domains, covering the helicase C-terminal,
the DNA polymerase domain, the helicase ATP-binding domain (containing the DEAD
box motif) and the ribonuclease H-like domain. In Ceccaldi et al. [2015], POLQ mutants
lacking either ATPase catalytic activity or interaction with RAD51 were found to fully
reduce RAD51 loci (increasing RAD51-ssDNA nucleofilament assembly) and increase
the recombination frequency compared to wild-type POLQ, whereas a POLQ mutant
lacking the polymerase domain was found to have the same effect on HR activity and
RAD51 foci as the wild-type POLQ. This suggested that the N-terminal half of POLQ,
containing the RAD51 binding domain and the ATPase domain, were sufficient for the
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Figure 6.7: Location of missense SNVs in POLQ within Signature 3. Plot
Protein has been used to visualise the locations of the 15 missense mutations called
in POLQ within the Signature 3 subset containing 375 patients, relative to functional
regions such as domains and post-translational modification sites. The plotted blue
points denote the amino acid changes present in the gene, with the amino acid positions
shown along the x-axis. The domains are highlighted in green with the following ab-
breviations: DEAD = helicase superfamily 1/2, ATP-binding domain (DEAD/ DEAH
box helicase motif); Helicase C = Helicase, C-terminal; RAD51-bd = RAD51 interact-
ing site; CC = coiled coil; and DNA pol A = DNA-directed DNA polymerase, family
A, palm domain. The post-translational modification site is highlighted in pink, and
represents N6-acetyllysine at amino acid residue 990. POLQ protein length = 2590
amino acids.
disruption of RAD51 foci (by negatively regulating RAD51-ssDNA assembly) as well as
the inhibition of HR. Conversely, the polymerase domain was found to be unnecessary
for the regulation of these processes. Based on this, the mutation in amino acid 176
resulting in a S to C change in the helicase ATP-binding domain (DEAD box) found
in the results of this analysis (Table 6.8) could potentially affect the function of POLQ
by upregulating the suppression of HR, as was shown in Ceccaldi et al. [2015], resulting
in the promotion of the more error-prone alt-NHEJ pathway which encourages a high
genomic instability pattern (through an increased rate of chromosomal translocations)
that is commonly observed in HR-deficient tumours. The polymerase domain of POLQ,
in which point mutations were also detected in the PAML analysis, was shown to be
required for the error-prone NHEJ pathway [Ceccaldi et al., 2015]. Therefore these par-
ticular mutations could be responsible for upregulating POLQ activity and promoting
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Table 6.8: Amino acid changes in POLQ within Signature 3. The protein
positions of all 15 amino acid changes in POLQ (protein ID NP 955452.3) within the
Signature 3 subset containing 375 patients. The domains are abbreviated as follows:
DNA-dir DNA pol A palm dom = DNA-directed DNA polymerase family A, palm do-
main; Helicase ATP-bd = Helicase superfamily 1/2, ATP-binding domain; and DEAD
= DEAD/DEAH box helicase motif. AA = amino acid; PTM = post-translational
modification.
AA position Ref AA Alt AA Domain PTM site
1479 P S Not in domain No
1628 S L Not in domain No
691 E A Not in domain No
1596 P A Not in domain No
1479 P A Not in domain No
448 S Y Helicase C-terminal No
2341 H Y DNA-dir DNA pol A palm dom No
2258 I M DNA-dir DNA pol A palm dom No
1840 F Y Not in domain No
176 S C Helicase ATP-bd (DEAD) No
1291 L V Not in domain No
12441 Q E DNA-dir DNA pol A palm dom No
2189 A V DNA-dir DNA pol A palm dom No
2059 Q E Ribonuclease H-like domain No
917 E K Not in domain No
alt-NHEJ to also lead to increased genomic instability and the subsequent development
of cancer. No mutations were observed in the RAD51 binding domain in this analy-
sis. However it has been suggested that the anti-recombinase activity of this domain
is responsible for maintaining genomic stability in HR-defective tumours, presenting
this region of POLQ as a good knockout target in tumours that are HR-deficient and
also treated with PARPi (inhibition of PARP), PARP1 being another crucial factor in
alt-NHEJ [Ceccaldi et al., 2015].
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Figure 6.8: Gene-based omega analysis in PAML for Signature 4. For each
gene in the group of 457 patients in Signature 4, the omega estimate and FDR value
from PAML analysis has been plotted to show the patterns of selection across the
dataset. R code used to generate plot in Supplementary Appendix H.
6.2.1.4 Signature 4
Signature 4 (Figure 6.2) contains 457 patients. These patients have a more uniform
mutation spectra than the other signatures with fairly even proportions of each of the
six single nucleotide changes.
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Table 6.9: Ranked list of significantly mutated genes in Signature 4. Signif-
icantly mutated genes (omega>1 and FDR<0.1) from PAML analysis of Signature 4
have been tabulated in ascending order by p-value (descending order of significance).
Code used to generate table in Supplementary Appendix I.
Gene Omega P-value Description
TP53 19.94 2.32e-32 tumor protein p53
PIK3CA 999.00 3.58e-25 phosphatidylinositol-4,5-bisphosphate 3-kinase, cat-
alytic subunit alpha
NRAS 999.00 4.76e-16 neuroblastoma RAS viral (v-ras) oncogene homolog
VHL 4.63 7.65e-10 von Hippel-Lindau tumor suppressor, E3 ubiquitin
protein ligase
KRAS 999.00 3.81e-07 Kirsten rat sarcoma viral oncogene homolog
KALRN 999.00 2.73e-06 kalirin, RhoGEF kinase
C9orf72 1.03 2.92e-06 chromosome 9 open reading frame 72
KLK10 63.49 3.91e-06 kallikrein-related peptidase 10
USH1C 999.00 4.25e-05 Usher syndrome 1C (autosomal recessive, severe)
ITGB7 1.39 6.15e-05 integrin, beta 7
EZH2 999.00 8.91e-05 enhancer of zeste homolog 2 (Drosophila)
BRAF 1.70 1.33e-04 v-raf murine sarcoma viral oncogene homolog B
In total, 12 genes were found to be significantly mutated in Signature 4, tabulated in
Table 6.9 with their omega estimate, p-values and gene descriptions.
GO term analysis in GOrilla has produced the top ten processes enriched for the sig-
nificant genes in this analysis (Table 6.10).
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Table 6.10: Enriched GO terms in Signature 4. Top 10 enriched GO terms in
Signature 4, using process ontology from GOrilla.
Process description P-value FDR q-value Enrichment (N, B, n, b)
regulation of neuron apoptotic
process
8.31E-8 1.09E-3 40.35 (18208,188,12,5)
regulation of neuron death 2.22E-7 1.46E-3 33.13 (18208,229,12,5)
neurotrophin TRK receptor sig-
naling pathway
5.6E-7 2.46E-3 27.49 (18208,276,12,5)
neurotrophin signaling pathway 6.02E-7 1.98E-3 27.10 (18208,280,12,5)
negative regulation of neuron
apoptotic process
1.21E-6 3.19E-3 46.33 (18208,131,12,4)
negative regulation of neuron
death
2.37E-6 5.2E-3 39.16 (18208,155,12,4)
positive regulation of protein
phosphorylation
2.41E-6 4.54E-3 12.99 (18208,701,12,6)
fibroblast growth factor recep-
tor signaling pathway
3.12E-6 5.13E-3 36.56 (18208,166,12,4)
visual learning 3.72E-6 5.44E-3 94.83 (18208,48,12,3)
positive regulation of Rac pro-
tein signal transduction
3.98E-6 5.24E-3 606.93 (18208,5,12,2)
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Figure 6.9: Gene-based omega analysis in PAML for Signature 5. For each
gene in the group of 1,526 patients in Signature 5, the omega estimate and FDR value
from PAML analysis has been plotted to show the patterns of selection across the
dataset. R code used to generate plot in Supplementary Appendix H.
6.2.1.5 Signature 5
Signature 5 (Figure 6.2) contains 1,526 patients. These patients have mostly C→T
changes, but this signature differs from Signature 2 as it has a much lower rate of these
changes reaching ∼60% whereas in Signature 2 the C→T rate reaches almost 100% in
some patients.
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In total, 58 genes were found to be significantly mutated in Signature 5, and the top
most significant 35 of these have been tabulated in Table 6.11 with their omega estimate,
p-values and gene descriptions.
GO term analysis in GOrilla has produced the top ten processes enriched for the sig-
nificant genes in this analysis (Table 6.12).
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Table 6.11: Ranked list of significantly mutated genes in Signature 5. Sig-
nificantly mutated genes (omega>1 and FDR<0.1) from PAML analysis of Signature
5 have been tabulated in ascending order by p-value (descending order of significance).
List has been truncated to n=35 rows out of a total of 58 significant genes. Full table
in Supplementary Appendix J. Code used to generate table in Supplementary Appendix
I.
Gene Omega P-value Description
SYNE1 1.23 0.00e+00 spectrin repeat containing, nuclear envelope 1
FLG 1.35 0.00e+00 filaggrin
LRP1B 1.13 0.00e+00 low density lipoprotein receptor-related protein
1B
KRAS 999.00 8.10e-97 Kirsten rat sarcoma viral oncogene homolog
PTEN 32.95 1.20e-56 phosphatase and tensin homolog
IDH1 14.85 2.85e-56 isocitrate dehydrogenase 1 (NADP+), soluble
EGFR 2.36 5.14e-51 epidermal growth factor receptor
NRAS 999.00 1.41e-49 neuroblastoma RAS viral (v-ras) oncogene ho-
molog
CTNNB1 11.93 2.02e-39 catenin (cadherin-associated protein), beta 1,
88kDa
FBXW7 8.20 5.95e-34 F-box and WD repeat domain containing 7, E3
ubiquitin protein ligase
SF3B1 2.17 9.47e-32 splicing factor 3b, subunit 1, 155kDa
BRAF 2.77 6.42e-22 v-raf murine sarcoma viral oncogene homolog B
FGFR2 1.71 2.45e-14 fibroblast growth factor receptor 2
CDKN2A 2.71 7.33e-13 cyclin-dependent kinase inhibitor 2A
DNMT3A 3.32 1.32e-12 DNA (cytosine-5-)-methyltransferase 3 alpha
MYD88 5.28 2.13e-12 myeloid differentiation primary response 88
PIK3R1 999.00 3.39e-11 phosphoinositide-3-kinase, regulatory subunit 1
(alpha)
IDH2 999.00 2.61e-10 isocitrate dehydrogenase 2 (NADP+), mitochon-
drial
SMAD4 999.00 3.91e-10 SMAD family member 4
VHL 7.81 7.62e-09 von Hippel-Lindau tumor suppressor, E3 ubiqui-
tin protein ligase
U2AF1 3.29 1.33e-08 U2 small nuclear RNA auxiliary factor 1
CTCF 6.05 2.07e-08 CCCTC-binding factor (zinc finger protein)
RUNX1 1.96 8.86e-08 runt-related transcription factor 1
SPOP 7.38 1.04e-07 speckle-type POZ protein
DCHS1 3.35 1.25e-07 dachsous cadherin-related 1
CDC27 1.83 1.54e-07 cell division cycle 27
AKT1 1.70 2.12e-07 v-akt murine thymoma viral oncogene homolog 1
CELSR3 4.43 3.70e-07 cadherin, EGF LAG seven-pass G-type receptor 3
ZDHHC4 999.00 5.59e-07 zinc finger, DHHC-type containing 4
DNAH2 1.24 1.39e-06 dynein, axonemal, heavy chain 2
PPP2R1A 1.76 1.42e-06 protein phosphatase 2, regulatory subunit A, al-
pha
KMT2D 2.14 1.59e-06 lysine (K)-specific methyltransferase 2D
TMEM109 999.00 3.36e-06 transmembrane protein 109
DCDC1 7.05 3.48e-06 doublecortin domain containing 1
TCEB1 999.00 8.43e-06 transcription elongation factor B (SIII), polypep-
tide 1 (15kDa, elongin C)
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Table 6.12: Enriched GO terms in Signature 5. Top 10 enriched GO terms in
Signature 5, using process ontology from GOrilla.
Process description P-value FDR q-value Enrichment (N, B, n, b)
fibroblast growth factor recep-
tor signaling pathway
1.08E-10 1.42E-6 18.91 (18208,166,58,10)
positive regulation of macro-
molecule metabolic process
2.76E-9 1.82E-5 3.44 (18208,2372,58,26)
positive regulation of gene ex-
pression
6.95E-9 3.05E-5 4.40 (18208,1428,58,20)
positive regulation of cellular
metabolic process
8.73E-9 2.87E-5 3.26 (18208,2503,58,26)
neurotrophin TRK receptor
signaling pathway
1.5E-8 3.94E-5 11.37 (18208,276,58,10)
positive regulation of nitrogen
compound metabolic process
1.56E-8 3.43E-5 3.97 (18208,1661,58,21)
neurotrophin signaling path-
way
1.72E-8 3.23E-5 11.21 (18208,280,58,10)
positive regulation of signaling 1.87E-8 3.07E-5 4.40 (18208,1356,58,19)
positive regulation of cell com-
munication
2.05E-8 3E-5 4.37 (18208,1364,58,19)
positive regulation of signal
transduction
2.72E-8 3.58E-5 4.58 (18208,1235,58,18)
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Figure 6.10: Gene-based omega analysis in PAML for Signature 6. For each
gene in the group of 706 patients in Signature 6, the omega estimate and FDR value
from PAML analysis has been plotted to show the patterns of selection across the
dataset. R code used to generate plot in Supplementary Appendix H.
6.2.1.6 Signature 6
Signature 6 (Figure 6.2) contains 706 patients. These patients have mostly C→T
changes again, but within the other five types of change C→A and C→G are slightly
elevated above T→A, T→C and T→G which are all more uniform.
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In total, 141 genes were found to be significantly mutated in Signature 6, and the
top most significant 35 of these have been tabulated in Table 6.13 with their omega
estimate, p-values and gene descriptions.
GO term analysis in GOrilla has produced the top ten processes enriched for the sig-
nificant genes in this analysis (Table 6.14).
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Table 6.13: Ranked list of significantly mutated genes in Signature 6. Sig-
nificantly mutated genes (omega>1 and FDR<0.1) from PAML analysis of Signature
6 have been tabulated in ascending order by p-value (descending order of significance).
List has been truncated to n=35 rows out of a total of 141 significant genes. Full table
in Supplementary Appendix J. Code used to generate table in Supplementary Appendix
I.
Gene Omega P-value Description
TP53 16.18 9.72e-89 tumor protein p53
PIK3CA 10.75 2.20e-86 phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha
KRAS 7.42 8.81e-35 Kirsten rat sarcoma viral oncogene homolog
PTEN 3.74 3.93e-13 phosphatase and tensin homolog
NFE2L2 5.81 1.10e-11 nuclear factor, erythroid 2-like 2
MACF1 1.06 5.01e-11 microtubule-actin crosslinking factor 1
VHL 4.63 5.49e-11 von Hippel-Lindau tumor suppressor, E3 ubiqui-
tin protein ligase
DCT 3.14 6.45e-11 dopachrome tautomerase
PIK3R1 7.93 1.22e-10 phosphoinositide-3-kinase, regulatory subunit 1
(alpha)
APC 4.07 2.43e-09 adenomatous polyposis coli
KIAA2026 1.47 3.87e-08 KIAA2026
DMXL2 13.91 2.72e-07 Dmx-like 2
LRP1B 1.14 2.74e-07 low density lipoprotein receptor-related protein
1B
ZNF749 1.85 3.14e-07 zinc finger protein 749
UVRAG 999.00 5.08e-07 UV radiation resistance associated
XPO1 1.96 5.20e-07 exportin 1 (CRM1 homolog, yeast)
WWTR1 2.55 5.66e-07 WW domain containing transcription regulator 1
ZNF283 999.00 7.77e-07 zinc finger protein 283
ARID1A 4.23 7.90e-07 AT rich interactive domain 1A (SWI-like)
ZNHIT6 999.00 8.82e-07 zinc finger, HIT-type containing 6
KMT2D 1.67 1.21e-06 lysine (K)-specific methyltransferase 2D
ASB15 999.00 1.37e-06 ankyrin repeat and SOCS box containing 15
CEP89 999.00 1.90e-06 centrosomal protein 89kDa
RBL2 999.00 2.37e-06 retinoblastoma-like 2 (p130)
STIM2 999.00 2.40e-06 stromal interaction molecule 2
CAPRIN2 1.58 4.67e-06 caprin family member 2
KCND3 1.37 5.13e-06 potassium voltage-gated channel, Shal-related
subfamily, member 3
DYM 2.56 5.34e-06 dymeclin
TOX 1.66 5.47e-06 thymocyte selection-associated high mobility
group box
NRAS 2.93 7.45e-06 neuroblastoma RAS viral (v-ras) oncogene ho-
molog
PDZD8 999.00 7.66e-06 PDZ domain containing 8
APOLD1 999.00 8.63e-06 apolipoprotein L domain containing 1
FBXW7 2.87 1.29e-05 F-box and WD repeat domain containing 7, E3
ubiquitin protein ligase
AP000295.9 2.85 1.30e-05
NEB 1.30 1.30e-05 nebulin
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Table 6.14: Enriched GO terms in Signature 6. Top 10 enriched GO terms in
Signature 6, using process ontology from GOrilla.
Process description P-value FDR q-value Enrichment (N, B, n, b)
fibroblast growth factor recep-
tor signaling pathway
4.63E-6 6.09E-2 7.21 (18208,166,137,9)
regulation of phosphorylation 3.79E-5 2.49E-1 2.51 (18208,1218,137,23)
neurotrophin TRK receptor sig-
naling pathway
4.6E-5 2.02E-1 4.82 (18208,276,137,10)
neurotrophin signaling pathway 5.19E-5 1.71E-1 4.75 (18208,280,137,10)
enzyme linked receptor protein
signaling pathway
6.25E-5 1.64E-1 2.84 (18208,843,137,18)
regulation of protein targeting 6.34E-5 1.39E-1 5.94 (18208,179,137,8)
positive regulation of response
to stimulus
6.65E-5 1.25E-1 2.17 (18208,1715,137,28)
regulation of phosphorus
metabolic process
6.78E-5 1.12E-1 2.30 (18208,1442,137,25)
regulation of intracellular pro-
tein transport
7.06E-5 1.03E-1 5.11 (18208,234,137,9)
Fc-epsilon receptor signaling
pathway
7.7E-5 1.01E-1 5.78 (18208,184,137,8)
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6.2.2 Measuring and estimating run times in PAML
Time constraints meant that the data running through PAML for this mutation spectra
sub-type analysis had to be reorganised to maximise and prioritise the efficiency of the
analysis.
Using the Lawrence dataset over all 4,728 patients and 21 cancer types, the run time
was measured for each gene that had successfully completed ten iterations in PAML,
in order to determine how long the genes in the mutation spectra sub-analysis would
take to complete analysis.
To ascertain whether number of patient alignments per gene or length of gene was the
more time-limiting factor in this analysis, the relationship between time taken and each
of these variables was measured and plotted in Figure 6.11 and Figure 6.12.
Figure 6.11 and Figure 6.12 show that run time in PAML is more correlated with patient
number rather than gene length, showing a strong positive correlation. Therefore, the
number of patients is a more important consideration when estimating how long each
gene will take to run through PAML.
Over the whole Lawrence dataset, TTN had the most number of patients (1400). How-
ever in this mutation spectra sub-type analysis, the gene with the largest number of
patients was TP53 in Signature 5 with 406 patients.
In Figure 6.13, a linear regression (Equation 6.1) has been fitted to the data from
Figure 6.11 and the straight line of best fit has been extrapolated to predict how long
TP53 will take to run through PAML ten times. According to the equation of the
straight line, TP53 with 406 patient alignments is estimated to take ∼40 hours.
y = 395.913x− 17255.573 (6.1)






























































































































































































































































































































































































































































Figure 6.11: Relationship between patient number and PAML run time.
For each gene in the whole Lawrence dataset of 4,728 patients that had successfully
run though PAML to completion, the number of patients with mutations in that gene
was plotted along the x-axis against the time it took (seconds) to run the gene through
PAML along the y-axis, to show relationship between these two variables.
6.3 Discussion
The Lawrence dataset has been stratified by mutation spectra in order to detect signals
of positive selection in candidate cancer driver genes specific to certain types of mutation
spectra. Signature 3 has revealed a potential candidate cancer gene.
6.3.1 Relating mutational profile to path of selection
Many of the same significantly mutated genes are found across almost all six mutational
signatures, such as TP53 and PIK3CA, however there are also genes such as POLQ
































































































































































































































































































































































































































































































































































































































Figure 6.12: Relationship between gene length and PAML run time. For
each gene in the whole Lawrence dataset of 4,728 patients that had successfully run
through PAML, the gene length was plotted along the x-axis against the time it took
(seconds) to run the gene through PAML along the y-axis, to show the relationship
between these two variables.
that are unique to a specific mutation spectra. Therefore it is worth accounting for the
mutation spectra of a cancer since it seems that the profile of a cancer may affect the
genes that are hit by driver mutations in cancer.
However, the classification system used in this analysis is fairly basic, and should be
further refined to include sequence context and CpG effects for example using the
classification systems of Alexandrov et al. [2013] and Kandoth et al. [2013], in order to
separate out the mutation spectra further. The way it has been done here, the mutation
spectra look quite similar in some cases between different signatures which may be why
the same significant genes are seen in several of the signatures.
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Figure 6.13: Extrapolation for PAML run time estimates. For each gene,
the number of patients with mutations in that gene has been plotted along the x-axis
against the time taken (seconds) to run the gene through PAML along the y-axis.
A linear regression (red straight line of best fit) has been fitted to this data and
extrapolated to estimate the PAML run time for the maximum patient number of 406
in TP53, which is estimated to take 143485 seconds (blue dotted lines).
6.3.2 Candidate cancer gene in Signature 3: POLQ
POLQ has been found to be significantly mutated in Signature 3. This is a very
interesting finding, since it has not come up as significant in any of the tissue of origin
sub-type analyses, and is only significant in Signature 3. This suggests that there is
merit in grouping the data in this way, as otherwise this gene would not have reached
significance.
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POLQ has not yet been confirmed as a cancer gene, however it has been recently pre-
sented as a druggable target in cancers with defective homologous recombination [Cec-
caldi et al., 2015, Mateos-Gomez et al., 2015], which makes this gene a good candidate
cancer gene.
6.4 Methods
6.4.1 Partitioning data by single nucleotide mutation patterns
The Lawrence data was stratified by mutation spectra in the following way:
• Over all 4,728 patients in the Lawrence dataset, the relative proportions of each
of the six classes of single nucleotide change (C→A, C→G, C→T, T→A, T→C,
T→G) were calculated for each patient.
• A Euclidean (default in R) distance matrix was created in R containing all six
relative single nucleotide change proportions for each patient.
• Cluster analysis was performed on this matrix using hclust in R, which scores
the similarities between each patient, to group together patients with similar
mutation spectra. This was done using hierarchical, agglomerative clustering
using complete linkage (furthest-neighbour joining).
• The cluster analysis scores were used to create a cluster dendrogram in R to
visualise the clustering, where the patients were clustered together based on their
similarity scores (similarities in mutation spectra).
• From this dendrogram, an arbitrary height cut-off of branch length 0.65 was
chosen to split the patients into 18 clusters, and six main groups were chosen
from this.
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6.4.2 PAML analysis
For each mutational signature, patient alignments edited with the Lawrence cancer-
specific mutations were run through PAML in the same way as was done for the tissue
of origin subsets, on a per gene basis as before.
An omega plot was generated in R for each of the six mutational signatures in the same
way as has been done for the tissue of origin sub-type analysis in Chapter 5. Tables
were also created listing the most significant genes for each mutational signature.
6.4.3 Gene ontology analysis
GOrilla (Gene ontology enrichment analysis and visualisation tool) was used to identify
and visualise enriched GO terms in the six different mutational signatures [Eden et al.,
2009].
GOrilla can be run in two modes, either using a single ranked list of genes as input or
two unranked lists of genes (a target list and a background list). GOrilla was used here
to search for enriched GO terms in a target list of genes compared to a background list
of genes. For each mutational signature, the target list provided was the unranked list
of significant genes (omega>1 and FDR<0.1) for that group and the background list
was an unranked list of all 63677 genes obtained from Ensembl 78.
Gorilla is able to search for various ontologies: process, function or component. In this
case process was the ontology searched for.
GOrilla calculated three values for each analysis:
• A p-value that is not corrected for multiple testing of 13167 GO terms. These
were used to rank the process ontologies (smallest p-value most statistically sig-
nificant).
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• A FDR q-value which is the p-value corrected for multiple testing using the
Benjamini and Hochberg method [Benjamini and Hochberg, 1995], so for the ith
term the FDR q-value (ranked by p-value) is (p-value * number of GO terms)/i.
• An enrichment score of (b/n)/(BN), where N = the total number of genes
(18208 genes from background list that were recognised, unique (highest ranking
instance of each duplicated gene kept) and associated with a GO term), B = the
total number of genes associated with a specific GO term, n = the number of genes
in the target set and b = the number of genes in the intersection.
Chapter 7
Mutation profile of FARP genes
7.1 Introduction
Following on from the finding in Chapter 3 that a subset of 16 glioblastoma multiforme
(GBM) patients exhibited an increased rate of called INDELs, and building on the SNV
analysis of varying mutation spectra in Chapter 3, the TCGA dataset was mined for
specific mutation spectra characterised by high rates of called INDELs.
Both FARP1 and FARP2 genes were found to exhibit a strikingly high rate of cancer-
specific INDELs in the TCGA dataset. These genes have also been identified as mech-
anistically novel regulators of autophagy in cancer cells (personal communication with
Simon Wilkinson, IGMM Edinburgh). Neither FARP1 nor FARP2 have been causally
implicated in cancer [Forbes et al., 2011]. Hence, it was speculated that these genes
could be important functional candidate cancer genes, undergoing an interesting mu-
tation spectrum defined by a high rate of INDELs.
FERM, RhoGEF, and pleckstrin homology domain protein 2 (FARP2) and its close
homolog FERM, RhoGEF, and pleckstrin homology domain protein 1 (FARP1) are
large multi-domain proteins sharing the same domain structures: FERM, RhoGEF,
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and pleckstrin homology domains. FARP2 is also known as FERM domain includ-
ing RhoGEF (FIR) and FGD1-related Cdc42-GEF (FRG), and FARP1 is also known
as chondrocyte-derived ezrin-like protein (CDEP) and pleckstrin homology domain-
containing family C member 2 (PLEKHC2). Functional studies of FARP1 and FARP2
have previously focused primarily on their roles in the regulation of neuronal develop-
ment and morphology, motivated by their abundant expression both in neurons at the
developmental stage and in the adult brain [He et al., 2013].
Interestingly, FARP1 and FARP2 are not shown to be significantly mutated in the
Lawrence et al. [2014] study, nor in the PAML analysis carried out in this project.
This suggests that these genes do not harbour driver SNVs, and so if they are causally
implicated in cancer they are likely to be altered by another type of genetic mutation.
This chapter seeks to investigate the high rate of INDELs called in FARP1 and FARP2,
to further understand their potential role in cancer.
7.2 Results
7.2.1 Initial COSMIC analysis of somatic mutations in FARP genes
Using the resource COSMIC [Forbes et al., 2010] to investigate acquired mutations in
FARP1 and FARP2 in cancer, it was found that out of a total of 22,894 unique sam-
ples, 214 were mutated (0.77%) in FARP1. And out of a total number of 22,770 unique
samples, 167 were mutated (0.73%) in FARP2. This included 12 mutant samples with
substitution nonsense mutations, 131 with substitution missense, 68 with substitution
synonymous, 1 with an insertion frameshift, 1 with deletion inframe and 3 with deletion
frameshifts in FARP1. In FARP2, 9 mutant samples had substitution nonsense muta-
tions, 96 had substitution missense, 49 had substitution synonymous, 3 had insertion
frameshift, 1 had a deletion inframe and 5 had a deletion frameshift. These numbers
do not necessarily equal the total number of mutated samples for each gene, as a single
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sample can have mutations in one or more categories, but will only be counted once in
the total number of mutated samples.
However, a limitation of using COSMIC to identify mutated genes in cancer is that
it presents an acquisition bias, making it difficult to score the significance of genes.
Mutations are recorded in COSMIC based on what has been found without accounting
for the different types of genes that have preferentially been searched. For example
more kinase genes will have been investigated due to their role in cancer, so there will
be a bias towards more mutations represented in these genes.
7.2.2 FARP SNVs in TCGA dataset
The mySQL database containing all called variants in the TCGA dataset was mined to
find SNVs targeting FARP1 and FARP2.
Over the whole TCGA dataset of 1,005 patients, FARP1 and FARP2 were shown to be
hit by 20 and 30 cancer-specific coding heterozygous SNVs respectively, corresponding
to a mean of 0.02 SNVs per patient in FARP1 and 0.03 in FARP2. Table 7.1 and
Table 7.2 show how the mutations are spread over the different cancer types in both
FARP1 and FARP2 respectively. In both genes, most mutations are found in the
GBM dataset. However after accounting for varying patients numbers between cancer
type subsets, of the seven cancer types that contain cancer-specific heterozygous SNV
mutations in FARP1 it is brain lower grade glioma (LGG) that is the most enriched
with SNVs (0.06), and of the eight cancer types hit by cancer-specific heterozygous
SNVs in FARP2 GBM remains the cancer type exhibiting the highest mutation rate
in this gene (0.09). Interestingly, the cancer types that are most enriched with FARP1
and FARP2 SNVs are both cancers of the brain, which is where these genes are known
to be abundantly expressed [He et al., 2013].
Of the coding SNVs reported, most are non-synonymous. In FARP1, 80% are non-
synonymous (Table 7.3), and in FARP2, 63% are non-synonymous (Table 7.4).
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Table 7.1: FARP1 cancer-specific SNV counts by tumour type. For each
tumour type, the cancer-specific heterozygous coding SNV counts over all 1005 patients
in the TCGA dataset have been tabulated for FARP1, with the mean number of SNVs
per patient for each dataset (calculated to 3dp).








Whole dataset 20 0.020
Table 7.2: FARP2 cancer-specific SNV counts by tumour type. For each
tumour type, the cancer-specific heterozygous coding SNV counts over all 1005 patients
in the TCGA dataset have been tabulated for FARP2, with the mean number of SNVs
per patient for each dataset (calculated to 3dp).









Whole dataset 30 0.030
Table 7.3: FARP1 cancer-specific SNV counts by variant consequence. For
each coding variant consequence, the cancer-specific heterozygous coding SNV counts
over all 1005 patients in the TCGA dataset have been tabulated for FARP1.
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Table 7.4: FARP2 cancer-specific SNV counts by variant consequence. For
each coding variant consequence, the cancer-specific heterozygous coding SNV counts
over all 1005 patients in the TCGA dataset have been tabulated for FARP2.




7.2.3 FARP INDELs in TCGA dataset
In the TCGA dataset of 1,005 patients, 52 patients were found to contain at least one
heterozygous coding cancer-specific INDEL in FARP1, and 74 were found to contain
at least one heterozygous coding cancer-specific INDEL in FARP2. The distribution
of INDELs among these patients is shown in Figure 7.1, in which it can be seen that
the distribution is more spread in FARP2 with more patients containing slightly higher
rates of INDELs. However overall the shape of the distributions are largely the same
with both patients in each gene exhibiting much smaller numbers of INDELs (i.e. one or
two per patient). The patient with the highest rate of INDELs in FARP1 contains seven
INDELs and is of the tumour type GBM. Of the 52 patients mutated with INDELs in
FARP1, 36 are GBM (69%). The patient with the most INDELs in FARP2 contains
12 INDELs and has the tumour type OV. Of the 74 patients mutated with INDELs in
FARP2, 17 are OV (23%).
It can be seen from Table 7.5, Table 7.6, Table 7.7 and Table 7.8 that INDEL rates are
much higher than SNV rates in FARP1 and FARP2, with 109 INDELs compared to
just 20 SNVs found in FARP1 across the whole TCGA dataset of 1,005 patients and
157 found in FARP2 compared to just 30 SNVs in this gene.
GBM generally has the highest mean rate of cancer-specific INDELs per patient in
FARP1 with a mean number of 0.40 INDELs per patient, followed by OV with the
second highest rate of 0.25 INDELs per patient (Table 7.5). The average number of
FARP1 INDELs per patient for the TCGA dataset of 1,005 patients is 0.108.
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Figure 7.1: Distribution of INDELs in FARP1 and FARP2. Histograms
showing the distribution of heterozygous coding cancer-specific INDELs in (A) FARP1
across 52 patients hit by INDELs in this gene and (B) FARP2 across 74 patients hit
by INDELs in this gene.
Table 7.5: FARP1 cancer-specific INDEL counts by tumour type. For each
tumour type, the cancer-specific heterozygous coding INDEL counts over all 1005
patients in the TCGA dataset have been tabulated for FARP1, with the mean number
of INDELs per patient for each dataset (calculated to 3dp).








Whole dataset 109 0.108
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Table 7.6: FARP2 cancer-specific INDEL counts by tumour type. For each
tumour type, the cancer-specific heterozygous coding INDEL counts over all 1005
patients in the TCGA dataset have been tabulated for FARP2, with the mean number
of INDELs per patient for each dataset (calculated to 3dp).












Whole dataset 157 0.156
OV generally has the highest rate of cancer-specific INDELs per patient in FARP2
with a mean number of 0.547 INDELs per patient (over all OV patients in the TCGA
dataset), followed by GBM with the second highest rate of INDELs per patient with a
mean number of 0.433 INDELs per patient (Table 7.6). The average number of FARP2
INDELs per patient for the TCGA dataset of 1,005 patients is 0.156, which is higher
than that for FARP1.
Table 7.7 shows the INDELs in FARP1 split by their variant consequence type. Frameshift
mutations are the most common with 56 of the 109 INDELs (51%) being reported as
frameshift.
Similarly, in Table 7.8 frameshift is the most common type of INDEL seen in FARP2,
reported at a frequency of 52% (82 out of 157). This is very similar to the proportion
of frameshifts observed in FARP1.
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Table 7.7: FARP1 cancer-specific INDEL counts by variant consequence.
For each coding variant consequence, the cancer-specific heterozygous coding INDEL
counts over all 1005 patients in the TCGA dataset have been tabulated for FARP1.
Consequence Number of INDELs
CODON CHANGE PLUS CODON DELETION 3




SPLICE SITE ACCEPTOR 1
SPLICE SITE DONOR 3
UTR 3 PRIME 3
UTR 5 PRIME 20
Total 109
Table 7.8: FARP2 cancer-specific INDEL counts by variant consequence.
For each coding variant consequence, the cancer-specific heterozygous coding INDEL
counts over all 1005 patients in the TCGA dataset have been tabulated for FARP2.
Consequence Number of INDELs
CODON CHANGE PLUS CODON DELETION 2




SPLICE SITE ACCEPTOR 5
SPLICE SITE DONOR 3
UTR 5 PRIME 24
Total 157
7.2.3.1 Clustering of FARP INDELs within patients
To examine where in the FARP patients INDELs were occurring, the degree of cluster-
ing was measured over all 52 patients containing FARP1 INDELs and all 74 patients
containing FARP2 INDELs. The frequency of distances between INDELs in patients
containing more than one INDEL was plotted in Figure 7.2. This histogram shows that
most INDELs tend to be called within 25bp of each other, indicative of clustering of
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INDELs within patients. However this plot has been truncated at 50bp along the x-axis
so does not show INDEL distances exceeding 50bp, of which there are some cases. On
the whole though, most INDELs can be located in clusters in the range of 0-10bp. It
is possible that these INDELs reportedly being called close together are actually the
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Frequency distribution of inter−indel distances in FARP1 and FARP2
Figure 7.2: Inter-indel distances in FARP1 and FARP2. Distances between heterozygous cancer-specific INDELs in patients
with FARP1 and FARP2 INDELs plotted as a frequency histogram. The frequency along the y-axis is the frequency of inter-indel
distances among all 52 FARP1 patients (purple) and all 74 FARP2 patients (green). The x-axis represents the distance between
two INDELs in a patient. Each patient may contain more than two INDELs in either FARP1 or FARP2 so in these cases multiple
inter-indel distances will be recorded for a single patient, therefore the y-axis frequency does not necessarily represent the frequency
of patients. The x-axis has been truncated at 50bp to focus on clusters of INDELs within patients. A red vertical dotted line has
been drawn at a distance of 25bp, to show that INDELs tend to occur within 25bp of each other in clusters.
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Table 7.9: Insertions and deletions in FARP genes. Heterozygous cancer-
specific INDEL counts for FARP1 and FARP2, split into insertion and deletion sub-
categories. Insertions have been split further into long insertions (≥8nt) and short
insertions (<8nt).
Type of INDEL FARP1 FARP2
Insertions 98 119
Long insertions 94 99
Short insertions 4 20
Deletions 11 38
Total 109 157
7.2.3.2 Long insertions (≥8nt)
To further investigate these INDELs, in Table 7.9 the INDELs in each FARP gene were
split into insertion and deletion categories, to show that there is a much higher rate of
called insertions compared to deletions. In FARP1, 90% of the INDELs are insertions,
and in FARP2, 76% of the INDELs are insertions rather than deletions. Micro-insertion
mutations have been sub-categorised further into short and long insertions using the
arbitrary threshold of ≥8nt to define long insertions. Based on this cut-off, Table 7.9
shows that there is an abundance of long insertions compared to short insertions, with
96% of the insertions classed as long in FARP1 and 83% of the insertions in FARP2
having length ≥8nt. All subsequent analysis in this Chapter has been carried out focus-
ing on the more abundant and easier to map (to the reference genome) long insertions
(≥8nt) in FARP1 and FARP2.
7.2.3.3 GBM and OV patients enriched with long (≥8nt) insertions
In Figure 7.3, the 94 long insertions in FARP1 and 99 long insertions in FARP2 have
been used to calculate the proportions of patients in each tumour type harbouring long
insertions. The figure shows that OV and GBM patients are enriched with FARP long
insertions. This is consistent with the results obtained for all INDELs in these patients,
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Proportion of patients with heterozygous cancer−specific long insertions (>=8nt) in FARP1 and FARP2 across all tumour types
● Patients with FARP1 or FARP2 mutations
Patients with FARP1 mutations
Patients with FARP2 mutations
Figure 7.3: Proportion of patients with long insertions (≥8nt) in FARP1 and FARP2. For each tumour type, this plot
shows the proportion of patients with coding INDELs in FARP1 (red), FARP2 (green) and either FARP1 or FARP2 (blue) out of
the total number of patients for that tumour type.
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7.2.3.4 Mapping long (≥8nt) insertions to the reference genome
The long insertions were aligned to the FARP loci reference genomes, in order to further
ascertain the mechanism taking place in these two genes. Of the 94 long insertions in
FARP1, only 27 were able to find an exact match to the reference, and in FARP2 only
30 of the 99 long insertions were able to be matched to the reference genome. Some
of the unique insertions were found to map to multiple locations in the reference, so
in these cases only the closest most realistic map position was considered. The results
were plotted for FARP1 and FARP2 in Figure 7.4 and Figure 7.5 respectively. These
INDELs are over 21 patients in FARP1 (16 GBM, 4 OV and 1 KIRC) and 20 patients in
FARP2 (15 GBM, 4 OV and 1 KIRC), meaning that some patients harboured multiple
INDELs within the same FARP gene. 5 of these patients had mapped long insertions
in both FARP1 and FARP2 (3 GBM, 1 OV and 1 KIRC).
Figures 7.4 and 7.5 show that the positions of the called long insertions are distal to
the position in the reference to which they have been mapped. This suggests that these
mutations may not be micro-insertions, in which case it would be expected that the
called insertions would be mapped to the same positions in the reference genome, but
rather a much larger genomic rearrangement event occurring. However, since most of
the called insertions have been mapped back to the FARP locus, this also suggests that
the mutational process is local.
Although none of these long insertions are recurrent (occurring at the same position
in multiple patients), these mapped insertions show that there is clustering of called
insertion positions in the cancer sample within and among patients. For example, in
Figure 7.5 there is a cluster of three red dots at position 242407653-242407682 that
represent three separate insertions within the same patient. However other clusters
















































































Long insertions (>=8nt) in FARP1 mapped back to hg19 reference genome
Genomic position on chromosome 13 (GRCh37 assembly coordinates)
●
●
Location of called insertion
Location of insertion in reference
Figure 7.4: Long insertions (≥8nt) in FARP1 mapped back to reference genome. The long insertion sequences called in
FARP1 have been plotted on this graph in red at the position on chromosome 13 where they have been called. In blue is the position
that these sequences have been mapped back to in the reference. If a unique insertion has been mapped to several positions in the
reference, only the closest has been shown on the plot. Light blue vertical segments represent exonic regions of the gene (over all
transcripts for FARP1). Red points should only be found in these exonic regions since only coding INDELs have been used in this
analysis, however the reference covers the whole genome so it is possible that called insertions are mapped back to intronic regions
which would explain why blue points are seen outside the exonic regions. All insertions have been mapped to the forward (+) strand





















































































Long insertions (>=8nt) in FARP2 mapped back to hg19 reference genome
Genomic position on chromosome 2 (GRCh37 assembly coordinates)
●
●
Location of called insertion
Location of insertion in reference
Figure 7.5: Long insertions (≥8nt) in FARP2 mapped back to reference genome. The long insertion sequences called in
FARP2 have been plotted on this graph in red at the position on chromosome 2 where they have been called. In blue is the position
that these sequences have been mapped back to in the reference. If a unique insertion has been mapped to several positions in the
reference, only the closest has been shown on the plot. Light blue vertical segments represent exonic regions of the gene (over all
transcripts for FARP2). Red points should only be found in these exonic regions since only coding INDELs have been used in this
analysis, however the reference covers the whole genome so it is possible that called insertions are mapped back to intronic regions
which would explain why blue points are seen outside the exonic regions. All insertions have been mapped to the forward (+) strand.
R code used to generate plot in Appendix D.
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Figure 7.6 shows the reads in the BAM file for a single GBM patient with a reported
long insertion at position 98896836 in FARP1 aligned to the reference. It can be seen
that an inserted sequence has been called at this position (denoted by asterisks in
the reference). However what seems to actually be happening is that the reported
“insertion” has come from elsewhere in the gene due to a large deletion event, hence
























Figure 7.6: Alignment of reads from GBM patient at position of called long insertion in FARP1. BAM reads viewed
through SAMtools text alignment viewer (tview) for a GBM patient with a reported long insertion in FARP1. The top line shows
the genome coordinates. The second line is the hg19 reference sequence that has been provided to Samtools tview and the third line
is the consensus sequence determined from the aligned reads. Uppercase bases indicate a match to the forward strand and lowercase
bases letters indicates that reads match the reverse strand. Similarly a “.” indicates a match to the reference on the forward strand
and a “,” is a match to the reverse strand. “*” in the reference indicates an insertion event. In this GBM patient a long insertion
(AGATATACCAAAGCGTGG) has been reported at position 98896836.
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7.2.4 Potential mutation spectra scenarios
Figure 7.7 shows the suspected mutation scenarios that could be taking place in FARP
genes. It has been concluded that an insertion as reported by GATK is not taking place,
because reads do not support the capture of two edges (“ab” and “bA” as shown in
Figure 7.7) which would be expected to be seen in the case of a long insertion. Instead
only one edge is captured.
Since long insertions are known not to be occurring in these genes, other mechanisms
must be explored. There are three other possibilities (as shown by Figure 7.7):
• Large-scale segmental deletion - one edge (“ab”) would be detected.
• Tandem duplication - change in order of sequence (“BA”).
• Inversion - opposite orientation would be seen (reverse strand).
The relative orientations of the edges of the called insertion sequences have been inves-
tigated and they are consistent with a deletion (“ab”). These events cannot be tandem
duplications since the order of the sequence has not been changed as would be expected
to happen with tandem duplications. Inversions were also ruled out since all called in-
sertion sequences were mapped to the forward strand and if an inversion was taking
place then reverse compliments would be seen where the inserted sequences would have
mapped to the reverse strand.
Chromothripsis “chromosome shattering” was also hypothesised to be a potential cause
of this mutation spectra. This is a process in which one or a few chromosomes in a
cancer cell bear dozens to hundreds of clustered rearrangements [Forment et al., 2012].
However this would also involve different orientations (+ and - strands) being observed
which is not seen, and would not be a local event.
In some cases in Figure 7.4 and Figure 7.5, the insertion sequence has been mapped
downstream in the reference (blue dot to the left of red dot), and in other cases the
insertion sequence has been mapped upstream (blue dot to the right). The orientation
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Figure 7.7: Possible mutational events occurring in FARP genes. This figure
shows the possible mutation scenarios that could be taking place in FARP genes:
large-scale deletion, tandem duplication and inversion. The disrupted exon is located
in the reference at “Aa”. The “b” from the reference genome has been reported as an
insertion in these genes, however it is suspected that large scale-deletions are actually
taking place so that the sequence in the cancer sample reads “ab”. If the disrupted
exon read “Bb” in the reference sequence then “a” would be reported as the reference
sequence.
depends on the type of event that has occurred. If a deletion is occurring as is suspected,
then a red dot to the left of the blue dot would correspond with Figure 7.7. The other
way around (blue dot to the left of the red dot) would suggest that an exon at “Bb”
had been disrupted with “a” read as the insertion sequence.
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7.3 Discussion
7.3.1 Unusual mutation spectrum
An unusual mutational profile was observed in the FARP1 and FARP2 genes in the
TCGA dataset: a mutator phenotype exhibiting a high rate of called INDELs. On
closer inspection, this phenomenon was discovered to be specific to cancer samples and
not detected in the control samples, suggesting that these mutations were implicated
in the progression of cancer either as driver mutations or as passengers highlighting a
mutational mechanism underlying the progression of these cancers.
7.3.2 Miscalled large-scale deletions
The called INDELs were found to be mostly small insertions. Modelling of these in-
sertions showed that all reads around the called insertions within these genes were
co-orientated and mapped to the forward strand at distal positions in the reference
genome. This lead to the conclusion that the called insertions were not actually micro-
INDELs at all, but instead a local mechanism consisting of larger segmental deletions
occurring within and limited to the FARP locus.
7.3.3 Measures of selection
This is a rare and interesting phenomenon, however it is not known whether selection is
occurring as opposed to mutation. Unfortunately there are no evolutionary models in
place in this project to look at any mutation type other than point mutations, as there
would be no background model and hence no null hypothesis. Therefore, it has not been
possible to determine whether these deletions are drivers of cancer or inconsequential
passenger events.
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7.3.4 Validation
It would be useful to validate such findings. One way in which this can be done is by
using coverage data available for the TCGA dataset. Reduced coverage at FARP loci
would confirm deletions as the mode of mutation in these genes.
7.3.5 Genome-wide phenomenon in GBM
It is possible that this mechanism is not just restricted to the FARP loci. To decipher
whether this is a gene-specific or genome-wide phenomenon, the rate of micro-insertions
called in the TCGA dataset could be analysed over the whole exome. GBM and OV
cancers were the cancer types exhibiting the highest enrichment of large-scale deletions
in FARP genes. Since FARP1 and FARP2 are known to be involved in function of
the brain, a genome-wide analysis in GBM would be the most interesting to pursue.
This would also support the results from Chapter 3 in which a subset of GBM patients
were found to exhibit a very high number of INDELs. It is possible in light of the
results from this chapter that these INDELs are also representative of a larger scale
rearrangement that has been miscalled. These particular INDELs were called over
multiple genes across the exome, supporting the hypothesis that this is a genome-wide
phenomenon. It is possible that in these 16 GBM patients with high INDEL rates,
the driver mutations are located within FARP genes, however 20% of the 208 patients
(42) in the TCGA dataset contain large-scale deletions in FARP genes, suggesting that
the 16 GBM patients alone cannot account for this mutator phenotype, so it is highly
possible that other genes are also experiencing this structural rearrangement event in
GBM patients.
7.3.6 Implications of novel discovery
There are many potential events that could be causing this observed mutation pheno-
type in FARP genes. For example, large-scale deletions could be an artefact of necrosis.
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However, this is unlikely in the TCGA dataset since samples have been filtered so that
only those with less than 50% necrosis have been sequenced.
The clustering seen in Figure 7.4 and Figure 7.5 could also be an artefact of using exome
sequencing (exome-seq) data rather than whole-genome sequencing (WGS) data. WGS
is superior at detecting genomic rearrangements compared to exome-seq [Meyerson
et al., 2010], and these results could be highlighting the limitations in using exome-seq
rather than WGS.
Additionally, this chapter highlights the problems encountered with current variant
calling tools that are not capable of accurately calling INDELs when other larger struc-
tural rearrangements are present in cancer genomes. A similar problem was illustrated
in Chapter 3, in which SNVs were incorrectly called in the presence of INDELs.
Therefore these limitations should be considerations for all cancer studies during vari-
ant identification stages especially if exome-seq is used, since the presence of genomic
rearrangements could have a detrimental affect on both the SNV and INDEL results,
as has been shown both in this Chapter and in Chapter 3.
However, since this phenomenon has been detected solely in cancer exomes, it is unlikely
to be an artefact of variant calling or exome sequencing. It is more plausible that
the large-scale deletions observed in FARP1 and FARP2 are demonstrating a mutation
spectrum defined by genomic instability, a characteristic of most cancers [Negrini et al.,
2010]. Moreover, extensive genomic instability is known to be one of the main features
of malignant gliomas [Milinkovic et al., 2012], in which FARP deletions have been shown
to be enriched. This supports the roles of FARP1 and FARP2 as putative candidate
cancer genes in GBM.
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7.4 Methods
7.4.1 FARP SNVs
The filtered set of heterozygous coding cancer-specific SNVs (non-synonymous and syn-
onymous) from the TCGA dataset used in Chapter 3 and in Chapter 4 for evolutionary
analysis were used here to look specifically for SNVs occurring in FARP1 and FARP2.
For these SNV counts, the mutation occurring on the transcript with the most severe
consequence was counted for each unique SNV, counting a specific mutation only once
if occurring in overlapping genes.
7.4.2 FARP INDELs
To create the tabulated cancer-specific coding heterozygous INDEL mutation counts for
each gene by variant consequence and tumour type, first the mySQL TCGA database
(tcga pair exome) was mined using the command in Listing 7.1. Genotypes as deter-
mined by GATK were used to specify cancer-specific INDELs. This is a less sensitive
approach than using alt read depth (0 in control and >0 in cancer) which is prone to
more false-positives and cannot be used to identify heterozygous only INDELs. Only
coding INDELs were selected from the database, since the consequence table was used
which only contains information for coding mutations.
1 s e l e c t gene name , p a t i e n t i d , v a r s i t e . type , chr , pos , r e f , a l t ,
consequence . type , d i s ea s e , cancer genotype , contro l genotype ,
cancer genotype qua l , cont ro l g enotype qua l , gene , t r a n s c r i p t from
sample , consequence , v a r s i t e , v a r s i t e s a m p l e where sample . sample id
= v a r s i t e s a m p l e . cance r samp le id and consequence . v a r s i t e i d =
v a r s i t e . v a r s i t e i d and v a r s i t e s a m p l e . v a r s i t e i d = v a r s i t e .
v a r s i t e i d and ( gene name = ”FARP1” or gene name = ”FARP2” ) and
con t ro l g eno type qua l >= 30 and cance r genotype qua l >= 30 and
v a r s i t e . type = ”INDEL” and cancer genotype = ”0/1” and
cont ro l g eno type = ”0/0” and p a t i e n t i d != ”TCGA−AB−2942” and
p a t i e n t i d != ”TCGA−EJ−5515”
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Listing 7.1: Mining mySQL database for cancer-specific heterozygous FARP INDEL
mutations
Patients TCGA-AB-2942 and TCGA-EJ-5515 were not selected from the TCGA database
for consistency with SNV analysis, since these patients have no cancer-specific SNVs
and so were not included in the SNV analysis in Chapter 3 or the evolutionary analysis
in Chapter 4.
The INDEL set was filtered to contain just the unique mutations for each gene for
each patient, by recording the most severe consequence for each INDEL (Perl code in
Appendix C).
INDELs were counted by variant consequence and tumour type, using the R code in
Listing 7.2.
1 #read in unique l i s t o f FARP INDELs
2 FARP i n d e l s<−read . t ab l e ( ”FARP i n d e l s unique ” , header=T, sep=”” , quote=”” )
3 FARP i n d e l s $ count=1
4
5 #c r e a t e subset o f FARP1 INDELs
6 FARP1 i n d e l s<−subset (FARP inde l s , (FARP i n d e l s $gene name == ”FARP1” ) )
7
8 #c r e a t e subset o f FARP2 INDELs
9 FARP2 i n d e l s<−subset (FARP inde l s , (FARP i n d e l s $gene name == ”FARP2” ) )
10
11 #count number o f INDELs in FARP1 by consequence type
12 aggregate (FARP1 i n d e l s $count , by=l i s t ( cons=FARP1 i n d e l s $ cons ) , sum)
13
14 #count number o f INDELs in FARP2 by consequence type
15 aggregate (FARP2 i n d e l s $count , by=l i s t ( cons=FARP2 i n d e l s $ cons ) , sum)
16
17 #count number o f INDELs in FARP1 by tumour type
18 aggregate (FARP1 i n d e l s $count , by=l i s t ( d i s e a s e=FARP1 i n d e l s $ d i s e a s e ) , sum)
19
20 #count number o f INDELs in FARP2 by tumour type
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21 aggregate (FARP2 i n d e l s $count , by=l i s t ( d i s e a s e=FARP2 i n d e l s $ d i s e a s e ) , sum)
Listing 7.2: R code to count FARP INDELs by consequence type and tumour type
For the counts by disease type, to calculate the mean number of INDELs per patient for
each tumour type and across the whole dataset of 1,005 patients, each total mutation
count across all patients with that disease type was divided by the total number of
patients with that disease type, for a direct comparison of mutation rates per patient
between tumour types.
7.4.3 Mapping long insertions (≥8nt) to reference
The called INDEL insertion sequences were mapped to the hg19 reference sequence
for each gene by using Perl to find a match for the alt allele sequence reported as an
insertion in the reference sequence. Only the closest match was plotted for each unique
insertion event using R code in Appendix D.
7.4.4 SAMtools tview
Samtools tview is a text alignment viewer [Li et al., 2009]. The reference genome
for FARP1 was input to tview, together with the target cancer sequence BAM file of a
patient known to have an insertion in FARP1 in the cancer sample. Using this function,
the known position of the called insertion can be specified in order to jump straight to




In this project I set out to identify cancer-specific single nucleotide variants in cancer
exomes obtained from The Cancer Genome Atlas, and distinguish the important driver
mutations from the inconsequential passenger mutations using methods from the field
of molecular evolution which allowed the detection of signals of positive selection in
cancer genomes to highlight genes enriched with driver mutations.
I also wanted to partition the data to ask how tissue of origin and mutation spectra
of the cancer influences the path of cancer development and the genes that are hit
by driver mutations. Additionally I planned to partition the data by functional sub-
regions such as kinase domains, to ask more interesting questions such as where exactly
in driver genes the driver mutations are targeted, to further understand the mechanism
underlying cancer progression. It was also intended to extend this sub-region analysis
to pathway analysis, concatenating a domain of interest over a pathway of interest to
obtain more power in the evolutionary analysis. Greenman et al. [2007] have done
this in 518 kinase genes, by estimating the selective pressures in the kinase domains of
these genes compared to regions outside the kinase domains, showing that the selective
pressure is higher in the kinase domains and even higher in the P-loops and activation
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segments of these domains, suggesting a greater selection pressure for mutations within
kinase domains and further validate their role in cancer. In this work pathway analysis
was also considered although the selection pressures across pathways were not esti-
mated. Clustering of mutations in genes involved in the JNK-pathway indicated that
mutations in this pathway are involved in cancer development, and the FGF signalling
pathway showed the highest enrichment for non-synonymous mutations. Both these
pathways would therefore be good candidates for pathway analysis in PAML.
I have successfully called cancer-specific variants in 1,005 TCGA patients, and per-
formed gene-based evolutionary analysis on the whole dataset consisting of 17 different
tumour types.
Several key papers relating to this work were published during the course of this project,
including studies using Pan-cancer data from TCGA. These included the Lawrence et al.
[2014] and Kandoth et al. [2013] studies. These publications helped shape the project
by redirecting it, since these papers had already covered some of the ground originally
aimed for in this project by addressing the question of tissue of origin [Lawrence et al.,
2014] and mutation spectra [Kandoth et al., 2013] based analysis.
The much larger Lawrence et al. [2014] dataset was used to complement the fully
processed TCGA dataset. Mutation data from Lawrence et al. [2014] was stratified by
tumour type, as was done in Lawrence et al. [2014], however gene-based evolutionary
analysis was then performed, and the results from the two different methodologies
(PAML and MutSig) were compared. As the methods in this project were distinct
from the MutSig analysis in Lawrence et al. [2014], there was merit in performing the
complementary analysis.
The Lawrence et al. [2014] data was also used to stratify the data by mutation spectra,
which had not been done by Lawrence et al. [2014], using the six classes of single
nucleotide mutations to classify six distinct mutational signature groups. Mutation
spectra was addressed in the Kandoth et al. [2013] study, where they have also used
six mutation categories. However again there is merit in performing this analysis, since
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Lawrence et al. [2014] have not considered mutation spectra so it is building on the
work in that analysis, and Kandoth et al. [2013] have used different methods to identify
significantly mutated genes.
Although Yang et al. [2003] and others have used codon models to look at cancer evo-
lution (analysing many patients over a single gene), and omega ratios have previously
been used in a cancer setting, what is new here is the systematic analysis of all genes
in the same set of patients. Innovations exist in the way such analysis has been im-
plemented, by editing variants onto a reference, adapting PAML to deal with missing
data and handle stop codons, as well as the huge scale of the analysis.
8.1.1 Comparison of called variants between TCGA and Lawrence
datasets
701 patient samples containing coding variants were shared between both the TCGA
and Lawrence datasets, permitting a direct comparison of their called variants by the
two different pipelines. I found results to be broadly consistent except for a subset
of GBM patients where SSNV calls were considerably more frequent in my analysis
than in the Lawrence analysis. This has been traced to an issue with INDELs, in
which it was suspected that a higher rate of INDELs in a subset of GBM patients
was causing a higher rate of miss-called SSNVs, likely to be due to the difficulty in
calling SSNVs around INDELs using current variant identification tools such as GATK.
This discrepancy represents the limitations of SSNV calling pipelines, but shows that
Lawrence is the more conservative approach.
8.1.2 Stratification of patients by tissue of origin and mutation spec-
tra
I set out to address how tissue of origin and mutation spectra affect the genes hit by
driver mutations in tumour samples, and which factor has more impact on the path
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of cancer development, to further the understanding of the mechanisms responsible for
the development of different cancers.
It has been shown in this project that the tissue of origin does not necessarily correlate
with the mutation spectrum of a particular cancer, and so it can be concluded in these
datasets that the mutational spectrum is not necessarily dependent on the tissue of
origin, therefore both the varying mutation spectra (observed over TCGA and Lawrence
datasets) and the tissue of origin were controlled for separately in the evolutionary
analyses of the Lawrence SSNVs. This was done by stratifying the data by tissue of
origin and mutation spectra before detecting selection at the gene level.
The results were compared and contrasted within and between the two types of strat-
ification methods to understand how each relates to the path of selection, and to ask
if the path of cancer development is dependent on mutation spectra. There are clear
contrasts between the tissue of origin and mutation spectra analyses, with different
patterns of positive selection and different genes reaching significance in the two types
of analysis. Within the mutation spectra analysis, the genes targeted by driver mu-
tations differ between the six different mutation profiles, showing that certain genes
are more prone to being hit by certain types of mutation. It is therefore hypothesised
that mutation spectra is more important than tissue of origin in determining where the
selection is acting, however experimental validation is needed in order to answer this
question.
However, it was also shown that some specific mutation spectra are tissue-restricted. For
example, lung cancers caused by smoking are known to have a specific mutation spec-
trum with an increased rate of C→A mutations as was shown in Chapter 3. Melanoma
caused by UV is another cancer type induced by environmental exposures known to
have a specific mutation spectrum of extremely high rates of C→T mutations. However,
within these cancer types, variation in mutation spectra was also observed suggesting
that the mutation spectrum of a cancer as well as the tissue of origin should be used
to diagnose and treat individual cancers. Other known specific mutational spectra in-
duced by endogenous mutator mechanisms, such as loss of mismatch repair or loss of
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DNA polymerase proofreading activity, are common to multiple cancer types, further
confirming the importance of mutation spectra in the characterisation of a cancer.
8.1.3 Significantly mutated novel candidate cancer genes
Evolutionary analysis in PAML has identified two novel candidate cancer genes not
previously implicated in cancer, that were significantly mutated in the Lawrence dataset
using codeml but were not picked up in the Lawrence et al. [2014] study.
In the tissue of origin analysis in Chapter 5, DNMT1 was found to be significantly
mutated in colorectal cancer (CRC). DNA methyltransferase I (DNMT1) is the pri-
mary regulator of DNA methylation patterns in mammalian cells [Song et al., 2015].
Altered methylation of DNA was among the first of the genetic aberrations identified
in CRC [Goel and Boland, 2012]. DNA methylation is the most prominent type of
epigenetic change. Epigenetic changes broadly encompass all alterations in the regula-
tion of gene expression that do not involve a change in the DNA sequence, occurring
through modified interactions between the regulatory portions of DNA or messenger
RNAs (mRNAs) [Goel and Boland, 2012]. Epigenetic change usually occurs through
changes in the promoters of genes, modification in the stability of transcripts or alter-
ations in the splicing of transcripts. However, genetic variants in a gene or regulatory
element distant may also cause epigenetic changes by modifying DNA methylation for
example. DNA Methylation is mediated by DNA methyltransferases (DNMTs) such as
DNMT1, that act by catalysing the covalent addition of a methyl group to the 5’ car-
bon of cytosine creating 5-methyl-cytosine in GC-rich promoter (CpG islands) regions.
This mechanism can completely silence gene expression by preventing transcription fac-
tors from interacting with the DNA. In this analysis, genetic SNVs have been detected
in DNMT1. It is therefore predicted that the putative driver mutations detected in
this gene are activating mutations that cause the DNMT1 to hypermethylate tumour
suppressor genes at their CG-rich promoter regions, diminishing the expression of the
tumour suppressor genes, leading to the development of cancer.
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In the mutation spectra analysis in Chapter 6, DNA polymerase theta (POLQ) was
found to be significantly mutated in Signature 3. This enzyme is a member of the
DNA polymerase A-family, which function by synthesising DNA in genome replication
and protecting the cell against DNA damage [Lange et al., 2011]. Another replicative
DNA polymerase, POLE, has recently been identified as a known cancer gene, which
has been found to harbour somatic mutations in sporadic colorectal and endometrial
cancers, as well as germline mutations predisposing to colorectal adenomas and car-
cinomas [Heitzer and Tomlinson, 2014]. However, POLQ has not yet been identified
as a cancer gene. The role of this gene in cancer has recently been investigated in
[Ceccaldi et al., 2015] and Mateos-Gomez et al. [2015], in which POLQ was identified
as a key factor in the error-prone alternative non-homologous end-joining (alt-NHEJ)
repair pathway, acting by suppressing homologous recombination (HR). Furthermore,
it was found that the inhibition of POLQ in cancers with defective HR, through the
absence of homology-directed repair genes such as BRCA1 or BRCA2, had a synthetic
lethal effect on cell survival, presenting POLQ as a promising therapeutic target in
HR-deficient tumours. In the context of this research, it is suspected that the SNVs
identified in my analysis are activating mutations causing the up-regulation of POLQ
which in turn promotes alt-NHEJ and suppresses HR, causing a higher rate of translo-
cation and genomic instability leading to the mutation spectrum characteristic of many
cancers. In HR-deficient tumours, such as epithelial ovarian cancers with mutations
in genes involved in HR, activating mutations in POLQ would be expected to further
promote the use of the compensatory alt-NHEJ repair pathway. Four mutations in
POLQ were mapped to the polymerase domain, which is required for the function of
alt-NHEJ, and one mutation was located in the helicase ATP-binding domain, a re-
gion found to be required for the inhibition of HR as well as the disruption of RAD51
foci which mediate HR. This further supports the POLQ mutations identified in this
PAML analysis as activating candidate drivers of cancer. Interestingly, POLQ was not
identified in any of the tissue type analyses, highlighting the merit of stratifying data
by mutation spectra to identify candidate cancer genes that would otherwise be missed
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when only tissue of origin is considered. POLQ has been identified as significantly mu-
tated in just one distinct mutational signature, characterised by a mutational pattern
typical of HR-deficient tumours, further confirming the role of POLQ in suppressing
HR in cancers.
8.1.4 FARP mutation profile
An interesting mutation profile characterised by a high incidence of INDELs was ob-
served in FARP1 and FARP2 genes in the TCGA dataset. Further investigation re-
vealed that the reported INDELs were actually large-scale deletions. Further analysis
is required to discover whether this is a genome-wide phenomenon or whether it is
restricted to these two genes in the human genome.
The high rate of called INDELs in FARP1 and FARP2 was more pronounced in GBM
and OV patients, which is in agreement with the high rate of INDELs that was observed
in a subset of GBM patients in Chapter 3. This is suggestive of this event being less
specific to FARP genes, and could suggest the presence of large-scale deletions in other
genes of the genome.
Glioblastoma multiforme (GBM) is a malignant brain cancer and is the highest grade
glioma, with an annual incidence of five cases per 100,000 people [Patanè et al., 2013].
The thorough characterisation of this cancer type has lead to the classification of GBM
into four molecular subtypes: classical, mesenchymal, proneural and neural. GBM de-
velops after the accumulation of genomic DNA damage that often includes gene ampli-
fications and/or deletions [Rao et al., 2010], further supporting the hypothesis that this
large-scale deletion phenomenon is genome-wide rather than specific to FARP genes.
The classical subtype is mostly characterized by loss of chromosome 10 and amplifi-
cation of the epidermal growth factor receptor gene (EGFR). However, heterozygous
deletions have been described in the NF-kB Inhibitor alpha gene (NFKBIA) in about
20% of GBM cases, so this gene may be a good target for the search of large deletions
in the TCGA dataset. These deletions were found to be mutually exclusive with EGFR
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amplifications, which is a frequent event in GBM [Patanè et al., 2013]. EGFR has been
detected as highly significantly mutated by SNVs in my PAML analysis, suggesting
that, if amplifications that cause overexpression are a common aberration in GBM,
these point variants may be activating mutations. Additionally, it is suggested that a
subset of GBM patients without EGFR amplifications are subject to deletions which
would indicate that the deletion spectrum observed in the FARP genes may not be
present in all GBM patients and specific only to a subset.
These findings highlighted the lack of power to successfully detect INDELs and large-
scale genomic rearrangements in the TCGA pipeline. Whole-genome sequencing data
would be required in order to accurately identify the presence of large-scale rearrange-
ments in GBM patients.
8.1.5 Challenges and limitations
The benefit of using sequencing data from TCGA is that very large amounts of data
were able to be obtained for meta-analysis. However, with this came certain technical
challenges in the bioinformatic analysis of the next-generation sequencing data, all of
which could have lead to systematic biases in the subsequent analyses. Throughout
this project, I have attempted to remove these biases.
Data consistency was a problem encountered with the exome sequences obtained from
TCGA, since not all sequences had been aligned using the same method and some were
aligned to an older version of the reference genome, hg18. To remove this inconsistency,
in the TCGA re-analysis all exomes were realigned to hg19 using a consistent pipeline.
Another challenge encountered was the varying coverage across the genome, which
is a major source of false-negative cancer-specific variants, where there is insufficient
coverage to confidently call a true variant in the tumour sample. This is not well dealt
with in other similar studies, however it has been quantified and accounted for in this
analysis by annotating sites of low coverage (<10X) as missing data before evolutionary
analysis, so that selection is not underestimated.
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The scale of data was also a huge challenge, with over 40Tb of exome data downloaded
from TCGA (∼20Gb per patient), requiring a large amount of time and computational
resources. Working with this large quantity of data was a logistical challenge and had
the potential to make the analysis very time consuming and difficult to handle. The
realignment and variant calling processing part of the pipeline alone took approximately
eight-ten days per patient, the time-limiting step attributed to the use of Stampy to
re-align exomes, taking up substantial CPU time to process. Therefore the need for
efficient pipelining was non-trivial, and was successfully put in place to manage this
computationally.
A problem encountered generally in cancer studies using primary tumour samples is
that of cellular heterogeneity. This refers to the presence of multiple different sub-clonal
populations within a tumour, so not all cells within a tumour population will contain the
same ancestral mutations. This can be a problem in exome sequencing, since sequencing
DNA from cells that have different cancer-specific mutations reduces the power to
detect these mutations, especially heterozygous mutations that are expected to be at
a frequency of about 50% in the tumour population, whereas homozygous mutations
should have a frequency of 100%. Cell lines can be used to avoid this problem, and are
available from TCGA, however these also have their disadvantages when evolutionary
models are used. Cell lines are grown in culture so the advantage is that there is less
heterogeneity. However, although these cells carry the genomic mutations from their
source tumour samples, they also gain additional mutations during the course of cell
line development and passage [Chang et al., 2011], which will confound any evolutionary
analysis when studying the effects of selection. Also cell lines that grow out of a tumour
do not just have the possibility of additional mutations, they may have represented a
very minor sub-population of the parent tumour, and may not be representative of the
driver mutations that have caused the cancer. This is the justification for using primary
tumour samples. It has however been shown by Neve et al. [2006] and Forbes et al.
[2010] that there are no significant differences in the spectrum of genomic mutations
between cell lines and primary tumours. Another option to help address this issue
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would be to sample tumours over time so that new mutations appearing in a clonal
population could be reported, however this was not addressed in this analysis.
A particular weakness of the work in the TCGA data processing pipeline is the miscall-
ing of INDELs in FARP1 and FARP2 genes, suggesting that Genome Analysis Toolkit
(used to call both SNVs and INDELs in the TCGA dataset) may also be calling INDELs
incorrectly across the whole exome and potentially representing larger scale mutations.
This technical challenge has not affected the evolutionary results since only SNVs were
used for this, however it does impact on the SNVs that are called, since it is known
that SNVs are miscalled near INDELs, as has been shown in a subset of GBM patients
in Chapter 3.
Despite the PAML evolutionary models used in my TCGA analysis not explicitly mod-
elling the clustering or recurrence of mutations, in general I observed good sensitivity
for detecting genes harbouring clustered mutations. For example, PIK3CA was reg-
ularly identified and has highly clustered mutation patterns. However in the most
extreme cases such as BRAF where a single codon is specifically mutated in many
cancers, including colorectal cancer, this gene was not detected in the PAML analysis
whereas it was identified in the MutSig analysis in Lawrence et al. [2014]. This appears
to a limitation of our approach where the evolutionary signature is too homogeneous.
The MutSig analysis seems better at dealing with this caveat, likely to be due to the
incorporation of a MutSigCL statistical test in the Lawrence et al. [2014] study which
accounts for the clustering of mutations in genes.
A high false-positive rate has been observed in implausible cancer genes, such as those
encoding olfactory receptors, in the PAML analysis. It seems that the PAML approach
is more prone to picking up likely false-positives, though Lawrence also shows some such
tendencies. This is a fundamental problem with cancer genome studies, in that as the
sample size increases the number of false-positives detected also rises [Lawrence et al.,
2013]. Despite many of these suspected false-positives genes encoding large proteins
such as the muscle protein titin (TTN) and membrane-associated mucin (MUC16),
the prominence of these genes in cancer studies is not simply the consequence of the
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length of their coding regions since statistical tests such as the one used in this PAML
analysis already account for the large target size. Instead it has been found that the
source of this problem stems largely from heterogeneity of mutational processes in
cancer. This refers to three types heterogeneity: the heterogeneity of mutation rates
across patients with a given cancer type as well as across patients within a cancer type;
the heterogeneity in the mutational spectrum of tumours (using 96 possible mutations
incorporating the single nucleotide mutation and the sequence context); and the most
important type, regional heterogeneity across the genome with differences exceeding
fivefold [Lawrence et al., 2013]. The latter heterogeneity type is known to be in part
caused by DNA replication time, with late-replicating regions exhibiting much higher
mutation rates, and gene expression level with low expression correlating with a higher
mutation rate. Both factors could explain the high frequency of somatic mutations in
large genes and olfactory receptor genes, which are known to have low expression and
be late-replicating, and hence explain why these genes are often presented as putative
cancer-associated genes [Lawrence et al., 2013]. Lawrence et al. [2014] have attempted
to control for this in their methods by incorporating mutational heterogeneity into
the analyses through the use of MutSigCV to eliminate false-positives Lawrence et al.
[2013]. A possible fix is needed in the PAML analysis to also account for this.
Having identified limitations in my own analysis, caveats in the Lawrence analysis were
also observed. For example, the varying depth of coverage across the genome was not
quantified and accounted for in the Lawrence et al. [2014] analysis, as it was in my
TCGA analysis by annotating regions of low coverage as missing data in the exome
sequence alignments prior to driver mutation detection in PAML. This is expected
to result in a higher rate of both false-positives and false-negatives where coverage is
too low to confidently call a variant in the control and cancer sequences respectively.
Lawrence et al. [2014] have also not used a uniform dataset with all exome sequences re-
aligned to the hg19 reference genome, as has been done in the TCGA dataset. Instead
they have used the UCSC Liftover tool to convert coordinates of each mutation to
build hg19 for tumour types originally aligned to build hg18. Although this is less time
consuming than re-aligning to hg19, the results will be less accurate and consistent.
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Both of these confounding factors will have introduced systematic biases into their
analysis, but have been taken into account and corrected for in the TCGA pipeline
resulting in an improved and more rigorous methodology.
Despite these caveats, Lawrence et al. [2014] provided a very large dataset to com-
plement the smaller TCGA dataset, which added power to the previous preliminary
evolutionary analysis, and allowed for a direct comparison of different driver gene de-
tection methods.
8.2 Future research
8.2.1 Validation of results
Evolutionary analysis in PAML has uncovered putative candidate cancer genes found
to be under positive selection in both the tissue of origin stratified sub-analysis and the
mutation spectra stratified sub-analysis. These results require both computational and
experimental validation to further provide evidence of their role in tumourigenesis.
8.2.1.1 Computational validation of results
If a loss of function is suspected to have taken place in a candidate cancer gene, the
result could be validated by looking for evidence of loss of heterozygosity (LOH) at the
locus. This can be done by examining the coverage data, however this is not available for
the Lawrence dataset. Additionally cancer-based transcriptome sequencing (RNA-seq)
data can be used to look for reduced expression in that gene which would support the
evidence for a loss of function. Another validation process would be to look for germline
mutations in the relevant datasets to see if they correlate with detected somatic muta-
tions, for example by using population exome cohort data containing germline variants
present in colorectal cancer to support findings (Dunlop and Farrington, unpublished
data). For example a heterozygous germline mutation in a suspected tumour suppressor
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gene thought to have undergone a loss of function mutation would support the tumour
suppressor hypothesis.
Computational validation using other types of data such as array-based expression, pro-
tein expression, copy number, microsatellite instability, DNA methylation and clinical
data is also available from TCGA, and would further support evidence for potential
candidate genes. The Catalogue of Somatic Mutations in Cancer (COSMIC) [Forbes
et al., 2010] can also be used as a resource to cross-reference the significant evolutionary
results.
8.2.1.2 Experimental validation of candidate cancer genes
Experimental follow-up in the laboratory is essential in order to complement these novel
discoveries and validate their role in tumourigenesis.
A classical approach is to functionally validated results using a model organism such as
a mouse, and introducing a knock out or activating mutation into the candidate gene.
The effect of the mutation can then be ascertained by seeing if cancer develops and
measuring the invasiveness of the cancer.
A xenograft, in which human cells are put into a mouse without an immune system so
that the human cells are not rejected, can also be used to measure how the targeted
mutated gene affects the phenotype of the model organism.
8.2.2 Sub-region analysis
Evolutionary analysis in this project has demonstrated the power to be able to detect
positive selection on whole genes. However this analysis has not revealed which regions
of significantly mutated genes specifically are driving cancer.
To refine this gene-based analysis to uncover the regional patterns of SNV selection
within genes, positive selection can be measured at the sub-region level to investigate
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where exactly driver mutations are preferentially found in driver genes. This can be
done by splitting the gene into functional sub-regions, for example using short lin-
ear motifs and globular protein domains as the units of analysis. Short linear motifs
are generally situated in disordered regions of the genome and can be split into two
high level classes: modification sites and ligand binding sites. The majority of known
interaction partners of short linear motifs are globular protein domains.
By looking more closely at where driver mutations occur within cancer genes, the
function of the gene can be more specifically related to its molecular consequence in
cancer.
8.2.2.1 Motivation
The importance of partitioning genes by functional sub-regions is motivated by evo-
lutionary results from PAML, which have shown certain genes to exhibit a significant
p-value supporting evidence of positive selection, but a contradictory omega value in-
dicative of negative selection or neutrality. These genes are suspected to be undergoing
both positive and negative selection (in different regions of the gene), which could be
why they have previously been missed as cancer genes (significantly enriched with driver
mutations) in earlier evolutionary-based screens for driver genes. It is hoped that this
type of refined analysis will help to separate out the potentially competing signals of
selection within these genes that are confounding whole-gene based analysis, by focus-
ing on specific functional regions to find where specifically positive selection is acting
in the gene.
8.2.2.2 Globular protein domains: protein kinase domains
The protein kinase domain is an example of a globular protein domain, and is the most
commonly found domain in known cancer genes [Greenman et al., 2007]. The kinase
domain has also shown to be an important therapeutic target in several classes of human
cancer with inhibitors of mutated protein kinases showing positive results in cancer
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treatment, for example the use of the kinase inhibitors trastuzumab to treat breast
cancer and inatimib to treat chronic myelogenous leukemia [Garber, 2006]. Therefore
this domain is a good subject for sub-domain analysis, and would be investigated first
from the set of domain coordinates previously obtained from Ensembl. Preparation for
domain-based analysis has already begun as described in Chapter 2 splitting MAPK1
into kinase domain and non-kinase domain, however the annotated alignments are yet
to be run through PAML (Figure 8.1).
Once in PAML, parameters such as substitution rate and omega ratio are co-estimated
across the whole gene as well as in the region of interest within the gene (in this case
the kinase domain) and in the remainder of the gene. This approach gives more free
parameters to provide a better fit to the model, and therefore more power to detect
selection compared with gene-based analysis, which is a benefit when using such a small
dataset such as a single gene and a complex codon model as is used in codeml. The
results from PAML indicate how strong the selection signals are in the specific domain
of interest relative to the remainder of the protein in the unstructured regions. The
more sequences available for this gene the more power the analysis has, so using all
cancer-types in the TCGA or Lawrence dataset as was done in Chapter 4 would be
best suited for this type of analysis.
Other domains that could be considered for sub-domain analysis are as follows: oxygen
dependent degradation domains (ODDs) versus the rest of gene in HIF1; surface do-
mains versus buried domains; or extracellular versus intracellular versus transmembrane
domains in genes encoding membrane protein.
8.2.2.3 Short linear motifs: phosphorylation sites
Phosphorylation sites are an example of a modification site, and are known to be the
targets of kinase domains. However less is known about the role of these sites in cancer
than is known about kinase domains, which makes them an interesting modification site
to study in this sub-region analysis. Preparation for modification site-based analysis has
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Figure 8.1: Sub-region analysis in PAML. PAML can be adapted to analyse
alignments at the sub-region level by partitioning genes using functional region an-
notations. This figure shows a single gene annotated with kinase domain coordinates
(indicated in green) obtained from Ensembl, and another instance where the gene is
annotated with phosphorylation sites (indicated in blue) obtained from PhosPhoSite.
The remainder of the gene is annotated with a 1 representing non-kinase domains or
non-phosphorylation sites. PAML estimates an omega for each unique annotation.
These regions can also be analysed in PAML over a whole pathway in the same way,
by concatenating alignments across all genes in the pathway before estimating omega
values for each annotated region.
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also already begun as described in Chapter 2 partitioning TP53 by phosphorylation site,
however again the annotated alignments are yet to be run through PAML (Figure 8.1).
This analysis could be extended by looking at de novo birth of phosphorylation sites
(i.e. enrichment for mutations that look like they might create a phosphorylation site).
8.2.2.4 Pathway analysis
The sub-region approach described above can be adapted to detect positive selection in
a specific region concatenated over multiple genes across a defined known pathway of
interest. The aim is to uncover more about the mechanism occurring and understand
exactly which part of a signalling cascade is affected by driver mutations in cancer.
Pathway-based analysis increases the power at the sub-gene level as more data is used
compared to looking at functional regions within a single gene, and detection power is
therefore increased for small effects.
For example, phosphorylation sites can be concatenated across all genes in a pathway
known to be involved in cancer, and separated from the non-phosphorylation sites of
the pathway. PAML will then estimate an omega ratio for all phosphorylation sites and
a separate one for the rest of the pathway, as well as an omega ratio over all genes in the
whole pathway (Figure 8.1), to uncover which part of a known cancer implicated path-
way is targeted by positive selection. This analysis can be refined by annotating several
different regions simultaneously across all genes in a pathway, for example both kinase
domains and phosphorylation sites within the JNK pathway [Greenman et al., 2007],
and then asking PAML to calculate an omega for each region of interest. The results
elucidate the specific origin of driver mutations in the pathway by detecting a stronger
signal of selection either the kinase domain or phosphorylation site within the path-
way. The MAPK/ERK signaling pathway is also a good candidate for the analysis of
pathways involving kinase activity since it is known to have upstream mutations in cell-
membrane-bound receptor tyrosine kinases such as EGFR, ERBB2, FGFR1, FGFR2,
Chapter 8. Discussion 336
FGFR3, PDGFRA and PDGFRB, as well as in downstream cytoplasmic components
such as NF1, PTPN11, HRAS, KRAS, NRAS and BRAF [Stratton et al., 2009].
Pathway analysis could also just be applied to whole-genes, by grouping together genes
involved in a particular pathway and concatenating all these gene alignments prior to
evolutionary analysis to produce a single omega value for the pathway of interest.
KEGG [Kanehisa et al., 2014] is a resource that can be utilised to obtain knowledge of
genes involved in particular pathways.
8.2.2.5 Novel approach
Neither the Lawrence et al. [2014] study nor the Kandoth et al. [2013] Pan-cancer
study have addressed the hypothesis-driven question of where in genes and pathways is
enriched for driver mutations detected in cancer, by dividing genes into functional sub-
divisions. In both studies, and in many studies using the omega ratio to detect selection,
genes have been used as the single unit of analysis. However, this has previously been
addressed on a single gene in the work of Yang et al. [2003], where functional domains
were partitioned in TP53 before using a codon model to measure selection using the
omega ratio, akin to the methods used in this analysis. So as an innovation and to
build on this work too, this approach could be applied at the whole genome-wide scale
across all genes in the genome, using functional domains as well as modification sites
concatenated across pathways as the units of analysis. Yang et al. [2003] also did not
account for the varying coverage depth across the genome, so application of variant
detection sensitivity correction in this context would be a further improvement to this
novel approach making it more robust than the methods in Yang et al. [2003].
Additionally, data can be split using arbitrary data positions in known cancer genes to
find novel candidate domains or sites involved in cancer.
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8.2.3 Alternative evolutionary-based models
Other molecular adaptation models are available for evolutionary-based analysis such as
the “sitewise likelihood-ratio” (SLR) [Massingham and Goldman, 2005] method which
uses a site by site approach rather than a codon model (as is used in codeml), and can
also be adapted to detect purifying selection. A comparison of the results from different
maximum likelihood methods could be useful in seeing which has more power.
Results can be complemented with simulation studies and permutation analyses, which
can act as a control set of results for evolutionary analyses.
8.2.4 Further ways to partition data
As well as tissue of origin, mutation spectra, functional sub-domains and pathways, data
could also be partitioned on many other conditions to further understand the underly-
ing biology of the cancer. For example, considering pre-existing mutations (germline),
prognosis, age of patient, etc. and accounting for each of these factors prior to evolu-
tionary analysis.
8.2.5 Improved mutation profiles
This analysis was intended to be a refinement of what has gone before, however more
work is needed to further characterise mutation spectra in cancers and relate it to the
path of cancer development.
In this analysis, only the six classes of single nucleotide mutations were considered.
However, the classification system in Kandoth et al. [2013] could be adopted in order to
improve these basic classifications before evolutionary analysis. For example, data could
be stratified further based on the context of the mutation, for example considering CpG
effects. Mutation rates are known to be elevated at CpG sites, and especially in cancer
with certain cancers found to have a much higher mutation rate at CpG sites [Kandoth
Chapter 8. Discussion 338
et al., 2013]. Since threonine and serine are both phosphorylated and also contain
CpG sites, investigating CpG effects would complement the sub-region analysis using
phosphorylation sites. Using the phosphorylation data, we could assess the incidence of
phosphorylation sites with CpG sites hit by driver mutations versus those without CpG
sites. This style of analysis could indicate how the CpG specific mutation rate affects
which genes are hit by driver mutations in cancer. For example, a CpG mutation in
arginine produces a stop codon, and stop codons are known to occur frequently in the
APC gene in colorectal cancer. We can ask if this high mutation rate of stop codons in
APC in colorectal cancer is caused by the presence of a CpG dinucleotide. Mutation
spectra (including CpG effects) across different cancer types has been addressed in
Kandoth et al. [2013], however they have not addressed how the mutation spectrum
influences which genes are hit by candidate driver mutations. The advantage is that
Kandoth et al. [2013] analysis can be built on by using the same classifications but
by then looking further using measures of selection to detect which genes are hit by
mutation in different mutation spectra scenarios.
8.2.6 Meta-analysis
TCGA and Cancer Genome Consortium projects are continuously expanding and gen-
erating genomic data, so the addition of further cancer exomes across many different
cancer types would increase the power of analysis. Whole-genome sequences are also
available, and could be used to investigate the non-coding regions of the genome in
cancer. Other major sequencing project datasets could also be incorporated, such as
the Wellcome Trust Sanger Institute’s Cancer Genome Project [Futreal et al., 2004].
This resource uses the human genome sequence and high-throughput mutation detec-
tion techniques to identify somatically acquired sequence variants and hence identify
genes critical to the development of human cancers. One of their projects consists of
the full coding sequence of 518 protein kinase genes over 210 diverse human tumour
samples together with their matched somatic sequences, for both primary and cell-line
samples [Greenman et al., 2007]. This dataset would be a good choice for the study of
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sub-region analysis in kinase domains and phosphorylation sites, especially since each
sample has a coding sequence of ∼1.3Mb of DNA which covers a large proportion of
the genome.
8.2.7 Purifying selection
A more neglected category of genes in cancer studies are those whose normal function
is required for cancer progression. These genes would be expected to exhibit strong
purifying selection in evolutionary studies, due to mutations deleterious to the cancer
being removed from these genes in the cancer population, showing evidence that these
genes are conserved in cancer. For example, MTH1 is a gene required for the survival
of many cancers, but it is non-essential in normal cells [Gad et al., 2014]. This would
be a good candidate gene for a prototype of purifying selection in cancer genomes.
However, this is a high risk approach at the gene level due to background noise con-
founding selection signals. This has been observed in our results where genes are seen
to have a significant p-value supporting positive selection, yet also an omega indicative
of neutrality or negative selection. It is speculated that these genes are undergoing
different modes of selection in different regions of the gene. Massingham and Goldman
[2005] used evolutionary approaches to find the location of both positive and purifying
selection acting in genes. Therefore, the sub-region analysis described above could be
combined with a screen for purifying selection in order to identify conserved regions
that may be important for cancer development.
8.2.8 INDELs and other types of mutation
INDELs have been explored briefly in this project in the FARP genes and in GBM,
however they have not been investigated in an evolutionary context. This is because
the models for this type of analysis do not exist in PAML. Lawrence et al. [2014] did
however include INDELs in their study, since their models were able to deal with this
type of mutation. INDELs are also more difficult to align and detect than SNVs, as
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has been discovered in the FARP genes, so the pipeline currently in place would need
to be adapted to deal with this type of mutation.
Large-scale structural deletions such as the deletions observed in FARP genes in this
project would also be interesting to look at using evolutionary models. In this case
whole-genome sequencing data would be required using physical coverage aided by the
analysis of paired reads to first detect unexpected read pairing indicative of the presence
of structural anomalies [Meyerson et al., 2010].
Investigating different types of mutation in the same cancers would give a more com-
prehensive understanding of the pattern of mutation profiles (not just limited to point
mutations) and how these link to the cancer phenotype, and would provide more infor-
mation to uncover the complex mechanisms underlying cancer progression.
8.3 Summary
To summarise, I have developed a protocol that is capable of rediscovering known cancer
genes such as TP53, as proof of concept. I have also identified novel genes using this
method that have not previously been identified as cancer driver genes. An interesting
cancer-specific mutational profile has been identified in FARP1 and FARP2, which is
not only a novel finding in cancer exomes but also highlights the difficulty in calling
INDELs using current variant calling tools.
Appendix A
Variations between TCGA and
Lawrence cancer type
classifications
Table A.1: Variations between TCGA and Lawrence cancer type classifi-
cations. The cancer type name has been stated in this table where the definitions
vary between TCGA and Lawrence classifications.
Cancer type abbreviation Full cancer type name
TCGA Lawrence
BLCA Bladder urothelial carci-
noma
Bladder
BRCA Breast invasive carcinoma Breast
CRC Colorectal carcinoma Colorectal
HNSC Head and neck squamous
cell carcinoma
Head and neck
KIRC Kidney renal clear cell car-
cinoma
Kidney clear cell
OV Ovarian serous cystadeno-
carcinoma
Ovarian






Example PAML control file for
TP53
1 s e q f i l e = ENSG00000141510 . a ln ∗ sequence data f i l e name
2 t r e e f i l e = ENSG00000141510 . dnd ∗ t r e e s t r u c t u r e f i l e name
3 o u t f i l e = ENSG00000141510 . codemlOUT ∗ main r e s u l t f i l e name
4
5 no i sy = 0 ∗ 0 , 1 , 2 , 3 , 9 : how much rubbish on the s c r e en
6 verbose = 0 ∗ 0 : c o n c i s e output ; 1 : d e t a i l e d output
7 runmode = 0 ∗ 0 : user t r e e ; 1 : semi−automatic ; 2 : automatic
8 ∗ 3 : StepwiseAddit ion ; ( 4 , 5 ) : PerturbationNNI ; −2: pa i rw i s e
9
10 seqtype = 1 ∗ 1 : codons ; 2 :AAs ; 3 : codons−−>AAs
11 CodonFreq = 2 ∗ 0 :1/61 each , 1 : F1X4 , 2 : F3X4 , 3 : codon t ab l e
12 ndata = 10
13 c l o ck = 0 ∗ 0 : no c lock , 1 : c l o ck ; 2 : l o c a l c l o ck
14
15 aaDist = 0 ∗ 0 : equal , +: geometr ic ; −: l i n e a r ,
∗ 1−6:G1974 , Miyata , c , p , v , a ; 7 : AAClasses
16 a a R a t e f i l e = dat / jone s . dat ∗ only used f o r aa seqs with model=e m p i r i c a l
( F )
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19 model = 0 ∗ models f o r codons :
20 ∗ 0 : one , 1 : b , 2 : 2 or more dN/dS r a t i o s f o r branches
21 ∗ models f o r AAs or codon−t r a n s l a t e d AAs :
22 ∗ 0 : poisson , 1 : p ropor t i ona l , 2 : Empir ica l
23 ∗ 3 : Empir ica l+F, 6 : FromCodon , 8 : REVaa 0
24 ∗ 9 :REVaa( nr =189)
25
26 NSs i te s = 0 1 2 ∗ 0 : one w; 1 : neu t ra l ; 2 : s e l e c t i o n ; 3 : d i s c r e t e ; 4 : f r e q s ;
27 ∗ 5 :gamma ; 6 : 2 gamma ; 7 : beta ; 8 : beta&w; 9 : beta&gamma;
28 ∗ 10 : beta&gamma+1; 11 : beta&normal >1; 12:0&2 normal >1;
29 ∗ 13 :3 normal>0
30
31 i c ode = 0 ∗ 0 : u n i v e r s a l code ; 1 : mammalian mt ; 2−10: s ee below
32 Mgene = 0 ∗ 0 : ra te s , 1 : s epara te
33
34 f i x kappa = 0 ∗ 1 : kappa f ixed , 0 : kappa to be est imated
35 kappa = 2 ∗ i n i t i a l or f i x e d kappa
36 f ix omega = 0 ∗ 1 : omega or omega 1 f ixed , 0 : e s t imate
37 omega = . 4 ∗ i n i t i a l or f i x e d omega , f o r codons or codon−based AAs
38
39 f i x a l p h a = 1 ∗ 0 : e s t imate gamma shape parameter ; 1 : f i x i t at alpha
40 alpha = 0 . ∗ i n i t i a l or f i x e d alpha , 0 : i n f i n i t y ( constant ra t e )
41 Malpha = 0 ∗ d i f f e r e n t a lphas f o r genes
42 ncatG = 8 ∗ # of c a t e g o r i e s in dG of NSs i t e s models
43
44 getSE = 0 ∗ 0 : don ’ t want them , 1 : want S .E. s o f e s t imate s
45 RateAncestor = 1 ∗ ( 0 , 1 , 2 ) : r a t e s ( alpha >0) or a n c e s t r a l s t a t e s (1 or
2)
46
47 S m a l l D i f f = . 5 e−6
48 c l eandata = 0 ∗ remove s i t e s with ambiguity data ( 1 : yes , 0 : no ) ?
Listing B.1: Input control file used in codeml analysis in PAML for TP53 gene
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13 Remove mul t ip l e t r a n s c r i p t s f o r each INDEL in a gene in a pat ient , us ing




17 use s t r i c t ;
18 use IO : : F i l e ;
19 use Getopt : : Long ;
20
21 my $usage = qq{USAGE:
22 $0 [−−help ]
345
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23 −− i n d e l s FARP indels
24 −−output FARP indels unique
25 } ;
26
27 my $help = 0 ;
28 my $ i n d e l s ;
29 my $output ;
30
31 GetOptions (
32 ’ he lp ’ => \$help ,
33 ’ i n d e l s=s ’ => \ $ i nde l s ,
34 ’ output=s ’ => \$output ,
35 ) or d i e $usage ;
36
37 i f ( $help | | ! $ i n d e l s | | ! $output )
38 {
39 pr in t $usage ;
40 e x i t (0 ) ;
41 }
42
43 my $INDELS = new IO : : F i l e ;
44 $INDELS−>open ( $ i nde l s , ” r ” ) or d i e ”Could not open $ i n d e l s \n$ ! ” ;
45
46 my $OUT = new IO : : F i l e ;
47 $OUT−>open ( $output , ”w” ) or d i e ”Could not open $output\n$ ! ” ;
48
49 my %data ;
50 my $ c u r r e n t l i n e ;
51 my $ sever i ty max = −1;
52
53 #using ranked s e v e r i t y o f consequences from snpEf f
54 my %s e v e r i t y = ( ”UTR 3 PRIME” => 0 ,
55 ”UTR 5 PRIME” => 1 ,
56 ”UTR 3 DELETED” => 2 ,
57 ”UTR 5 DELETED” => 3 ,
58 ”CODON CHANGE PLUS CODON DELETION” => 4 ,
59 ”CODON DELETION” => 5 ,
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60 ”CODON CHANGE PLUS CODON INSERTION” => 6 ,
61 ”CODON INSERTION” => 7 ,
62 ”FRAME SHIFT” => 8 ,
63 ”EXON DELETED” => 9 ,
64 ”SPLICE SITE DONOR” => 10 ,
65 ”SPLICE SITE ACCCEPTOR” => 11) ;
66
67 whi le (my $ l i n e = <$INDELS>)
68 {
69 chomp $ l i n e ;




74 my ( $gene name , $pa t i en t i d , $type , $chr , $pos , $ r e f , $a l t , $cons ,
$d i s ease , $cancer genotype , $contro l genotype , $cancer genotype qua l ,
$cont ro l genotype qua l , $gene , $ t r a n s c r i p t ) = s p l i t (/\ t / , $ l i n e ) ;
75 my $var iant = ” $p a t i e n t i d : $gene name : $chr : $pos : $ r e f : $a l t ” ;
76 i f ( $ c u r r e n t l i n e eq ” $p a t i e n t i d : $gene name : $chr : $pos : $ r e f : $a l t ” )
77 {
78 i f ( $ s e v e r i t y { $cons } > $ sever i ty max )
79 {
80 $ sever i ty max = $ s e v e r i t y { $cons } ;
81 $data{ $var iant } = $ l i n e ;
82 }
83 }
84 e l s e
85 {
86 $data{ $var iant } = $ l i n e ;
87 }
88 $ c u r r e n t l i n e = ” $p a t i e n t i d : $gene name : $chr : $pos : $ r e f : $a l t ” ;
89 $ sever i ty max = −1;
90 }
91 pr in t $OUT ”gene name\ t p a t i e n t i d \ ttype \ tchr \ tpos \ t r e f \ t a l t \ tcons \ t d i s e a s e
\ t cancer genotype \ t c on t ro l g eno type \ t cance r genotype qua l \
t c o n t r o l g e n o t y p e q u a l \ tgene \ t t r a n s c r i p t \n” ;
92 f o r each my $var iant ( keys %data )
Appendix C. FARP analysis: Perl code 348
93 {
94 pr in t $OUT ”$data{ $var iant }\n” ;
95 }
Listing C.1: Perl code to find most severe consequence for each heterozygous cancer-
specific INDEL mutation in FARP1 and FARP2 genes
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FARP analysis: R code
1 l o n g I n s e r t i o n s 1<−read . t ab l e ( ” i n s e r t i o n matches fa rp1 . unique ” , header = T)
2 l o n g I n s e r t i o n s 1<−l o n g I n s e r t i o n s 1 [ order ( l o n g I n s e r t i o n s 1$New p o s i t i o n o f
sequence ) , ]
3 x11 ( width =16, he ight =7)
4 #use GRCh37 coo rd ina t e s f o r where gene maps to in GRCh37 assembly
5 p lo t ( l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n , c ( 1 : l ength (
l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n ) ) , type=”n” , ann=FALSE
, yaxt=’n ’ , xl im=c (98794816 ,99107430) )
6 l i b r a r y ( ”RMySQL” )
7 dbh <− dbConnect ( dbDriver ( ”MySQL” ) , dbname=”hg19” , host=” blackadder ” , user
=” myse lect ” , password=” s i n g l e t o n ” , c l i e n t . f l a g=CLIENT MULTI STATEMENTS
)
8 #use a l l t r a n s c r i p t exons
9 qu<− ’ s e l e c t name2 , name , chrom , strand , txStart , txEnd , exonStarts ,
exonEnds from ensGene where name2=”ENSG00000152767 ” ; ’
10 qurt<−dbGetQuery (dbh , qu )
11 ymin <− 0
12 ymax <− 28
13 yv<−c ( 1 : l ength ( l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n ) )
14 f o r ( i in 1 : l ength ( qurt [ , 1 ] ) )
15 {
16 s t a r t <− as . numeric ( u n l i s t ( s t r s p l i t ( qurt $ exonStart s [ i ] , ” , ” ) ) )
17 end <− as . numeric ( u n l i s t ( s t r s p l i t ( qurt $exonEnds [ i ] , ” , ” ) ) )
349
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18
19 f o r ( j in 1 : l ength ( s t a r t ) )
20 {
21 y <− c ( ymin , ymax , ymax , ymin )
22 x <− c ( s t a r t [ j ] , s t a r t [ j ] , end [ j ] , end [ j ] )




27 segments ( l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n , yv ,
l o n g I n s e r t i o n s 1$New p o s i t i o n o f sequence , yv , c o l=” grey ” )
28
29 po in t s ( l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n , c ( 1 : l ength (
l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n ) ) , c o l = ” blue ” , pch =
20 , cex = 0 . 5 )
30 po in t s ( l o n g I n s e r t i o n s 1$New p o s i t i o n o f sequence , c ( 1 : l ength (
l o n g I n s e r t i o n s 1$ Or ig ina l p o s i t i o n o f i n s e r t i o n ) ) , c o l = ” red ” , pch =
20 , cex = 0 . 5 )
31 t i t l e ( main=”Long i n s e r t i o n s (>=8nt ) in FARP1 mapped back to hg19 r e f e r e n c e
genome” )
32 t i t l e ( xlab=”Genomic p o s i t i o n on chromosome 13 (GRCh37 assembly coo rd ina t e s
) ” )
33 l egend ( ” t o p l e f t ” , i n s e t =0.05 , c ( ” Locat ion o f c a l l e d i n s e r t i o n ” , ” Locat ion o f
i n s e r t i o n in r e f e r e n c e ” ) , c o l=c ( ” red ” , ” blue ” ) , pch=20, cex =0.8)
34 dev . copy2pdf ( f i l e=”FARP1 map . pdf ” )
Listing D.1: R code used to map long insertion (≥8nc) sequences in FARP1 back to
the hg19 reference genome (script was modified for use on FARP2)
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13 Remove mul t ip l e t r a n s c r i p t s f o r each mutation in a gene in a pat ient , by
choos ing the most s eve r e consequence ( non−synonymous ) . I f a mutation
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17 use s t r i c t ;
18 use IO : : F i l e ;
19 use Getopt : : Long ;
20
21 my $usage = qq{USAGE:
22 $0 [−−help ]
23 −−tcga a l l p a t i e n t s or t c g a s n v s a l l C o n s
24 −−output a l l p a t i e n t s f i l t e r e d or t c g a s n v s a l l C o n s f i l t e r e d
25 } ;
26
27 my $help = 0 ;
28 my $tcga ;
29 my $output ;
30
31 GetOptions (
32 ’ he lp ’ => \$help ,
33 ’ tcga=s ’ => \$tcga ,
34 ’ output=s ’ => \$output ,
35 ) or d i e $usage ;
36
37 i f ( $help | | ! $tcga | | ! $output )
38 {
39 pr in t $usage ;
40 e x i t (0 ) ;
41 }
42
43 my $TCGA = new IO : : F i l e ;
44 $TCGA−>open ( $tcga , ” r ” ) or d i e ”Could not open $tcga \n$ ! ” ;
45 my $OUT = new IO : : F i l e ;
46 $OUT−>open ( $output , ”w” ) or d i e ”Could not open $output\n$ ! ” ;
47 pr in t $OUT ” p a t i e n t i d \ t d i s e a s e \ tdbsnp\ t1kg maf\ t 1 k g m i n o r a l l e l e \ tchr \
tpos \ t r e f a l l e l e \ t a l t a l l e l e \ tconsequence \ tgene \ t t r a n s c r i p t \ tpep pos \n
” ;
48 my %data ;
49 my $ c u r r e n t l i n e ;
50 my $most severe ;
51 my %s e v e r i t y = ( ”UTR 3 PRIME” => 0 ,
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52 ”UTR 5 PRIME” => 1 ,
53 ”SYNONYMOUS STOP” => 2 ,
54 ”SYNONYMOUS CODING” => 3 ,
55 ”NON SYNONYMOUS START” => 4 ,
56 ”SYNONYMOUS START” => 5 ,
57 ”NON SYNONYMOUS CODING” => 6 ,
58 ”STOP LOST” => 7 ,
59 ”STOP GAINED” => 8 ,
60 ”START LOST” => 9 ,
61 ”SPLICE SITE DONOR” => 10 ,
62 ”SPLICE SITE ACCEPTOR” => 11
63 ) ;
64 whi le (my $ l i n e = <$TCGA>)
65 {
66 chomp $ l i n e ;




71 my ( $pat ient , $d i s ease , $dbsnp , $maf , $m i n o r a l l e l e , $chr , $pos i t i on ,
$ r e f a l l e l e , $ a l t a l l e l e , $consequence , $gene , $ t r a n s c r i p t , $pep pos )
= s p l i t (/\ t / , $ l i n e ) ;
72 my $var iant = ” $pat i en t : $chr : $p o s i t i o n : $ r e f a l l e l e : $ a l t a l l e l e ” ;
73 i f ( $ c u r r e n t l i n e eq ” $pat i en t : $chr : $p o s i t i o n : $ r e f a l l e l e : $ a l t a l l e l e ” )
74 {
75 i f ( $ s e v e r i t y { $consequence } == 1)
76 {
77 $data{ $var iant } = $ l i n e ;
78 }
79 }
80 e l s e
81 {
82 $data{ $var iant } = $ l i n e ;
83 }
84 $ c u r r e n t l i n e = ” $pat i en t : $chr : $p o s i t i o n : $ r e f a l l e l e : $ a l t a l l e l e ” ;
85 }
86 f o r each my $var iant ( keys %data )
Appendix E. Unique TCGA SNVs filtering by most severe consequence: Perl code 354
87 {
88 pr in t $OUT ”$data{ $var iant }\n” ;
89 }
Listing E.1: Perl code used to filter the heterozygous cancer-specific TCGA SNVs
to output the mutation on the transcript with the most severe consequence for each
gene for each patient to obtain a set of unique SSNVs and for mutations occurring in
overlapping genes the mutation has been counted once for patient/disease/genome-
based analysis (script was modified for gene-based analysis to allow mutations in
overlapping genes to be counted separately in each gene).
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M. Kool, S. R. Lakhani, C. López-Ot́ın, S. Martin, N. C. Munshi, H. Nakamura,
P. A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. V. Pearson, X. S.
Puente, K. Raine, M. Ramakrishna, A. L. Richardson, J. Richter, P. Rosenstiel,
M. Schlesner, T. N. Schumacher, P. N. Span, J. W. Teague, Y. Totoki, A. N. J. Tutt,
R. Valdés-Mas, M. M. van Buuren, L. van ’t Veer, A. Vincent-Salomon, N. Waddell,
L. R. Yates, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Can-
cer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, J. Zucman-Rossi,
P. A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. M. Grimmond, R. Siebert,
E. Campo, T. Shibata, S. M. Pfister, P. J. Campbell, and M. R. Stratton
2013. Signatures of mutational processes in human cancer. Nature, 500(7463):415–
421.
Alioto, T. S., S. Derdak, T. A. Beck, P. C. Boutros, L. Bower, I. Buchhalter, M. D.
Eldridge, N. J. Harding, L. E. Heisler, E. Hovig, D. T. W. Jones, A. G. Lynch,
S. Nakken, P. Ribeca, A.-S. Sertier, J. T. Simpson, P. Spellmen, P. Tarpey, L. Tonon,
D. Vodk, T. N. Yamaguchi, S. B. Agullo, M. Dabad, R. E. Denroche, P. Ginsbach,
S. C. Heath, E. Raineri, C. L. Anderson, B. Brors, R. Drews, R. Eils, A. Fujimoto,
F. C. Giner, M. He, P. Hennings-Yeomans, B. Hutter, N. Jger, R. Kabbe, C. Kandoth,
355
Bibliography 356
S. Lee, L. Ltourneau, S. Ma, H. Nakagawa, N. Paramasivam, A.-M. Patch, M. Peto,
M. Schlesner, S. Seth, D. Torrents, D. A. Wheeler, L. Xi, J. Zhang, D. S. Gerhard,
V. Quesada, R. Valds-Mas, M. Gut, T. J. Hudson, J. D. McPherson, X. S. Puente,
and I. G. Gut
2014. A comprehensive assessment of somatic mutation calling in cancer genomes.
bioRxiv, P. 012997.
AmericanCancerSociety
2015. Global Cancer Facts & Figures 3rd Edition. Atlanta: American Cancer Society.
Ascierto, P. A., J. M. Kirkwood, J.-J. Grob, E. Simeone, A. M. Grimaldi, M. Maio,
G. Palmieri, A. Testori, F. M. Marincola, and N. Mozzillo
2012. The role of braf v600 mutation in melanoma. Journal of translational medicine,
10:85.
Atefi, M., B. Titz, E. Avramis, C. Ng, D. Wong, A. Lassen, M. Cerniglia, H. Escuin-
Ordinas, D. Foulad, B. Comin-Anduix, T. G. Graeber, and A. Ribas
2015. Combination of pan-raf and mek inhibitors in nras mutant melanoma. Molec-
ular cancer, 14(1):27.
Bálint E, E. and K. H. Vousden
2001. Activation and activities of the p53 tumour suppressor protein. British journal
of cancer, 85(12):1813–1823.
Bao, R., L. Huang, J. Andrade, W. Tan, W. A. Kibbe, H. Jiang, and G. Feng
2014. Review of current methods, applications, and data management for the bioin-
formatics analysis of whole exome sequencing. Cancer informatics, 13(Suppl 2):67.
Baylin, S. B.
2005. Dna methylation and gene silencing in cancer. Nature clinical practice. Oncol-
ogy, 2 Suppl 1:S4–11.
Benjamini, Y. and Y. Hochberg
1995. Controlling the false discovery rate: a practical and powerful approach to
multiple testing. Journal of the Royal Statistical Society Series B, 57:289300.
Bibliography 357
Beroukhim, R., G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh, D. Linhart, I. Vivanco,
J. C. Lee, J. H. Huang, S. Alexander, J. Du, T. Kau, R. K. Thomas, K. Shah, H. Soto,
S. Perner, J. Prensner, R. M. Debiasi, F. Demichelis, C. Hatton, M. A. Rubin, L. A.
Garraway, S. F. Nelson, L. Liau, P. S. Mischel, T. F. Cloughesy, M. Meyerson, T. A.
Golub, E. S. Lander, I. K. Mellinghoff, and W. R. Sellers
2007. Assessing the significance of chromosomal aberrations in cancer: methodology
and application to glioma. Proceedings of the National Academy of Sciences of the
United States of America, 104(50):20007–20012.
Beroukhim, R., C. H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Bar-
retina, J. S. Boehm, J. Dobson, M. Urashima, K. T. Mc Henry, R. M. Pinchback,
A. H. Ligon, Y.-J. Cho, L. Haery, H. Greulich, M. Reich, W. Winckler, M. S.
Lawrence, B. A. Weir, K. E. Tanaka, D. Y. Chiang, A. J. Bass, A. Loo, C. Hoff-
man, J. Prensner, T. Liefeld, Q. Gao, D. Yecies, S. Signoretti, E. Maher, F. J.
Kaye, H. Sasaki, J. E. Tepper, J. A. Fletcher, J. Tabernero, J. Baselga, M.-S. Tsao,
F. Demichelis, M. A. Rubin, P. A. Janne, M. J. Daly, C. Nucera, R. L. Levine, B. L.
Ebert, S. Gabriel, A. K. Rustgi, C. R. Antonescu, M. Ladanyi, A. Letai, L. A. Gar-
raway, M. Loda, D. G. Beer, L. D. True, A. Okamoto, S. L. Pomeroy, S. Singer, T. R.
Golub, E. S. Lander, G. Getz, W. R. Sellers, and M. Meyerson
2010. The landscape of somatic copy-number alteration across human cancers. Na-
ture, 463(7283):899–905.
Bestor, T., A. Laudano, R. Mattaliano, and V. Ingram
1988. Cloning and sequencing of a cdna encoding dna methyltransferase of mouse
cells: the carboxyl-terminal domain of the mammalian enzymes is related to bacterial
restriction methyltransferases. Journal of molecular biology, 203(4):971–983.
Betteridge, D. J.
2000. What is oxidative stress? Metabolism: clinical and experimental, 49(2 Suppl
1):3–8.
Bignell, G., R. Smith, C. Hunter, P. Stephens, H. Davies, C. Greenman, J. Teague,
A. Butler, S. Edkins, C. Stevens, S. O’Meara, A. Parker, T. Avis, S. Barthorpe,
Bibliography 358
L. Brackenbury, G. Buck, J. Clements, J. Cole, E. Dicks, K. Edwards, S. Forbes,
M. Gorton, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, D. Jones, V. Kos-
midou, R. Laman, R. Lugg, A. Menzies, J. Perry, R. Petty, K. Raine, R. Shepherd,
A. Small, H. Solomon, Y. Stephens, C. Tofts, J. Varian, A. Webb, S. West, S. Widaa,
A. Yates, A. J. M. Gillis, H. J. Stoop, R. J. H. L. M. van Gurp, J. W. Oosterhuis,
L. H. J. Looijenga, P. A. Futreal, R. Wooster, and M. R. Stratton
2006. Sequence analysis of the protein kinase gene family in human testicular germ-
cell tumors of adolescents and adults. Genes, chromosomes & cancer, 45(1):42–46.
Bignell, G. R., C. D. Greenman, H. Davies, A. P. Butler, S. Edkins, J. M. Andrews,
G. Buck, L. Chen, D. Beare, C. Latimer, S. Widaa, J. Hinton, C. Fahey, B. Fu,
S. Swamy, G. L. Dalgliesh, B. T. Teh, P. Deloukas, F. Yang, P. J. Campbell, P. A.
Futreal, and M. R. Stratton
2010. Signatures of mutation and selection in the cancer genome. Nature,
463(7283):893–898.
Bignell, G. R., J. Huang, J. Greshock, S. Watt, A. Butler, S. West, M. Grigorova,
K. W. Jones, W. Wei, M. R. Stratton, P. A. Futreal, B. Weber, M. H. Shapero, and
R. Wooster
2004. High-resolution analysis of dna copy number using oligonucleotide microarrays.
Genome research, 14(2):287–295.
Boulton, S. J.
2006. Cellular functions of the brca tumour-suppressor proteins. Biochemical Society
transactions, 34(Pt 5):633–645.
Boulton, S. J.
2010. Dna repair: Decision at the break point. Nature, 465(7296):301–302.
Bouwman, P., A. Aly, J. M. Escandell, M. Pieterse, J. Bartkova, H. van der Gulden,
S. Hiddingh, M. Thanasoula, A. Kulkarni, Q. Yang, B. G. Haffty, J. Tommiska,
C. Blomqvist, R. Drapkin, D. J. Adams, H. Nevanlinna, J. Bartek, M. Tarsounas,
Bibliography 359
S. Ganesan, and J. Jonkers
2010. 53bp1 loss rescues brca1 deficiency and is associated with triple-negative and
brca-mutated breast cancers. Nature structural & molecular biology, 17(6):688–695.
Bunting, S. F., E. Callén, N. Wong, H.-T. Chen, F. Polato, A. Gunn, A. Both-
mer, N. Feldhahn, O. Fernandez-Capetillo, L. Cao, X. Xu, C.-X. Deng, T. Finkel,
M. Nussenzweig, J. M. Stark, and A. Nussenzweig
2010. 53bp1 inhibits homologous recombination in brca1-deficient cells by blocking
resection of dna breaks. Cell, 141(2):243–254.
Bunting, S. F. and A. Nussenzweig
2013. End-joining, translocations and cancer. Nature reviews. Cancer, 13(7):443–454.
Burrell, R. A., N. McGranahan, J. Bartek, and C. Swanton
2013. The causes and consequences of genetic heterogeneity in cancer evolution.
Nature, 501(7467):338–345.
Cancer Genome Atlas Research Network
2008. Comprehensive genomic characterization defines human glioblastoma genes
and core pathways. Nature, 455(7216):1061–1068.
Cancer Genome Atlas Research Network
2011. Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353):609–615.
Cancer Research UK
2014. Cancer Statistics Report: Cancer Survival in the UK up to 2011.
Carter, H., S. Chen, L. Isik, S. Tyekucheva, V. E. Velculescu, K. W. Kinzler, B. Vogel-
stein, and R. Karchin
2009. Cancer-specific high-throughput annotation of somatic mutations: computa-
tional prediction of driver missense mutations. Cancer research, 69(16):6660–6667.
Ceccaldi, R., J. C. Liu, R. Amunugama, I. Hajdu, B. Primack, M. I. R. Petalcorin,
K. W. O’Connor, P. A. Konstantinopoulos, S. J. Elledge, S. J. Boulton, T. Yusufzai,
Bibliography 360
and A. D. D’Andrea
2015. Homologous-recombination-deficient tumours are dependent on polθ-mediated
repair. Nature.
Chang, H., D. G. Jackson, P. S. Kayne, P. B. Ross-Macdonald, R.-P. Ryseck, and N. O.
Siemers
2011. Exome sequencing reveals comprehensive genomic alterations across eight can-
cer cell lines. PloS one, 6(6):e21097.
Chilamakuri, C. S. R., S. Lorenz, M.-A. Madoui, D. Vodák, J. Sun, E. Hovig, O. Myk-
lebost, and L. A. Meza-Zepeda
2014. Performance comparison of four exome capture systems for deep sequencing.
BMC genomics, 15(1):449.
Chung, W., J. Bondaruk, J. Jelinek, Y. Lotan, S. Liang, B. Czerniak, and J.-P. J. Issa
2011. Detection of bladder cancer using novel dna methylation biomarkers in urine
sediments. Cancer Epidemiology Biomarkers & Prevention, 20(7):1483–1491.
Cingolani, P., A. Platts, L. L. Wang, M. Coon, T. Nguyen, L. Wang, S. J. Land, X. Lu,
and D. M. Ruden
2012. A program for annotating and predicting the effects of single nucleotide poly-
morphisms, snpeff: Snps in the genome of drosophila melanogaster strain w1118;
iso-2; iso-3. Fly, 6(2):80–92.
Cleary, A. S., T. L. Leonard, S. A. Gestl, and E. J. Gunther
2014. Tumour cell heterogeneity maintained by cooperating subclones in wnt-driven
mammary cancers. Nature, 508(7494):113–117.
Cleaver, J. E.
2005. Cancer in xeroderma pigmentosum and related disorders of dna repair. Nature
reviews. Cancer, 5(7):564–573.
Consortium, . G. P. et al.
2012. An integrated map of genetic variation from 1,092 human genomes. Nature,
491(7422):56–65.
Bibliography 361
Consortium, I. H. . et al.
2010. Integrating common and rare genetic variation in diverse human populations.
Nature, 467(7311):52–58.
Consortium, U. et al.
2014. Uniprot: a hub for protein information. Nucleic acids research, P. gku989.
Croce, C. M.
2008. Oncogenes and cancer. The New England journal of medicine, 358(5):502–511.
Damore, J. A. and J. Gore
2011. A slowly evolving host moves first in symbiotic interactions. Evolution; inter-
national journal of organic evolution, 65(8):2391–2398.
Darwin, C. and A. R. Wallace
1858. On the tendency of species to form varieties; and on the perpetuation of
varieties and species by natural means of selection. In Proceedings of the Linnean
Society of London, volume 3, Pp. 45–62, London, UK. The Linnean Society.
de Boer, J. and J. H. Hoeijmakers
2000. Nucleotide excision repair and human syndromes. Carcinogenesis, 21(3):453–
460.
de Cavanagh, E., A. E. Honegger, E. Hofer, R. H. Bordenave, E. O. Bullorsky, N. A.
Chasseing, and C. Fraga
2002. Higher oxidation and lower antioxidant levels in peripheral blood plasma and
bone marrow plasma from advanced cancer patients. Cancer, 94(12):3247–3251.
de Miranda, N. F., F. J. Hes, T. van Wezel, and H. Morreau
2012. Role of the microenvironment in the tumourigenesis of microsatellite unstable
and mutyh-associated polyposis colorectal cancers. Mutagenesis, 27(2):247–253.
Deininger, M., E. Buchdunger, and B. J. Druker
2005. The development of imatinib as a therapeutic agent for chronic myeloid
leukemia. Blood, 105(7):2640–2653.
Bibliography 362
DePristo, M. A., E. Banks, R. Poplin, K. V. Garimella, J. R. Maguire, C. Hartl, A. A.
Philippakis, G. del Angel, M. A. Rivas, M. Hanna, A. McKenna, T. J. Fennell, A. M.
Kernytsky, A. Y. Sivachenko, K. Cibulskis, S. B. Gabriel, D. Altshuler, and M. J.
Daly
2011. A framework for variation discovery and genotyping using next-generation dna
sequencing data. Nature genetics, 43(5):491–498.
DeVita, V. T., T. S. Lawrence, and S. A. Rosenberg
2010. Cancer: principles and practice of oncology-advances in oncology, volume 1.
Lippincott Williams & Wilkins.
Dong, J. T.
2001. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer
metastasis reviews, 20(3-4):173–193.
Dow, L. E., J. Fisher, K. P. O’Rourke, A. Muley, E. R. Kastenhuber, G. Livshits, D. F.
Tschaharganeh, N. D. Socci, and S. W. Lowe
2015. Inducible in vivo genome editing with crispr-cas9. Nature biotechnology,
33(4):390–394.
Du, J., Y. Shi, Y. Pan, X. Jin, C. Liu, N. Liu, Q. Han, Y. Lu, T. Qiao, and D. Fan
2005. Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer
cells. Cancer biology & therapy, 4(2):242–247.
Dürst, M., L. Gissmann, H. Ikenberg, and H. zur Hausen
1983. A papillomavirus dna from a cervical carcinoma and its prevalence in can-
cer biopsy samples from different geographic regions. Proceedings of the National
Academy of Sciences of the United States of America, 80(12):3812–3815.
Dutt, A., H. B. Salvesen, T.-H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nico-
letti, W. Winckler, R. Grewal, M. Hanna, et al.
2008. Drug-sensitive fgfr2 mutations in endometrial carcinoma. Proceedings of the
National Academy of Sciences, 105(25):8713–8717.
Bibliography 363
Eads, C. A., K. D. Danenberg, K. Kawakami, L. B. Saltz, P. V. Danenberg, and P. W.
Laird
1999. Cpg island hypermethylation in human colorectal tumors is not associated with
dna methyltransferase overexpression. Cancer research, 59(10):2302–2306.
Eden, E., R. Navon, I. Steinfeld, D. Lipson, and Z. Yakhini
2009. Gorilla: a tool for discovery and visualization of enriched go terms in ranked
gene lists. BMC bioinformatics, 10:48.
Felsenstein, J.
2005. Phylip: Phylogenetic inference program. University of Washington:Seattle,
Version 3.6.
Fernald, G. H., E. Capriotti, R. Daneshjou, K. J. Karczewski, and R. B. Altman
2011. Bioinformatics challenges for personalized medicine. Bioinformatics (Oxford,
England), 27(13):1741–1748.
Fishel, R., M. K. Lescoe, M. R. Rao, N. G. Copeland, N. A. Jenkins, J. Garber,
M. Kane, and R. Kolodner
1994. The human mutator gene homolog msh2 and its association with hereditary
nonpolyposis colon cancer. Cell, 77(1):1 p following 166.
Flanagan, S. E., A.-M. Patch, and S. Ellard
2010. Using sift and polyphen to predict loss-of-function and gain-of-function muta-
tions. Genetic testing and molecular biomarkers, 14(4):533–537.
Fletcher, M. N. C., M. A. A. Castro, X. Wang, I. de Santiago, M. O’Reilly, S.-F. Chin,
O. M. Rueda, C. Caldas, B. A. J. Ponder, F. Markowetz, and K. B. Meyer
2013. Master regulators of fgfr2 signalling and breast cancer risk. Nature communi-
cations, 4:2464.
Flicek, P., I. Ahmed, M. R. Amode, D. Barrell, K. Beal, S. Brent, D. Carvalho-
Silva, P. Clapham, G. Coates, S. Fairley, S. Fitzgerald, L. Gil, C. Garćıa-Girón,
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